0001683168-21-005701.txt : 20211115 0001683168-21-005701.hdr.sgml : 20211115 20211115161122 ACCESSION NUMBER: 0001683168-21-005701 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACACIA RESEARCH CORP CENTRAL INDEX KEY: 0000934549 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 954405754 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37721 FILM NUMBER: 211410648 BUSINESS ADDRESS: STREET 1: 767 3RD AVENUE STREET 2: SUITE 602 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 949-480-8300 MAIL ADDRESS: STREET 1: 767 3RD AVENUE STREET 2: SUITE 602 CITY: NEW YORK STATE: NY ZIP: 10017 10-Q 1 acacia_i10q-93021.htm FORM 10-Q
0000934549 false Q3 2021 12/31 0000934549 2021-01-01 2021-09-30 0000934549 2021-11-08 0000934549 2021-09-30 0000934549 2020-12-31 0000934549 us-gaap:RedeemablePreferredStockMember 2021-09-30 0000934549 us-gaap:RedeemablePreferredStockMember 2020-12-31 0000934549 2021-07-01 2021-09-30 0000934549 2020-07-01 2020-09-30 0000934549 2020-01-01 2020-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-06-30 0000934549 us-gaap:CommonStockMember 2021-06-30 0000934549 us-gaap:TreasuryStockMember 2021-06-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000934549 us-gaap:RetainedEarningsMember 2021-06-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-06-30 0000934549 2021-06-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000934549 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-09-30 0000934549 us-gaap:CommonStockMember 2021-09-30 0000934549 us-gaap:TreasuryStockMember 2021-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000934549 us-gaap:RetainedEarningsMember 2021-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-06-30 0000934549 us-gaap:CommonStockMember 2020-06-30 0000934549 us-gaap:TreasuryStockMember 2020-06-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000934549 us-gaap:RetainedEarningsMember 2020-06-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-06-30 0000934549 2020-06-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000934549 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-09-30 0000934549 us-gaap:TreasuryStockMember 2020-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000934549 us-gaap:RetainedEarningsMember 2020-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-09-30 0000934549 2020-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-12-31 0000934549 us-gaap:CommonStockMember 2020-12-31 0000934549 us-gaap:TreasuryStockMember 2020-12-31 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000934549 us-gaap:RetainedEarningsMember 2020-12-31 0000934549 us-gaap:NoncontrollingInterestMember 2020-12-31 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000934549 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2019-12-31 0000934549 us-gaap:CommonStockMember 2019-12-31 0000934549 us-gaap:TreasuryStockMember 2019-12-31 0000934549 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000934549 us-gaap:RetainedEarningsMember 2019-12-31 0000934549 us-gaap:NoncontrollingInterestMember 2019-12-31 0000934549 2019-12-31 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-01-01 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000934549 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000934549 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0000934549 2020-01-01 2020-12-31 0000934549 ACTG:PaidUpRevenueAgreementsMember 2021-07-01 2021-09-30 0000934549 ACTG:PaidUpRevenueAgreementsMember 2020-07-01 2020-09-30 0000934549 ACTG:PaidUpRevenueAgreementsMember 2021-01-01 2021-09-30 0000934549 ACTG:PaidUpRevenueAgreementsMember 2020-01-01 2020-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2021-07-01 2021-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2020-07-01 2020-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2021-01-01 2021-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2020-01-01 2020-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicenseeMember 2021-07-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:TwoLicenseeMember 2021-07-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:ThreeLicenseeMember 2021-07-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicensee2Member 2021-07-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicenseeMember 2020-07-01 2020-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicenseeMember 2021-01-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:TwoLicenseeMember 2021-01-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:ThreeLicenseeMember 2021-01-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicensee3Member 2020-01-01 2020-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:TwoLicenseeMember 2020-01-01 2020-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:ForeignLicenseeMember 2021-07-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:ForeignLicenseeMember 2021-01-01 2021-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:ForeignLicenseeMember 2020-07-01 2020-09-30 0000934549 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ACTG:ForeignLicenseeMember 2020-01-01 2020-09-30 0000934549 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicenseeMember 2021-01-01 2021-09-30 0000934549 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ACTG:TwoLicenseeMember 2021-01-01 2021-09-30 0000934549 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicenseeMember 2020-01-01 2020-12-31 0000934549 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ACTG:OneLicensee2Member 2020-01-01 2020-12-31 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2021-09-30 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2020-12-31 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2020-01-01 2020-12-31 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2020-12-31 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2020-01-01 2020-12-31 0000934549 us-gaap:MeasurementInputRiskFreeInterestRateMember ACTG:BlackScholesMethodMember ACTG:RestrictedStockUnitsMember 2021-01-01 2021-09-30 0000934549 us-gaap:MeasurementInputExpectedTermMember ACTG:BlackScholesMethodMember ACTG:RestrictedStockUnitsMember 2021-01-01 2021-09-30 0000934549 us-gaap:MeasurementInputPriceVolatilityMember ACTG:BlackScholesMethodMember ACTG:RestrictedStockUnitsMember 2021-01-01 2021-09-30 0000934549 us-gaap:MeasurementInputExpectedDividendRateMember ACTG:BlackScholesMethodMember ACTG:RestrictedStockUnitsMember 2021-01-01 2021-09-30 0000934549 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000934549 ACTG:RSAsMember 2021-01-01 2021-09-30 0000934549 ACTG:NonQualifiedStockOptionsMember 2021-01-01 2021-09-30 0000934549 ACTG:OptionAgreementMember ACTG:PortfolioCompaniesMember 2020-01-01 2020-04-03 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2020-01-01 2020-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2020-01-01 2020-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2020-01-01 2020-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2020-01-01 2020-09-30 0000934549 ACTG:LFFundSecuritiesMember 2021-07-01 2021-09-30 0000934549 ACTG:LFFundSecuritiesMember 2020-07-01 2020-09-30 0000934549 ACTG:LFFundSecuritiesMember 2021-01-01 2021-09-30 0000934549 ACTG:LFFundSecuritiesMember 2020-01-01 2020-09-30 0000934549 ACTG:WarrantInvestmentMember 2021-07-01 2021-09-30 0000934549 ACTG:WarrantInvestmentMember 2020-07-01 2020-09-30 0000934549 ACTG:WarrantInvestmentMember 2021-01-01 2021-09-30 0000934549 ACTG:WarrantInvestmentMember 2020-01-01 2020-09-30 0000934549 ACTG:CommonStockInvestmentMember 2021-07-01 2021-09-30 0000934549 ACTG:CommonStockInvestmentMember 2020-07-01 2020-09-30 0000934549 ACTG:CommonStockInvestmentMember 2021-01-01 2021-09-30 0000934549 ACTG:CommonStockInvestmentMember 2020-01-01 2020-09-30 0000934549 ACTG:StarboardValueMember us-gaap:SeriesAPreferredStockMember 2019-11-01 2019-11-18 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2019-11-18 0000934549 ACTG:StarboardValueMember us-gaap:SeriesAPreferredStockMember 2019-11-18 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2020-05-19 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2020-12-31 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2020-02-25 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2020-02-01 2020-02-25 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember 2020-01-01 2020-06-04 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:SeptemberRedemptionMember 2020-09-30 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:DecemberRedemptionMember 2020-12-31 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:MertonMember 2020-01-01 2020-09-30 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:MertonMember 2020-01-01 2020-06-30 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:MertonMember 2020-09-30 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:MertonMember 2021-09-30 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:MertonMember 2021-01-01 2021-01-29 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:MertonMember 2021-01-01 2021-09-30 0000934549 ACTG:NewNotesMember 2021-09-30 0000934549 ACTG:NewNotesMember 2020-12-31 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 ACTG:SecuritiesPurchaseAgreementMember ACTG:SeniorSecuredNotesMember ACTG:SeriesBWarrantsMember 2021-01-01 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-12-31 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2019-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2019-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2019-12-31 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000934549 ACTG:StockRepurchaseProgramMember 2019-08-05 0000934549 us-gaap:CommonStockMember 2020-09-20 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-04-01 2020-04-23 0000934549 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000934549 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:SeriesAPreferredStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2021-07-01 2021-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2020-07-01 2020-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2021-01-01 2021-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2020-01-01 2020-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2021-07-01 2021-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2020-07-01 2020-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2021-01-01 2021-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-01-01 2020-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2021-07-01 2021-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2020-07-01 2020-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2021-01-01 2021-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-01-01 2020-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ACTG:Integer

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

  

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ______________

 

Commission file number: 1-37721

 

Acacia Research Corporation

(Name of registrant as specified in its charter)

 

delaware 95-4405754
(State or other jurisdiction of Incorporation or Organization) (I.R.S. Employer identification No.)

 

767 THIRD AVENUE, SUITE 602, New York, NY 10017
(Address of principal executive offices) (Zip Code)

 

(949) 480-8300

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock ACTG The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated Filer ☐ Accelerated Filer ☐
Non-accelerated Filer ☒ Smaller reporting company ☒
Emerging Growth Company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

 

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of November 8, 2021, was 49,591,852.

 

 

 

   

 

 

ACACIA RESEARCH CORPORATION

 

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED

 

September 30, 2021

 

INDEX

 

    Page
     
  CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 3
     
PART I. FINANCIAL INFORMATION 4
     
Item 1. Financial Statements 4
     
  Unaudited Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020 4
     
  Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020 5
     
  Unaudited Condensed Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders' Equity for the Three and Nine Months Ended September 30, 2021 and 2020 6
     
  Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 8
     
  Notes to Unaudited Condensed Consolidated Financial Statements 9
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 46
     
Item 4. Controls and Procedures 47
     
Part II. OTHER INFORMATION 48
     
Item 1. Legal Proceedings 48
     
Item 1A. Risk Factors 49
     
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds 49
     
Item 3.  Defaults Upon Senior Securities 49
     
Item 4.  Mine Safety Disclosures 49
     
Item 5.  Other Information 49
     
Item 6. Exhibits 50

 

 

 

 2 

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q for the three months ended September 30, 2021, or this Report, contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report, or incorporated by reference into this Report, are forward-looking statements. Throughout this Report, we have attempted to identify forward-looking statements by using words such as “may,” “believe,” “will,” “could,” “project,” “anticipate,” “expect,” “estimate,” “should,” “continue,” “potential,” “plan,” “forecasts,” “goal,” “seek,” “intend,” “predict,” other forms of these words or similar words or expressions or the negative thereof, although not all forward-looking statements contain these terms. Such statements address future events and conditions concerning, among other things, intellectual property, or IP, acquisition and development, licensing and enforcement activities, other related business activities, the impact of the COVID-19 pandemic, capital expenditures, earnings, litigation, regulatory matters, markets for our services, liquidity and capital resources and accounting matters. Actual results in each case could differ materially from those anticipated in such statements by reason of factors such as our ability to invest in new technologies and patents, future global economic conditions, changes in demand for our services, legislative, regulatory and competitive developments in markets in which we and our subsidiaries operate, results of litigation and other circumstances affecting anticipated revenues and costs.

 

We have based our forward-looking statements on management’s current expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this Report. Some of the risks and uncertainties that may cause actual results to differ from those expressed or implied in the forward-looking statements are described in “Risk Factors” included in Part II, Item1A of this Report, and in “Risk Factors” included in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission, or the Securities and Exchange Commission (“SEC”), on March 29, 2021, or our Annual Report, as well as in our other public filings with the SEC. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business.

 

The information contained in this Report is not a complete description of our business or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this Report and in our other reports filed with the SEC. You should read this Report in its entirety, together with the documents that we file as exhibits to this Report and the documents that we incorporate by reference into this Report, with the understanding that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of The Nasdaq Stock Market, LLC. If we do update or correct any forward-looking statements, investors should not conclude that we will make additional updates or corrections.

 

We qualify all of our forward-looking statements by these cautionary statements.

 

 

 

 

 

 

 3 

 

 

PART I--FINANCIAL INFORMATION

 

Item 1. Financial Statements

ACACIA RESEARCH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

           
   September 30,   December 31, 
   2021   2020 
         
ASSETS 
Current assets:          
Cash and cash equivalents  $217,957   $165,546 
Restricted cash   761    – 
Equity securities at fair value   387,120    109,103 
Equity securities without readily determinable fair value   5,816    143,257 
Investment securities - equity method investments   31,840    30,673 
Investment at fair value   –    2,752 
Accounts receivable   412    506 
Other receivable (Note 3)   21,539    – 
Prepaid expenses and other current assets   3,986    5,832 
Total current assets   669,431    457,669 
           
Long-term restricted cash   35,424    35,000 
Patents, net of accumulated amortization   39,826    16,912 
Leased right-of-use assets   671    951 
Other non-current assets   4,482    4,988 
Total assets  $749,834   $515,520 
           
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY 
Current liabilities:          
Accounts payable  $2,196   $1,019 
Accrued expenses and other current liabilities   5,586    3,707 
Accrued compensation   4,019    2,265 
Royalties and contingent legal fees payable   1,793    2,162 
Accrued patent investment costs   8,000    – 
Senior Secured Notes Payable   182,855    115,663 
Total current liabilities   204,449    124,816 
           
Series A warrant liabilities   18,527    6,640 
Series A embedded derivative liabilities   41,411    26,728 
Series B warrant liabilities   229,637    52,341 
Long-term lease liabilities   671    951 
Other long-term liabilities   5,591    591 
Total liabilities   500,286    212,067 
           
Commitments and contingencies   –    – 
           
Series A redeemable convertible preferred stock, par value $0.001 per share; stated value $100 per share; 350,000 shares authorized, issued and outstanding as of September 30, 2021 and December 31, 2020; aggregate liquidation preference of $35,000 as of September 30, 2021 and December 31, 2020   13,686    10,924 
           
Stockholders' equity:          
Common stock, par value $0.001 per share; 300,000,000 shares authorized; 49,591,852 and 49,279,453 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively   50    49 
Treasury stock, at cost, 4,604,365 shares as of September 30, 2021 and December 31, 2020   (43,270)   (43,270)
Additional paid-in capital   649,349    651,416 
Accumulated deficit   (382,215)   (326,708)
Total Acacia Research Corporation stockholders' equity   223,914    281,487 
           
Noncontrolling interests   11,948    11,042 
           
Total stockholders' equity   235,862    292,529 
           
Total liabilities, redeemable convertible preferred stock, and stockholders' equity  $749,834   $515,520 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 

 4 

 

 

ACACIA RESEARCH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

                     
  Three Months Ended   Nine Months Ended 
  September 30,   September 30, 
   2021   2020   2021   2020 
Revenues  $1,582   $19,466   $24,785   $25,399 
                     
Patent portfolio operations:                    
Inventor royalties   280    5,772    823    6,843 
Contingent legal fees   285    6,609    5,735    6,855 
Litigation and licensing expenses - patents   782    1,001    4,881    3,497 
Amortization of patents   2,612    1,174    7,086    3,522 
Other patent portfolio income   –    –    –    (308)
Patent portfolio expenses   3,959    14,556    18,525    20,409 
Net patent portfolio (loss) income   (2,377)   4,910    6,260    4,990 
General and administrative expenses   10,345    7,692    23,014    18,089 
Operating loss   (12,722)   (2,782)   (16,754)   (13,099)
                     
Other income (expense):                    
Change in fair value of investment, net   –    (3,081)   (2,752)   3,704 
Gain (loss) on sale of investment   –    –    3,591    (2,762)
Change in fair value of the Series A and B warrants and embedded derivatives   619    20,672    (203,866)   (46,612)
Gain on sale of prepaid investment and derivative   –    2,845    –    2,845 
Change in fair value of equity securities   66,502    20,488    115,509    99,449 
Gain (loss) on sale of equity securities   37,688    2,737    53,124    (4,272)
Earnings on equity investment in joint venture   –    –    2,737    – 
Loss on foreign currency exchange   (17)   (48)   (193)   (4,938)
Interest expense on Senior Secured Notes   (2,531)   (2,410)   (5,601)   (3,178)
Interest income and other   76    10    135    811 
Total other income (expense)   102,337    41,213    (37,316)   45,047 
                     
Income (loss) before income taxes   89,615    38,431    (54,070)   31,948 
                     
Income tax (expense) benefit   (11)   (83)   (531)   1,257 
                     
Net income (loss) including noncontrolling interests in subsidiaries   89,604    38,348    (54,601)   33,205 
                     
Net income attributable to noncontrolling interests in subsidiaries   –    –    (906)   – 
                     
Net income (loss) attributable to Acacia Research Corporation  $89,604   $38,348   $(55,507)  $33,205 
                     
Net income (loss) attributable to common stockholders - Basic  $72,984   $30,529   $(59,054)  $24,838 
Basic net income (loss) per common share  $1.49   $0.63   $(1.21)  $0.51 
Weighted average number of shares outstanding - Basic   48,949,504    48,467,885    48,759,873    48,949,706 
                     
Net income (loss) attributable to common stockholders - Diluted  $80,171   $29,204   $(59,054)  $21,380 
Diluted net income (loss) per common share  $0.86   $0.32   $(1.21)  $0.36 
Weighted average number of shares outstanding - Diluted   93,081,502    90,624,702    48,759,873    60,153,773 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 5 

 

 

ACACIA RESEARCH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY

(In thousands, except share data)

 

 

                                       
  For the Three Months Ended September 30, 2021 
  Series A Redeemable Convertible Preferred Stock    Common Stock  Treasury   Additional
Paid-in		  Accumulated   Noncontrolling
Interests in
Operating		  Total
Stockholders'		 
  Shares  Amount    Shares  Amount  Stock  Capital  Deficit  Subsidiaries  Equity 
Balance at June 30, 2021  350,000  $12,695     49,616,602  $50  $(43,270) $650,194  $(471,819) $11,948  $147,103 
Net income including noncontrolling interests in subsidiaries  –   –     –   –   –   –   89,604   –   89,604 
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value  –   991     –   –   –   (991)  –   –   (991)
Dividend on Series A Redeemable Convertible Preferred Stock  –   –     –   –   –   (262)  –   –   (262)
Stock options exercised  –   –     30,000   –   –   108   –   –   108 
Issuance of common stock for unvested restricted stock awards, net of forfeitures  –   –     (54,750)  –   –   –   –   –   – 
Compensation expense for share-based awards  –   –     –   –   –   300   –   –   300 
Balance at September 30, 2021  350,000  $13,686     49,591,852  $50  $(43,270) $649,349  $(382,215) $11,948  $235,862 

 

 

  For the Three Months Ended September 30, 2020 
  Series A Redeemable Convertible Preferred Stock    Common Stock  Treasury   Additional
Paid-in		  Accumulated   Noncontrolling
Interests in
Operating		  Total
Stockholders'		 
  Shares  Amount    Shares  Amount  Stock  Capital  Deficit  Subsidiaries  Equity 
Balance at June 30, 2020  350,000  $9,400     49,306,137  $49  $(43,270) $650,843  $(444,799) $1,833  $164,656 
Net income attributable to Acacia Research Corporation  –   –     –   –   –   –   38,348   –   38,348 
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value  –   734     –   –   –   (734)  –   –   (734)
Dividend on Series A Redeemable Convertible Preferred Stock  –   –     –   –   –   (467)  –   –   (467)
Issuance of common stock for unvested restricted stock awards, net of forfeitures  –   –     (26,684)  –   –   –   –   –   – 
Compensation expense for share-based awards  –   –     –   –   –   488   –   –   488 
Balance at September 30, 2020  350,000  $10,134     49,279,453  $49  $(43,270) $650,130  $(406,451) $1,833  $202,291 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 6 

 

 

ACACIA RESEARCH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY

(In thousands, except share data)

(continued)

 

  For the Nine Months Ended September 30, 2021 
  Series A Redeemable Convertible Preferred Stock    Common Stock  Treasury   Additional
Paid-in		  Accumulated   Noncontrolling
Interests in
Operating		  Total
Stockholders'		 
  Shares  Amount    Shares  Amount  Stock  Capital  Deficit  Subsidiaries  Equity 
Balance at December 31, 2020  350,000  $10,924     49,279,453  $49  $(43,270) $651,416  $(326,708) $11,042  $292,529 
Net (loss) income including noncontrolling interests in subsidiaries  –   –     –   –   –   –   (55,507)  906   (54,601)
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value  –   2,762     –   –   –   (2,762)  –   –   (2,762)
Dividend on Series A Redeemable Convertible Preferred Stock  –   –     –   –   –   (785)  –   –   (785)
Stock options exercised  –   –     60,000   1   –   201   –   –   202 
Issuance of common stock for vesting of restricted stock units  –   –     28,834   –   –   –   –   –   – 
Issuance of common stock for unvested restricted stock awards, net of forfeitures  –   –     223,565   –   –   –   –   –   – 
Compensation expense for share-based awards  –   –     –   –   –   1,279   –   –   1,279 
Balance at September 30, 2021  350,000  $13,686     49,591,852  $50  $(43,270) $649,349  $(382,215) $11,948  $235,862 

 

 

  For the Nine Months Ended September 30, 2020 
  Series A Redeemable Convertible Preferred Stock    Common Stock  Treasury   Additional
Paid-in		  Accumulated   Noncontrolling
Interests in
Operating		  Total
Stockholders'		 
  Shares  Amount    Shares  Amount  Stock  Capital  Deficit  Subsidiaries  Equity 
Balance at December 31, 2019  350,000  $8,089     50,370,987  $50  $(39,272) $652,003  $(439,656) $1,833  $174,958 
Net income attributable to Acacia Research Corporation  –   –     –   –   –   –   33,205   –   33,205 
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value  –   2,045     –   –   –   (2,045)  –   –   (2,045)
Dividend on Series A Redeemable Convertible Preferred Stock  –   –     –   –   –   (1,119)  –   –   (1,119)
Stock options exercised  –   –     13,333   –   –   48   –   –   48 
Issuance of common stock for vesting of restricted stock units  –   –     14,354   –   –   –   –   –   – 
Issuance of common stock for unvested restricted stock awards, net of forfeitures  –   –     565,316   –   –   –   –   –   – 
Compensation expense for share-based awards  –   –     –   –   –   1,243   –   –   1,243 
Repurchase of common stock  –   –     (1,684,537)  (1)  (3,998)  –   –   –   (3,999)
Balance at September 30, 2020  350,000  $10,134     49,279,453  $49  $(43,270) $650,130  $(406,451) $1,833  $202,291 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

 

 

 

 7 

 

 

ACACIA RESEARCH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

         
  Nine Months Ended 
  September 
  2021  2020 
Cash flows from operating activities:        
Net (loss) income including noncontrolling interests in subsidiaries $(54,601) $33,205 
Adjustments to reconcile net (loss) income including noncontrolling interests in subsidiaries to net cash (used in) provided by operating activities:        
Change in fair value of investment, net  2,752   (3,704)
(Gain) loss on sale of investment  (3,591)  2,762 
Depreciation and amortization  7,198   3,609 
Amortization of debt discount and issuance costs  460   955 
Change in fair value of Series A redeemable convertible preferred stock embedded derivative  14,683   7,708 
Change in fair value of Series A warrants  11,887   2,036 
Change in fair value of Series B warrants  177,296   36,867 
Non-cash stock compensation  1,279   1,243 
Loss on foreign currency exchange  193   4,938 
Change in fair value of equity securities  (115,509)  (99,449)
(Gain) loss on sale of equity securities  (53,124)  4,272 
Gain on sale of prepaid investment and derivative  –   (2,845)
Earnings on equity investment in joint venture, net of distributions received  (907)  – 
Changes in assets and liabilities:        
Accounts receivable  94   248 
Prepaid expenses and other assets  (2,345)  1,038 
Accounts payable and accrued expenses  7,002   614 
Royalties and contingent legal fees payable  (369)  12,052 
Net cash (used in) provided by operating activities  (7,602)  5,549 
         
Cash flows from investing activities:        
Patent acquisition  (13,000)  (13,780)
Sale of investment at fair value  3,591   1,460 
Purchases of equity securities  (57,978)  (33,800)
Maturities and sales of equity securities  64,235   316,746 
Purchases of prepaid investment  –   (276,275)
Equity securities derivative and forward contract acquisition cost  –   (3,989)
Purchases of property and equipment  (67)  (177)
Net cash used in investing activities  (3,219)  (9,815)
         
Cash flows from financing activities:        
Repurchase of common stock  –   (3,998)
Issuance of Senior Secured Notes, net of lender fee  65,000   110,437 
Senior Secured Notes issuance costs paid to other parties  –   (496)
Dividend on Series A Redeemable Convertible Preferred Stock  (785)  (1,120)
Issuance of Series B warrants  –   4,600 
Proceeds from exercise of stock options  202   48 
Paydown of Senior Secured Notes  (50,000)  – 
Reissuance of Senior Secured Notes  50,000   – 
Net cash provided by financing activities  64,417   109,471 
         
Increase in cash and cash equivalents and restricted cash  53,596   105,205 
         
Cash and cash equivalents and restricted cash, beginning  200,546   92,359 
         
Cash and cash equivalents and restricted cash, ending $254,142  $197,564 
         
Supplemental schedule of cash flow information:        
Interest paid $2,340  $– 
Income taxes paid  9   164 
Noncash investing activities:        
Trade date receivable from sale of equity securities (Note 3)  21,539   – 
Patent acquisition in exchange of notes receivable  4,000   – 
Patent acquisition accrued liability - short-term  8,000   – 
Patent acquisition accrued liability - long-term  5,000   – 
Acquisition of prepaid investment securities  –   231,480 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 8 

 

 

ACACIA RESEARCH CORPORATION

 

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Description of Business

 

As used herein, “we,” “us,” “our,” “Acacia” and the “Company” refer to Acacia Research Corporation and/or its wholly and majority-owned and controlled operating subsidiaries, and/or where applicable, its management.

 

Acacia was incorporated on January 25, 1993 under the laws of the State of California. In December 1999, Acacia changed its state of incorporation from California to Delaware.

 

Acacia acquires businesses and operating assets that the Company believes to be undervalued and where the Company believes it can leverage its resources and skill sets to realize and unlock value. The Company intends to leverage its (i) access to flexible capital that can be deployed unconditionally, (ii) expertise in corporate governance and operational restructuring, (iii) willingness to invest in out of favor industries and businesses that suffer from a complexity discount and untangle complex, multi-factor situations, and (iv) expertise and relationships in certain sectors, to complete strategic acquisitions of businesses, divisions, and/or assets with a focus on mature technology, healthcare, industrial and certain financial segments. Acacia seeks to identify opportunities where the Company believes it is an advantaged buyer, where the Company can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to the Company’s unique capabilities, relationships, or expertise, or where Acacia believes the target would be worth more to the Company than to other buyers.

 

Acacia operates its business based on three key principles of People, Process and Performance and has built a management team with identified expertise in Research, Execution and Operation of the Company’s targeted acquisitions.

 

Acacia, through its operating subsidiaries, also currently engages in its legacy business of investing in, licensing and enforcing patented technologies. Acacia’s operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. In recent years, Acacia has also invested in technology companies. Acacia leverages its experience, expertise, data and relationships developed as a leader in the intellectual property (“IP”) industry to pursue these opportunities. In some cases, these opportunities will complement and/or supplement Acacia’s primary licensing and enforcement business.

 

Acacia’s operating subsidiaries generate revenues and related cash flows from the granting of IP rights (hereinafter, “IP Rights”) for the use of patented technologies that its operating subsidiaries control or own. Acacia’s operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation.

 

Acacia’s operating subsidiaries are principals in the licensing and enforcement effort, obtaining control of the rights in the patent portfolio, or control of the patent portfolio outright. Acacia’s operating subsidiaries own or control the rights to multiple patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.

 

Neither Acacia nor its operating subsidiaries invent new technologies or products; rather, Acacia depends upon the identification and investment in new patents, inventions and companies that own IP through its relationships with inventors, universities, research institutions, technology companies and others. If Acacia’s operating subsidiaries are unable to maintain those relationships and identify and grow new relationships, then they may not be able to identify new technology-based opportunities for sustainable revenue and/or revenue growth.

 

 

 

 9 

 

 

During the nine months ended September 30, 2021, Acacia obtained control of one new patent portfolio. During fiscal year 2020, Acacia obtained control of five new patent portfolios.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

  

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures required by U.S. GAAP in annual financial statements have been omitted or condensed in accordance with quarterly reporting requirements of the Securities and Exchange Commission (“SEC”). These interim unaudited condensed consolidated financial statements and notes hereto should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2020, as reported by Acacia in its Annual Report on Form 10-K filed with the SEC on March 29, 2021, as well as in our other public filings with the SEC. The condensed consolidated interim financial statements of Acacia include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of Acacia’s consolidated financial position as of September 30, 2021, and results of its operations and its cash flows for the interim periods presented. The consolidated results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the entire fiscal year.

 

Reclassifications

 

Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated results of operations or cash flows.

  

COVID-19 Pandemic

 

The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. While the Company does not expect the current situation to present direct risks to its business, and it has not had a material impact to date, the COVID-19 pandemic could adversely impact the Company’s operations, as well as the operations of its licensees and other business partners. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, results of operations and financial condition.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounting Principles

 

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. GAAP.

 

Principles of Consolidation

 

The accompanying unaudited consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

 

Noncontrolling interests in Acacia’s majority-owned and controlled operating subsidiaries (“noncontrolling interests”) are separately presented as a component of stockholders’ equity. Consolidated net income or (loss) is adjusted to include the net (income) or loss attributed to noncontrolling interests in the consolidated statements of operations. Refer to the accompanying Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders’ Equity for total noncontrolling interests.

 

 

 

 10 

 

 

In 2020, in connection with the transaction with Link Fund Solutions Limited, which is more fully described in Note 3, the Company acquired equity securities of Malin J1 Limited (“MalinJ1”). MalinJ1 is included in the Company’s consolidated financial statements because the Company, through its interest in the equity securities of MalinJ1, has the ability to control the operations and activities of MalinJ1. Viamet HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of Acacia, is the majority shareholder of MalinJ1.

 

A wholly-owned subsidiary of Acacia is the general partner of the Acacia Intellectual Property Fund, L.P. (the “Acacia IP Fund”), which was formed in August 2010. The Acacia IP Fund has been included in the Company’s consolidated financial statements since 2010, as Acacia’s wholly-owned subsidiary, the general partner of Acacia IP Fund, has the ability to control the operations and activities of the Acacia IP Fund. The Acacia IP Fund was terminated as of December 31, 2017 and dissolved in 2020.

 

Segment Reporting

 

Acacia uses the management approach, which designates the internal organization that is used by management for making operating decisions and assessing performance as the basis of Acacia’s reportable segments. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Acacia believes that, of the significant accounting policies described herein, the accounting policies associated with revenue recognition, the valuation of the equity instruments, the valuation of Series A redeemable convertible preferred stock (the “Series A Redeemable Convertible Preferred Stock”), embedded derivatives, Series A warrants (the “Series A Warrants”), Series B warrants (the “Series B Warrants”), stock-based compensation expense, impairment of patent-related intangible assets, the determination of the economic useful life of amortizable intangible assets, income taxes and valuation allowances against net deferred tax assets, require its most difficult, subjective or complex judgments.

 

Revenue Recognition

 

Revenue is recognized upon transfer of control (i.e., by the granting) of promised bundled IP Rights and other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive in exchange for those IP Rights. Revenue contracts that provide promises to grant the right to use IP Rights as they exist at the point in time at which the IP Rights are granted, are accounted for as performance obligations satisfied at a point in time and revenue is recognized at the point in time that the applicable performance obligations are satisfied and all other revenue recognition criteria have been met.

 

For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technologies owned or controlled by Acacia. Revenues also included license fees from sales-based revenue contracts, the majority of which were originally executed in prior periods, which provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees (“Recurring Revenue Agreements”). Revenues may also include court ordered settlements or awards related to our patent portfolio or sales of our patent portfolio. IP Rights granted included the following, as applicable: (i) the grant of a non-exclusive, future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The IP Rights granted were generally perpetual in nature, extending until the legal expiration date of the related patents. The individual IP Rights are not accounted for as separate performance obligations, as (i) the nature of the promise, within the context of the contract, is to grant combined items to which the promised IP Rights are inputs and (ii) the Company's promise to grant each individual IP right described above to the customer is not separately identifiable from other promises to grant IP Rights in the contract.

 

 

 

 11 

 

 

Since the promised IP Rights are not individually distinct, the Company combined each individual IP Right in the contract into a bundle of IP Rights that is distinct, and accounted for all of the IP Rights promised in the contract as a single performance obligation. The IP Rights granted were “functional IP rights” that have significant standalone functionality. Acacia’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. Acacia’s operating subsidiaries have no further obligation with respect to the grant of IP Rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the IP Rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 15-90 days of execution of the contract, or the end of the quarter in which the sale or usage occurs for Recurring Revenue Agreements. Contractual payments made by licensees are generally non-refundable.

 

For sales-based royalties, the Company includes in the transaction price some or all of an amount of estimated variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Notwithstanding, revenue is recognized for a sales-based royalty promised in exchange for a license of IP Rights when the later of (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied. Estimates are generally based on historical levels of activity, if available.

 

Revenues from contracts with significant financing components (either explicit or implicit) are recognized at an amount that reflects the price that a licensee would have paid if the licensee had paid cash for the IP Rights when they are granted to the licensee. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money. As a practical expedient, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the entity grants promised IP Rights to a customer and when the customer pays for the IP Rights will be one year or less.

 

In general, the Company is required to make certain judgments and estimates in connection with the accounting for revenue contracts with customers. Such areas may include identifying performance obligations in the contract, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services, evaluating whether a license transfers to a customer at a point in time or over time, allocating the transaction price to separate performance obligations, determining whether contracts contain a significant financing component, and estimating revenues recognized at a point in time for sales-based royalties.

 

Revenues were comprised of the following for the periods presented: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Paid-up revenue agreements  $1,100   $19,385   $23,110   $24,477 
Recurring Revenue Agreements   482    81    1,675    922 
Total revenue  $1,582   $19,466   $24,785   $25,399 

 

Refer to “Inventor Royalties and Contingent Legal Expenses” below for information on related direct costs of revenues.

  

Patent Portfolio Operations

 

Cost of revenues include the costs and expenses incurred in connection with Acacia’s patent licensing and enforcement activities, including inventor royalties paid to original patent owners, patent maintenance and prosecution costs, contingent legal fees paid to external patent counsel, other patent-related legal expenses paid to external patent counsel, licensing and enforcement related research, consulting and other expenses paid to third-parties and the amortization of patent-related investment costs. These costs are included under the caption “Patent portfolio operations” in the consolidated statements of operations. 

 

 

 

 12 

 

 

Inventor Royalties and Contingent Legal Expenses

 

Inventor royalties are expensed in the consolidated statements of operations in the period that the related revenues are recognized. Patent costs, including any upfront advances paid to patent owners by Acacia’s operating subsidiaries, that are recoverable from future net revenues are amortized over the estimated economic useful life of the related patents, or as the prepaid royalties are earned by the inventor, as appropriate, and the related expense is included in amortization expense in the consolidated statements of operations. Any unamortized upfront advances recovered from net revenues are expensed in the period recovered and included in amortization expense in the consolidated statements of operations.

 

Contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. In instances where there are no recoveries from potential infringers, no contingent legal fees are paid; however, Acacia’s operating subsidiaries may be liable for certain out of pocket legal costs incurred pursuant to the underlying legal services agreement.

 

Inventor royalty and contingent legal agreements generally provide for payment by the Company of contractual amounts 30 days subsequent to the fiscal quarter end during which related license fee payments are received from licensees by the Company.

 

Concentrations

 

Financial instruments that potentially subject Acacia to concentrations of credit risk are cash equivalents, equity securities and accounts receivable. Acacia places its cash equivalents and equity securities primarily in highly rated money market funds and investment grade marketable securities. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. Acacia has not experienced any significant losses on its deposits of cash and cash equivalents.

 

Four licensees individually accounted for 32%, 25%, 22% and 13% of revenues recognized during the three months ended September 30, 2021, and one licensee accounted for 98% of revenues recognized during the three months ended September 30, 2020. Three licensees individually accounted for 50%, 19% and 12% of revenues recognized during the nine months ended September 30, 2021, and two licensees accounted for 75% and 9% of revenues recognized during the nine months ended September 30, 2020.

 

The Company does not have any material foreign operations. Based on the jurisdiction of the entity obligated to satisfy payment obligations pursuant to the applicable revenue arrangement, for the three and nine months ended September 30, 2021, 8% and 15%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions. For the three and nine months ended September 30, 2020, 0.1% and 5%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions.

 

Two licensees represented 100% of accounts receivable at September 30, 2021. Two licensees individually represented approximately 62% and 21% of accounts receivable at December 31, 2020.

 

Related Party Transactions

 

During 2019, the Company purchased shares of common stock of Drive Shack, Inc. (“Drive Shack”) for an aggregate purchase price of $2.4 million. At the time, Drive Shack and Clifford Press, Chief Executive Officer and director of Acacia, were related parties as Mr. Press was a board member of Drive Shack until June 2021. The market value of the investment was $1.4 million as of December 31, 2020. During the nine months ended September 30, 2021, the Company sold its investment receiving proceeds of $1.8 million and recognized a loss of $515,000.

  

Cash and Cash Equivalents

 

Acacia considers all highly liquid, equity securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Acacia’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily includes: domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Acacia’s cash equivalents are measured at fair value using observable inputs.

 

 

 

 13 

 

 

Equity Securities at Fair Value

 

Investments in equity securities are reported at fair value on a recurring basis, with related realized and unrealized gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or (expense). Dividend income is included in the consolidated statements of operations in other income or (expense). Refer to Note 7 for additional information related to fair value measurements.

 

Equity securities at fair value for the periods presented were comprised of the following: 

                    
Security Type  Cost   Gross
Unrealized
Gain		   Gross
Unrealized
Loss		   Fair Value 
   (In thousands) 
September 30, 2021:                
Equity securities - Life Sciences Portfolio (Note 3)  $62,042   $288,508   $(1,812)  $348,738 
Equity securities - other equity   35,178    3,289    (85)   38,382 
Total  $97,220   $291,797   $(1,897)  $387,120 
                     
December 31, 2020:                    
Equity securities - Life Sciences Portfolio (Note 3)  $32,765   $72,689   $(583)  $104,871 
Equity securities - other equity   4,086    1,410    (1,264)   4,232 
Total  $36,851   $74,099   $(1,847)  $109,103 

 

Equity Securities Without Readily Determinable Fair Value

 

For equity securities that do not have readily determinable fair value, the Company elected to report them under the measurement alternative. They are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in any adjustments for illiquidity or preference of these securities. Changes in fair value are reported in the consolidated statements of operations in other income or (expense). Refer to Note 3 for additional information.

 

Equity Method Investments

 

Equity investments in common stock and in-substance common stock without readily determinable fair values in companies over which the Company has the ability to exercise significant influence, are accounted for using the equity method of accounting. Acacia includes its proportionate share of earnings and/or losses of its equity method investees in earnings on equity investment in joint venture in the consolidated statements of operations. Refer to Note 3 for additional information.

 

Investment at Fair Value

 

On an individual investment basis, Acacia may elect to account for investments in companies where the Company has the ability to exercise significant influence over operating and financial policies of the investee, at fair value. If the fair value method is applied to an investment that would otherwise be accounted for under the equity method of accounting, it is applied to all of the financial interests in the same entity that are eligible items (i.e., common stock and warrants). We elected the fair value method for our investment in Veritone, Inc. (“Veritone”) upon acquisition of the investment. Since March 2021, we have no more investment in Veritone stocks and warrants. Refer to Note 4 for additional information.

 

 

 

 14 

 

 

Impairment of Investments

 

Acacia reviews its investments quarterly for indicators of other-than-temporary impairment. This determination requires significant judgment. In making this judgment, Acacia considers available quantitative and qualitative evidence in evaluating potential impairment of its investments. If the cost of an investment exceeds its fair value, Acacia evaluates, among other factors, general market conditions and the duration and extent to which the fair value is less than cost. Acacia also considers specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of operations and a new cost basis in the investment is established.

 

Long-Term Restricted Cash

 

Restricted cash relates primarily to the proceeds received from the issuance of Series A Redeemable Convertible Preferred Stock which are held in an escrow account (refer to Note 6). The amounts are to be released to the Company upon, among other things, (i) the consummation of a suitable investment or acquisition by the Company or (ii) the conversion of Series A Redeemable Convertible Preferred Stock into common stock. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Refer to Note 11 for additional information related to the subsequent period acquisition.

 

Patents

 

Patents include the cost of patents or patent rights acquired from third-parties or obtained in connection with business combinations. Patent costs are amortized utilizing the straight-line method over their remaining economic useful lives. Refer to Note 5 for additional information.

 

Impairment of Long-lived Assets

 

Acacia reviews long-lived assets and intangible assets for potential impairment annually (quarterly for patents) and when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss is recorded in an amount equal to the excess of the asset’s carrying value over its fair value. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. In the event that management decides to no longer allocate resources to a patent portfolio, an impairment loss equal to the remaining carrying value of the asset is recorded. Refer to Note 5 for additional information.

 

Fair value is generally estimated using the “Income Approach,” focusing on the estimated future net income-producing capability of the patent portfolios over their estimated remaining economic useful life. Estimates of future after-tax cash flows are converted to present value through “discounting,” including an estimated rate of return that accounts for both the time value of money and investment risk factors. Estimated cash inflows are typically based on estimates of reasonable royalty rates for the applicable technology, applied to estimated market data. Estimated cash outflows are based on existing contractual obligations, such as contingent legal fee and inventor royalty obligations, applied to estimated license fee revenues, in addition to other estimates of out-of-pocket expenses associated with a specific patent portfolio’s licensing and enforcement program. The analysis also contemplates consideration of current information about the patent portfolio including, status and stage of litigation, periodic results of the litigation process, strength of the patent portfolio, technology coverage and other pertinent information that could impact future net cash flows.

 

Series A and B Warrants

 

The fair value of the Series A and B Warrants are estimated using a Black-Scholes option-pricing model. Refer to Notes 6 and 7 for additional information related to the Series A and B Warrants and their fair value measurements.

 

Embedded derivatives

 

Embedded derivatives that are required to be bifurcated from their host contract are valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019. Refer to Notes 6 and 7 for additional information related to the embedded derivatives and their fair value measurements.

 

 

 

 15 

 

 

Fair Value Measurements

 

U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. Refer to Note 7 for additional information.

 

Treasury Stock

 

Repurchases of the Company’s outstanding common stock are accounted for using the cost method. The applicable par value is deducted from the appropriate capital stock account on the formal or constructive retirement of treasury stock. Any excess of the cost of treasury stock over its par value is charged to additional paid-in capital and reflected as treasury stock in the consolidated balance sheets. Refer to Note 9 for additional information.

 

Stock-Based Compensation

 

The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which is generally one to three years. The fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) are determined by the product of the number of shares or units granted and the grant date market price of the underlying common stock. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing model. Forfeitures are accounted for as they occur.

 

RSUs granted in September 2019 with market-based vesting conditions vest based upon the Company achieving specified stock price targets over a three-year period. The effect of a market condition is reflected in the estimate of the grant-date fair value of the options utilizing a Monte Carlo valuation technique. Compensation cost is recognized with a market-based vesting condition provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Assumptions utilized in connection with the Monte Carlo valuation technique, that resulted in a fair value of $1.42 per unit, included: estimated risk-free interest rate of 1.38 percent; term of 3.00 years; expected volatility of 38 percent; and expected dividend yield of 0 percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. During the nine months ended September 30, 2021, 450,000 RSUs were forfeited, leaving 450,000 units with market-based vesting conditions outstanding and unvested at period end.

 

During the nine months ended September 30, 2021, the Company granted 324,401 RSAs at a weighted average grant-date fair value of $5.56 per share, 473,000 RSUs at a weighted average grant-date fair value of $5.86 per unit and 393,750 non-qualified stock options at a grant-date fair value of $1.79 per share.

 

Stock-based compensation is reported in the consolidated statements of operations in general and administrative expenses. Total stock-based compensation for the three and nine months ended September 30, 2021 was $300,000 and $1,279,000, respectively. Total unrecognized stock-based compensation expense as of September 30, 2021 was $5,952,000, which will be amortized over a weighted average remaining vesting period of 2.20 years. Total stock-based compensation for the three and nine months ended September 30, 2020 was $488,000 and $1,243,000, respectively.

 

Profits Interest Units (“PIUs”) were accounted for in accordance with Accounting Standards Codification (“ASC”) 718-10, “Compensation - Stock Compensation.” The vesting conditions did not meet the definition of service, market or performance conditions, as defined in ASC 718. As such, the PIUs were classified as liability awards. Compensation expense was adjusted for changes in fair value prorated for the portion of the requisite service period rendered. Initially, compensation expense was recognized on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which was five years. Upon full vesting of the award, which occurred during the three months ended September 30, 2017, previously unrecognized compensation expense was immediately recognized in the period. The Company has a purchase option to purchase the vested PIUs that are not otherwise forfeited after termination of continuous service. The exercise price of the purchase option is the fair market value of the PIUs on the date of termination of continuous service. The individuals holding PIUs are no longer employed by the Company. Included in other long-term liabilities in the consolidated balance sheets as of September 30, 2021 and December 31, 2020, the PIUs totaled $591,000, which was their fair value as of December 31, 2018 after termination of service.

 

 

 

 16 

 

 

Income Taxes

 

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in Acacia’s consolidated financial statements or consolidated income tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized, or if it is determined that there is uncertainty regarding future realization of such assets.

 

The provision for income taxes for interim periods is determined using an estimate of Acacia’s annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, Acacia updates the estimate of the annual effective tax rate, and if the estimated tax rate changes, a cumulative adjustment is recorded.

 

The Company’s effective tax rates were 0% and (1%) for the three and nine months ended September 30, 2021, respectively, and 0% and (4%) for the three and nine months ended September 30, 2020, respectively. Tax expense/benefit for the periods presented primarily reflects the impact of state taxes and foreign tax withholding (or refund) incurred on revenue agreements executed with third-party licensees domiciled in foreign jurisdictions. The Company has recorded a full valuation allowance against our net deferred tax assets as of September 30, 2021 and December 31, 2020. These assets primarily consist of foreign tax credits, capital loss carryforwards and net operating loss carryforwards.

  

Recent Accounting Pronouncements

 

Recently Adopted

 

In December of 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The update removed certain exceptions to the general principles in Topic 740 in U.S. GAAP. The Company adopted the update on January 1, 2021. The adoption of the update did not have a material effect on the Company’s financial position, results of operations or financial statement disclosures.

 

Not Yet Adopted

 

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” to replace the incurred loss methodology with an expected credit loss model that requires consideration of a broader range of information to estimate credit losses over the lifetime of the asset, including current conditions and reasonable and supportable forecasts in addition to historical loss information, to determine expected credit losses. Pooling of assets with similar risk characteristics and the use of a loss model are also required. Also, in April 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,” to clarify the inclusion of recoveries of trade receivables previously written off when estimating an allowance for credit losses. The amendments in these updates will currently be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in these updates may have on the Company’s consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” to simplify the accounting for convertible instruments by eliminating large sections of the existing guidance in this area. It also eliminates several triggers for derivative accounting, including a requirement to settle certain contracts by delivering registered shares. This update reduces the number of accounting models for convertible instruments, revises the derivatives scope exception, and provides targeted improvements for earnings per share. Upon adoption, companies have the option to apply a modified or full retrospective transition approach. The amendments in this update will currently be effective for the Company on January 1, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.

 

 

 

 17 

 

 

In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,” to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with “Revenue from Contracts with Customers (Topic 606).” At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and will be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.

 

3. EQUITY SECURITIES PORTFOLIO INVESTMENT

 

On April 3, 2020, the Company entered into an Option Agreement with LF Equity Income Fund (“Seller”), which included general terms through which the Company was provided the option to purchase life sciences equity securities in a portfolio of public and private companies (“Life Sciences Portfolio”) for an aggregate purchase price of £223.9 million, approximately $277.5 million at the exchange rate on April 3, 2020.

 

On June 4, 2020, the Company executed the Transaction Agreement between Link Fund Solutions Limited, Seller, and the Company. Pursuant to the Transaction Agreement, the Company agreed to purchase from Seller and Seller agreed to transfer to the Company the specified equity securities of all companies in the Life Sciences Portfolio at set prices at various future dates. The transfer dates would vary among the Life Sciences Portfolio companies as the Transaction Agreement gives the Company the exclusive right to determine when to call for transfer of each security, and because each Life Sciences Portfolio company (or its existing equity holders) may be required to approve the transfer due to rights of first refusals and other company-specific terms and conditions. Thus, the execution of the Transaction Agreement resulted in forward contracts for the Company to purchase equity securities in each public and private company at a specified price on a future date.

 

In accordance with the Transaction Agreement, the Company transferred the total purchase price of £223.9 million into an escrow account. Upon the transfer of equity securities in the Life Sciences Portfolio to the Company, the associated funds were released from the escrow account to Seller based on the consideration amount assigned to the equity securities for such Life Sciences Portfolio company in the Transaction Agreement. As of December 31, 2020, all of the equity securities in the Life Sciences Portfolio were transferred to the Company pursuant to the Transaction Agreement. The Company has sold a portion of the equity securities of such Life Sciences Portfolio while retaining an interest in a number of operating businesses, including a controlling interest in one of the companies.

 

For accounting purposes, the total purchase price of the Life Sciences Portfolio was allocated to the individual equity securities based on their individual fair values as of April 3, 2020, in order to establish an appropriate cost basis for each of the acquired securities. The fair values of the public company securities were based on their quoted market price. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in a discount for the illiquidity of these securities. As of September 30, 2021 and December 31, 2020, the fair value of the Life Sciences Portfolio equity securities, excluding the equity method investment discussed below, was $354.6 million and $248.1 million, respectively.

 

Changes in the fair value of Acacia’s investment in the Life Sciences Portfolio are recorded as unrealized gains or losses in the consolidated statements of operations. In late September 2021, the Company sold one security which resulted in a gain of $18.6 million. The proceeds of that sale were settled and received in early October 2021, and therefore the Company recorded a $21.5 million other receivable as included in the consolidated balance sheet as of September 30, 2021. Accordingly, this trade date receivable from the sale of equity securities has been reflected as a noncash investing activity in the consolidated statement of cash flows for the nine months ended September 30, 2021.

 

 

 

 18 

 

 

For the three and nine months ended September 30, 2021 and 2020, the consolidated statements of operations reflected the following from the Life Sciences Portfolio: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Change in fair value of equity securities  $63,907   $84,299   $112,180   $83,230 
Change in fair value of equity securities derivative   –    10,651    –    17,542 
Change in fair value of equity securities forward contract   –    (74,662)   –    – 
Gain (loss) on sale of equity securities   37,112    1,908    52,167    (4,202)
Gain on sale of prepaid investment and derivative   –    2,845    –    2,845 
Net realized and unrealized gain  $101,019   $25,041   $164,347   $99,415 

 

As part of the Company’s acquisition of equity securities in the Life Sciences Portfolio, the Company acquired a majority interest in the equity securities of MalinJ1 (63.9%), which were transferred to the Company on December 3, 2020. The acquisition of the MalinJ1 securities was accounted for as an asset acquisition as there was a change of control of MalinJ1 and substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset, an investment in Viamet Pharmaceuticals Holdings, LLC (“Viamet”). As such, the cost basis of the MalinJ1 securities was used to allocate to the Viamet investment, the single identifiable asset, and no goodwill was recognized. The Company through its consolidation of MalinJ1 accounts for the Viamet investment under the equity method as MalinJ1 owns 41.0% of outstanding shares of Viamet.

 

4. INVESTMENT AT FAIR VALUE

 

During 2016 and 2017, Acacia made certain investments in Veritone. As a result of these transactions, Acacia received an aggregate total of 4,119,521 shares of Veritone common stock and warrants to purchase a total of 1,120,432 shares of Veritone common stock at an exercise price of $13.61 per share expiring between 2020 and 2027. During the nine months ended September 30, 2020, Acacia sold all remaining 298,450 shares Veritone common stock and recorded a realized loss of $3.3 million.

 

During the nine months ended September 30, 2020, Acacia exercised 154,312 warrants, and recognized a realized gain of $554,000 on the sale of common stock. During the nine months ended September 30, 2021, Acacia exercised all remaining 156,720 warrants, and recognized a realized gain of $3.6 million on the sale of common stock. The Company no longer has an investment in Veritone common stock and warrants.

 

Changes in the fair value of Acacia’s investment in Veritone are recorded as unrealized gains or losses in the consolidated statements of operations. For the three and nine months ended September 30, 2021 and 2020, the consolidated statements of operations reflected the following: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Change in fair value of investment, warrants  $–   $(3,081)  $(2,752)  $225 
Change in fair value of investment, common stock   –    –    –    3,479 
Gain on sale of investment, warrants   –    –    3,591    554 
Loss on sale of investment, common stock   –    –    –    (3,316)
Net realized and unrealized (loss) gain  $–   $(3,081)  $839   $942 

 

 

 

 19 

 

 

5. PATENTS, NET OF ACCUMULATED AMORTIZATION

 

Acacia’s only identifiable intangible assets as of September 30, 2021 and December 31, 2020 are patents and patent rights. Patent-related accumulated amortization totaled $291.6 million and $319.9 million as of September 30, 2021 and December 31, 2020, respectively. Acacia’s patents have remaining estimated economic useful lives ranging from twenty-six to fifty-two months. The weighted average remaining estimated economic useful life of Acacia’s patents is approximately four years.

 

The following table presents the scheduled annual aggregate amortization expense as of September 30, 2021: 

   
For the years ending December 31,   
(In thousands)
Remainder of 2021 $2,612 
2022  10,448 
2023  10,381 
2024  9,005 
2025  6,630 
Thereafter  750 
Patents, net   $39,826 

 

For the nine months ended September 30, 2021, Acacia accrued patent and patent rights acquisition costs totaling $13.0 million, of which $8.0 million is due December 1, 2021 and $5.0 million is due February 18, 2023. Such amounts are included in accrued patent investment costs and other long-term liabilities in the consolidated balance sheet as of September 30, 2021, respectively.

 

6. STARBOARD INVESTMENT

 

Series A Redeemable Convertible Preferred Stock 

 

On November 18, 2019, the Company entered into a Securities Purchase Agreement with Starboard Value LP (“Starboard”) and certain funds and accounts affiliated with, or managed by, Starboard (collectively, the “Buyers”) pursuant to which the Company issued (i) 350,000 shares of Series A Redeemable Convertible Preferred Stock with a par value of $0.001 per share and a stated value of $100 per share, and (ii) Series A Warrants to purchase up to 5,000,000 shares of the Company’s common stock to the Buyers. The Securities Purchase Agreement also established the terms of certain senior secured notes and additional Series B Warrants which may be issued to Starboard in the future. On June 4, 2020, the Company entered into a Supplemental Agreement, as defined below under “Senior Secured Notes”, with certain contractual agreements affecting the Series A Redeemable Convertible Preferred Stock, reflected below.

 

The Series A Redeemable Convertible Preferred Stock can be converted into a number of shares of common stock equal to (i) the stated value thereof plus accrued and unpaid dividends, divided by (ii) the conversion price of $3.65 (subject to certain anti-dilution adjustments). Holders may elect to convert the Series A Redeemable Convertible Preferred Stock into common stock at any time. The Company may elect to convert the Series A Redeemable Convertible Preferred Stock into shares of Common Stock any time on or after November 15, 2025, provided that the closing price of the Company’s common stock equals or exceeds 190% of the conversion price for 30 consecutive trading days and assuming certain other conditions of the common stock have been met.

 

Holders have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock during the periods of May 15, 2021 through August 15, 2021 and May 15, 2022 through August 15, 2022, provided that there is not outstanding at least $50.0 million aggregate principal of senior secured notes to the Buyers pursuant to the Securities Purchase Agreement at the time of the redemption. Holders also have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock during the period of November 15, 2024 through February 15, 2025. Additionally, holders have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock upon the occurrence of (i) a change of control or (ii) various other triggering events, such as the suspension from trading or delisting of the Company’s common stock. If the Series A Redeemable Convertible Preferred Stock is redeemed at the option of the holders, the redemption price may include a make-whole amount or a stated premium, depending on the redemption scenario.

 

 

 

 20 

 

 

The Company may redeem all, and not less than all, of the Series A Redeemable Convertible Preferred Stock (i) upon a change of control or (ii) during the period of May 15, 2022 through August 15, 2022, provided that there is not outstanding at least $50.0 million aggregate principal of the senior secured notes at the time of the redemption, and assuming certain conditions of the common stock have been met. If the Series A Redeemable Convertible Preferred Stock is redeemed at the option of the Company, the redemption price would include a make-whole amount or a 15% premium depending on the circumstances.

 

If any Series A Redeemable Convertible Preferred Stock remains outstanding on November 15, 2027, the Company shall redeem such Series A Redeemable Convertible Preferred Stock in cash.

 

In all redemption scenarios, the redemption price for the Series A Redeemable Convertible Preferred Stock includes the stated value plus accrued and unpaid dividends. In addition, depending on the redemption scenario, the redemption price may also include a make-whole amount or stated premium as described above.

 

When the Company issues Notes, the Holder may exchange the Series A Redeemable Convertible Preferred Stock for (i) Notes and (ii) Series B Warrants to purchase common stock.

 

The Series A Redeemable Convertible Preferred Stock accrues cumulative dividends quarterly at annual rate of 3.0% on the stated value. Upon consummation of the approved investment in June 2020, the dividend rate increased to 8.0% on the stated value. Upon certain triggering events, the dividend rate will increase to 7.0% if the triggering event occurs before an approved investment or 10.0% on the stated value if the triggering event occurs after an approved investment. In connection with the approved investment in June 2020, the Company and the Buyers agreed that the dividend rate on the Series A Redeemable Convertible Preferred Stock would accrue at 3.0% so long as no triggering event occurs and the Company maintains $35.0 million in escrow. Series A Redeemable Convertible Preferred Stock also participates on an as-converted basis in any regular or special dividends paid to common stockholders. No accrued and unpaid dividends as of September 30, 2021. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Upon consummation of the approved acquisition in October 2021, the dividend rate increased to 8.0% on the stated value. Refer to Note 11 for additional information related to the subsequent period acquisition.

 

Holders of the Series A Redeemable Convertible Preferred Stock have the right to vote with common stockholders on an as-converted basis on all matters. Holders of Series A Redeemable Convertible Preferred Stock will also be entitled to a separate class vote with respect to amendments to the Company’s organizational documents that generally have an adverse effect on the Series A Redeemable Convertible Preferred Stock.

 

Upon liquidation of the Company, holders of Series A Redeemable Convertible Preferred Stock have a liquidation preference over holders of our common stock and will be entitled to receive, prior to any distribution to holders of our common stock, an amount equal to the greater of (i) the stated value plus accrued and unpaid dividends or (ii) the amount that would have been received if the Series A Redeemable Convertible Preferred Stock had been converted into common stock immediately prior to the liquidation event at the then effective conversion price.

 

The Company determined that certain features of the Series A Redeemable Convertible Preferred Stock should be bifurcated and accounted for as a derivative. Each of these features are bundled together as a single, compound embedded derivative.

 

During 2019, total proceeds received and transaction costs incurred from the issuance of the Series A Redeemable Convertible Preferred Stock amounted to $35.0 million and $1.3 million, respectively. Proceeds received were allocated based on the fair value of the instrument without the Series A Warrants and of the Series A Warrants themselves at the time of issuance. The proceeds allocated to the Series A Redeemable Convertible Preferred Stock were then further allocated between the host preferred stock instrument and the embedded derivative, with the embedded derivative recorded at fair value and the Series A Redeemable Convertible Preferred Stock recorded at the residual amount. The portion of the proceeds allocated to the Series A Warrants, embedded derivative, and Series A Redeemable Convertible Preferred Stock was $4.8 million, $21.2 million, and $8.9 million, respectively. Transaction costs were also allocated between the Series A Redeemable Convertible Preferred Stock and the Series A Warrants on the same basis as the proceeds. The transaction costs allocated to the Series A Redeemable Convertible Preferred Stock were treated as a discount to the Series A Redeemable Convertible Preferred Stock. The transaction costs allocated to the Series A Warrants were expensed as incurred.

 

 

 

 21 

 

 

The Company classifies the Series A Redeemable Convertible Preferred Stock as mezzanine equity as the instrument will become redeemable at the option of the holder in various scenarios or otherwise on November 15, 2027. As it is probable that the Series A Redeemable Convertible Preferred Stock will become redeemable, the Company accretes the instrument to its redemption value using the effective interest method and recognizes any changes against additional paid in capital in the absence of retained earnings. Accretion for the three and nine months ended September 30, 2021 was $991,000 and $2.8 million, respectively.

 

In connection with the issuance of the Series A Redeemable Convertible Preferred Stock, the Company executed a Registration Rights Agreement with Starboard and the Buyers and a Governance Agreement with Starboard and certain affiliates of Starboard. Under the Registration Rights Agreement, the Company agreed to provide certain registration rights with respect to the Series A Redeemable Convertible Preferred Stock and shares of Common Stock issued upon conversion. In accordance with the Governance Agreement, the Company agreed to (i) increase the size of the Board of Directors from six to seven members, (ii) appoint Jonathan Sagal as a director of the Company, (iii) grant Starboard the right to recommend two additional directors for appointment to the board, (iv) form a Strategic Committee of the Board tasked with sourcing and performing due diligence on potential acquisition targets, (v) appoint certain directors to the Strategic Committee, and (vi) appoint a director to the Nominating and Corporate Governance Committee.

 

The following features of the Series A Redeemable Convertible Preferred Stock are required to be bifurcated from the host preferred stock and accounted for separately as an embedded derivative: (i) the right of the holders to redeem the shares (the “put option”), (ii) the right of the holders to receive common stock upon conversion of the shares (the “conversion option”), (iii) the right of the Company to redeem the shares (the “call option”), and (iv) the change in dividend rate upon consummation of an approved investment or a triggering event (the “contingent dividend rate feature”).

 

These features are required to be accounted for separately from the Series A Redeemable Convertible Preferred Stock because the features were determined to be not clearly and closely related to the debt-like host and also did not meet any other scope exceptions for derivative accounting. Therefore, these features are bundled together and are accounted for as a single, compound embedded derivative liability.

 

Accordingly, we have recorded an embedded derivative liability representing the combined fair value of each of these features. The embedded derivative liability is adjusted to reflect fair value at each period end with changes in fair value recorded other income or (expense) in the “Change in fair value of the Series A and B warrants and embedded derivatives” financial statement line item of the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series A embedded derivative liabilities was $41.4 million and $26.7 million, respectively.

 

Series A Warrants

 

On November 18, 2019, in connection with the issuance of the Series A Redeemable Convertible Preferred Stock, the Company issued a detachable Series A Warrants to acquire up to purchase 5 million shares of common stock at a price of $3.65 per share (subject to certain anti-dilution adjustments) at any time during a period of eight years beginning on the instrument’s issuance date of the Series A Warrants. The fair value of the Series A Warrants was $4.8 million upon issuance. The Series A Warrants will be recognized at fair value at each reporting period until exercised, with changes in fair value recognized in other income or (expense) in the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series A Warrants was $18.5 million and $6.6 million, respectively. As of September 30, 2021, the Series A Warrants have not been exercised.

 

The Series A Warrants are classified as a liability in accordance with ASC 480, “Distinguishing Liabilities from Equity”, as the agreement provides for net cash settlement upon a change in control, which is outside the control of the Company.

 

Series B Warrants

 

On February 25, 2020, pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, the Company issued Series B Warrants to purchase up to 100 million shares of the Company’s common stock at an exercise price (subject to certain price-based anti-dilution adjustments) of either (i) $5.25 per share, if exercising by cash payment, within 30 months from the issuance date (i.e., August 25, 2022); or (ii) $3.65 per share, if exercising by cancellation of a portion of Notes. The Company issued the Series B Warrants for an aggregate purchase price of $4.6 million. The Series B Warrants expire on November 15, 2027.

 

 

 

 22 

 

 

In connection with the issuance of the Notes on June 4, 2020, the terms of certain of the Series B Warrants were amended to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration date of November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms. As of September 30, 2021, the Series B Warrants have not been exercised.

 

The Series B Warrants will be recognized at fair value at each reporting period until exercised, with changes in fair value recognized in other income or (expense) in the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series B Warrants was $229.6 million and $52.3 million, respectively.

 

The Series B Warrants are classified as a liability in accordance with ASC 480, “Distinguishing Liabilities from Equity”, as the agreement provides for net cash settlement upon a change in control, which is outside the control of the Company.

 

Senior Secured Notes

 

Pursuant to the Securities Purchase Agreement dated November 18, 2019 with Starboard and the Buyers, on June 4, 2020, the Company issued $115.0 million in Notes to the Buyers. Also on June 4, 2020, in connection with the issuance of the Notes, the Company entered into a Supplemental Agreement with Starboard (the “Supplemental Agreement”), pursuant to which the Company agreed to redeem $80.0 million aggregate principal amount of the Notes by September 30, 2020, and $35.0 million aggregate principal amount of the Notes by December 31, 2020, resulting in the total principal outstanding being paid by December 31, 2020. Per the Supplemental Agreement, interest is payable semiannually at a rate of 6.00% per annum, and in an event of default, the interest rate is increased to 10.00% per annum. The Notes include certain financial and non-financial covenants. Additionally, all or any portion of the principal amount outstanding under the Notes may, at the election of Starboard, be surrendered to the Company for cancellation in payment of the exercise price upon the exercise of Series B Warrants.

 

On June 30, 2020, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with Merton Acquisition HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“Merton”) and Starboard, on behalf of itself and on behalf of certain funds and accounts under its management, including the holders of the Notes. Pursuant to the Exchange Agreement, the holders of the Notes exchanged the entire outstanding principal amount for new senior notes (the “New Notes”) issued by Merton having an aggregate outstanding original principal amount of $115.0 million.

 

The New Notes bear interest at a rate of 6.00% per annum and had a maturity date of December 31, 2020. The New Notes are fully guaranteed by the Company and are secured by an all-assets pledge of the Company and Merton and non-recourse equity pledges of each of the Company’s material subsidiaries. Pursuant to the Exchange Agreement, the New Notes (i) are deemed to be “Notes” for purposes of the Securities Purchase Agreement, (ii) are deemed to be “June 2020 Approved Investment Notes” for purposes of the Supplemental Agreement, and with the Company agreeing to redeem $80 million principal amount of the New Notes by September 30, 2020 and $35 million principal amount of the New Notes by December 31, 2020, and (iii) are deemed to be “Notes” for the purposes of the Series B Warrants, and therefore may be tendered pursuant to a Note Cancellation under the Series B Warrants on the terms set forth in the Series B Warrants and the New Notes. Delivery of notes in the form of the New Notes will also satisfy the delivery of Exchange Notes pursuant to Section 16(i) of the Certificate of Designations of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share. The New Notes will not be deemed to be “Notes” for the purposes of the Registration Rights Agreement, dated as of November 18, 2019, by and among the Company, Starboard and the Buyers.

 

Because the New Notes are to be settled within twelve months pursuant to their terms, they are classified as current liabilities in the consolidated balance sheets. The Company capitalized $4.6 million in lender fees and $0.5 million in other issuance costs associated with the issuance of the Notes. The $4.6 million of lender fees are recognized as long-term deferred debt issuance costs and are included in other non-current assets in the consolidated balance sheets, and will be amortized to interest expense until November 15, 2027, the maturity date of Series A Redeemable Convertible Preferred Stock. The $0.5 million issuance costs are recognized as a discount on the Notes and will be amortized to interest expense over the contractual life of the Notes. There was $3.1 million and $863,000 accrued and unpaid interest on the New Notes as of September 30, 2021 and December 31, 2020, respectively.

 

On January 29, 2021, the Company redeemed $50.0 million of the New Notes and on March 31, 2021, the Company reissued $50.0 million of the New Notes. On June 30, 2021, the Company issued $30.0 million in additional New Notes (the “June 2021 Merton Notes”) and amended the maturity date of the New Notes to October 15, 2021. On September 30, 2021, the Company issued $35.0 million in additional New Notes (the “September 2021 Merton Notes”) and amended the maturity date of the New Notes to December 1, 2021. The June and September 2021 Merton Notes cannot be used to exercise Series B Warrants issued to Starboard Value. The total principal amount outstanding of New Notes as of September 30, 2021 and December 31, 2020 was $180.0 million and $115.0 million, respectively.

 

 

 

 23 

 

 

Modifications to Series A Redeemable Convertible Preferred Stock and Series B Warrants

 

The June 4, 2020 Supplemental Agreement also provided for (i) a waiver of increased dividends under the original terms of the Series A Redeemable Convertible Preferred Stock that would have otherwise accrued due to the Company’s use of the $35.0 million proceeds received from Starboard and the Buyers upon the issuance of the Series A Redeemable Convertible Preferred Stock in November 2019, (ii) the replacement of original optional redemption rights for the Series A Redeemable Convertible Preferred Stock provided to both the Company and the holders that otherwise would have been nullified through the issuance of the Notes, and (iii) an amendment to the terms of the previously issued Series B Warrants to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration of the Series B Warrants on November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms.

 

We analyzed the amendments to the terms of the Series A Redeemable Convertible Preferred Stock and determined that the amendments were not significant. Therefore, the amendments are accounted for as a modification on a prospective basis.

 

The incremental fair value of the Series B Warrants associated with the modification of their terms in connection with the issuance of the Notes was $1.3 million and is recognized as a discount on the Notes and will be amortized to interest expense over the contractual life of the Notes. As of September 30, 2021, $1.2 million was amortized to interest expense and $151,000 is remaining to be amortized until the maturity date of December 1, 2021.

 

7. FAIR VALUE MEASUREMENTS

 

U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:

 

(i) Level 1 - Observable Inputs:  Quoted prices in active markets for identical investments;

 

(ii) Level 2 - Pricing Models with Significant Observable Inputs:  Other significant observable inputs, including quoted prices for similar investments, interest rates, credit risk, etc.; and

 

(iii) Level 3 - Unobservable Inputs:  Unobservable inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entity’s own assumptions in determining the fair value of derivatives and certain investments.

 

Whenever possible, the Company is required to use observable market inputs (Level 1 - quoted market prices) when measuring fair value. In such cases, the level at which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input requires judgment and considers factors specific to the asset or liability being measured. In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy.

 

Acacia holds the following types of financial instruments at September 30, 2021 and December 31, 2020:

 

Equity Securities at Fair Value. Equity securities includes investments in public company common stock and are recorded at fair value based on the quoted market price of each share on the valuation date. The fair value of these securities are within Level 1 of the valuation hierarchy. Equity investments that do not have regular market pricing, but for which fair value can be determined based on other data values or market prices, are recorded at fair value within Level 2 of the valuation hierarchy. At September 30, 2021, our Level 2 equity securities include an investment measured with an applied pricing model that includes significant observable inputs to the public company common stock value. The fair value of the Level 2 equity securities investment as of September 30, 2021 was estimated based on a discount of 7.5 percent determined using the following significant inputs to the pricing model: expected term of restriction of 6 months and volatility of approximately 45 percent.

 

 

 24 

 

 

Investments at Fair Value - Common Stock and Warrants. Acacia’s equity investment in Veritone common stock was recorded at fair value based on the quoted market price of Veritone’s common stock on the applicable valuation date (Level 1). Warrants were recorded at fair value, as based on the Black-Scholes option-pricing model (Level 2). Refer to Note 4 for additional information.

 

Series A Warrants. Series A Warrants are recorded at fair value, using Black-Scholes option-pricing model (Level 3). In the quarter ended March 31, 2021, there was a change in estimate with regard to the calculation of the volatility assumption used in the Black Scholes option-pricing model. As a result, the Series A Warrants are now measured as Level 3 as opposed to Level 2 as measured previously. The fair value of the Series A Warrants as of September 30, 2021 was estimated based on the following significant assumptions: volatility of 30 percent, risk-free rate of 1.16 percent, term of 6.04 years and a dividend yield of 0 percent. 

 

Series B Warrants. Series B Warrants are recorded at fair value, using Black-Scholes option-pricing model (Level 3). In the quarter ended March 31, 2021, there was a change in methodology used to an acceptable Black-Scholes option-pricing model from a Monte Carlo valuation technique used to value the Series B Warrants as of December 31, 2020. The fair value of the Series B Warrants as of September 30, 2021 was estimated based on the following significant assumptions: (1) volatility of 30 percent, risk-free rate of 1.17 percent, term of 6.13 years and a dividend yield of 0 percent, and (2) volatility of 25 percent, risk-free rate of 0.08 percent, term of 0.90 years and a dividend yield of 0 percent.

 

Embedded Derivative Liability. Embedded derivatives that are required to be bifurcated from their host contract are evaluated and valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019 (Level 3). The binomial model utilizes the Tsiveriotis and Fernandes implementation in which a convertible instrument is split into two separate components within a single lattice framework: a cash-only component which is subject to the selected risk-adjusted discount rate and an equity component which is subject only to the risk-free rate. The model considers the (i) implied volatility of the value of our common stock, (ii) appropriate risk-free interest rate, (iii) credit spread, (iv) dividend yield, (v) dividend accrual (and a step-up in rates), and (vi) event probabilities of the various conversion and redemption scenarios.

 

The volatility of the Company’s common stock is estimated by analyzing the Company’s historical volatility, implied volatility of publicly traded stock options, and the Company’s current asset composition and financial leverage. The selected volatility, as described below, represents a haircut from the Company’s actual realized historical volatility. A volatility haircut is a concept used to describe a commonly observed occurrence in which the volatility implied by market prices involving options, warrants, and convertible debt is lower than historical actual realized volatility. The assumed base case term used in the valuation model is the period remaining until November 15, 2027, the Series A Redeemable Convertible Preferred Stock maturity date. The risk-free interest rate is based on the yield on the U.S. Treasury with a remaining term equal to the expected term of the conversion and early redemption options. The significant assumptions utilized in the Company’s valuation of the embedded derivative at September 30, 2021 are as follows: volatility of 30 percent, risk-free rate of 1.20 percent, term of 6.13 years, discount rate of 9.40 percent and a dividend yield of 0 percent. The fair value measurement of the embedded derivative is sensitive to these assumptions and changes in these assumptions could result in a materially different fair value measurement.

 

 

 

 25 

 

 

Financial assets and liabilities measured at fair value on a recurring basis were as follows: 

                    
   Level 1   Level 2   Level 3   Total 
Assets  (In thousands) 
September 30, 2021:                
Equity securities at fair value  $119,280   $267,840   $–   $387,120 
Total  $119,280   $267,840   $–   $387,120 
                     
December 31, 2020:                    
Equity securities at fair value  $109,103   $–   $–   $109,103 
Investment at fair value - warrants   –    2,752    –    2,752 
Total  $109,103   $2,752   $–   $111,855 
                     
Liabilities                    
September 30, 2021:                    
Series A warrants  $–   $–   $18,527   $18,527 
Series A embedded derivative liabilities   –    –    41,411    41,411 
Series B warrants   –    –    229,637    229,637 
Total  $–   $–   $289,575   $289,575 
                     
December 31, 2020:                    
Series A warrants  $–   $6,640   $–   $6,640 
Series A embedded derivative liabilities   –    –    26,728    26,728 
Series B warrants   –    –    52,341    52,341 
Total  $–   $6,640   $79,069   $85,709 

 

The following tables set forth a summary of the changes in the estimated fair value of the Company’s Level 3 liabilities, which are measured at fair value on a recurring basis: 

                    
   Series A
Warrant
Liability		   Series A
Embedded
Derivative
Liability		   Series B
Warrant
Liability		   Total 
   (In thousands) 
                 
Balance at January 1, 2021  $–   $26,728   $52,341   $79,069 
Transfers to Level 3
   6,640    –    –    6,640 
Remeasurement to fair value   11,824    14,463    178,198    204,485 
Balance at June 30, 2021   18,464    41,191    230,539    290,194 
Remeasurement to fair value   63    220    (902)    (619) 
Balance at September 30, 2021  $18,527   $41,411   $229,637   $289,575 

 

   Series A
Warrant
Liability		   Series A
Embedded
Derivative
Liability		   Series B
Warrant
Liability		   Total 
   (In thousands) 
                 
Balance at January 1, 2020  $3,568   $17,974   $–   $21,542 
Transfers to Level 3
   –    –    5,929    5,929 
Remeasurement to fair value   3,384    11,539    52,361    67,284 
Balance at June 30, 2020   6,952    29,513    58,290    94,755 
Remeasurement to fair value   (1,348)   (3,831)   (15,493)    (20,672) 
Balance at September 30, 2020  $5,604   $25,682   $42,797   $74,083 

 

In accordance with U.S. GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of equity securities without readily determinable fair value, equity method investments and patents on a quarterly basis for indications of impairment, and other long-lived assets at least annually. When indications of potential impairment are identified, the Company may be required to determine the fair value of those assets and record an adjustment for the carrying amount in excess of the fair value determined. Any fair value determination would be based on valuation approaches, which are appropriate under the circumstances and utilize Level 2 and Level 3 measurements as required.

 

 

 

 26 
 

 

 

8. COMMITMENTS AND CONTINGENCIES

 

Facility Leases

 

The Company primarily leases office facilities under operating lease arrangements that will end in various years through July 2024.

 

On June 7, 2019, we entered into a building lease agreement (the “New Lease”) with Jamboree Center 4 LLC (the “Landlord”). Pursuant to the New Lease, we have leased approximately 8,293 square feet of office space in Irvine, California. The New Lease commenced on August 1, 2019. The term of the New Lease is 60 months from the commencement date, provides for annual rent increases, and does not provide us the right to early terminate or extend our lease terms.

  

On January 7, 2020, we entered into a building lease agreement (the “New York Office Lease”) with Sage Realty Corporation (the “New York Office Landlord”). Pursuant to the New York Office Lease, we have leased approximately 4,000 square feet of office space for our corporate headquarters in New York, New York. The New York Office Lease commenced on February 1, 2020. The term of the New York Office Lease is 24 months from the commencement date, provides for annual rent increases, and does not provide us the right to early terminate or extend our lease terms. During August 2021, we entered into a first amendment of the New York Office Lease, to commence for a period of three years upon landlords’ substantial completion of adequate substitution space, as defined. To date, the substitution space is not ready for use, accordingly the term extension has not begun.

 

Operating lease costs were $155,000 and $174,000 for the three months ended September 30, 2021 and 2020, respectively, and $457,000 and $459,000 for the nine months ended September 30, 2021 and 2020, respectively.

 

The table below presents aggregate future minimum payments due under the New Lease and the New York Office Lease discussed above, reconciled to long-term lease liabilities and short-term lease liabilities (included in accrued expenses and other current liabilities) included in the consolidated balance sheet as of September 30, 2021:

     
   Operating Leases 
   (In thousands) 
Remainder of 2021  $149 
2022   370 
2023   364 
2024   218 
Thereafter   – 
Total minimum payments   1,101 
Less: short-term lease liabilities   (430)
Long-term lease liabilities  $671 

 

 

 27 

 

 

Inventor Royalties and Contingent Legal Expenses

 

In connection with the investment in certain patents and patent rights, certain of Acacia’s operating subsidiaries executed related agreements which grant to the former owners of the respective patents or patent rights, the right to receive inventor royalties based on future net revenues (as defined in the respective agreements) generated as a result of licensing and otherwise enforcing the respective patents or patent portfolios.

 

Acacia’s operating subsidiaries may retain the services of law firms that specialize in patent licensing and enforcement and patent law in connection with their licensing and enforcement activities. These law firms may be retained on a contingent fee basis whereby such law firms are paid on a scaled percentage of any negotiated fees, settlements or judgments awarded based on how and when the fees, settlements or judgments are obtained.

 

Patent Enforcement

 

Certain of Acacia’s operating subsidiaries are often required to engage in litigation to enforce their patents and patent rights. In connection with any of Acacia’s operating subsidiaries’ patent enforcement actions, it is possible that a defendant may request and/or a court may rule that an operating subsidiary has violated statutory authority, regulatory authority, federal rules, local court rules, or governing standards relating to the substantive or procedural aspects of such enforcement actions. In such event, a court may issue monetary sanctions against Acacia or its operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material.

 

Acacia is subject to claims, counterclaims and legal actions that arise in the ordinary course of business. Management believes that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on Acacia’s consolidated financial position, results of operations or cash flows.

 

In December 2017, the Federal Court of Canada allowed a counterclaim for invalidity of a patent asserted by Rapid Completions LLC and awarded costs payable by Rapid Completions LLC in amounts that are included in the 2021 and 2020 accrual balances discussed below. During the three months ended September 30, 2021, the Company made approximately $1.0 million in settlement payments.

 

On September 6, 2019, Slingshot Technologies, LLC, or Slingshot, filed a lawsuit in Delaware Chancery Court against the Company and Acacia Research Group, LLC, or collectively, the Acacia Entities, Monarch Networking Solutions LLC (“Monarch”), Acacia board member Katharine Wolanyk, and Transpacific IP Group, Ltd., or Transpacific. Slingshot alleges that the Acacia Entities and Monarch misappropriated its confidential and proprietary information, purportedly furnished to the Acacia Entities and Monarch by Ms. Wolanyk, in acquiring a patent portfolio from Transpacific after Slingshot’s exclusive option to purchase the same patent portfolio from Transpacific had already expired. Slingshot seeks monetary damages, as well as equitable and injunctive relief related to its alleged right to own the portfolio. On March 15, 2021, the court issued orders granting Monarch’s motion to dismiss for lack of personal jurisdiction and Ms. Wolanyk’s motion to dismiss for lack of subject matter jurisdiction. The remaining parties then commenced discovery, and have since served initial written requests and responses, and notices of the depositions of the parties’ corporate designees. The Acacia Entities maintain that Slingshot’s allegations are baseless, that the Acacia Entities neither had access to nor used Slingshot’s information in acquiring the portfolio, that the Acacia Entities acquired the portfolio as a result of the independent efforts of its IP licensing group, and that Slingshot suffered no damages given its exclusive option to purchase the portfolio had already ended and it has proven itself incapable of closing on the portfolio purchase.

 

During the three months ended September 30, 2021 and 2020, there were no operating expenses related to settlement and contingency accruals. During the nine months ended September 30, 2021, we incurred $338,000 in operating expenses for settlement and contingency accruals. During the nine months ended September 30, 2020, operating expenses included a net income for settlement offset by contingency accruals totaling $308,000, net of prior accruals. At September 30, 2021 and December 31, 2020, our contingency accrual balance was $587,000 and $1.3 million, respectively.

 

 

 

 28 

 

 

9. STOCKHOLDERS’ EQUITY

 

Repurchases of Common Stock

 

On August 5, 2019, Acacia’s Board of Directors approved a stock repurchase program, which authorized the purchase of up to $10.0 million of the Company’s common stock through open market purchases, through block trades, through 10b5-1 plans, or by means of private purchases, from time to time, through July 31, 2020. Stock repurchases for the periods presented, all of which were purchased as part of a publicly announced plan or program, were as follows: 

                  
   Total Number
of Shares
Purchased		   Average
Price
paid per
Share		   Approximate
Dollar
Value of Shares
that
May Yet be
Purchased
under the
Program		   Plan Expiration Date
                
March 20, 2020 - March 31, 2020   576,898   $2.28   $8,686,000   July 31, 2020
April 1, 2020 - April 23, 2020   1,107,639   $2.42   $6,001,000   July 31, 2020
Total repurchases in 2020   1,684,537   $2.37         

 

In determining whether or not to repurchase any shares of Acacia’s common stock, Acacia’s Board of Directors consider such factors, among others, as the impact of the repurchase on Acacia’s cash position, as well as Acacia’s capital needs and whether there is a better alternative use of Acacia’s capital. Acacia has no obligation to repurchase any amount of its common stock under the Stock Repurchase Program. Repurchases to date were made in the open market in compliance with applicable SEC rules. The authorization to repurchase shares presented an opportunity to reduce the outstanding share count and enhance stockholder value. 

 

Tax Benefits Preservation Plan

 

On March 12, 2019, Acacia’s Board of Directors announced that it had unanimously approved the adoption of a Tax Benefits Preservation Plan (the “Plan”). Our stockholders ratified the adoption of the Plan in July 2019. The purpose of the Plan is to protect the Company’s ability to utilize potential tax assets, such as net operating loss carryforwards and tax credits to offset potential future taxable income.

 

The Plan is designed to reduce the likelihood that the Company will experience an ownership change by discouraging (i) any person or group from acquiring beneficial ownership of 4.9% or more of the Company’s outstanding common stock and (ii) any existing stockholders who, as of the time of the first public announcement of the adoption of the Plan, beneficially own more than 4.9% of the Company’s then-outstanding shares of the Company’s common stock from acquiring additional shares of the Company’s common stock (subject to certain exceptions). There is no guarantee, however, that the Plan will prevent the Company from experiencing an ownership change.

 

In connection with the adoption of the Plan, Acacia’s Board of Directors authorized and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on March 16, 2019. On or after the distribution date, each right would initially entitle the holder to purchase one one-thousandth of a share of the Company’s Series B Junior Participating Preferred Stock, $0.001 par value for a purchase price of $12.00. On March 15, 2021 the rights expired pursuant to their terms.

 

The Company has a provision in its Amended and Restated Certificate of Incorporation, as amended (the “Charter Provision”) which generally prohibits transfers of its common stock that could result in an ownership change. Like the Plan, the purpose of the Charter Provision is to protect the Company’s ability to utilize potential tax assets, such as net operating loss carryforwards and tax credits to offset potential future taxable income. The Charter Provision was approved by the Company’s stockholders on July 15, 2019.

  

 

 

 29 

 

 

10. INCOME/LOSS PER SHARE

 

The following table presents the shares of common stock outstanding used in the calculation of basic and diluted net income (loss) per share: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands, except share and per share information) 
Numerator:                
Net income (loss) attributable to Acacia Research Corporation  $89,604   $38,348   $(55,507)  $33,205 
Dividend on Series A redeemable convertible preferred stock   (262)   (467)   (785)   (1,118)
Accretion of Series A redeemable convertible preferred stock   (991)   (733)   (2,762)   (2,045)
Undistributed earnings allocated to participating securities   (15,367)   (6,619)   –    (5,204)
Net income (loss) attributable to common stockholders - Basic   72,984    30,529    (59,054)   24,838 
                     
Add: Dividend on Series A redeemable convertible preferred stock   –    467    –    – 
Add: Accretion of Series A redeemable convertible preferred stock   –    733    –    – 
Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative   –    (3,831)   –    – 
Less: Change in fair value of Series A warrants   63    (1,348)   –    (1,348)
Less: Change in fair value of dilutive Series B warrants   (902)   (5,557)   –    (5,557)
Add: Interest expense associated with Starboard Notes, net of tax   1,536    1,889    –    1,889 
Add: Undistributed earnings allocated to participating securities   15,367    6,619    –    5,204 
Reallocation of undistributed earnings to participating securities   (8,877)   (296)   –    (3,645)
Net income (loss) attributable to common stockholders - Diluted  $80,171   $29,205   $(59,054)  $21,381 
                     
Denominator:                    
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic   48,949,504    48,467,885    48,759,873    48,949,706 
Potentially dilutive common shares:                    
Series A Preferred Stock   –    9,589,041    –    – 
Restricted stock   798,356    728,936    –    598,328 
Stock options   35,815    21,624    –    – 
Series A Warrants   2,019,724    310,367    –    103,456 
Series B Warrants   41,278,103    31,506,849    –    10,502,283 
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted   93,081,502    90,624,702    48,759,873    60,153,773 
                     
Basic net income (loss) per common share  $1.49   $0.63   $(1.21)  $0.51 
Diluted net income (loss) per common share  $0.86   $0.32   $(1.21)  $0.36 
                     
Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:                    
Equity-based incentive awards   398,168    191,312    2,230,624    310,083 
Series A warrants   –    –    5,000,000    – 
Series B warrants   –    68,493,151    100,000,000    68,493,151 
Total   398,168    68,684,463    107,230,624    68,803,234 

 

11. SUBSEQUENT EVENT

 

On October 8, 2021, the Company acquired all of the outstanding stock of a leading printing technology company, for a cash purchase price of $37.0 million, which includes an initial $33.0 million cash payment and a $4.0 million working capital adjustment. The business services a diverse group of customers that operate across healthcare, food and beverage, manufacturing and logistics, and other sectors. The acquisition triggered the release of $35.0 million held in escrow (refer to Note 2 “Long-Term Restricted Cash” for additional information).

 

 


 30 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

 

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and the related notes included in Part I, Item1 of this Quarterly Report on Form10-Q for the three and nine months ended September 30, 2021, or this Report. This discussion and analysis contains forward-looking statements that are based on our current expectations and reflect our plans, estimates and anticipated future financial performance. See the section of this Report entitled “Cautionary Statement Regarding Forward-Looking Statements” for additional information. These statements involve numerous risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those set forth in “Risk Factors” in Part II, Item1A. of this Report.

 

General

 

Acacia Research Corporation (the “Company,” “we,” “us,” or “our”) acquires businesses and operating assets that we believe to be undervalued and where we believe we can leverage our resources and skill sets to realize and unlock value. We leverage our (i) access to flexible capital that can be deployed unconditionally, (ii) expertise in corporate governance and operational restructuring, (iii) willingness to invest in out of favor industries and businesses that suffer from a complexity discount and untangle complex, multi-factor situations, and (iv) expertise and relationships in certain sectors, to complete strategic acquisitions of businesses, divisions, and/or assets with a focus on mature technology, healthcare, industrial and certain financial segments. We seek to identify opportunities where we believe we are advantaged buyers, where we can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to our unique capabilities, relationships, or expertise, or where we believe the target would be worth more to us than to other buyers.

 

We operate our business based on three key principles of People, Process and Performance and have built a management team with identified expertise in Research, Execution and Operation of our targeted acquisitions.

 

We utilized these skill sets and resources to acquire a portfolio of equity securities of public and private life science businesses, or the “Life Sciences Portfolio”, in June 2020. As of September 30, 2021, we have monetized a portion of the portfolio while retaining an interest in a number of operating businesses, including a controlling interest in one of the companies in the portfolio. Further, some of the businesses in which we continue to hold an interest generate revenues through the receipt of royalties.

 

We also operate our legacy business of investing in intellectual property, or IP, and related absolute return assets and engaging in the licensing and enforcement of patented technologies. We partner with inventors and patent owners, from small entities to large corporations, applying our legal and technology expertise to patent assets to unlock the financial value in their patented inventions. We are an intermediary in the patent marketplace, bridging the gap between invention and application, and facilitating efficiency in connection with the monetization of patent assets.

 

We generate revenues and related cash flows from the granting of IP rights for the use of patented technologies that our operating subsidiaries control or own. We assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. Currently, on a consolidated basis, our operating subsidiaries own or control the rights to multiple patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a variety of industries.

 

We have established a proven track record of licensing and enforcement success with over 1,600 license agreements executed to date, across nearly 200 patent portfolio licensing and enforcement programs. To date, we have generated gross licensing revenue of approximately $1.7 billion, and have returned $828.7 million to our patent partners.

 

 

 

 31 

 

 

COVID-19 Pandemic

 

The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. While the Company does not expect the current situation to present direct risks to its business, and it has not had a material impact to date, the COVID-19 pandemic could adversely impact the Company’s operations, as well as the operations of its licensees and other business partners. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, results of operations and financial condition.

 

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. The CARES Act has not had a material impact on the Company’s income tax provision.

 

On December 27, 2020, the President of the United States signed the Consolidated Appropriations Act, 2021 (“Consolidated Appropriations Act”) into law. The Consolidated Appropriations Act is intended to enhance and expand certain provisions of the CARES Act, allows for the deductions of expenses related to the Payroll Protection Program funds received by companies, and provides an update to meals and entertainment expensing for 2021. The Consolidated Appropriations Act did not have a material impact to the Company’s income tax provision for 2020. The Company will continue to evaluate the impact of the Consolidated Appropriations Act on its financial position, results of operations and cash flows, if any.

 

On March 11, 2021 the United States enacted the American Rescue Plan Act of 2021. This Act includes various income and payroll tax measures. The Company does not expect a material impact of the American Rescue Plan on its consolidated financial statements and related disclosures.

 

Executive Summary

 

Overview

 

Our operating activities during the periods presented were focused on the continued operation of our patent licensing and enforcement business, including the continued pursuit of our ongoing patent licensing and enforcement programs.

  

Patent Licensing and Enforcement

 

  - Patent Litigation Trial Dates and Related Trials

 

As of the date of this report, our operating subsidiaries have nine pending patent infringement cases with scheduled trial dates in the next twelve months. Patent infringement trials are components of our overall patent licensing process and are one of many factors that contribute to possible future revenue generating opportunities for us. Scheduled trial dates, as promulgated by the respective court, merely provide an indication of when, in future periods, the trials may occur according to the court’s scheduling calendar at a specific point in time. A court may change previously scheduled trial dates. In fact, courts often reschedule trial dates for various reasons that are unrelated to the underlying patent assets and typically for reasons that are beyond our control. While scheduled trial dates provide an indication of the timing of possible future revenue generating opportunities for us, the trials themselves and the immediately preceding periods represent the possible future revenue generating opportunities. These future opportunities can result in varying outcomes. In fact, it is difficult to predict the outcome of patent enforcement litigation at the trial level and outcomes can be unfavorable. It can be difficult to understand complex patented technologies, and as a result, this may lead to a higher rate of unfavorable litigation outcomes. Moreover, in the event of a favorable outcome, there is, in our experience, a higher rate of successful appeals in patent enforcement litigation than more standard business litigation. Such appeals are expensive and time consuming, resulting in increased costs and a potential for delayed or foregone revenue opportunities in the event of modification or reversal of favorable outcomes. Although we diligently pursue enforcement litigation, we cannot predict with reliability the decisions made by juries and trial courts. Please refer to Part II, Item 1A. “Risk Factors” for additional information regarding trials, patent litigation and related risks.

 

 

 

 32 

 

 

  - Litigation and Licensing Expense

 

We expect patent-related legal expenses to continue to fluctuate from period to period based on the factors summarized herein, in connection with future trial dates, international enforcement, strategic patent portfolio prosecution and our current and future patent portfolio investment, prosecution, licensing and enforcement activities. The pursuit of enforcement actions in connection with our licensing and enforcement programs can involve certain risks and uncertainties, including the following:

 

  · Increases in patent-related legal expenses associated with patent infringement litigation, including, but not limited to, increases in costs billed by outside legal counsel for discovery, depositions, economic analyses, damages assessments, expert witnesses and other consultants, re-exam and inter partes review costs, case-related audio/video presentations and other litigation support and administrative costs, could increase our operating costs and decrease our profit generating opportunities;

 

  · Our patented technologies and enforcement actions are complex and, as a result, we may be required to appeal adverse decisions by trial courts in order to successfully enforce our patents. Moreover, such appeals may not be successful;

 

  · New legislation, regulations or rules related to enforcement actions, including any fee or cost shifting provisions, could significantly increase our operating costs and decrease our profit generating opportunities. Increased focus on the growing number of patent-related lawsuits may result in legislative changes which increase our costs and related risks of asserting patent enforcement actions;

 

  · Courts may rule that our subsidiaries have violated certain statutory, regulatory, federal, local or governing rules or standards by pursuing such enforcement actions, which may expose us and our operating subsidiaries to material liabilities, which could harm our operating results and our financial position;

 

  · The complexity of negotiations and potential magnitude of exposure for potential infringers associated with higher quality patent portfolios may lead to increased intervals of time between the filing of litigation and potential revenue events (i.e., markman dates, trial dates), which may lead to increased legal expenses, consistent with the higher revenue potential of such portfolios; and

 

  · Fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above could harm our operating results and our financial position.

 

Investments in Patent Portfolios

 

With respect to our licensing, enforcement and overall business, neither we nor our operating subsidiaries invent new technologies or products; rather, we depend upon the identification and investment in patents, inventions and companies that own IP through our relationships with inventors, universities, research institutions, technology companies and others. If our operating subsidiaries are unable to maintain those relationships and identify and grow new relationships, then we may not be able to identify new technology-based patent opportunities for sustainable revenue and /or revenue growth.

 

Our current or future relationships may not provide the volume or quality of technologies necessary to sustain our licensing, enforcement and overall business. In some cases, universities and other technology sources compete against us as they seek to develop and commercialize technologies. Universities may receive financing for basic research in exchange for the exclusive right to commercialize resulting inventions. These and other strategies employed by potential partners may reduce the number of technology sources and potential clients to whom we can market our solutions. If we are unable to maintain current relationships and sources of technology or to secure new relationships and sources of technology, such inability may have a material adverse effect on our revenues, operating results, financial condition and ability to maintain our licensing and enforcement business.

 

 

 

 33 

 

 

Patent Portfolio Intake

 

One of the significant challenges in our industry continues to be quality patent intake due to the challenges and complexity associated with the current patent environment.

 

During the nine months ended September 30, 2021, we acquired one new patent portfolio consisting of Wi-Fi 6 standard essential patents. The patents and patent rights acquired during the nine months ended September 30, 2021 have estimated economic useful lives of approximately five years. In fiscal year 2020, we acquired five patent portfolios.

 

Starboard Securities

 

In 2019, as part of its strategy to grow, the Company began evaluating a wide range of strategic opportunities that culminated in the strategic investment in the Company by certain funds and accounts, or the Buyers, affiliated with, or managed by, Starboard Value LP, or Starboard. On November 18, 2019, the Company entered into a Securities Purchase Agreement with Starboard and the Buyers, or the Securities Purchase Agreement, pursuant to which the Buyers purchased (i) 350,000 shares of the Company’s newly designated Series A Convertible Preferred Stock, or Series A Preferred Stock, at an aggregate purchase price of $35.0 million, and warrants to purchase up to 5 million shares of the Company’s common stock, or Series A Warrants. The Securities Purchase Agreements also established the terms of certain senior secured notes, or Notes, and additional warrants, or the Series B Warrants, which may be issued to the Buyers in the future. Refer to Notes 2 and 6 to the consolidated financial statements elsewhere herein for additional information related to the Series A Preferred Stock, Series A Warrants and Series B Warrants. In connection with the Buyer’s investment, Starboard was granted certain corporate governance rights, including the right to appoint Jonathan Sagal, Managing Director of Starboard, as a director of the Company and recommend two additional directors for appointment to our Board of Directors. The investment by the Buyers is referred to herein as the “Starboard Investment,” and the Series A Preferred Stock, Series A Warrants and Series B Warrants are referred to herein as, collectively, the “Starboard Securities.”

 

On February 14, 2020, the Company’s stockholders approved, for purposes of Nasdaq Rules 5635(b) and 5635(d), as applicable, (i) the voting of the Series A Preferred Stock on an as-converted basis and (ii) the issuance of the maximum number of shares of common stock issuable in connection with the potential future (A) conversion of the Series A Preferred Stock and (B) exercise of the Series A and Series B Warrants, in each case, without giving effect to the exchange cap set forth in the Series A Preferred Stock Certificate of Designations and in the Series A Warrants, issued pursuant to the Securities Purchase Agreement dated November 18, 2019. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information. The Company’s stockholders also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock by 200 million shares, from 100 million shares to 300 million shares.

 

On February 25, 2020, pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, the Company issued Series B Warrants to purchase up to 100 million shares of the Company’s common stock at an exercise price of either (i) $5.25 per share, if exercising by cash payment, or (ii) $3.65 per share, if exercising by cancellation of a portion of Notes. The Company issued the Series B Warrants for an aggregate purchase price of $4.6 million. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information.

 

Pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, on June 4, 2020, the Company issued $115.0 million in Notes to the Buyers. Also on June 4, 2020, in connection with the issuance of the Notes, the Company entered into a Supplemental Agreement with Starboard, or the Supplemental Agreement, through which, the Company agreed to redeem $80.0 million aggregate principal amount of the Notes by September 30, 2020, and $35.0 million aggregate principal amount of the Notes by December 31, 2020, resulting in the total principal outstanding being paid by December 31, 2020. Per the Supplemental Agreement, interest is payable semiannually at a rate of 6.00% per annum, and in an event of default, the interest rate is increased to 10.00% per annum. The Notes outlined certain financial and non-financial covenants. Additionally, all or any portion of the principal amount outstanding under the Notes may, at the election of the holders, be surrendered to the Company for cancellation in payment of the exercise price upon the exercise of the Series B Warrants.

 

 

 

 34 

 

 

On June 30, 2020, the Company entered into an Exchange Agreement, or the Exchange Agreement, with Merton Acquisition HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, or Merton, and Starboard, on behalf of itself and on behalf of the Buyers, including the holders of the Notes. Pursuant to the Exchange Agreement, the holders of the Notes exchanged the entire outstanding principal amount of the Notes for new senior notes, or the New Notes, issued by Merton and having an aggregate outstanding original principal amount of $115.0 million. The New Notes bear interest at a rate of 6.00% per annum and had a maturity date of December 31, 2020. The New Notes are fully guaranteed by the Company and are secured by an all-assets pledge of the Company and Merton and non-recourse equity pledges of each of the Company’s material subsidiaries. Pursuant to the Exchange Agreement, the New Notes (i) are deemed to be “Notes” for purposes of the Securities Purchase Agreement, (ii) are deemed to be “June 2020 Approved Investment Notes” for purposes of the Supplemental Agreement, and with the Company agreeing to redeem $80.0 million principal amount of the New Notes by September 30, 2020 and $35.0 million principal amount of the New Notes by December 31, 2020, and (iii) are deemed to be “Notes” for the purposes of the Series B Warrants, and therefore may be tendered pursuant to a Note Cancellation under the Series B Warrants on the terms set forth in the Series B Warrants and the New Notes. Delivery of notes in the form of the New Notes will satisfy the delivery of Exchange Notes pursuant to Section 16(i) of the Certificate of Designations of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share. The New Notes will not be deemed to be “Notes” for the purposes of the Registration Rights Agreement, dated as of November 18, 2019, by and between the Company, Starboard and the Buyers.

 

On January 29, 2021, the Company redeemed $50.0 million of the New Notes and on March 31, 2021, the Company reissued $50.0 million of the New Notes. On June 30, 2021, the Company issued $30.0 million in additional New Notes (the “June 2021 Merton Notes”) and amended the maturity date of the New Notes to October 15, 2021. On September 30, 2021, the Company issued $35.0 million in additional New Notes (the “September 2021 Merton Notes”) and amended the maturity date of the New Notes to December 1, 2021. The June and September 2021 Merton Notes cannot be used to exercise Series B Warrants issued to Starboard Value. The total principal amount outstanding of New Notes as of September 30, 2021 and December 31, 2020 was $180.0 million and $115.0 million, respectively. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information.

 

Equity Securities Portfolio Investment

 

On April 3, 2020, the Company entered into an Option Agreement with Seller to purchase equity securities in the Life Sciences Portfolio, for an aggregate purchase price of £223.9 million, approximately $277.5 million at the exchange rate on April 3, 2020.

 

On June 4, 2020, the Company executed the Transaction Agreement between Link Fund Solutions Limited, or Link, Seller, and the Company. Pursuant to the Transaction Agreement, the Company will purchase from Seller and Seller will transfer to the Company the specified equity securities of all companies in the Life Sciences Portfolio at set prices at various future dates. In accordance with the Transaction Agreement, the Company transferred the total purchase price of £223.9 million into an escrow account. Upon the transfer of equity securities in the Life Sciences Portfolio to the Company, the associated funds were released from the escrow account to Seller based on the consideration amount assigned to the equity securities for such Life Sciences Portfolio company in the Transaction Agreement. As of December 31, 2020, all of the equity securities in the Life Sciences Portfolio were transferred to the Company pursuant to the Transaction Agreement. Refer to Note 3 to the consolidated financial statements elsewhere herein for additional information.

 

Operating Activities

 

Our revenues historically have fluctuated quarterly, and can vary significantly, based on a number of factors including the following:

 

  · the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee;

  

  · the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments;

  

  · fluctuations in the total number of agreements executed each period;

  

 

 

 35 

 

 

  · the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs;

  

  · the relative maturity of licensing programs during the applicable periods;  

 

  · other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors;

  

  · the willingness of prospective licensees to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as such infringement cases approached a court determined trial date; and

 

  · fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above.

 

Our management does not attempt to manage for smooth sequential periodic growth in revenues from period to period, and therefore, periodic results can be uneven. Unlike most operating businesses and industries, licensing revenues not generated in a current period are not necessarily foregone but, depending on whether negotiations, litigation or both continue into subsequent periods, and depending on a number of other factors, such potential revenues may be pushed into subsequent fiscal periods.

  

Revenues for the nine months ended September 30, 2021 and 2020 included fees from the following technology licensing and enforcement programs:

 

• Bone Wedge technology(1)(2)   • Wireless Mesh Networking technology(1)
• Flash Memory technology(1)   • MIPI DSI technology(2)
• Internet search, advertising and cloud computing technology (1)(2)   • Semiconductor and Memory-Related technology(2)
• Speech codecs used in wireless and wireline systems technology(1)(2)   • Super Resolutions Microscopy technology(2)
• Wireless Infrastructure and User Equipment technology(1)   • Video Conferencing technology(2)
• Networking and Security technology(1)   • Internet radio ad placement(2)
  __________________________      
  (1) Licensing and enforcement program generating revenue in 2021.
  (2) Licensing and enforcement program generating revenue in 2020.

 

Consolidated Results of Operations

 

Summary for the Three and Nine Months Ended September 30, 2021 and 2020

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   $ Change   % Change   2021   2020   $ Change   % Change 
   (In thousands, except percentage change values) 
                                 
Revenues  $1,582   $19,466   $(17,884)   (92%)  $24,785   $25,399   $(614)   (2%)
Operating costs and expenses   14,304    22,248    (7,944)   (36%)   41,539    38,498    3,041    8% 
Operating loss   (12,722)   (2,782)   (9,940)   357%    (16,754)   (13,099)   (3,655)   28% 
Other income (expense)   102,337    41,213    61,124    148%    (37,316)   45,047    (82,363)   (183%)
Income (loss) before income taxes   89,615    38,431    51,184    133%    (54,070)   31,948    (86,018)   (269%)
Income tax (expense) benefit   (11)   (83)   72    (87%)   (531)   1,257    (1,788)   (142%)
Net income (loss) attributable to Acacia Research Corporation   89,604    38,348    51,256    134%    (55,507)   33,205    (88,712)   (267%)

 

 

 


 36 

 

 

Results of Operations – Three months ended September 30, 2021 compared with the three months ended September 30, 2020

 

Revenues decreased $17.9 million to $1.6 million for the three months ended September 30, 2021, as compared to $19.5 million in the comparable prior year quarter, primarily due to a decrease in revenues from licensing and enforcement programs during the quarter. New agreements executed were flat quarter over quarter. Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.

  

Income before income taxes was $89.6 million for the three months ended September 30, 2021, as compared to $38.4 million for the three months ended September 30, 2020. The net change was comprised of the change in revenues described above and other changes in operating expenses and other income (expense) as follows:

 

  · Paid-up revenue decreased $18.3 million primarily due to a decrease in average revenue per agreement executed during the quarter, offset by an increase of $401,000 in recurring revenue that provides for quarterly sales-based license fees. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding certain sales-based revenue contracts that provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees.
     
  · Inventor royalties and contingent legal fees, on a combined basis, decreased $11.8 million, from $12.4 million to $565,000, primarily due to the net decrease in revenues described above.
     
  · Litigation and licensing expenses - patents decreased $219,000, from $1.0 million to $782,000, primarily due to a net decrease in litigation support and third-party technical consulting expenses associated with ongoing litigation.
     
  · Amortization of patents expense increased $1.4 million, from $1.2 million to $2.6 million, due to an increase in scheduled amortization resulting from the new portfolios acquired in 2021.
     
  · General and administrative expenses, excluding non-cash stock compensation, increased $2.8 million, from $7.2 million to $10.0 million, primarily due to higher corporate, general and administrative costs related to legal and other business development expenses, and to a lesser extent from non-recurring employee severance costs, personnel cost and board fees.
     
  · Net non-cash stock compensation expense decreased $188,000, from $488,000 to $300,000, primarily due to forfeitures in the third quarter partially offset by higher expense from stock grants issued to employees and the Board of Directors in 2021.
     
  · There was no unrealized gain or loss on our fair value investment for the three months ended September 30, 2021, as compared to an unrealized loss of $3.1 million for the three months ended September 30, 2020. There was no realized gain or loss on our fair value investment for the three months ended September 30, 2021 and 2020. Refer to Note 4 to the consolidated financial statements elsewhere herein for additional information.
     
  · Unrealized gain from the fair value measurements of the Series A and Series B warrants and the embedded derivative decreased to $619,000 for the three months ended September 30, 2021, as compared to an unrealized gain of $20.7 million for the three months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Securities.
     
  · Unrealized gain from equity securities increased to $66.5 million for the three months ended September 30, 2021, as compared to an unrealized gain of $20.5 million for the three months ended September 30, 2020. The current period unrealized gain primarily relates to one Life Sciences Portfolio company’s valuation increase in connection with its initial public offering. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in equity securities.

 

 

 

 37 

 

 

  · Realized gain from the sale of our equity securities increased to $37.7 million for the three months ended September 30, 2021, as compared to a gain of $2.7 million for the three months ended September 30, 2020. The current period realized gain primarily relates to the partial sale of two Life Sciences Portfolio securities. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in equity securities.
     
  · We incurred losses on foreign currency exchange of $17,000 and $48,000 during the three months ended September 30, 2021 and 2020, respectively.
     
  · We incurred interest expense of $2.5 million during the three months ended September 30, 2021 from the Notes issued in 2020 and 2021, as compared to $2.4 million during the three months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Senior Secured Notes.
     
  · Interest income and other increased to $76,000 for the three months ended September 30, 2021 from $10,000 for the three months ended September 30, 2020. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our cash and cash equivalents and investments in equity securities.

 

Results of Operations – Nine months ended September 30, 2021 compared with the nine months ended September 30, 2020

 

Revenues decreased $614,000 to $24.8 million for the nine months ended September 30, 2021, as compared to $25.4 million in the comparable prior year, primarily due to a decrease in revenues from licensing and enforcement programs generating revenue during the period. Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.

  

Loss before income taxes was $54.1 million for the nine months ended September 30, 2021, as compared to income before income taxes of $31.9 million for the nine months ended September 30, 2020. The net change was comprised of the change in revenues described above and other changes in operating expenses and other income (expense) as follows:

 

  · Paid-up revenue decreased $1.4 million primarily due to a decrease in average revenue per agreement executed during the period, offset by an increase of $753,000 in recurring revenue that provides for quarterly sales-based license fees. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding certain sales-based revenue contracts that provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees.
     
  · Inventor royalties and contingent legal fees, on a combined basis, decreased $7.1 million, from $13.7 million to $6.6 million, primarily due to a higher percentage of revenues generated during the nine months ended September 30, 2021 having no inventor royalty obligations.
     
  · Litigation and licensing expenses - patents increased $1.4 million, from $3.5 million to $4.9 million, primarily due to a net increase in litigation support and third-party technical consulting expenses associated with ongoing litigation.
     
  · Amortization of patents expense increased $3.6 million, from $3.5 million to $7.1 million, due to an increase in scheduled amortization resulting from the new portfolios acquired in 2020 and 2021.
     
  · Other patent portfolio income for the nine months ended September 30, 2020 was $308,000 due to the reversal of previously recorded expenses for settlement and contingency accruals.
     
  · General and administrative expenses, excluding non-cash stock compensation, increased $4.9 million, from $16.8 million to $21.7 million, primarily due to higher corporate, general and administrative costs related to legal and other business development expenses, personnel cost and board fees, and to a lesser extent from increased variable performance-based compensation costs.
     
  · Net non-cash stock compensation expense increased $36,000, from $1.2 million to $1.3 million, primarily due to stock grants issued to employees and the Board of Directors in 2021, partially offset by forfeitures for terminated employees.

 

 

 

 38 

 

 

  · We recognized an unrealized loss of $2.8 million on our fair value investment for the nine months ended September 30, 2021, as compared to an unrealized gain of $3.7 million for the nine months ended September 30, 2020. There was a realized gain of $3.6 million on our fair value investment for the nine months ended September 30, 2021, as compared to a realized loss of $2.8 million for the nine months ended September 30, 2020. Refer to Note 4 to the consolidated financial statements elsewhere herein for additional information.
     
  · We incurred an unrealized net loss of $203.9 million from the fair value measurements of the Series A and Series B warrants and the embedded derivative for the nine months ended September 30, 2021, as compared to an unrealized loss of $46.6 million for the nine months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Securities.
     
  · Unrealized gain from equity securities increased to $115.5 million for the nine months ended September 30, 2021, as compared to an unrealized gain of $99.4 million for the nine months ended September 30, 2020. The current period unrealized gain primarily relates to one Life Sciences Portfolio company’s valuation increase in connection with its initial public offering. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment equity securities.
     
  · Realized gain from the sale of our equity securities increased to $53.1 million for the nine months ended September 30, 2021, as compared to a loss of $4.3 million for the nine months ended September 30, 2020. The current period realized gain primarily relates to the sale of three Life Sciences Portfolio securities. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in equity securities.
     
  · Earnings on equity investment in joint venture was $2.7 million for the nine months ended September 30, 2021. Refer to Note 3 to the consolidated financial statements elsewhere herein for additional information regarding our equity method investment.
     
  · We incurred losses on foreign currency exchange of $193,000 and $4.9 million during the nine months ended September 30, 2021 and 2020, respectively.
     
  · We incurred interest expense of $5.6 million during the nine months ended September 30, 2021 from the Notes issued in 2020 and 2021, as compared to $3.2 million during the nine months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Senior Secured Notes.
     
  · Interest income and other decreased to $135,000 for the nine months ended September 30, 2021 from $811,000 for the nine months ended September 30, 2020, mainly due to a decrease in interest income from our former investment in debt securities, which was sold in 2020. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our cash and cash equivalents and investments in equity securities.

 

Revenues

 

Revenue for the periods presented included the following:

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   $ Change   % Change   2021   2020   $ Change   % Change 
                                 
Revenues (in thousands, except percentage change values)  $1,582   $19,466   $(17,884)   (92%)  $24,785   $25,399   $(614)   (2%)
New agreements executed   3    3    –    0%    16    11    5    45% 
Licensing and enforcement programs generating revenues   3    5    (2)   (40%)   7    8    (1)   (13%)
Licensing and enforcement programs with initial revenues   –    1    (1)   (100%)   3    2    1    50% 
New patent portfolios   –    –    –    0%    1    4    (3)   (75%)

 

 

 

 39 

 

 

For the periods presented herein, the majority of the revenue agreements executed provided for the payment of one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technology rights owned by our operating subsidiaries. These rights were primarily granted on a perpetual basis, extending until the expiration of the underlying patents.

 

Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our revenue arrangements and related concentrations for the periods presented herein.

 

Refer to “Investments in Patent Portfolios” above for information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.

 

Cost of Revenues

 

Inventor Royalties and Contingent Legal Fees Expense

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   $ Change   % Change   2021   2020   $ Change   % Change 
   (In thousands, except percentage change values) 
                                 
Inventor royalties  $280   $5,772   $(5,492)   (95%)  $823   $6,843   $(6,020)   (88%)
Contingent legal fees   285    6,609    (6,324)   (96%)   5,735    6,855    (1,120)   (16%)
Total  $565   $12,381   $(11,816)   (95%)  $6,558   $13,698   $(7,140)   (52%)

 

For the three months ended September 30, 20201, inventor royalties and contingent legal fees, on a combined basis, decreased $11.8 million, or 95%. For the nine months ended September 30, 20201, inventor royalties and contingent legal fees, on a combined basis, decreased $7.1 million, or 52%. Inventor royalties and contingent legal fee expenses fluctuate from period to period based on the amount of revenues recognized each period, the terms and conditions of agreements executed each period and the mix of specific patent portfolios, with varying economic terms and obligations, generating revenues each period.

 

Litigation and Licensing Expenses - Patents and Amortization of Patents

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   $ Change   % Change   2021   2020   $ Change   % Change 
   (In thousands, except percentage change values) 
                                 
Litigation and licensing expenses - patents  $782   $1,001   $(219)   (22%)  $4,881   $3,497   $1,384    40% 
Amortization of patents   2,612    1,174    1,438    122%    7,086    3,522    3,564    101% 
Total  $3,394   $2,175   $1,219    56%   $11,967   $7,019   $4,948    70% 

 

For the three months ended September 30, 2021, litigation and licensing expenses-patents decreased $219,000, or 22%. For the nine months ended September 30, 2021, litigation and licensing expenses-patents increased $1.4 million, or 40%. The changes were due to fluctuations in litigation support and third-party technical consulting expenses during the periods presented.

 

For the three months ended September 30, 2021, amortization expense increased $1.4 million, or 122%. For the nine months ended September 30, 2021, amortization expense increased $3.6 million, or 101%. These increases were due to new patents acquired in 2020 and 2021.

  

 

 40 

 

 

Operating Expenses

 

General and Administrative Expenses

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   $ Change   % Change   2021   2020   $ Change   % Change 
   (In thousands, except percentage change values) 
                                 
General and administrative expenses  $10,045   $7,204   $2,841    39%   $21,735   $16,846   $4,889    29% 
Non-cash stock compensation expense   300    488    (188)   (39%)   1,279    1,243    36    3% 
Total general and administrative expenses  $10,345   $7,692   $2,653    34%   $23,014   $18,089   $4,925    27% 

 

 

A summary of the main drivers of the change in general and administrative expenses for the periods presented, is as follows:

  

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021 vs. 2020   2021 vs. 2020 
   (In thousands) 
         
Personnel costs and board fees  $415   $1,563 
Variable performance-based compensation costs   (172)   268 
Corporate, general and administrative costs   2,111    2,973 
Non-cash stock compensation expense   (188)   36 
Non-recurring employee severance costs   487    85 
Total change in general and administrative expenses  $2,653   $4,925 

 

The increases in personnel cost and board fees for the periods presented were primarily due to an increase in headcount and related costs. The changes in variable performance-based compensation costs were primarily due to fluctuations in performance-based compensation accruals. The increases in corporate, general and administrative costs were primarily due to higher legal and business development related expenses. The decrease in non-cash stock compensation expense for the three months ended September 30, 2021, was primarily due to forfeitures in the third quarter partially offset by higher expense from stock grants issued to employees and the Board of Directors in 2021. Non-recurring employee severance costs fluctuate based on the severance arrangements of terminated employees.

 

Other Income (Expense)

 

Our equity investments in Veritone, the Life Sciences Portfolio and other equity securities are recorded at fair value at each balance sheet date.

 

Our quarterly results included no unrealized or realized gain or loss on our fair value investment in Veritone for the three months ended September 30, 2021, as compared to an unrealized loss of $3.1 million for the three months ended September 30, 2020. Our year-to-date results included an unrealized loss of $2.8 million on our fair value investment in Veritone for the nine months ended September 30, 2021, as compared to an unrealized gain of $3.7 million for the nine months ended September 30, 2020. There was a realized gain of $3.6 million on our equity investment in Veritone for the nine months ended September 30, 2021, as compared to a realized loss of $2.8 million for the nine months ended September 30, 2020. Refer to Note 4 to the consolidated financial statements elsewhere herein for additional information regarding our investment in Veritone.

 

 

 

 41 

 

 

Our quarterly results included an unrealized gain from equity securities of $66.5 million for the three months ended September 30, 2021, as compared to an unrealized gain of $20.5 million for the three months ended September 30, 2020. Realized gain from the sale of our equity securities increased to $37.7 million for the three months ended September 30, 2021, as compared to a gain of $2.7 million for the three months ended September 30, 2020. Our year-to-date results included an unrealized gain from equity securities of $115.5 million for the nine months ended September 30, 2021, as compared to an unrealized gain of $99.4 million for the nine months ended September 30, 2020. Realized gain from the sale of our equity securities increased to $53.1 million for the nine months ended September 30, 2021, as compared to a loss of $4.3 million for the nine months ended September 30, 2020. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in the Life Sciences Portfolio and other equity securities.

 

Income Taxes

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   $ Change   % Change   2021   2020   $ Change   % Change 
   (In thousands, except percentage values) 
                                 
Income tax (expense) benefit  $(11)  $(83)  $72    (87%)  $(531)  $1,257   $(1,788)   (142%)
Effective tax rate   0%    0%    –    0%    (1%)   (4%)   –    3% 

 

The provision for income taxes is determined using an effective tax rate. For the three and nine months ended September 30, 2021, the Company’s estimated annual effective tax rates were lower than the U.S. federal statutory rate primarily due to the change in valuation allowance, as well as state income taxes. The effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions used to estimate the effective tax rate, including factors such as expected utilization of net operating loss carryforwards, changes in or the interpretation of tax laws in jurisdictions where the Company conducts business, the Company’s expansion into new states or foreign countries, and the amount of valuation allowances against deferred tax assets. For the nine months ended September 30, 2020, the Company recorded a benefit for income taxes of which primarily reflects the impact of state taxes and foreign tax withholding or refund incurred on revenue agreements executed with third-party licensees domiciled in foreign jurisdictions.

 

The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities along with net operating loss and tax credit carryforwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. For the nine months ended September 30, 2021, the Company has recorded a full valuation allowance against its deferred tax assets as they are not expected to be realized.

 

On March 27, 2020, the United States enacted the CARES Act which provides certain income tax benefits including the ability to carryback federal NOLs generated in 2018 through 2020 for an extended five-year period and increased the limitation for the deduction of interest expense from 30 percent to 50 percent of modified taxable income. The CARES Act also provides other economic benefits such as allowing employers to defer payment of the employer’s portion of payroll taxes for 2020 and a refundable employee retention credit of up to $5,000 per eligible employee wages. The Company did not realize benefits from the provisions of the CARES Act including the extended NOL carryback period, the payroll tax deferral, and the employee retention credit.

 

On December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended many of the benefits of the CARES Act that were scheduled to expire. The Company does not expect a material impact of Consolidated Appropriations Act on its consolidated financial statements and related disclosures.

 

On March 11, 2021 the United States enacted the American Rescue Plan Act of 2021. These Acts includes various income and payroll tax measures. The Company does not expect a material impact of the American Rescue Plan on its consolidated financial statements and related disclosures.

 

On June 29, 2020, the state of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5.0 million). The Company anticipates a California income tax liability for 2021, however it is not expected to materially impact the consolidated financial statements.

 

 

 

 42 

 

 

Liquidity and Capital Resources

 

General

 

Our primary sources of liquidity are cash and cash equivalents on hand generated from our operating activities, and as deemed appropriate by management from our Senior Secured Notes (discussed below under the caption “Starboard Investment and Senior Secured Notes”). Our management believes that our cash and cash equivalent balances, anticipated cash flows from operations and proceeds from our Senior Secured Notes will be sufficient to meet our cash requirements through at least twelve months from the date of this report and for the foreseeable future. We may, however, encounter unforeseen difficulties that may deplete our capital resources more rapidly than anticipated, including those set forth under Part II, Item 1A, “Risk Factors”. Any efforts to seek additional funding could be made through issuances of equity or debt, or other external financing. However, additional funding may not be available to us on favorable terms, or at all. The capital and credit markets have experienced extreme volatility and disruption in recent years, and the volatility and impact of the disruption may continue. At times during this period, the volatility and disruption has reached unprecedented levels. In several cases, the markets have exerted downward pressure on stock prices and credit capacity for certain issuers, and the commercial paper markets may not be a reliable source of short-term financing for us. If we fail to obtain additional financing when needed, we may not be able to execute our business plans and our business, conducted by our operating subsidiaries, may suffer.

 

Certain of our operating subsidiaries are often required to engage in litigation to enforce their patents and patent rights. In connection with any of our operating subsidiaries’ patent enforcement actions, it is possible that a defendant may request and/or a court may rule that an operating subsidiary has violated statutory authority, regulatory authority, federal rules, local court rules, or governing standards relating to the substantive or procedural aspects of such enforcement actions. In such event, a court may issue monetary sanctions against us or our operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material.

  

Cash, Cash Equivalents and Investments

 

Our consolidated cash, cash equivalents, equity securities at fair value, and long-term restricted cash totaled $640.5 million at September 30, 2021, compared to $309.6 million at December 31, 2020.

 

The net change in cash, cash equivalents and restricted cash for the periods presented was comprised of the following:

 

   Nine Months Ended 
   September 30, 
   2021   2020 
   (In thousands) 
Net cash (used in) provided by:          
Operating activities  $(7,602)  $5,549 
Investing activities   (3,219)   (9,815)
Financing activities   64,417    109,471 
Increase in cash and cash equivalents and restricted cash  $53,596   $105,205 

 

Cash Flows from Operating Activities

 

Cash receipts from licensees for the nine months ended September 30, 2021 decreased to $24.9 million, as compared to $25.6 million in the comparable 2020 period, mainly due to the timing on cash collected from accounts receivables in prior year.

 

 

 

 43 

 

 

Cash outflows from operations for the nine months ended September 30, 2021 increased to $7.6 million, as compared to a $5.5 million cash inflow in the comparable 2020 period, primarily due to our higher net loss (discussed above under the caption “Results of Operations – Nine months ended September 30, 2021 compared with the nine months ended September 30, 2020”) and a gain on sale of equity securities, partially offset by the net changes in fair value of Series A and B warrants, embedded derivatives and equity securities and to a lesser extent the changes in working capital cash flows. Refer to “Working Capital” below for additional information.

  

Cash Flows from Investing Activities

 

Cash flows from investing activities and related changes were comprised of the following for the periods presented:

 

   Nine Months Ended 
   September 30, 
   2021   2020 
   (In thousands) 
         
Patent acquisition  $(13,000)  $(13,780)
Sale of investment at fair value   3,591    1,460 
Purchases of equity securities   (57,978)   (33,800)
Maturities and sales of equity securities   64,235    316,746 
Purchases of prepaid investment   –    (276,275)
Equity securities derivative and forward contract acquisition cost   –    (3,989)
Purchases of property and equipment   (67)   (177)
Net cash used in investing activities  $(3,219)  $(9,815)

 

Cash Flows from Financing Activities

 

Cash flows from financing activities and related changes were comprised of the following for the periods presented:

 

   Nine Months Ended 
   September 30, 
   2021   2020 
   (In thousands) 
         
Repurchase of common stock  $–   $(3,998)
Issuance of Senior Secured Notes, net of lender fee   65,000    110,437 
Senior Secured Notes issuance costs paid to other parties   –    (496)
Dividend on Series A Redeemable Convertible Preferred Stock   (785)   (1,120)
Issuance of Series B warrants   –    4,600 
Proceeds from exercise of stock options   202    48 
Paydown of Senior Secured Notes - short-term   (50,000)   – 
Reissuance of Senior Secured Notes - short-term   50,000    – 
Net cash provided by financing activities  $64,417   $109,471 

 

Starboard Investment and Senior Secured Notes

 

On November 18, 2019, the Company entered into the Securities Purchase Agreement with Starboard and the Buyers pursuant to which the Buyers purchased (i) 350,000 shares of Series A Preferred Stock at an aggregate purchase price of $35.0 million, and Series A Warrants to purchase up to 5 million shares of the Company’s common stock.

 

 

 

 44 

 

 

On February 25, 2020, pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, the Company issued Series B Warrants to purchase up to 100 million shares of the Company’s common stock at an exercise price of either (i) $5.25 per share, if exercising by cash payment, or (ii) $3.65 per share, if exercising by cancellation of a portion of Notes. The Company issued the Series B Warrants for an aggregate purchase price of $4.6 million.

 

On June 4, 2020, pursuant to the Securities Purchase Agreement dated November 2019, the Company issued $115.0 million in Notes to the Buyer. Per the Supplemental Agreement, interest is payable semiannually at a rate of 6.00% per annum, and in an event of default, the interest rate is increased to 10.00% per annum. In connection with the issuance of the Notes, the terms of certain of the Series B Warrants were amended to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration date of November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms.

 

On June 30, 2020, the Company entered into the Exchange Agreement with Merton and Starboard, on behalf of itself and on behalf of certain funds and accounts under its management, including the holders of the Notes. Pursuant to the Exchange Agreement, the holders of the Notes exchanged the entire outstanding principal amount for New Notes issued by Merton having an aggregate outstanding original principal amount of $115.0 million.

 

On January 29, 2021, the Company redeemed $50.0 million of the New Notes and on March 31, 2021, the Company reissued $50.0 million of the New Notes. On June 30, 2021, the Company issued $30.0 million in additional New Notes (the “June 2021 Merton Notes”) and amended the maturity date of the New Notes to October 15, 2021. On September 30, 2021, the Company issued $35.0 million in additional New Notes (the “September 2021 Merton Notes”) and amended the maturity date of the New Notes to December 1, 2021. The June and September 2021 Merton Notes cannot be used to exercise Series B Warrants issued to Starboard Value. The total principal amount outstanding of New Notes as of September 30, 2021 and December 31, 2020 was $180.0 million and $115.0 million, respectively.

 

Refer to Notes 2 and 6 to the consolidated financial statements elsewhere herein for additional information related to the Starboard Securities and Senior Secured Notes.

 

Working Capital

 

Working capital at September 30, 2021 increased to $465.0 million, as compared to $332.9 million at December 31, 2020. Accounts receivable from licensees decreased to $412,000 at September 30, 2021, compared to $506,000 at December 31, 2020. Accounts payable, accrued expenses and accrued compensation increased to $11.8 million at September 30, 2021, from $7.0 million at December 31, 2020. Royalties and contingent legal fees payable decreased to $1.8 million at September 30, 2021, from $2.2 million at December 31, 2020.

 

The royalties and contingent legal fees payable are generally scheduled to be paid in the subsequent quarter upon our receipt of the related fee payments from licensees, in accordance with the underlying contractual arrangements.

 

Critical Accounting Policies and Estimates

 

Our unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Preparation of these condensed consolidated statements requires management to make assumptions, judgments and estimates that can have a significant impact on amounts reported in these condensed consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.

 

The Securities and Exchange Commission (“SEC”) has defined a company’s critical accounting policies as the ones that are most important to the portrayal of a company’s financial condition and results of operations, and which require a company to make its most difficult and subjective judgments. A summary of significant accounting policies and a description of accounting policies that are considered critical may be found in the audited consolidated financial statements and notes thereto and under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies” included in our Annual Report. In addition, as set forth in Note 2 (under the caption “Use of Estimates”) to the consolidated financial statements included in this report, certain accounting policies were identified during the current period, based on activities occurring during the current period, as critical and requiring significant judgments and estimates.

 

 

 

 45 

 

  

Recently Adopted Accounting Pronouncements

 

Refer to Note 2 (under the caption “Recent Accounting Pronouncements”) to the consolidated financial statements included in this report for additional information.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2021, we did not have any relationships with any unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established to facilitate any off-balance sheet arrangements or for any other contractually specified purposes.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

The primary objective of our short-term investment activities is to preserve principal while concurrently maximizing the income we receive from our equity securities at fair value without significantly increasing risk. Some of the securities that we invest in may be subject to interest rate risk and/or market risk. This means that a change in prevailing interest rates, with respect to interest rate risk, or a change in the value of the United States equity markets, with respect to market risk, may cause the principal amount or market value of the equity securities at fair value to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later rises, the current value of the principal amount of our investment may decline. To minimize these risks in the future, we intend to maintain our portfolio of cash equivalents and equity securities at fair value in a variety of securities, including commercial paper, money market funds, government and non-government debt securities, certificates of deposit and equity securities. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate. Accordingly, a 100 basis point increase in interest rates or a 10% decline in the value of the United States equity markets would not be expected to have a material impact on the value of such money market funds. Declines in interest rates over time will, however, reduce our interest income.

 

During 2020, we sold all of our investment in debt securities, comprised of AAA rated money market funds that invested in first-tier only securities, which primarily included domestic commercial paper, securities issued or guaranteed by the U.S. government or its agencies, U.S. bank obligations and fully collateralized repurchase agreements, and direct investments in short-term, highly liquid, investment grade, U.S. government and corporate securities.

 

Investment Risk

 

We are exposed to investment risks related to changes in the underlying financial condition of certain of our equity investments in technology companies. The fair value of these investments can be significantly impacted by the risk of adverse changes in securities markets generally, as well as risks related to the performance of the companies whose securities we have invested in, risks associated with specific industries, and other factors. These investments are subject to significant fluctuations in fair value due to the volatility of the securities markets and of the underlying businesses.

 

As of September 30, 2021 and December 31, 2020, the carrying value of our common stock and warrants in public and private companies was $424.8 million and $285.8 million, respectively.

 

Foreign Currency Exchange Risk

 

Although we do not have any material foreign operations, we are also exposed to market risks related to fluctuations in foreign currency exchange rates between the U.S. dollar, and the British Pound and Euro currency exchange rates, primarily related to revenue agreements with licensees domiciled in foreign jurisdictions and certain equity security investments. A hypothetical 10% change in exchange rates related to our at risk foreign denominated equity securities would have approximately a $32.4 million effect on our financial position and results of operations.

 

 

 

 46 

 

 

Item 4. Controls and Procedures

 

(i). Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

 

Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2021, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure, and that such information is recorded, processed, summarized and reported within the time periods prescribed by the SEC.

 

(ii). Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during our last fiscal quarter (the quarter ended September 30, 2021) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

(iii). Inherent Limitations on Effectiveness of Controls

 

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of the effectiveness of controls to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

  

 

 

 

 

 

 

 

 47 

 

 

PART II--OTHER INFORMATION

 

Item 1. Legal Proceedings

 

In the ordinary course of business, we are the subject of, or party to, various pending or threatened legal actions, including various counterclaims in connection with our patent enforcement activities. We believe that any liability arising from these actions will not have a material adverse effect on our consolidated financial position, results of operations or cash flows.

 

Our operating subsidiaries are often required to engage in litigation to enforce their patents and patent rights. Certain of our operating subsidiaries are parties to ongoing patent enforcement related litigation, alleging infringement by third-parties of certain of the patented technologies owned or controlled by our operating subsidiaries.

 

In connection with any of our patent enforcement actions, it is possible that a defendant may claim and/or a court may rule that we have violated statutory authority, regulatory authority, federal rules, local court rules, or governing standards relating to the substantive or procedural aspects of such enforcement actions. In such event, a court may issue monetary sanctions against us or our operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material, and if required to be paid by us or our operating subsidiaries, could materially harm our operating results and our financial position.

 

We spend a significant amount of our financial and management resources to pursue our current litigation matters. We believe that these litigation matters and others that we may in the future determine to pursue could continue for years and continue to consume significant financial and management resources. The counterparties to our litigation are sometimes large, well-financed companies with substantially greater resources than us. We cannot assure you that any of our current or future litigation matters will result in a favorable outcome for us. In addition, in part due to the appeals process and other legal processes, even if we obtain favorable interim rulings or verdicts in particular litigation matters, they may not be predictive of the ultimate resolution of the dispute. Also, we cannot assure you that we will not be exposed to claims or sanctions against us which may be costly or impossible for us to defend. Unfavorable or adverse outcomes may result in losses, exhaustion of financial resources or other adverse effects which could encumber our ability to effectively and efficiently monetize our assets.

 

On September 6, 2019, Slingshot Technologies, LLC, or Slingshot, filed a lawsuit in Delaware Chancery Court against the Company and Acacia Research Group, LLC, or collectively, the Acacia Entities, Monarch Networking Solutions LLC (“Monarch”), Acacia board member Katharine Wolanyk, and Transpacific IP Group, Ltd., or Transpacific. Slingshot alleges that the Acacia Entities and Monarch misappropriated its confidential and proprietary information, purportedly furnished to the Acacia Entities and Monarch by Ms. Wolanyk, in acquiring a patent portfolio from Transpacific after Slingshot’s exclusive option to purchase the same patent portfolio from Transpacific had already expired. Slingshot seeks monetary damages, as well as equitable and injunctive relief related to its alleged right to own the portfolio. On March 15, 2021, the court issued orders granting Monarch’s motion to dismiss for lack of personal jurisdiction and Ms. Wolanyk’s motion to dismiss for lack of subject matter jurisdiction. The remaining parties then commenced discovery, and have since served initial written requests and responses, and notices of the depositions of the parties’ corporate designees. The Acacia Entities maintain that Slingshot’s allegations are baseless, that the Acacia Entities neither had access to nor used Slingshot’s information in acquiring the portfolio, that the Acacia Entities acquired the portfolio as a result of the independent efforts of its IP licensing group, and that Slingshot suffered no damages given its exclusive option to purchase the portfolio had already ended and it has proven itself incapable of closing on the portfolio purchase.

 

During the three months ended September 30, 2021 and 2020, there were no operating expenses related to settlement and contingency accruals. During the nine months ended September 30, 2021, we incurred $338,000 in operating expenses for settlement and contingency accruals. During the nine months ended September 30, 2020, operating expenses included a net income for settlement offset by contingency accruals totaling $308,000, net of prior accruals. At September 30, 2021 and December 31, 2020, our contingency accrual balance was $587,000 and $1.3 million, respectively.

 

 

 48 

 

 

Item 1A. Risk Factors

 

An investment in our common stock involves risks. Before making an investment decision, you should carefully consider all of the information in this Quarterly Report on Form 10-Q, including in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part I, Item 2, as well as our consolidated financial statements and the accompanying notes thereto. In addition, you should carefully consider the risks and uncertainties described below, and in the section entitled “Risk Factors” in Part I, Item 1A of our Annual Report, as well as in our other public filings with the SEC. If any of the identified risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that case, the trading price of our common stock may decline, and you could lose all or part of your investment. In addition, other risks of which we are currently unaware, or which we do not currently view as material, could have a material adverse effect on our business, financial condition, operating results and prospects.

 

Risks related to COVID-19

 

The COVID-19 pandemic could have a material adverse effect on our operations, the operations of our business partners, and the global economy as a whole.

 

The ongoing COVID-19 pandemic, and governmental and societal responses thereto, have had a severe impact on recent global economic and market conditions, including significant disruption of, and volatility in, financial markets, global supply chain, and the institution of social distancing and shelter-in-place requirements that have resulted in temporary closures of many businesses, lost revenues, and increased unemployment.

 

These conditions could adversely impact our operations, as well as the operations of our licensees and other business partners. With regard to the COVID-19 pandemic, we do not expect the current situation to present direct risks to our business. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies, and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. While governmental authorities have taken measures to provide economic assistance to individual households and businesses, stabilize the markets, and support economic growth, the ultimate success of these measures is unknown and they may not be sufficient to mitigate fully the negative impact of the ongoing pandemic. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, financial condition, operating results, and/or prospects.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

During August 2021, we entered into a first amendment of an office lease, to commence for a period of three years upon landlords’ substantial completion of adequate substitution space, as defined. To date, the substitution space is not ready for use, accordingly the term extension has not begun. Refer to Note 8 to the consolidated financial statements elsewhere herein for additional information. This agreement is filed herewith, refer to Part II, Item 6, “Exhibits” below.

  

 

 

 49 

 

 

Item 6. Exhibits

 

EXHIBIT
NUMBER		 EXHIBIT
4.1 Form of Note (incorporated by reference to Exhibit 10.1)
10.1 Fourth Supplemental Agreement, dated as of September 30, 2021, between Starboard Value, L.P., Acacia Research Corporation, Merton Acquisition Holdco LLC and certain other direct and indirect subsidiaries of the Company (incorporated by reference to the Current Report on Form 8-K filed on October 6, 2021)
10.2# First Amendment of Lease, dated as of August 5, 2021, between Sage Realty Corporation and Acacia Research Corporation (filed herewith pursuant to Part II, Item 5)
31.1# Certification of Principal Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
31.2# Certification of Principal Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934
32.1*# Certification of Principal Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
32.2*# Certification of Principal Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350
101# The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders' Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104# Cover Page Interactive Data File (formatted in iXBRL and included in Exhibit 101).

  

___________________________

# Filed herewith.

 

* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.

 

 

 

 50 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ACACIA RESEARCH CORPORATION
   
Date: November 15, 2021 /s/ Clifford Press                                                       
  By: Clifford Press
  President and Chief Executive Officer
  (Principal Executive Officer and Duly Authorized Signatory)
 

 

 

 

Date: November 15, 2021 /s/ Richard Rosenstein                                                    
  By: Richard Rosenstein
  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

 

 

 

 

 51 

 

 

 

 EX-10.2 2 acacia_ex1002.htm FIRST AMENDMENT OF LEASE

Exhibit 10.2

 

 

FIRST AMENDMENT OF LEASE

 

THIS FIRST AMENDMENT OF LEASE (this “First Amendment of Lease”), dated as of the 5th day of August, 2021 (the“Effective Date”), between SAGE REALTY CORPORATION, a New York corporation having an office at 767 Third Avenue, New York, New York 10017, as agent for the owner of the building hereinafter mentioned (“Landlord”), and ACACIA RESEARCH CORPORATION, a Delaware corporation authorized to do business in New York State, having an office at 767 Third Avenue, New York, New York 10017 (“Tenant”).

 

W I T N E S S E T H

 

WHEREAS, Landlord and Tenant entered into an Indenture of Lease, dated as of January 7, 2020 (the “Lease”), pursuant to which Landlord leases to Tenant, and Tenant hires from Landlord, a portion of the sixth (6th) floor (the “Existing Premises”) in the building known as 767 Third Avenue, New York, New York 10017 (the “Building”); and

 

WHEREAS, Landlord and Tenant desire to amend the Lease to provide, among other things, for a substitution of the Existing Premises and for an extension of the term of the Lease.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.           Defined Terms. All capitalized terms used herein shall have the same meaning ascribed to them in the Lease, unless otherwise herein indicated, or unless the context hereof shall otherwise require.

 

2.           Extension of Term. Effective as of the date hereof, the Term is hereby extended to the last day of the month in which the three (3) year and one (1) month anniversary of the Substitution Space Commencement Date (as such term is defined below) occurs. Said date shall hereafter be deemed the “Expiration Date”.

 

3.           Substitution Space.

 

A.          Effective as of the date of Substantial Completion of Landlord’s Substitution Space Work (as such terms are defined below) (the “Substitution Space Commencement Date”), that portion of the sixth (6th) floor of the Building as shown by diagonal lines on Schedule A attached hereto (the “Substitution Space”), including all fixtures and equipment which as of the Substitution Space Commencement Date or during the Term of the Lease are attached thereto or become a part thereof, shall be substituted in lieu of the Existing Premises, and from and after such date the Substitution Space shall be deemed to be the “Premises” for all purposes under the Lease.

 

B.           On or before the date that is five (5) days from and after the Substitution Space Commencement Date (the “Surrender Date”), Tenant shall vacate and surrender the Existing Premises to Landlord broom clean, free of all tenancies and Tenant’s personal property, and otherwise in the condition required by the Lease upon the Expiration Date. From and after the later to occur of the Substitution Space Commencement Date and the actual date Tenant surrenders the Existing Premises to Landlord in accordance with the Lease, Tenant shall have no further responsibility with respect to the Existing Premises, provided, however, notwithstanding such surrender, Tenant shall be and remain liable for all obligations relating to the Existing Premises which expressly survive the expiration of the Term of the Lease and for all obligations relating to the Existing Premises arising prior to the Substitution Space Commencement Date, including, without limitation, any and all Fixed Rent and additional rent due and owing for the Existing Premises, whether or not theretofore billed, for the period through and including the day immediately preceding the Substitution Space Commencement Date, and Tenant's failure to pay any such sums and/or deliver the Existing Premises to Landlord as herein required shall be deemed a default entitling Landlord to all remedies provided for in the Lease or otherwise available at law. Tenant acknowledges that Tenant’s failure to surrender the Existing Premises to Landlord upon the Surrender Date pursuant to this paragraph will cause substantial damage to Landlord and shall be deemed a holdover governed by Article 16B of the Lease.

 

 

 

 1 

 

 

C.           Subject to the provisions of Section 7 herein, the taking of possession by Tenant of the Substitution Space for occupancy by Tenant shall be deemed an acceptance of same by Tenant. Such taking of possession shall also be conclusive evidence, as against Tenant, that the Substitution Space and the Building of which the same form a part were in good and satisfactory condition (subject to Landlord’s obligation to remedy any latent defects discovered in the Substitution Space and reported to Landlord within six (6) months of the Substitution Space Commencement Date) at the time of such occupancy and that the Substitution Space were substantially as shown on Schedule A. The foregoing provisions shall not be construed to modify Landlord’s repair, maintenance and replacement obligations set forth in the Lease.

 

D.          If Landlord shall be unable to give possession of the Substitution Space on the date anticipated herein for any reason whatsoever, Landlord shall not be subject to any liability, nor shall the validity of the Lease and this First Amendment of Lease, nor the obligations of Tenant hereunder be thereby affected (except as may be otherwise expressly set forth herein). The parties hereto expressly negate the provisions of Section 223-a of the Real Property Law and agree that such Section shall be inapplicable hereto. Tenant agrees that the provisions of this paragraph are intended to constitute "an express provision to the contrary" within the meaning of said Section 223-a. Notwithstanding anything to the contrary contained herein, in the event that Landlord shall be unable to give possession of the Substitution Space to Tenant with Landlord’s Work substantially complete on or prior to the date that is one hundred twenty (120) days from and after the later of (x) the date on which Tenant has selected its paint and carpet colors for the Substitution Space, and (y) the Effective Date (the “Completion Date”) (subject to extension for a period of up to three (3) months in the aggregate by reason of force majeure [set forth immediately below]), Tenant shall be granted, in addition to the Initial Abatement (as defined below) an abatement of Fixed Rent hereunder in an amount equal to one (1) day of Fixed Rent for each day after the Completion Date that the Substitution Space Commencement Date does not occur. Force majeure shall mean any delay in Landlord’s substantial completion of Landlord’s Substitution Space Work caused by labor trouble, governmental controls, acts of God, or any other cause beyond Landlord’s reasonable control, provided that Landlord’s lack of funds shall not be deemed to be a force majeure event.

 

4.           Fixed Rent.

 

A.          From and after the Substitution Space Commencement Date, Section 1C of the Lease amended such that the annual Fixed Rent shall be as follows:

 

(a)            $258,525.00 during the period beginning on the Substitution Space Commencement Date and continuing through the last day of the month in which occurs the date which immediately precedes the first (1st) anniversary of the Substitution Space Commencement Date;

 

(b)            $263,396.76 during the period beginning on the first day of the month immediately following the month in which occurs the date which immediately precedes the first (1st) anniversary of the Substitution Space Commencement Date and continuing through the last day of the month in which occurs the date which immediately precedes the second (2nd) anniversary of the Substitution Space Commencement Date;

 

(c)            $268,365.96 during the period beginning on the first day of the month immediately following the month in which occurs the date which immediately precedes the second (2nd) anniversary of the Substitution Space Commencement Date and continuing through the last day of the month in which occurs the date which immediately precedes the third (3rd) anniversary of the Substitution Space Commencement Date; and

 

(d)            $273,434.53 during the period beginning on the first day of the month immediately following the month in which occurs the date which immediately precedes the third (3rd) anniversary of the Substitution Space Commencement Date and continuing through the Expiration Date.

 

B.           Anything herein to the contrary notwithstanding, provided that this First Amendment of Lease and the Lease shall be in full force and effect and Tenant shall not then be in default hereunder or thereunder beyond any applicable notice and cure periods, the Fixed Rent attributable to the Substitution Space shall abate at the rate of $20,299.00 per month for the first (1st) month following the Substitution Space Commencement Date (the “Initial Abatement”).

 

 

 

 2 

 

 

5.            Real Estate Taxes. From and after the Substitution Space Commencement Date, Article 5 of the Lease shall also be amended as follows:

 

A.         Subparagraphs (I) of Section 5A shall be amended and restated in their entirety as follows:

 

“I. The term “Base Tax Year” as hereinafter set forth for the determination of real estate tax escalation shall mean calendar year 2021 (i.e., Real Estate Taxes, as hereinafter defined, for the Base Tax Year shall be the average of Real Estate Taxes for the period commencing on July 1, 2020, and ending on June 30, 2021, and Real Estate Taxes for the period commencing on July 1, 2021, and ending on June 30, 2022).

 

II. The term “the Percentage” shall mean 1.55%.”

 

6.          Electric. From and after the Substitution Space Commencement Date, Section 5C of the Lease is hereby amended to delete “$1,075.21” and replace it with “$1,244.75”.

 

7.          Landlord’s Substitution Space Work.

 

A.        Tenant hereby acknowledges that, except as provided in Section 4B above and Section 7B below, Landlord is not required to perform any work, furnish any materials, or give Tenant any rent credit or work allowance or any sum of money in connection with this First Amendment of Lease and the Substitution Space, and Tenant is taking the same “as-is” as of the Substitution Space Commencement Date. The foregoing provisions shall not be construed to modify Landlord’s repair, maintenance and replacement obligations set forth in the Lease.

 

B.         With reasonable promptness after the date hereof, Landlord agrees to perform the following work in the Substitution Space at Landlord’s sole cost and expense in accordance with the Building standard (collectively, “Landlord's Substitution Space Work”):

 

(i)              install new carpet in the Substitution Space with carpet selected by Tenant from the Building-standard carpet options;

 

(ii)              install new Building standard ceiling tiles throughout the Substitution Space; and

 

(iii)            Paint the Substitution Space one coat and one color, with the color selected by Tenant from the Building-standard color chart.

 

C.         For purposes of this First Amendment of Lease, the Substitution Space shall be deemed substantially completed (herein, "Substantial Completion" or "Substantially Completed") on the date when Landlord's Substitution Space Work has been substantially completed, notwithstanding the fact that minor changes or insubstantial details of construction, mechanical adjustment or decoration remain to be completed (any such items, “punchlist items”), provided Tenant's use and occupancy of the Substitution Space is not thereby materially affected.

 

 

 

 3 

 

 

8.          Extension Option. The following new Article 27 is hereby added to the Lease at the end of Article 26:

 

“ARTICLE 27: TENANT’S EXTENSION OPTION

 

A.           Provided (i) this Lease shall then be in full force and effect, (ii) Tenant shall not then be in default hereunder beyond any applicable notice or grace period as of the date of Tenant’s exercise of the extension option described herein (which conditions regarding default may be waived by Landlord in its sole discretion), and (iii) named Tenant herein and/or any of its affiliates that are permitted to occupy the Premises (and their respective employees, agents and visitors) shall be in actual occupancy of the Premises as of the date of Tenant’s exercise of the extension option described herein and as of the day which would otherwise be the first day of the Extension Term, Tenant shall have the right, at its option, to extend the Term for a single two (2) year period (the “Extension Term”). The Extension Term shall commence on the day immediately following the original Expiration Date and shall expire on the last day of the month in which occurs the date which immediately precedes the second (2nd) anniversary of such date unless the Extension Term shall sooner end pursuant to any of the terms, covenants or conditions of this Lease or pursuant to law. Tenant shall give Landlord written notice of Tenant’s intention to exercise such option on or before the date which is nine (9) months prior to the then-scheduled Expiration Date, the time of exercise being of the essence, and upon the giving of such notice, this Lease and the Term shall be extended without execution or delivery of any other or further documents, with the same force and effect as if the Extension Term had originally been included in the Term and the Expiration Date shall thereupon be deemed to be the last day of the Extension Term. All of the terms, covenants and conditions of this Lease shall continue in full force and effect during the Extension Term, including items of additional rent and escalation which shall remain payable on the terms herein set forth, except that (i) the Fixed Rent shall be as determined in accordance with Section 27B of this Article, (ii) the Base Tax Year shall be revised to the fiscal tax year in which the Extension Term commences and (iii) Tenant shall have no further right to extend the Term pursuant to this Article. Tenant shall accept the Premises in its then present “as-is” condition on the commencement of Extension Term and Landlord shall have no obligation to perform any work or give Tenant any work allowance, offset or rent credit in connection with the Extension Term. The foregoing provisions shall not be construed to modify Landlord’s repair, maintenance and replacement obligations set forth in the Lease.

 

B.          The Fixed Rent payable by Tenant for the Premises during the Extension Term shall be the fair market rental value of the Premises taking into consideration all relevant factors (fair market rental value taking into account the foregoing is hereinafter referred to as the “FMRV”). The FMRV shall be determined in accordance with the following procedure:

 

1.Immediately after the exercise by Tenant of its option under Section 27A above, Landlord and Tenant shall use their good faith efforts to agree upon the FMRV. In the event Landlord and Tenant cannot reach agreement within fifteen (15) Business Days after the date of Tenant’s notice of exercise of its option, Landlord and Tenant shall each select a reputable, independent, qualified, licensed real estate broker having an office in New York County and familiar with the rentals then being charged in the Building and in comparable buildings (respectively, “Landlord’s Broker” and “Tenant’s Broker”) who shall confer promptly after their selection by Landlord and Tenant and shall use their good faith efforts to agree upon the FMRV. If Landlord’s Broker and Tenant’s Broker cannot reach agreement within sixty (60) days after the date of Tenant’s notice of exercise of its option, then within ten (10) days thereafter, they shall designate a third reputable, independent, qualified, licensed real estate broker having an office in New York County (the “Independent Broker”). Upon the failure of Landlord’s Broker and Tenant’s Broker to agree upon the designation of the Independent Broker, then the Independent Broker shall be appointed by a Justice of the Supreme Court of the State of New York upon ten (10) days’ notice, or by any other court in New York County having jurisdiction and exercising functions similar to those exercised by the Supreme Court of the State of New York. Concurrently with such appointment, Landlord’s Broker and Tenant’s Broker shall each submit a letter to the Independent Broker, with a copy to Landlord and Tenant, setting forth such broker’s estimate of the FMRV (respectively, “Landlord’s Broker’s Letter” and “Tenant’s Broker’s Letter”).

 

  2. In the event the FMRV set forth in Landlord’s Broker’s Letter and Tenant’s Broker’s Letter shall differ by $2.50 or less per square foot for each year during the Extension Term, then the FMRV shall not be determined by the Independent Broker, and the FMRV shall be the average of the FMRV set forth in Landlord’s Broker’s Letter and Tenant’s Broker’s Letter. In the event the FMRV set forth in Landlord’s Broker’s Letter and Tenant’s Broker’s Letter shall differ by more than $2.50 per square foot per annum for any year during the Extension Term, the Independent Broker shall conduct such investigations and hearings as he may deem appropriate and shall, within sixty (60) days after the date of his designation, choose either the rental set forth in Landlord’s Broker’s Letter or Tenant’s Broker’s Letter to be the FMRV during the Extension Term and such choice shall be binding upon Landlord and Tenant. Landlord and Tenant shall each pay the fees and expenses of its respective broker. The fees and expenses of the Independent Broker shall be shared equally by Landlord and Tenant.

 

 

 

 4 

 

 

C.           In the event the Extension Term shall commence prior to determination of the Fixed Rent during the Extension Term as herein provided, then the Fixed Rent to be paid by Tenant to Landlord until such determination has been made shall be the Fixed Rent for the twelve (12) month period immediately preceding the commencement of the Extension Term. After such determination has been made for the Fixed Rent during the Extension Term, any excess rental for the Extension Term theretofore paid by Tenant to Landlord shall be credited by Landlord against the next ensuing monthly Fixed Rent payable by Tenant to Landlord and any deficiency in Fixed Rent due from Tenant to Landlord during the Extension Term shall be paid within fifteen (15) days after written demand.”

 

9.            Termination Option. The following new Article 28 is hereby added to the Lease at the end of Article 27:

 

“ARTICLE 28: TENANT’S TERMINATION OPTION

 

A.         Subject to the provisions of Section 28B hereof, Tenant shall have the option to cancel and terminate this Lease (The “Termination Option”) effective as of the last day of the month that is nineteen (19) months after the Substitution Space Commencement Date (such date is herein referred to as the “Early Termination Date”) by written notice (“Tenant’s Termination Notice”) delivered to Landlord no later than nine (9) months prior to such Early Termination Date, time being of the essence as to the giving of Tenant’s Termination Notice. Within fifteen (15) days after receipt of Tenant’s Termination Notice, Landlord shall deliver to Tenant a statement setting forth the amount of the Termination Payment (hereinafter defined) that will be due from Tenant in order to exercise such Termination Option, along with reasonable supporting documentation of the amount of the same. Within fifteen (15) days of receipt of such statement (and such supporting documentation), Tenant shall deliver to Landlord an unendorsed official bank check drawn on a bank which is a member of the New York City Clearing House Association or a wire transfer of funds to an account designated by Landlord in an amount equal to the Termination Payment. Upon timely delivery of Tenant’s Termination Notice and the Termination Payment, this Lease will expire on the Early Termination Date as if such date were the Expiration Date set forth herein and Tenant shall vacate the Premises on or before the Early Termination Date leaving the same in the condition otherwise required upon the expiration or sooner termination of this Lease. As used herein, the term “Termination Payment” shall mean an amount equal to the sum of (a) the unamortized costs (on a straight line basis over the period from the Substitution Space Commencement Date through the Expiration Date, as extended hereby) of any brokerage fees paid, the actual out-of-pocket cost of Landlord’s Substitution Space Work, and any legal fees related to the negotiation of this First Amendment of Lease, plus (b) one month (1) of the then current monthly Fixed Rent payment (less the Electric Charge) and monthly Tenant’s Tax Payment.

 

B.          The effectiveness of the foregoing option is expressly conditioned upon there not being any uncured default by Tenant beyond any applicable notice or grace periods hereunder at the time of the exercise of said option and at the time of termination (unless Landlord, in its sole discretion, elects to waive such condition). The Termination Payment shall be paid by Tenant and received by Landlord as consideration for the privilege of termination when, as, and if Tenant exercises the said option to terminate this Lease, as aforesaid.”

 

10.        Assignment Subletting. From and after the Effective Date, Article 11 of the Lease shall be deleted and replaced with the following:

 

“Tenant will not by operation of law or otherwise, assign, mortgage or otherwise encumber this Lease, nor the estate and Term hereby granted, nor sublet or permit the Premises or any part thereof to be used by others without Landlord’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. For the purposes of this Lease, any sale, transfer or assignment of any of fifty percent (50%) or more of the stock of a corporate Tenant or any transfer in the control of Tenant by operation of law or otherwise shall be deemed an assignment.”

 

11.        Tenant Work. Landlord hereby acknowledges and agrees that Tenant may (x) install a variable speed fan by the overhead compressor and (y) relocate the thermostat located in the Demised Premises to a location approved by Landlord (with Tenant acknowledging that Landlord has determined that there is no reason to relocate the thermostat); provided, however, that (i) Tenant shall perform all such work in accordance with the terms and provisions of the Lease, (ii) Tenant shall deliver to Landlord plans for such work, which must be approved by Landlord (such approval not to be unreasonably withheld, conditioned or delayed) prior to performing such work and (iii) Tenant shall be responsible all costs associated with the foregoing work and shall be responsible for all maintenance, repair and replacement of the relocated thermostat, fan and associated systems.

 

 

 

 5 

 

 

12.          Miscellaneous.

 

A.           The parties hereto agree that Sage Realty Corporation and Jones Lang LaSalle (collectively, the “Brokers”), were the only brokers who negotiated and brought about this transaction, and Landlord agrees to pay the Brokers a commission therefor as per separate agreement. Tenant represents and warrants that it has not dealt with any broker other than the Brokers, and Tenant agrees to indemnify and save Landlord harmless from and against any claims made by other brokers claiming to have dealt with Tenant. Landlord represents and warrants that it has not dealt with any broker other than the Brokers, and Landlord agrees to indemnify and save Tenant harmless from and against any claims made by the Brokers or other brokers claiming to have dealt with Landlord.

 

B.           Tenant warrants and represents that, to its actual knowledge, as of the date hereof, Landlord has performed all of its obligations under the Lease. Landlord warrants and represents that, to its actual knowledge, as of the date hereof, Tenant has performed all of its obligations under the Lease.

 

C.             It is expressly understood and agreed that, pursuant to this First Amendment of Lease, the Term of the Lease is only extended until the date which is three (3) years and one (1) month following the Substitution Space Commencement Date. Except as otherwise set forth in Article 27 of the Lease, any further extension of the Term of the Lease if the parties hereafter shall agree to same shall require a written agreement between the parties hereto and any such agreement shall not be binding upon Landlord or Tenant unless same is fully executed and unconditionally delivered by Landlord and Tenant.

 

D.           Except as modified by this First Amendment of Lease, the Lease and each of the covenants, terms and conditions set forth therein are and shall remain in full force and effect.

 

E.           This Lease may be signed by facsimile signature or electronic mail in portable document format and may be executed in counterparts, all such counterparts shall constitute the same agreement, and the signature of any party to any counterpart shall be deemed a signature to, and may be attached to, any other counterparts provided, however, that original signed pages shall be sent by the parties to each other promptly thereafter.

 

[Signatures appear on following page.]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 6 

 

 

 

 

IN WITNESS WHEREOF, Landlord and Tenant have respectively executed this First Amendment of Lease as of the day and year first above written.

 

   

SAGE REALTY CORPORATION, as Agent

 

 

By:/s/ Jonathan Kaufman Iger

Name:Jonathan Kaufman Iger

Title: CEO

 

 

ACACIA RESEARCH CORPORATION

 

By: /s/ Richard Rosenstein

Name:Richard Rosenstein

Title: Chief Financial officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 7 

 

 

 

SCHEDULE A

 

SUBSTITUTION SPACE FLOOR PLAN

 

[See attached]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   

 

 

 

 

 

 

   

 

 EX-31.1 3 acacia_ex3101.htm CERTIFICATION

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Clifford Press, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Acacia Research Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a). Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b). Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c). Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d). Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a). All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b). Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 15, 2021

 

/s/ Clifford Press           

 

Clifford Press

President and Chief Executive Officer

(Principal Executive Officer)

 

 EX-31.2 4 acacia_ex3102.htm CERTIFICATION

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Richard Rosenstein, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Acacia Research Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a). Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b). Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c). Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d). Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a). All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b). Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: November 15, 2021             /s/ Richard Rosenstein            
 

Richard Rosenstein

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 EX-32.1 5 acacia_ex3201.htm CERTIFICATION

EXHIBIT 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Acacia Research Corporation (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on November 15, 2021 (the “Report”), I, Clifford Press, President and Chief Executive Officer of the Company, hereby certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: November 15, 2021 By: /s/ Clifford Press                                     
         Clifford Press
         President and Chief Executive Officer
         (Principal Executive Officer)
   

 

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

 

 

 

 EX-32.2 6 acacia_ex3202.htm CERTIFICATION

EXHIBIT 32.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Acacia Research Corporation (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on November 15, 2021 (the “Report”), I, Richard Rosenstein, Chief Financial Officer of the Company, hereby certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: November 15, 2021 By: /s/ Richard Rosenstein                                            
         Richard Rosenstein
         Chief Financial Officer
         (Principal Financial Officer)
   

 

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

 

 

 GRAPHIC 7 ex1002_image1.jpg GRAPHIC begin 644 ex1002_image1.jpg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
) 2!\P9C\IQC)Q^O _'ZU',"6BY'WP#QS1+"TWE MJPV[6).&(/0\#'UY'XB@"8>X]\>P[CN/KU%')Z@GMR.G<\?T_$57^R1XSYDV M,YSYS?SSSGUZ'H:3[''@!GF';_6, >>>,Y_JOTH EG)^SRL.28R>#P>..?Z] M#C![5'HQ']HZA@Y 6(#CV/\ 7/%1W%FI@E.^XSL;CS22"1TP#^G0YXYIVAH( M]0U *Q8;8>2Q;^$]SU_R.U &Y1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!6/_ ,QZXX_A@_\ 9ZV*Q_\ F/7'^[!_[/0!L4444 ,E_P!4_./E-,,$>TGY MNG]\_P"-2, RE3T(Q47V?C'FR_\ ?5 $D?\ JU^@I](H"@ = ,4M !1110 4 M444 %&*** "BBB@"O=?=C_ZZ"K':J]U]V/\ ZZ"K':@ HHHH **** "BBB@ MHHHH **** "BBB@ K&M1_HYY(_>/U[_.>X]/7M6S6/:?ZE@.,2.3GY?XSSGU MQT/X&@"8X&!M)QGC'3VQ_3OU%!SG@^GS9S^/_P!?OT-!QC)(QUZ$<#^@_,4$ M'..>N""/7KQWSZ=#U'- "'ICT'(_S_\ K%+SGDG.>HQ_G)_(T=>>W49[>G_Z M^W0T#)8C'/(Z9^H_^M^(H 3H.>"0..Q[=#0AHSCE< XSUP#ST)]!^:_2@".3_ %L7/\?<^Q_SGOT/-/Y MZ9'\O_K#\UQZ=&R;%0O(<*O))XQ^ ]<\COU%-MV=XP6!4$@QDGYL$=3Z'L#^ M!YH E'!]>O/!S[?CZ=#U%(,@=>.._P"N[^1_ TI./3CJ!TX_I[=1VXI,9]X.?E//'^33I MS_HTK9PWEDG!P#QCKU_'MT--T<8U+4.H&(N,8['MVH V:*** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "D)Q2UD:_>7UG;+)I]I-=SD,%BC,8RVT[2V]T&W/7!S0!K9I:R] M%GN[FVDDO+6XMG,AVQ3^7N"[1_<9AC..M:E !6/_ ,QZX/\ LP?^SUL5 MC_\ ,>N/]V#_ -GH V**** "BBB@ HHHH **** "BBB@ HHHH **** *]U]V M/_KH*L=JKW7W8_\ KH*L=J "BBB@ HHHH **** "BBB@ HHHH **** "L>U_ MU'!P?-D P,X)8G_([]JV*Q[0Y@/^_(!GD??)/_ZNU $O4;N >&(S^7/\C^!I M<#!].1T[#KQ_3\10"<_Q9X/;(S^F?T/UI 1U&,>H/0#W]/?L>* %''XD'.>I M/]AZ&@!,' MH0<\@'&3SRXZ[A MZ@$@G]/P[]O< KW$2RM"KL0%W8^U.$ )VB27GL7.,G_/T/UI9 M>'C/3!SU[ ''/\C^!J3G!'&.0>,>Y_\ KCJ.HH A\D8W%YL?>&9&S[?_ *^H MZ&E^SC)4R2YY!)8_CQ_3\14I)!SD^H.>I/3\?T-' &.,#\!@?Y_"@"O/ /(F M.^4D(_-&BH$U"_QTVQ?Q$]CW//X=NE2SY^SR 9#!&P2.^.>/ MYCOU%1Z.1]?K6MVKG_%HM&TU5OKB2*V#&21$E5/."J3Y9W## M_P!W@'OQF@";PRZS:2MRMQ#.+B1I ]O$T<6"<#8&YV\9ST))(ZUM5E:%<)@#8HHHH 1F"@D]J89D"ECN SG::60$HP'7!J.1W9&40R<@C.5_QH F! MS2TB]!2T %%%% !1110 4W>HZL!^-./2JT4:-),612?,[CV% %@,&Z$'Z&EJ MO;J%EG"@ >8.!_N+5B@"O=?=C_ZZ"K':J]U]V/\ ZZ"K':@ HHHH **** $9 M@HR2!]:02*3@,"?0&HIU#2P[@",G@CVILD:+)#M10=_4#_9- %FBBB@ HHHH M **** G%8UJR_9R=PQYCYRV.-S_0]#[@#R"< CGG (X)^GZD?B*7G.?QP3D^Q],^A[]#2#&!PO3IV/_P!; M_P!!^E1&)^G3@^P'?Z=NHK$BU@2B)@+P"1=ZG:K<;2W) P"=I M')^;ZUJ64S7%E',Z,I9O3G\C386 MD92S@JN?E+9!V^I]/YKG!I+RW,\:[6*LK;ACY03Z$?J1^(]*9#$LOS"6X# X M96E/!_Q]#T(^N: +6#N)P?0C'K_GD?B*,^_'!R&Z>G/\CWZ&H/L@V@":<\=3 M(?\ (_F*#:_-_KK@\_\ /3/^<^G?ZT /N,_9I00/]61RN!C&?R_4?2F:1_R$ M]0YZK"?_ !T_Y]ZCGM1]FD/GW'"'.)R.W7/\C^!I=$C,=_?KN=OEBY;_ '3^ M5 &W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 5DZ]))%:>9$DYD7)5XYTB6,X^\[/QM] M>&Z_=-:U9.N16$L,"WU@UZ1,K01+'O;S "0PZ $#)R2 /6@!OAV^EU#2Q-// M:3S!RLDEF#Y1/'W6/W^"/F /8"MBLW1(HH-.2*%I_)C.R.*?&Z%5&T)D=0, M=223ZGK6E0 5C_\ ,>N/]V#_ -GK8K''_(>N/]V#_P!GH V!1110 4444 %% M%% !1110 4444 %1M!"S%FB0L>I*CFI** &I&D8PB*HZ\#%.HHH KW7W8_\ MKH*L=JKW7W8_^N@JQVH **** "BBB@!KQI(,.BL/1AFFK!$C;EB0$=PHJ2B@ M HHHH **** "BBB@!" 000"#V-8MG#$(P']/;J M#TJ$&6-F1;=R-QP59>2>3P3C/Z&CSI"H[T ,DVBZRYQ\C= M\9^[^9_G4Z'Y!R#Z'/;.!^'OU'>J%S*1HH )RP"!3M)8#@X& M.W/7'Z@^U+\\8Y5"I?:<9SDG!^I]>Q XHERQBYY#@^O8X_\ K'\#2LC. &=< M9!^[Z'.#SQTZ=1SB@"3)[8SQWX^O] ?P-(>A!Z<\$=AVQ_3L>1Q1CG/O@CT) M_KC\#]:#PN1C'7.<>P]_Q[=^* &3\P2#)SL;!R"1Q^6?T/UJ/1\?VEJ&% ^6 M'H/]D_Y]NE23C_1I5(!^1A@CVST_F/Q%1Z1_R$K_ #UV0]\_PGOWH V:*** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "N=\7:E;:7IT=S=3I"@9(V"@$GE@0>G2@"'PI8WWB,#H,=JWZR]%%T+5Q>I.DWFDD32K(V,#NH Q[8K4H *Q_\ MF/7'^[!_[/6Q6.#_ ,3ZXX/W8/\ V>@#8HHHH **** "BBB@ HHHH ***,T M%%)D49H 6BBB@"O=?=C_ .N@JQVJO=?=C_ZZ"K':@ HHHH **** "BBB@ HH MHH **** "BBB@ K'M>+T$;<#'3&./?C^G;M09 MQ[]#VI!:6R\"%!Q_=_/\OS M% "R;XY/M"J70@;E[@=B"?Q^O3KUDC97C4HP*$<8SC ]!U_#J.U,%K &XA&[ M)R,9Y_E_C]:(-JV\6/N[5.=W'3KG^O8\&@!)XGD"&-RCJV1T^8D<@_A^?6DA M(E3B20,.60MT_P G'/;Z4Z5B)(4!*[V*D;1Z$XQ^1(_$5(JJ@RN<9SPW4'W.?\ #\10(N/Y?2DT52NH M:@"2?EBY)Y^Z>O\ GGKWJ6<@6TASD;#@ANV#CG^1_ U'HYSJ5_P1A81TQV/_ M ->@#9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH .U9.MVZW0MXGL;>]4LX(] M>U:U)CF@#/TBW^RP21C3[>Q4R[A% 05Q@<\ =\]ATK1HHH *Q_\ F/7'^[!_ M[/6Q6/C_ (GUP<_PP?\ L] &Q1110 A.*A-RF,[9?^_3?X5)("8V ZD&F&?* M_P"JE_[YH E4Y&:6FQC$:@]<"G4 %%%% !6?>-(LQ**[_*ORK(5Y)(K0[569 M%DNV5AD>6I_4_P#UJ *:F<\-$Z-NV8:Y;KC/;-/@N%BF(N)5CR/E#3%LC)&> M?I5OR4"A4)7#;NN>:BB&W4749X@3_P!":@"07UIC_CYA_P"^Q1]NM/\ GYA_ M[[%.64LH8(<$9'(I?,?_ )Y_^/"@"I1GDB@!GV^T_Y^8?^^Q1]OM/^?F'_ +[%/\QAU3_Q MX4CS,B,YC.%!/!% #?M]I_S\P_\ ?8H^WVG_ #\P_P#?8IRRLRAA&<$ _>%+ MYC?\\_\ QX4 ,^WVG_/S#_WV*?'K'V].W MXBMB;)B? ).#P.]9?VD2!R$E(+/SMST)'Y Y]P?:@";/ .>N/F!Z_CT_'OT- M'4$>WOZ^O7C\UI>^,=>"",_7CW].AZCO2'.1R2>"#WSZ_P! 3]#0 <8SVS^O MI[G]#]:7'3'!&/\ ]>?Z_@:0=>!R1CIU'I_];MU'% Z]21Z@_P!>^?R/UH , M XXZ=B.GMC^GY4R#_41=SM7 XYX_($_D:?W&#CW''T_SU'T-,A&((LYQL&5Q M[=A_3\10!'/@20MD;0QRV>V",Y]CQZK4OF*3@D@DD8(ZY[8_IT/44R?.Z$\E MA(#P>>G7)XZ=#WZ&FSJTT80*ZGOG^O?H> M]!QCMC'/](N",XSNR?I^/Z]N:/L^.?M,P[YWX'US^F?P- #Y MR3#-QGY&..N>#_/\C]Q[]_\CM4=S:_Z/*!-< !&.W/3 MCIC]<=>@#8HHHH 3%&!2T M4 %%%% !1110 =J@'_'ZW_7-?YFIS4 _X_'_ .N:_P S0!231D22W=;F8^2P M8!\-GY0O4\_P]O4U9C(_M27!Z0H/_'FI[CS9"ASY:CG!ZGT_SZU! JKJ]R%4 M "&/@#W:@!J)*\$IC=@^T*JEB!G:"/IR:I)!J*.B?;FD"PLA9FPYD.2&V[<< M<=\8'>KD-RD0:-G1&RIR[ #8O/O4@>U'/VJ/SY24+&'1G!)^1L@C:>?: MI!V,?*/SH RY8-6"2I;W:NWD>7$7D*-YF?O%0A'ZX_G6I+&1 M"[EFR588W''W31OM<%A9C[^]<_P#ZO:DDN4EC>/>A?:Q^1LY&T\T 1B.9 MK:7R)&63: N6. =HP1_G%9\MMJX$Z0WRNS0+'"6?8PE#$EF 4YXQWQQ^-:,- MU&FZ/S(U;(SO8#'R+^=/,EH"6%U$)".9#("?Q]O:@!MPK*A)9N58;=Q('!JR MW_'^G_7-OYBJL]PDOR!T+!6/RL#D8J6\^])_U[R?TH N9HS52.-8+5'C 0*@ M)4#@C%-EC$UE))(-P:,L%;D#CTH O4A.!1D8ZTV0C8W(Z&@"K_:UC_S]1?G1 M_:UC_P _<7_?55+3BSB _U8&,=21SQ_3OVJ88P#G/0YSR/[I_\ K_GWH E_ MM6Q_Y^HOSK/M9XO)/[Q?ON>>,_,<<_U_.K8QTXXXZ<8'7CZ]NHHRUQ@JS1VX/#A2&8#K@=0 <<=?3BI!/&0 [A6Z$?[1Z_C^AJ M7.3N!&#SG/! Z9/7\>W0T 8^4]^-N.OJ,?KC\10!%]HB//F*>_7IZ?\ Z^W0 M\4?:(2?]8I/?YF#^(/ MM0!&+F+J)5SQSN[GOD^W?OT-+ 0+>(\!?+7!(QP!T]>/3J/I4G.<<[NXZD'O M_P#7'?J.:3<A/OC\\C.#0 M!*!U'<9!^@_^OVZCM1SUR6W/(&!TY[?S'TIFCX&I:@ " !%P1CG:<\5)<$_9Y M"#R4)R&ZY& <^OO^!J/1_P#D(W_.1MAQQ_LG/_ZJ -FBBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "L?_F/7'^[!_[/6Q6/G_B?7 _V8/\ V>@#8HHHH ** M** "BBB@ HHHH #5(A+I5E:SWY48+$=*NFJI8QR[8QO!/*YQM- #[6!88%14 M"\ D =\9)$C/C&XCG%3 Y&:-P]10!7^P6V,""/';Y:F,2$8VK^5/ MSFB@"O\ 8;7_ )X1_P#?-'V&UQCR(_\ OFK%% $9@C*E2BX(QTJ+[!;?\\(\ M?[M6:* *_P!AMO\ GBGY5+Y28QL7\J?10!5.G6C*5:",J1@C%-&E60W8MUY& M#R>E7"0!DTFX>HH ".*0H"NT],8IU% %;[!;?\\A^9H^PV__ #R'YFK-% &/ M);QVEX%@M_D,6" V.,^Y_ER*>DC,[!D*$#.3@@DY&.._'T.:DO6*W8*H6Q'D MC/3GK_\ 7J.'E"Q.XGKGCGH1CMC'*]NHH > /3OC., >_I[]NAHP3Z\<#*_ MB>/UQ^(I?<-W&"#_ %]\=>AHZ\<9].0#_7C\Q0 G.XDG/]?P-1R0QY>4#YMN" 3C\ MO;\QVXQ2Q%C''\J_=&"#UX^G?\C0 _'&#V&.GY\?TZCMQ2G)SZDY(&" ]SZ'H3T/!]:6(-,A99Y.ZE2JD@]U(QU]5_$4IG,EPB1Y*,<;P02W M';_'H<8J5$5,\_>.6;_/8<#U'TZ #?*;J+ER"<@C;^!SCD^_0]#2>2^,&=_3 M[HQCOQC/7\5^E3'(;GC/XY/I^/IW[O;OC\<_U_ T 5IHY/(E_?RE@C M<80D$CZ8Z=N_44NBJ5U'4,N7^6'YCW^4]\H=?NPYR<_PG_/O0!LT444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C M_P#,>N/I!_[/6Q6/(/*UN60MPR1,?8*6!/ZT ;%%(.E+0 A(49-1?:8\9VR_ M]^F_PI\HS&P]C33*N" KY_W#_A0!("&&1TI:9&,(H]A3Z "C-%4+YW28%2Y M3) >G%/%O(Q+FYN=G M'"OR/E!_&@#3I,U0-LH3>;ZZV^TF?Z5');S(A?[3<@<@!GR>G6@#4HK+2WE8 M;VNKDIWVORO ]N:D-LH3=]MNMO8B3.?TH FOP&LI 0",#@_6FK#%#?+Y<<:9 MC;.U0,\BJLUO(J,6GG*E6PCOGH,Y-6Y[=)[M-^[A#C!QW% %K1RN?+7> -V. >.A/?M51+?465M]O)$?*1ANE0@N<;E.#P!_G- '2; MAZBG9S6++:;%:19)2FQBH8]?ESG&.*V$^X/I0!0NF(OU 5F_=]@/7I_G@_E4 M:@[WRH"$ \GOZ_0<8/4?2DOD!OXR6==Q$9VD\J03C\Q2QVW[UO,DG*DY4Y;* MG&/?/?GB@!_1CQCD]LY]O_K=^HI>W'/3G.2/Q[_7OT-1"V'F$&2;R< !06XQ MG!_EQCBI+6UCDT^"5S(7:(,3YK=2!GOWH .F#QG'X'V]>#VZBH2P%[V^YWP, M\^GO^1IH@<-_A0]J6/S13,,;/\Y'XBJBVZK-?YXQVH UZ*** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH *SM3MG8)G7_#Z4 ; M.**R/L>I?]0__OVW^-)]CU/_ *A_M^[;_&@#8 Q161]CU/\ ZA__ '[;_&D^ MR:F!_P P_P#[]M_C0!L9JI<%1*J3K57:(P>WN33D_Y";GU MX]/\FHXI;81+OQN*C/R'_"I//L\=O^^#_A0 RXD5HXUY#"094]1P:>D@"LB_ M-)P0N<=AU]!44T]H8SL*[@1T7WY[>QIRW-GM&YEW #/RGM^'M0 _R&5S*"&? MN,X!_P ^M-N)5:+;T?/*GKTI?M-D,_,G'^P??V]C4GUID4UIL7=MWX&[Y#G./I[4_S[/V_ M[X/^% #+J16C('#!6R#U'!JP?^/L?]"%QQ4 M-I#<1V4,3[ RQA#WZ#%5+&+4Y;-);\0Q7Z<;H>49>.V>AY^GKZZ,$QGMXY@- MN\ X/:@"100N#3JQ[;Q1I-ZVVVNC(<[<")\YXXP1U^8<>_L:O6=_;:A$9;64 M2QYQN (YP#W]B* *UWC[1(!P64#/MRQ_]!IL'_'M"<,#GU]^_0TYP M!+/V$G8,G:W7'7_ !% %_;SC P>V../UQG\ M0:7!)!&=P/!QSD\G/X=NAJF--U '&+';Q@#<"/Q_D?YT'3=0QTL"<=U;'Y>G MM0!--N66)PI(7)('.../_P!?X&E5U=R@5PP!R"I!&>OZ]A]14']FZAD$_8CS MG)5N/\_K4?\ 9%_]I,Q^PG]V$QM;L2?Z\>E %\$'##C=SD'@YZ$'O['H>_-( MQ55(? 0#/.1@#]< ]^H-5?[-U#G'V'G/56Z^O3\Q31H]^S MW-;&G6GV*S2'.2,ECZDG)I MMEIEO9Y9 6D8?-(QR6J[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ I&^Z?I2TC?=/TH HG_CUD_P"O=?Y-3)]#T^XNI+I[8&>0 M;6D#E6QQW!XZ#]?6G,P%J^2!FW7'Y&GSW30NBK\^\XR.QZ]@?UQ0!37PQHZ, MS)81C>],$$00/(G!)4$>O&>U4 MMVL*M8?9O-+C>;AFY7;G Q[G\.>M3644DEQ_IP@DN!"NYH@=H.YNF>G&* +< M$<2R;HD1(P-J[5 !_P#K4S4H[Z6U*Z?<1P3$_?DCW@#Z9&:AGM;JX6P>"Z:! M8G5Y5P3YB_W>H_7(YZ5-J!U 6X_L](6FSTF)"X_"@#/F9AYR_:(> PPR\Y_> M>X]?UJ(-=A[HRW]FZ,SF,)"5*KE^"?,.3[X'TJ5A<&-R\$._8=V'/WL29Q\O MK4CK-^]_T>'H^/G/J_\ LT 5!)=BZNB]]9M"P/E(L!#+S+G)\P[NW85=\T[G M_P!+MN=W\/NW^U59A??;IE-I:_9?+;$@F;?NS+QMV8QTYW?A4I^W?:55;&T\ MDA_,#SW)'^ !+(US(K);7=L)B1M.W/\1)[GMGM5RS2ZCM56[F M6:8=71-H/X56<72Y,-O!Y@/'SGU;/\([59LC=FU3[:L:W'\0B)*C\P* &7$$ M4DH:8L49=N-Y 'UP>_\ 05+#:P6[%HDP6'7<258'!PI]L_IWH UI)(XD+ MR,%4=S3E*D @@@],564"[6&4AU49;81C/;G/--MXY(9I(%D_=* R C)&2W&? M3CB@!LHF^V.T)!*KRA_B''&>W^>*17N2[R9)48/DL " 1[=_QQUJ.[G%M<9> M4!G7CD ^^,\=!3'OE"$B9=SXZ,OI[\>E ")JL<$]Q%=2X82X0$J,*0N![\DU M5Y&+QDOAADCD8J:Q=4LH5=@K! "#UH R6TW6B/^ M/BS8E&!)A'4J .,=CD]3G &!UK3TR"]@MR+ZY2>4L2"D80*.PXZ_6KBNK#*D M$>QI$7_? J:B@"'[+;_P#/"/\ [X%.:&*3!>-7(Z;E MSBI** (OLMO_ ,\(O^^!1]F@_P">,?\ WR*EHH B^RV__/"/_O@4Y(HXB3'& MJ9Z[1C-/HH KR0&2<2"1E^7;@ '//N*/LQ_Y[O\ ]\I_A5BB@"NL!24/YC, M",%5'7'H/:IR.*6B@"#RFW,0Y&3G'/\ C1Y3_P!\_F?\:GHH @,+=W_G_C4L M:[(D3^Z *=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !112'I0 M%9]U?/:R_-"3#@?.KY.2< ;?J0.OK3#JFR55DB/E MN55'1M^2W3( X'O2NAV9IYHK+_MB *&?>HP=WRL2#E0 !CG.XHJA#JUG/#@KM/3.,_3/&:+H=F7:*J)J M%O+%YLWVI1WLZP^&Y;F/*_OUNHUWA>00"G/&-%M2Y5T )'[L$D_C@@?A2]F_YOP17M8_R_G_ )F5]OU;<6'A*<$YSMOH MQU.3GGU)-1O<:E(I5_!\K#+'!OH_XL[N_?)SZUOQV\T>I7,^U#'*L:@ACGC= MGC'N*K_9+^/4-1F@$2BYC012,Q.QE1ADKCD9QWH]F_YOR#VL?Y5^/^9E)=:I M'*LJ^#Y@ZG<#]OCX/S>_^TWYU9_MO7L_\BM/_P"!L57TBU+$!>1,@YD ;C[Z M\=.<+N'XC\$>#4'2-LIYR%N=_!XX(XZ''3MFA4W_ #?@@=2+^ROQ_P RC_;> MO?\ 0JS_ /@;%1_;6O?]"K/_ .!L56Y(M9\V8Q2P["V4#G/&\G'08^7 [\C\ M:M64-['+*;J82+M0)C R=OS$@#CGWI\DOYOP0O:1_E7X_P"9E?VUKW_0JS_^ M!L5']M:]_P!"K/\ ^!L5=%Q1@4N27\WX(.>/\J_'_,YW^VM>_P"A5G_\#8J/ M[:U[_H59_P#P-BKHL4';1R2_F_!!SQ_E7X_YG._VUKW_ $*L_P#X&Q4?VUKW M_0JS_P#@;%71<48%')+^;\$'/'^5?C_F<[_;6O?]"K/_ .!L5']M:]_T*L__ M (&Q5T7&<48%')+^;\$'/'^5?C_F<[_;6O?]"K/_ .!L5']M:]_T*L__ (&Q M5T>WVHV^U'++^;\$'/'^5?C_ )G.?VUKW_0JS_\ @;%1_;6O?]"K/_X&Q5T> MWVHV^U'++^;\$'/'^5?C_FWVH MV^U'++^;\$'/'^5?C_FWVHV^U'++^;\$'/'^5?C_FWVHV^U'++^;\$'/'^5?C_ )G.?VUK MW_0JS_\ @;%1_;6O?]"K/_X&Q5T>WVHV^U'++^;\$'/'^5?C_FWVHV^U'++^;\$'/'^5?C_FSD_M?@A^U5OA_%_YG)O= MZO)(&/A.XQT?-]&=PP1@\].3^=+]IU/SO._X0^;S,$;A?1]"F><5U?%* M![4>S?\ -^"#VJ_E_%_YG)K=ZJD:HGA&X"H %'V]!M Z8YXX.*;)6;_C^CZL&!/7N&;\ZZ['M2;?:G[-_S?D'M5_+^+_S,W19;F6&0W.EOIY\P MD1M,LF[/).16K30,=J=6B5D9MW=PHHHIB"BBB@ HHHH **** "BBB@ HHHH M*1NE+10!E"S4:L\OGQF%L.("1D2[=I(]BI''J,]Z1(;R.'89XA(454^? X"[ MAC'LW(YP>G%23VCB^>[AA@:3R=J!^,OG(R0#@>]%S +RXMI42&2..3?YF_D$ M'H.#QU[CD4 0WMG)>064/FQF6*>.9]YY95ZXXY/X"F30R1F1+2]BC"!!L>3H M-Q+Y 'RY! !'3VJ>.S=+FT)AAV0I@/GY@<$<#'3\?Y5'1W688/WS;=\ M9V-M&.2P')W#..G S0 UK:_EW:&/3M22XDD M-W#YL@C$S(3E@HDZ1A6*KU(5 "!T7[IR. M0?E]#2M9G^T78W7E,ZN!L;#L&VX_+:VUQ?+"]E/$5C5L$R'E^,);W*M,#(\S-&=QPJ$\#IQQ]>M-M;">.]^T3R!\1; M$^G0G! SUXK1R*6@#+%G>1VQBB:./,SOE6.2K.S>G!&5]>A'O226NI M2-<[;A$#JHB.22O3.1@=3GH?3FM7%% &3+9Z@6+0S1H2V[ 8C)PF,\?[+?F/ MP33C>M>7#72RA2Q\O=]T ,V./7&/R'WL5E+&XU.Y_U=HBX[8.68G 'K77&N/\=:%/K%O9 M36NGIJ4]I(S1V=Q*$MW8XPTH)&X#' '<\\9IH4MCS;^V+O\ Z*Y'_P" LG^% M>B>#=6N;WP;=7=M)?:C-$T@MY[T!#>,JC#*/X4+94=^#WKE?[%\:]?\ A!_! M^?>"/_XJNX\-Z1K-EH%Q!J=_&=1N'=U>!/W=KE J)&O3:H4''3.?6AD1N4?VAHU_&(0J@_.D:;=P9>Q[XYKIKOXB:)97-XA2_FM[ M-VBN+V"U9[>*0=8RXXW=!Z9(YYK&O="\4ZZVF6VJ:;I<5Q9W<<\NKPS?/(J- MD!4VY5CWYQQ^3%T'Q9IFAZKX;T^PTZXL[EIS;WLUP5*QR$DJZ8RS\X!Z>O3D M'=HWI/B#I&Z%;:WU*]9X4GE%G:-*;9' *F7;]W(.<=<41_$'2+BPM+FSAU"\ M>[,GDVUM;%YBJ-M9BN>%![DBN7T.UUCP?>WMO9II%[)/;6S744O R7=@>G<, ? M]VMNB@#)BL+V,*&G#+N^92S'(VJ,YZYR"<=.:&TZZ(8)*%4ONP'8=W)Y_P"! M+^5:U% &&VEZD\,ZM?LSO&%0ABH4X7)X'JIP?]JIAI4G]KF\,Q,7!6/I@CN? M7_ZP^M:U% &'_9NI)';XO-S0Y+9)S)][ )Z=".<#I^26=CJAC@:>.J!B9(P<[OFR.3[#!%11Z3?8 FN4< MAG(8%OE!CV#& EX-101.SCH 8 actg-20210930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - INVESTMENT AT FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STARBOARD INVESTMENT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - INCOME/LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INVESTMENT AT FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - INCOME/LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - INVESTMENT AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STARBOARD INVESTMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - INCOME/LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 actg-20210930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 actg-20210930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 actg-20210930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Redeemable Preferred Stock [Member] Equity Components [Axis] Series A Redeemable Convertible Preferred Stock [Member] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Product and Service [Axis] Paid Up Revenue Agreements [Member] Recurring Revenue Agreements [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] One Licensee [Member] Two Licensee [Member] Three Licensee [Member] One Licensee 2 [Member] One Licensee 3 [Member] Foreign Licensee [Member] Accounts Receivable [Member] Financial Instrument [Axis] Equity Securites Lf Fund Public Securities [Member] Equity Securities Other Equity [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Valuation Approach and Technique [Axis] Black Scholes Method [Member] Award Type [Axis] Restricted Stock Units [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Restricted Stock Units (RSUs) [Member] R S As [Member] Non Qualified Stock Options [Member] Transaction Type [Axis] Option Agreement [Member] Counterparty Name [Axis] Portfolio Companies [Member] Equity Securites Lf Fund Securities [Member] Equity Securites Derivative [Member] Equity Securites Forward Contract [Member] Equity Securities L F Fund Trading Security [Member] L F Fund Securities [Member] Investment Type [Axis] Warrant Investment [Member] Common Stock Investment [Member] Starboard Value [Member] Series A Preferred Stock [Member] Series A Warrants [Member] Securities Financing Transaction [Axis] Series A Redeemable Convertible Stock [Member] Series B Warrants [Member] Securities Purchase Agreement [Member] Long-term Debt, Type [Axis] Senior Secured Notes [Member] September Redemption [Member] December Redemption [Member] Merton [Member] New Notes [Member] Balance Sheet Location [Axis] Assets [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Equity Securities [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Liability [Member] Series A Embedded Derivative Liability [Member] Series A Warrants Liability [Member] Series B Warrants Liability [Member] Share Repurchase Program [Axis] Stock Repurchase Program [Member] Employee Stock Options [Member] Antidilutive Securities [Axis] Equity Based Incentive Awards [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Restricted cash Equity securities at fair value Equity securities without readily determinable fair value Investment securities - equity method investments Investment at fair value Accounts receivable Other receivable (Note 3) Prepaid expenses and other current assets Total current assets Long-term restricted cash Patents, net of accumulated amortization Leased right-of-use assets Other non-current assets Total assets LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Accrued compensation Royalties and contingent legal fees payable Accrued patent investment costs Senior Secured Notes Payable Total current liabilities Series A warrant liabilities Series A embedded derivative liabilities Series B warrant liabilities Long-term lease liabilities Other long-term liabilities Total liabilities Commitments and contingencies Series A redeemable convertible preferred stock, par value $0.001 per share; stated value $100 per share; 350,000 shares authorized, issued and outstanding as of September 30, 2021 and December 31, 2020; aggregate liquidation preference of $35,000 as of September 30, 2021 and December 31, 2020 Stockholders' equity: Common stock, par value $0.001 per share; 300,000,000 shares authorized; 49,591,852 and 49,279,453 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively Treasury stock, at cost, 4,604,365 shares as of September 30, 2021 and December 31, 2020 Additional paid-in capital Accumulated deficit Total Acacia Research Corporation stockholders' equity Noncontrolling interests Total stockholders' equity Total liabilities, redeemable convertible preferred stock, and stockholders' equity Statement [Table] Statement [Line Items] Series A redeemable convertible preferred stock, par value Series A redeemable convertible preferred stock, value per share Series A redeemable convertible preferred stock, shares authorized Series A redeemable convertible preferred stock, liquidation preference Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Revenues Patent portfolio operations: Inventor royalties Contingent legal fees Litigation and licensing expenses - patents Amortization of patents Other patent portfolio income Patent portfolio expenses Net patent portfolio (loss) income General and administrative expenses Operating loss Other income (expense): Change in fair value of investment, net Gain (loss) on sale of investment Change in fair value of the Series A and B warrants and embedded derivatives Gain on sale of prepaid investment and derivative Change in fair value of equity securities Gain (loss) on sale of equity securities Earnings on equity investment in joint venture Loss on foreign currency exchange Interest expense on Senior Secured Notes Interest income and other Total other income (expense) Income (loss) before income taxes Income tax (expense) benefit Net income (loss) including noncontrolling interests in subsidiaries Net income attributable to noncontrolling interests in subsidiaries Net income (loss) attributable to Acacia Research Corporation Net income (loss) attributable to common stockholders - Basic Basic net income (loss) per common share Weighted average number of shares outstanding - Basic Net income (loss) attributable to common stockholders - Diluted Diluted net income (loss) per common share Weighted average number of shares outstanding - Diluted Beginning balance, value Balance at beginning, shares Net income attributable to Acacia Research Corporation Net (loss) income including noncontrolling interests in subsidiaries Accretion of Series A Redeemable Convertible Preferred Stock to redemption value Dividend on Series A Redeemable Convertible Preferred Stock Stock options exercised Stock options exercised, Shares Issuance of common stock for vesting of restricted stock units Issuance of common stock for vesting of restricted stock units, shares Issuance of common stock for unvested restricted stock awards, net of forfeitures Issuance of common stock for unvested restricted stock awards, net of forfeitures, shares Compensation expense for share-based awards Repurchase of common stock Repurchase of common stock, Shares Ending balance, value Balance at ending, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net (loss) income including noncontrolling interests in subsidiaries Adjustments to reconcile net (loss) income including noncontrolling interests in subsidiaries to net cash (used in) provided by operating activities: Change in fair value of investment, net (Gain) loss on sale of investment Depreciation and amortization Amortization of debt discount and issuance costs Change in fair value of Series A redeemable convertible preferred stock embedded derivative Change in fair value of Series A warrants Change in fair value of Series B warrants Non-cash stock compensation Loss on foreign currency exchange Change in fair value of equity securities (Gain) loss on sale of equity securities Gain on sale of prepaid investment and derivative Earnings on equity investment in joint venture, net of distributions received Changes in assets and liabilities: Accounts receivable Prepaid expenses and other assets Accounts payable and accrued expenses Royalties and contingent legal fees payable Net cash (used in) provided by operating activities Cash flows from investing activities: Patent acquisition Sale of investment at fair value Purchases of equity securities Maturities and sales of equity securities Purchases of prepaid investment Equity securities derivative and forward contract acquisition cost Purchases of property and equipment Net cash used in investing activities Cash flows from financing activities: Repurchase of common stock Issuance of Senior Secured Notes, net of lender fee Senior Secured Notes issuance costs paid to other parties Dividend on Series A Redeemable Convertible Preferred Stock Issuance of Series B warrants Proceeds from exercise of stock options Paydown of Senior Secured Notes Reissuance of Senior Secured Notes Net cash provided by financing activities Increase in cash and cash equivalents and restricted cash Cash and cash equivalents and restricted cash, beginning Cash and cash equivalents and restricted cash, ending Supplemental schedule of cash flow information: Interest paid Income taxes paid Noncash investing activities: Trade date receivable from sale of equity securities (Note 3) Patent acquisition in exchange of notes receivable Patent acquisition accrued liability - short-term Patent acquisition accrued liability - long-term Acquisition of prepaid investment securities Description Of Business And Basis Of Presentation DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Investments, Debt and Equity Securities [Abstract] EQUITY SECURITIES PORTFOLIO INVESTMENT Schedule of Investments [Abstract] INVESTMENT AT FAIR VALUE Patents Net Of Accumulated Amortization PATENTS, NET OF ACCUMULATED AMORTIZATION Starboard Investment STARBOARD INVESTMENT Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] STOCKHOLDERS’ EQUITY Earnings Per Share [Abstract] INCOME/LOSS PER SHARE Subsequent Events [Abstract] SUBSEQUENT EVENT Description of Business Basis of Presentation COVID-19 Pandemic Accounting Principles Principles of Consolidation Segment Reporting Use of Estimates Revenue Recognition Patent Portfolio Operations Concentrations Related Party Transactions Cash and Cash Equivalents Equity Securities at Fair Value Equity Securities Without Readily Determinable Fair Value Equity Method Investments Investment at Fair Value Impairment of Investments Long-Term Restricted Cash Patents Impairment of Long-lived Assets Series A and B Warrants Embedded derivatives Fair Value Measurements Treasury Stock Stock-Based Compensation Income Taxes Recent Accounting Pronouncements Disaggregation of revenue Schedule of equity securities Schedule of unrealized gains or losses Schedule of gain on investments Schedule of intangible assets Schedule of financial assets and liabilities at fair value Schedule of changes in fair value Level 3 liabilities Schedule of future minimum operating lease payments Schedule of repurchased shares Calculation of basic and diluted net loss per share Number of new patent portfolios acquired Schedule of Product Information [Table] Product Information [Line Items] Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items] Equity securities - cost Available-for-sale Securities, Gross Unrealized Gain Available-for-sale Securities, Gross Unrealized Loss Equity securities at fair value Concentration risk percentage Proceeds from sale of investment Loss on sale of investment Assumptions used for derivatives Option Forfeited Option Forfeited Weighted Average Grant Weighted average grant-date fair value Stock-based compensation Unrecognized stock-based compensation expense Weighted-average remaining vesting period Effective tax rate Marketable Securities [Table] Marketable Securities [Line Items] Change in fair value of investment Loss on sale of trading security Gain on sale of prepaid investment and derivative Gain on sale of prepaid investment and derivativey Net realized and unrealized gain (loss) on investment Offsetting Assets [Table] Offsetting Assets [Line Items] Payment to acquire equity securities Investment Holdings [Table] Investment Holdings [Line Items] Change in fair value of investment Change in fair value of investment Gain on sale of investment Loss on sale of investment Net realized and unrealized gain (loss) on investment Remainder of 2021 2022 2023 2024 2025 Thereafter Patents, net   Accumulated amortization Accrued patent acquisition costs Accrued patent acquisition costs due within a year Accrued patent acquisition costs due within 2 years Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Stock issued Warrants issued, shares Conversion price Proceeds from issuance of preferred stock Payment of stock issuance costs Accretion expense Fair value of embedded derivative Fair value of warrants Warrants exercised Proceeds from issuance of debt Repayment of debt Debt stated interest rate Notes exchanged Capitalized lender fees Unamortized discount Accrued interest Repayment of debt Debt maturity date Long-term Debt Amortization of discount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of assets Derivative liability, beginning balance Transfers into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance Remainder of 2021 2022 2023 2024 Thereafter Total minimum payments Less: short-term lease liabilities Operating lease costs, net of sublease income Income from settlement Contingency accruals Schedule of Stock by Class [Table] Class of Stock [Line Items] Number of shares repurchased Average price paid per share Approximate value of shares that may yet be purchased Stock Repurchase Program Expiration Date Class of Treasury Stock [Table] Equity, Class of Treasury Stock [Line Items] Stock Repurchase Program, Remaining Authorized Repurchase Amount Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Numerator: Net income (loss) attributable to Acacia Research Corporation Dividend on Series A redeemable convertible preferred stock Accretion of Series A redeemable convertible preferred stock Undistributed earnings allocated to participating securities Net income (loss) attributable to common stockholders - Basic Add: Dividend on Series A redeemable convertible preferred stock Add: Accretion of Series A redeemable convertible preferred stock Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative Less: Change in fair value of Series A warrants Less: Change in fair value of dilutive Series B warrants Add: Interest expense associated with Starboard Notes, net of tax Add: Undistributed earnings allocated to participating securities Reallocation of undistributed earnings to participating securities Net income (loss) attributable to common stockholders - Diluted Denominator: Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic Potentially dilutive common shares: Potentially dilutive common shares Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted Basic net income (loss) per common share Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share: Antidilutive shares Accretion of Series A Convertible Preferred Stock to redemption value Number of patent portfolios acquired Accrued patent acquisition costs Warrants exercised Approximate value of shares that may yet be purchased Denominator [Abstract] Assets, Current Assets Liabilities, Current Liabilities Treasury Stock, Value Stockholders' Equity Attributable to Parent Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Other Operating Income (Expense), Net Cost of Goods and Services Sold NetPortfolioIncomeLoss Operating Income (Loss) Interest Expense, Debt Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Net Income (Loss) Attributable to Noncontrolling Interest Shares, Outstanding AccretionOfSeriesConvertiblePreferredStockToRedemptionValue Dividends, Preferred Stock, Stock Stock Repurchased and Retired During Period, Value ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockEmbeddedDerivative Unrealized Gain (Loss) on Derivatives UnrealizedGainLossOnDerivatives1 Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax GainOnSaleOfPrepaidInvestmentAndDerivative Income (Loss) from Equity Method Investments Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets IncreaseDecreaseInRoyaltiesAndContingentLegalFeesPayable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Payments to Acquire Short-term Investments Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments for Repurchase of Common Stock SeniorSecuredNotesIssuanceCostsPaidToOtherParties Payments of Dividends Repayments of Secured Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Restricted Cash and Cash Equivalents, Current Equity Securities, FV-NI, Unrealized Loss Equity Method Investments, Fair Value Disclosure Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five Lessee, Operating Lease, Liability, to be Paid Operating Lease, Liability, Current Preferred Stock Dividends, Income Statement Impact Preferred Stock, Accretion of Redemption Discount Net Income (Loss) Available to Common Stockholders, Basic NetIncomeLossAvailableToCommonStockholderDiluted Earnings Per Share, Basic EX-101.PRE 12 actg-20210930_pre.xml XBRL PRESENTATION FILE XML 13 acacia_i10q-93021_htm.xml IDEA: XBRL DOCUMENT 0000934549 2021-01-01 2021-09-30 0000934549 2021-11-08 0000934549 2021-09-30 0000934549 2020-12-31 0000934549 us-gaap:RedeemablePreferredStockMember 2021-09-30 0000934549 us-gaap:RedeemablePreferredStockMember 2020-12-31 0000934549 2021-07-01 2021-09-30 0000934549 2020-07-01 2020-09-30 0000934549 2020-01-01 2020-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-06-30 0000934549 us-gaap:CommonStockMember 2021-06-30 0000934549 us-gaap:TreasuryStockMember 2021-06-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000934549 us-gaap:RetainedEarningsMember 2021-06-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-06-30 0000934549 2021-06-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000934549 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-09-30 0000934549 us-gaap:CommonStockMember 2021-09-30 0000934549 us-gaap:TreasuryStockMember 2021-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000934549 us-gaap:RetainedEarningsMember 2021-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-06-30 0000934549 us-gaap:CommonStockMember 2020-06-30 0000934549 us-gaap:TreasuryStockMember 2020-06-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000934549 us-gaap:RetainedEarningsMember 2020-06-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-06-30 0000934549 2020-06-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000934549 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-09-30 0000934549 us-gaap:TreasuryStockMember 2020-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000934549 us-gaap:RetainedEarningsMember 2020-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-09-30 0000934549 2020-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-12-31 0000934549 us-gaap:CommonStockMember 2020-12-31 0000934549 us-gaap:TreasuryStockMember 2020-12-31 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000934549 us-gaap:RetainedEarningsMember 2020-12-31 0000934549 us-gaap:NoncontrollingInterestMember 2020-12-31 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:TreasuryStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000934549 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2019-12-31 0000934549 us-gaap:CommonStockMember 2019-12-31 0000934549 us-gaap:TreasuryStockMember 2019-12-31 0000934549 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000934549 us-gaap:RetainedEarningsMember 2019-12-31 0000934549 us-gaap:NoncontrollingInterestMember 2019-12-31 0000934549 2019-12-31 0000934549 ACTG:SeriesARedeemableConvertiblePreferredStockMember 2020-01-01 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000934549 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000934549 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000934549 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000934549 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0000934549 2020-01-01 2020-12-31 0000934549 ACTG:PaidUpRevenueAgreementsMember 2021-07-01 2021-09-30 0000934549 ACTG:PaidUpRevenueAgreementsMember 2020-07-01 2020-09-30 0000934549 ACTG:PaidUpRevenueAgreementsMember 2021-01-01 2021-09-30 0000934549 ACTG:PaidUpRevenueAgreementsMember 2020-01-01 2020-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2021-07-01 2021-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2020-07-01 2020-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2021-01-01 2021-09-30 0000934549 ACTG:RecurringRevenueAgreementsMember 2020-01-01 2020-09-30 0000934549 ACTG:OneLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000934549 ACTG:TwoLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000934549 ACTG:ThreeLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000934549 ACTG:OneLicensee2Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000934549 ACTG:OneLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000934549 ACTG:OneLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000934549 ACTG:TwoLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000934549 ACTG:ThreeLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000934549 ACTG:OneLicensee3Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000934549 ACTG:TwoLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000934549 ACTG:ForeignLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000934549 ACTG:ForeignLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000934549 ACTG:ForeignLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000934549 ACTG:ForeignLicenseeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000934549 ACTG:OneLicenseeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000934549 ACTG:TwoLicenseeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000934549 ACTG:OneLicenseeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000934549 ACTG:OneLicensee2Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2021-09-30 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2020-12-31 0000934549 ACTG:EquitySecuritesLfFundPublicSecuritiesMember 2020-01-01 2020-12-31 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2020-12-31 0000934549 ACTG:EquitySecuritiesOtherEquityMember 2020-01-01 2020-12-31 0000934549 ACTG:RestrictedStockUnitsMember us-gaap:MeasurementInputRiskFreeInterestRateMember ACTG:BlackScholesMethodMember 2021-01-01 2021-09-30 0000934549 ACTG:RestrictedStockUnitsMember us-gaap:MeasurementInputExpectedTermMember ACTG:BlackScholesMethodMember 2021-01-01 2021-09-30 0000934549 ACTG:RestrictedStockUnitsMember us-gaap:MeasurementInputPriceVolatilityMember ACTG:BlackScholesMethodMember 2021-01-01 2021-09-30 0000934549 ACTG:RestrictedStockUnitsMember us-gaap:MeasurementInputExpectedDividendRateMember ACTG:BlackScholesMethodMember 2021-01-01 2021-09-30 0000934549 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000934549 ACTG:RSAsMember 2021-01-01 2021-09-30 0000934549 ACTG:NonQualifiedStockOptionsMember 2021-01-01 2021-09-30 0000934549 ACTG:PortfolioCompaniesMember ACTG:OptionAgreementMember 2020-01-01 2020-04-03 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesLfFundSecuritiesMember 2020-01-01 2020-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesDerivativeMember 2020-01-01 2020-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritesForwardContractMember 2020-01-01 2020-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2021-07-01 2021-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2020-07-01 2020-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2021-01-01 2021-09-30 0000934549 ACTG:EquitySecuritiesLFFundTradingSecurityMember 2020-01-01 2020-09-30 0000934549 ACTG:LFFundSecuritiesMember 2021-07-01 2021-09-30 0000934549 ACTG:LFFundSecuritiesMember 2020-07-01 2020-09-30 0000934549 ACTG:LFFundSecuritiesMember 2021-01-01 2021-09-30 0000934549 ACTG:LFFundSecuritiesMember 2020-01-01 2020-09-30 0000934549 ACTG:WarrantInvestmentMember 2021-07-01 2021-09-30 0000934549 ACTG:WarrantInvestmentMember 2020-07-01 2020-09-30 0000934549 ACTG:WarrantInvestmentMember 2021-01-01 2021-09-30 0000934549 ACTG:WarrantInvestmentMember 2020-01-01 2020-09-30 0000934549 ACTG:CommonStockInvestmentMember 2021-07-01 2021-09-30 0000934549 ACTG:CommonStockInvestmentMember 2020-07-01 2020-09-30 0000934549 ACTG:CommonStockInvestmentMember 2021-01-01 2021-09-30 0000934549 ACTG:CommonStockInvestmentMember 2020-01-01 2020-09-30 0000934549 ACTG:StarboardValueMember us-gaap:SeriesAPreferredStockMember 2019-11-01 2019-11-18 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2019-11-18 0000934549 ACTG:StarboardValueMember us-gaap:SeriesAPreferredStockMember 2019-11-18 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2020-05-19 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2021-09-30 0000934549 ACTG:SeriesARedeemableConvertibleStockMember 2020-12-31 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 ACTG:StarboardValueMember ACTG:SeriesAWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2020-02-25 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2020-02-01 2020-02-25 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 ACTG:StarboardValueMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 ACTG:SeniorSecuredNotesMember ACTG:SecuritiesPurchaseAgreementMember 2020-01-01 2020-06-04 0000934549 ACTG:SeniorSecuredNotesMember ACTG:SeptemberRedemptionMember ACTG:SecuritiesPurchaseAgreementMember 2020-09-30 0000934549 ACTG:SeniorSecuredNotesMember ACTG:DecemberRedemptionMember ACTG:SecuritiesPurchaseAgreementMember 2020-12-31 0000934549 ACTG:MertonMember ACTG:SeniorSecuredNotesMember ACTG:SecuritiesPurchaseAgreementMember 2020-01-01 2020-09-30 0000934549 ACTG:MertonMember ACTG:SeniorSecuredNotesMember ACTG:SecuritiesPurchaseAgreementMember 2020-01-01 2020-06-30 0000934549 ACTG:MertonMember ACTG:SeniorSecuredNotesMember ACTG:SecuritiesPurchaseAgreementMember 2020-09-30 0000934549 ACTG:MertonMember ACTG:SeniorSecuredNotesMember ACTG:SecuritiesPurchaseAgreementMember 2021-09-30 0000934549 ACTG:MertonMember ACTG:SeniorSecuredNotesMember ACTG:SecuritiesPurchaseAgreementMember 2021-01-01 2021-01-29 0000934549 ACTG:MertonMember ACTG:SeniorSecuredNotesMember ACTG:SecuritiesPurchaseAgreementMember 2021-01-01 2021-09-30 0000934549 ACTG:NewNotesMember 2021-09-30 0000934549 ACTG:NewNotesMember 2020-12-31 0000934549 ACTG:SeniorSecuredNotesMember ACTG:SeriesBWarrantsMember ACTG:SecuritiesPurchaseAgreementMember 2021-09-30 0000934549 ACTG:SeniorSecuredNotesMember ACTG:SeriesBWarrantsMember ACTG:SecuritiesPurchaseAgreementMember 2021-01-01 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember ACTG:WarrantInvestmentMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:AssetsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:LiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-12-31 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-01-01 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-07-01 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2021-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2019-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2019-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2019-12-31 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-06-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-07-01 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAWarrantsLiabilityMember 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesAEmbeddedDerivativeLiabilityMember 2020-09-30 0000934549 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ACTG:SeriesBWarrantsLiabilityMember 2020-09-30 0000934549 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000934549 ACTG:StockRepurchaseProgramMember 2019-08-05 0000934549 us-gaap:CommonStockMember 2020-09-20 2020-09-30 0000934549 us-gaap:CommonStockMember 2020-04-01 2020-04-23 0000934549 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000934549 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0000934549 us-gaap:SeriesAPreferredStockMember 2020-07-01 2020-09-30 0000934549 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-09-30 0000934549 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2021-07-01 2021-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2020-07-01 2020-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2021-01-01 2021-09-30 0000934549 ACTG:RestrictedStockUnitsMember 2020-01-01 2020-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2021-07-01 2021-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2020-07-01 2020-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2021-01-01 2021-09-30 0000934549 ACTG:EmployeeStockOptionsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-01-01 2020-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2021-07-01 2021-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2020-07-01 2020-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2021-01-01 2021-09-30 0000934549 ACTG:EquityBasedIncentiveAwardsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesAWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesAWarrantsMember 2020-01-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-07-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-07-01 2020-09-30 0000934549 ACTG:SeriesBWarrantsMember 2021-01-01 2021-09-30 0000934549 ACTG:SeriesBWarrantsMember 2020-01-01 2020-09-30 iso4217:USD shares iso4217:USD shares pure ACTG:Integer 0000934549 false Q3 2021 --12-31 10-Q true 2021-09-30 false 1-37721 Acacia Research Corporation DE 95-4405754 767 THIRD AVENUE SUITE 602 New York NY 10017 (949) 480-8300 Yes Yes Non-accelerated Filer true false false 49591852 217957000 165546000 761000 0 387120000 109103000 5816000 143257000 31840000 30673000 0 2752000 412000 506000 21539000 0 3986000 5832000 669431000 457669000 35424000 35000000 39826000 16912000 671000 951000 4482000 4988000 749834000 515520000 2196000 1019000 5586000 3707000 4019000 2265000 1793000 2162000 8000000 0 182855000 115663000 204449000 124816000 18527000 6640000 41411000 26728000 229637000 52341000 671000 951000 5591000 591000 500286000 212067000 0.001 0.001 100 100 350000 350000 35000000 35000000 13686000 10924000 0.001 0.001 300000000 300000000 49591852 49591852 49279453 49279453 50000 49000 4604365 4604365 43270000 43270000 649349000 651416000 -382215000 -326708000 223914000 281487000 11948000 11042000 235862000 292529000 749834000 515520000 1582000 19466000 24785000 25399000 280000 5772000 823000 6843000 285000 6609000 5735000 6855000 782000 1001000 4881000 3497000 2612000 1174000 7086000 3522000 -0 -0 -0 308000 3959000 14556000 18525000 20409000 -2377000 4910000 6260000 4990000 10345000 7692000 23014000 18089000 -12722000 -2782000 -16754000 -13099000 0 -3081000 -2752000 3704000 0 0 3591000 -2762000 619000 20672000 -203866000 -46612000 0 2845000 0 2845000 66502000 20488000 115509000 99449000 37688000 2737000 53124000 -4272000 0 0 2737000 0 -17000 -48000 -193000 -4938000 2531000 2410000 5601000 3178000 76000 10000 135000 811000 102337000 41213000 -37316000 45047000 89615000 38431000 -54070000 31948000 11000 83000 531000 -1257000 89604000 38348000 -54601000 33205000 -0 -0 906000 -0 89604000 38348000 -55507000 33205000 72984 30529 -59054 24838 1.49 0.63 -1.21 0.51 48949504 48467885 48759873 48949706 80171000 29204000 -59054000 21380000 0.86 0.32 -1.21 0.36 93081502 90624702 48759873 60153773 350000 12695000 49616602 50000 -43270000 650194000 -471819000 11948000 147103000 89604000 89604000 -991000 991000 991000 262000 262000 30000 108000 108000 -54750 300000 300000 350000 13686000 49591852 50000 -43270000 649349000 -382215000 11948000 235862000 350000 9400000 49306137 49000 -43270000 650843000 -444799000 1833000 164656000 38348000 38348000 -734000 734000 734000 467000 467000 -26684 488000 488000 350000 10134000 49279453 49000 -43270000 650130000 -406451000 1833000 202291000 350000 10924000 49279453 49000 -43270000 651416000 -326708000 11042000 292529000 -55507000 906000 -54601000 -2762000 2762000 2762000 785000 785000 60000 1000 201000 202000 28834 223565 1279000 1279000 350000 13686000 49591852 50000 -43270000 649349000 -382215000 11948000 235862000 350000 8089000 50370987 50000 -39272000 652003000 -439656000 1833000 174958000 33205000 33205000 -2045000 2045000 2045000 1119000 1119000 13333 48000 48000 14354 565316 1243000 1243000 -1684537 1000 3998000 3999000 350000 10134000 49279453 49000 -43270000 650130000 -406451000 1833000 202291000 -54601000 33205000 -2752000 3704000 3591000 -2762000 7198000 3609000 460000 955000 -14683000 -7708000 -11887000 -2036000 -177296000 -36867000 1279000 1243000 -193000 -4938000 115509000 99449000 53124000 -4272000 -0 2845000 907000 -0 -94000 -248000 2345000 -1038000 7002000 614000 -369000 12052000 -7602000 5549000 13000000 13780000 3591000 1460000 57978000 33800000 64235000 316746000 0 -276275000 0 -3989000 67000 177000 -3219000 -9815000 -0 3998000 65000000 110437000 -0 496000 785000 1120000 0 4600000 202000 48000 50000000 -0 50000000 0 64417000 109471000 53596000 105205000 200546000 92359000 254142000 197564000 2340000 0 9000 164000 21539000 0 4000000 0 8000000 0 5000000 0 0 231480000 <p id="xdx_808_ecustom--BusinessDescriptionTextBlock_zLQd26KmL4Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. <span id="xdx_823_zVPOKEhMhwLg">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84A_ecustom--DescriptionOfBusinessPolicyTextBlock_znfMED2mVuqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_861_z58pdAAvzUra">Description of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As used herein, “we,” “us,” “our,” “Acacia” and the “Company” refer to Acacia Research Corporation and/or its wholly and majority-owned and controlled operating subsidiaries, and/or where applicable, its management.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia was incorporated on January 25, 1993 under the laws of the State of California. In December 1999, Acacia changed its state of incorporation from California to Delaware.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia acquires businesses and operating assets that the Company believes to be undervalued and where the Company believes it can leverage its resources and skill sets to realize and unlock value. The Company intends to leverage its (i) access to flexible capital that can be deployed unconditionally, (ii) expertise in corporate governance and operational restructuring, (iii) willingness to invest in out of favor industries and businesses that suffer from a complexity discount and untangle complex, multi-factor situations, and (iv) expertise and relationships in certain sectors, to complete strategic acquisitions of businesses, divisions, and/or assets with a focus on mature technology, healthcare, industrial and certain financial segments. Acacia seeks to identify opportunities where the Company believes it is an advantaged buyer, where the Company can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to the Company’s unique capabilities, relationships, or expertise, or where Acacia believes the target would be worth more to the Company than to other buyers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia operates its business based on three key principles of People, Process and Performance and has built a management team with identified expertise in Research, Execution and Operation of the Company’s targeted acquisitions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia, through its operating subsidiaries, also currently engages in its legacy business of investing in, licensing and enforcing patented technologies. Acacia’s operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. In recent years, Acacia has also invested in technology companies. Acacia leverages its experience, expertise, data and relationships developed as a leader in the intellectual property (“IP”) industry to pursue these opportunities. In some cases, these opportunities will complement and/or supplement Acacia’s primary licensing and enforcement business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia’s operating subsidiaries generate revenues and related cash flows from the granting of IP rights (hereinafter, “IP Rights”) for the use of patented technologies that its operating subsidiaries control or own. Acacia’s operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia’s operating subsidiaries are principals in the licensing and enforcement effort, obtaining control of the rights in the patent portfolio, or control of the patent portfolio outright. Acacia’s operating subsidiaries own or control the rights to multiple patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neither Acacia nor its operating subsidiaries invent new technologies or products; rather, Acacia depends upon the identification and investment in new patents, inventions and companies that own IP through its relationships with inventors, universities, research institutions, technology companies and others. If Acacia’s operating subsidiaries are unable to maintain those relationships and identify and grow new relationships, then they may not be able to identify new technology-based opportunities for sustainable revenue and/or revenue growth.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended September 30, 2021, Acacia obtained control of one <span id="xdx_90D_ecustom--NumberOfPatentPortfoliosAcquired_uInteger_c20210101__20210930_zFPmsscH2NBj" style="display: none" title="Number of new patent portfolios acquired">1</span> new patent portfolio. During fiscal year 2020, Acacia obtained control of five <span id="xdx_907_ecustom--NumberOfPatentPortfoliosAcquired_uInteger_c20200101__20201231_z0DlQoQ7KXz8" style="display: none" title="Number of new patent portfolios acquired">5</span> new patent portfolios.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p id="xdx_846_ecustom--BasisOfAccountingPoliesPolicyTextBlock_zTkfyraUtA34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zJRRpXQOfCwi">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures required by U.S. GAAP in annual financial statements have been omitted or condensed in accordance with quarterly reporting requirements of the Securities and Exchange Commission (“SEC”). These interim unaudited condensed consolidated financial statements and notes hereto should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2020, as reported by Acacia in its Annual Report on Form 10-K filed with the SEC on March 29, 2021, as well as in our other public filings with the SEC. The condensed consolidated interim financial statements of Acacia include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of Acacia’s consolidated financial position as of September 30, 2021, and results of its operations and its cash flows for the interim periods presented. The consolidated results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the entire fiscal year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated results of operations or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p id="xdx_84E_ecustom--Covid19PandemicAndCaresActPolicyTextBlock_zazWKBu653X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_869_zJQM5ugWaLIa">COVID-19 Pandemic</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. While the Company does not expect the current situation to present direct risks to its business, and it has not had a material impact to date, the COVID-19 pandemic could adversely impact the Company’s operations, as well as the operations of its licensees and other business partners. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, results of operations and financial condition.</p> <p id="xdx_84A_ecustom--DescriptionOfBusinessPolicyTextBlock_znfMED2mVuqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_861_z58pdAAvzUra">Description of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As used herein, “we,” “us,” “our,” “Acacia” and the “Company” refer to Acacia Research Corporation and/or its wholly and majority-owned and controlled operating subsidiaries, and/or where applicable, its management.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia was incorporated on January 25, 1993 under the laws of the State of California. In December 1999, Acacia changed its state of incorporation from California to Delaware.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia acquires businesses and operating assets that the Company believes to be undervalued and where the Company believes it can leverage its resources and skill sets to realize and unlock value. The Company intends to leverage its (i) access to flexible capital that can be deployed unconditionally, (ii) expertise in corporate governance and operational restructuring, (iii) willingness to invest in out of favor industries and businesses that suffer from a complexity discount and untangle complex, multi-factor situations, and (iv) expertise and relationships in certain sectors, to complete strategic acquisitions of businesses, divisions, and/or assets with a focus on mature technology, healthcare, industrial and certain financial segments. Acacia seeks to identify opportunities where the Company believes it is an advantaged buyer, where the Company can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to the Company’s unique capabilities, relationships, or expertise, or where Acacia believes the target would be worth more to the Company than to other buyers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia operates its business based on three key principles of People, Process and Performance and has built a management team with identified expertise in Research, Execution and Operation of the Company’s targeted acquisitions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia, through its operating subsidiaries, also currently engages in its legacy business of investing in, licensing and enforcing patented technologies. Acacia’s operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. In recent years, Acacia has also invested in technology companies. Acacia leverages its experience, expertise, data and relationships developed as a leader in the intellectual property (“IP”) industry to pursue these opportunities. In some cases, these opportunities will complement and/or supplement Acacia’s primary licensing and enforcement business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia’s operating subsidiaries generate revenues and related cash flows from the granting of IP rights (hereinafter, “IP Rights”) for the use of patented technologies that its operating subsidiaries control or own. Acacia’s operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia’s operating subsidiaries are principals in the licensing and enforcement effort, obtaining control of the rights in the patent portfolio, or control of the patent portfolio outright. Acacia’s operating subsidiaries own or control the rights to multiple patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neither Acacia nor its operating subsidiaries invent new technologies or products; rather, Acacia depends upon the identification and investment in new patents, inventions and companies that own IP through its relationships with inventors, universities, research institutions, technology companies and others. If Acacia’s operating subsidiaries are unable to maintain those relationships and identify and grow new relationships, then they may not be able to identify new technology-based opportunities for sustainable revenue and/or revenue growth.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended September 30, 2021, Acacia obtained control of one <span id="xdx_90D_ecustom--NumberOfPatentPortfoliosAcquired_uInteger_c20210101__20210930_zFPmsscH2NBj" style="display: none" title="Number of new patent portfolios acquired">1</span> new patent portfolio. During fiscal year 2020, Acacia obtained control of five <span id="xdx_907_ecustom--NumberOfPatentPortfoliosAcquired_uInteger_c20200101__20201231_z0DlQoQ7KXz8" style="display: none" title="Number of new patent portfolios acquired">5</span> new patent portfolios.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> 1 5 <p id="xdx_846_ecustom--BasisOfAccountingPoliesPolicyTextBlock_zTkfyraUtA34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zJRRpXQOfCwi">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures required by U.S. GAAP in annual financial statements have been omitted or condensed in accordance with quarterly reporting requirements of the Securities and Exchange Commission (“SEC”). These interim unaudited condensed consolidated financial statements and notes hereto should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2020, as reported by Acacia in its Annual Report on Form 10-K filed with the SEC on March 29, 2021, as well as in our other public filings with the SEC. The condensed consolidated interim financial statements of Acacia include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of Acacia’s consolidated financial position as of September 30, 2021, and results of its operations and its cash flows for the interim periods presented. The consolidated results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the entire fiscal year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated results of operations or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p id="xdx_84E_ecustom--Covid19PandemicAndCaresActPolicyTextBlock_zazWKBu653X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_869_zJQM5ugWaLIa">COVID-19 Pandemic</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. While the Company does not expect the current situation to present direct risks to its business, and it has not had a material impact to date, the COVID-19 pandemic could adversely impact the Company’s operations, as well as the operations of its licensees and other business partners. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, results of operations and financial condition.</p> <p id="xdx_803_eus-gaap--SignificantAccountingPoliciesTextBlock_zxLzCpbkUtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. <span id="xdx_82F_zUjdVBQzojDh">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1ORXFzaCLxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zDJple5wwSO8">Accounting Principles</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. GAAP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zZGNypmCv9a6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zfiRWS9j1Ysd">Principles of Consolidation</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying unaudited consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Noncontrolling interests in Acacia’s majority-owned and controlled operating subsidiaries (“noncontrolling interests”) are separately presented as a component of stockholders’ equity. Consolidated net income or (loss) is adjusted to include the net (income) or loss attributed to noncontrolling interests in the consolidated statements of operations. Refer to the accompanying Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders’ Equity for total noncontrolling interests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2020, in connection with the transaction with Link Fund Solutions Limited, which is more fully described in Note 3, the Company acquired equity securities of Malin J1 Limited (“MalinJ1”). MalinJ1 is included in the Company’s consolidated financial statements because the Company, through its interest in the equity securities of MalinJ1, has the ability to control the operations and activities of MalinJ1. Viamet HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of Acacia, is the majority shareholder of MalinJ1.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A wholly-owned subsidiary of Acacia is the general partner of the Acacia Intellectual Property Fund, L.P. (the “Acacia IP Fund”), which was formed in August 2010. The Acacia IP Fund has been included in the Company’s consolidated financial statements since 2010, as Acacia’s wholly-owned subsidiary, the general partner of Acacia IP Fund, has the ability to control the operations and activities of the Acacia IP Fund. The Acacia IP Fund was terminated as of December 31, 2017 and dissolved in 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_844_ecustom--SegmentReportingPolicyTextBlock_zADk5K4ldVx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zeJga3udMrb8">Segment Reporting</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia uses the management approach, which designates the internal organization that is used by management for making operating decisions and assessing performance as the basis of Acacia’s reportable segments. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84C_ecustom--EstimatesPolicytextBlock_z7iuQVnnEnC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zSX0sSXVwUHk">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Acacia believes that, of the significant accounting policies described herein, the accounting policies associated with revenue recognition, the valuation of the equity instruments, the valuation of Series A redeemable convertible preferred stock (the “Series A Redeemable Convertible Preferred Stock”), embedded derivatives, Series A warrants (the “Series A Warrants”), Series B warrants (the “Series B Warrants”), stock-based compensation expense, impairment of patent-related intangible assets, the determination of the economic useful life of amortizable intangible assets, income taxes and valuation allowances against net deferred tax assets, require its most difficult, subjective or complex judgments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zp4pqpx2Pche" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86F_z0axyN6kaGS5">Revenue Recognition</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue is recognized upon transfer of control (i.e., by the granting) of promised bundled IP Rights and other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive in exchange for those IP Rights. Revenue contracts that provide promises to grant the right to use IP Rights as they exist at the point in time at which the IP Rights are granted, are accounted for as performance obligations satisfied at a point in time and revenue is recognized at the point in time that the applicable performance obligations are satisfied and all other revenue recognition criteria have been met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technologies owned or controlled by Acacia. Revenues also included license fees from sales-based revenue contracts, the majority of which were originally executed in prior periods, which provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees (“Recurring Revenue Agreements”). Revenues may also include court ordered settlements or awards related to our patent portfolio or sales of our patent portfolio. IP Rights granted included the following, as applicable: (i) the grant of a non-exclusive, future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The IP Rights granted were generally perpetual in nature, extending until the legal expiration date of the related patents. The individual IP Rights are not accounted for as separate performance obligations, as (i) the nature of the promise, within the context of the contract, is to grant combined items to which the promised IP Rights are inputs and (ii) the Company's promise to grant each individual IP right described above to the customer is not separately identifiable from other promises to grant IP Rights in the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since the promised IP Rights are not individually distinct, the Company combined each individual IP Right in the contract into a bundle of IP Rights that is distinct, and accounted for all of the IP Rights promised in the contract as a single performance obligation. The IP Rights granted were “functional IP rights” that have significant standalone functionality. Acacia’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. Acacia’s operating subsidiaries have no further obligation with respect to the grant of IP Rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the IP Rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 15-90 days of execution of the contract, or the end of the quarter in which the sale or usage occurs for Recurring Revenue Agreements. Contractual payments made by licensees are generally non-refundable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For sales-based royalties, the Company includes in the transaction price some or all of an amount of estimated variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Notwithstanding, revenue is recognized for a sales-based royalty promised in exchange for a license of IP Rights when the later of (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied. Estimates are generally based on historical levels of activity, if available.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenues from contracts with significant financing components (either explicit or implicit) are recognized at an amount that reflects the price that a licensee would have paid if the licensee had paid cash for the IP Rights when they are granted to the licensee. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money. As a practical expedient, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the entity grants promised IP Rights to a customer and when the customer pays for the IP Rights will be one year or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In general, the Company is required to make certain judgments and estimates in connection with the accounting for revenue contracts with customers. Such areas may include identifying performance obligations in the contract, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services, evaluating whether a license transfers to a customer at a point in time or over time, allocating the transaction price to separate performance obligations, determining whether contracts contain a significant financing component, and estimating revenues recognized at a point in time for sales-based royalties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Revenues were comprised of the following for the periods presented: </span></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zJ9sIY37LBn9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B7_zFDerkJoCRt2" style="font: 10pt Times New Roman, Times, Serif; display: none">Disaggregation of revenue</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Paid-up revenue agreements</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210701__20210930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_zxcmXZAq1LAd" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,100</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">19,385</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">23,110</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">24,477</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Recurring Revenue Agreements</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20210930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">482</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">81</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,675</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">922</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total revenue</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,582</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">19,466</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">24,785</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">25,399</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_z9c4bc72xOyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 9pt Sans-Serif; color: Red"><b/></span><span style="font: 10pt Times New Roman, Times, Serif">Refer to “<i>Inventor Royalties and Contingent Legal Expenses</i>” below for information on related direct costs of revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </p> <p id="xdx_847_ecustom--PatentPortfolioOperationsPolicyTextBlock_zt9WnCalrHff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_869_zqjcrZxcdwW3">Patent Portfolio Operations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues include the costs and expenses incurred in connection with Acacia’s patent licensing and enforcement activities, including inventor royalties paid to original patent owners, patent maintenance and prosecution costs, contingent legal fees paid to external patent counsel, other patent-related legal expenses paid to external patent counsel, licensing and enforcement related research, consulting and other expenses paid to third-parties and the amortization of patent-related investment costs. These costs are included under the caption “Patent portfolio operations” in the consolidated statements of operations. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Inventor Royalties and Contingent Legal Expenses </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventor royalties are expensed in the consolidated statements of operations in the period that the related revenues are recognized. Patent costs, including any upfront advances paid to patent owners by Acacia’s operating subsidiaries, that are recoverable from future net revenues are amortized over the estimated economic useful life of the related patents, or as the prepaid royalties are earned by the inventor, as appropriate, and the related expense is included in amortization expense in the consolidated statements of operations. Any unamortized upfront advances recovered from net revenues are expensed in the period recovered and included in amortization expense in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. In instances where there are no recoveries from potential infringers, no contingent legal fees are paid; however, Acacia’s operating subsidiaries may be liable for certain out of pocket legal costs incurred pursuant to the underlying legal services agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventor royalty and contingent legal agreements generally provide for payment by the Company of contractual amounts 30 days subsequent to the fiscal quarter end during which related license fee payments are received from licensees by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p id="xdx_845_ecustom--ConcentrationsPolicyTextBlock_zdCisWyLDcGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_z629mh8x2Fg3">Concentrations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject Acacia to concentrations of credit risk are cash equivalents, equity securities and accounts receivable. Acacia places its cash equivalents and equity securities primarily in highly rated money market funds and investment grade marketable securities. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. Acacia has not experienced any significant losses on its deposits of cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Four licensees individually accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_z08Z9l632Sma" title="Concentration risk percentage">32</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_z3sOv6LAIQUd" title="Concentration risk percentage">25</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeLicenseeMember_zxTh9mIiCwge" title="Concentration risk percentage">22</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicensee2Member_zLScaSSvNJK9" title="Concentration risk percentage">13</span>% of revenues recognized during the three months ended September 30, 2021, and one licensee accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_z30FpxRpeW0k" title="Concentration risk percentage">98</span>% of revenues recognized during the three months ended September 30, 2020. Three licensees individually accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_znyPUuufBOm3" title="Concentration risk percentage">50</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_zx39kZPTH5Yd" title="Concentration risk percentage">19</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeLicenseeMember_zENUWIIMvvqc" title="Concentration risk percentage">12</span>% of revenues recognized during the nine months ended September 30, 2021, and two licensees accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicensee3Member_z2vQAS6oMQnh" title="Concentration risk percentage">75</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_z7RGndZS4Sr1" title="Concentration risk percentage">9</span>% of revenues recognized during the nine months ended September 30, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company does not have any material foreign operations. Based on the jurisdiction of the entity obligated to satisfy payment obligations pursuant to the applicable revenue arrangement, for the three and nine months ended September 30, 2021, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_zXbwkFsoK2F8" title="Concentration risk percentage">8</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_z9U13b52KX1g" title="Concentration risk percentage">15</span>%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions. For the three and nine months ended September 30, 2020, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_zzAcapFYsMyg" title="Concentration risk percentage">0.1</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_zdyx2eenqfSb" title="Concentration risk percentage">5</span>%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Two licensees represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_zlW1ntM3cEX8" title="Concentration risk percentage"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_zPMhqdsSsote">100</span></span>% of accounts receivable at September 30, 2021. Two licensees individually represented approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_zg6fPuOeDpqc" title="Concentration risk percentage">62</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicensee2Member_zVRo2X70XVZk" title="Concentration risk percentage">21</span>% of accounts receivable at December 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_842_ecustom--RelatedPartyTransactionsPolicyTextBlock_zUtnhFN0ysLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zZ9svsDlVKPl">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2019, the Company purchased shares of common stock of Drive Shack, Inc. (“Drive Shack”) for an aggregate purchase price of $2.4 million. At the time, Drive Shack and Clifford Press, Chief Executive Officer and director of Acacia, were related parties as Mr. Press was a board member of Drive Shack until June 2021. The market value of the investment was $1.4 million as of December 31, 2020. During the nine months ended September 30, 2021, the Company sold its investment receiving proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromSaleOfLongtermInvestments_pn3n3_dm_c20210101__20210930_z8wZGQ7XLEvl" title="Proceeds from sale of investment">1.8 </span>million and recognized a loss of $<span id="xdx_909_eus-gaap--LossOnSaleOfInvestments_pn3p0_c20210101__20210930_zbEpXupgctJj" title="Loss on sale of investment">515,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znBggoYpGtE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zApTIkBILrjc">Cash and Cash Equivalents</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia considers all highly liquid, equity securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Acacia’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily includes: domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Acacia’s cash equivalents are measured at fair value using observable inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p id="xdx_845_ecustom--EquitySecuritiesAtFairValuePolicyTextBlock_zKwKzjxaIxTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86A_zMr6TNNWWq8h">Equity Securities at Fair Value </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investments in equity securities are reported at fair value on a recurring basis, with related realized and unrealized gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or (expense). Dividend income is included in the consolidated statements of operations in other income or (expense). Refer to Note 7 for additional information related to fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equity securities at fair value for the periods presented were comprised of the following: </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--EquityMethodInvestmentsTextBlock_zmq1bnZ0ZgYa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B5_zKRfThUHtiU4" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Security Type</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Gross<br/> Unrealized<br/> Gain</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Gross<br/> Unrealized<br/> Loss</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2021:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - Life Sciences Portfolio (Note 3)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiCost_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">62,042</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">288,508</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zDnSvqc9dW89" style="width: 11%; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,812</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">348,738</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - other equity</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--EquitySecuritiesFvNiCost_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">35,178</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">3,289</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_zazoZSkOV5Gk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(85</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">38,382</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiCost_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">97,220</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">291,797</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930_znk7BHULQWn7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,897</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">387,120</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - Life Sciences Portfolio (Note 3)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiCost_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zMbxkYAtU5we" style="font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">32,765</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">72,689</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zMVeXtbV9Jy9" style="font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(583</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">104,871</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - other equity</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCost_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">4,086</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">1,410</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_z00aWUyRTGWh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,264</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">4,232</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNiCost_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">36,851</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">74,099</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231_zvWlukMVK3Q6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,847</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A6_zpdhH9K9HW7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84E_eus-gaap--EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_zA5jIua165jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_ztj8KnAgfmB2">Equity Securities Without Readily Determinable Fair Value</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For equity securities that do not have readily determinable fair value, the Company elected to report them under the measurement alternative. They are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in any adjustments for illiquidity or preference of these securities. Changes in fair value are reported in the consolidated statements of operations in other income or (expense). Refer to Note 3 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_844_eus-gaap--EquityMethodInvestmentsPolicy_zEKMmci1k7Kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_zLpxVmZXnVai">Equity Method Investments </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equity investments in common stock and in-substance common stock without readily determinable fair values in companies over which the Company has the ability to exercise significant influence, are accounted for using the equity method of accounting. Acacia includes its proportionate share of earnings and/or losses of its equity method investees in earnings on equity investment in joint venture in the consolidated statements of operations. Refer to Note 3 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_840_eus-gaap--InvestmentPolicyTextBlock_znHRNqpxtPPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zSHlKiT5CP7b">Investment at Fair Value</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On an individual investment basis, Acacia may elect to account for investments in companies where the Company has the ability to exercise significant influence over operating and financial policies of the investee, at fair value. If the fair value method is applied to an investment that would otherwise be accounted for under the equity method of accounting, it is applied to all of the financial interests in the same entity that are eligible items (i.e., common stock and warrants). We elected the fair value method for our investment in Veritone, Inc. (“Veritone”) upon acquisition of the investment. Since March 2021, we have no more investment in Veritone stocks and warrants. Refer to Note 4 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_847_ecustom--ImpairmentOfInvestmentPolicyTextBlock_zRWgCZILRST4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86F_z8aUtYt7Lw5e">Impairment of Investments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia reviews its investments quarterly for indicators of other-than-temporary impairment. This determination requires significant judgment. In making this judgment, Acacia considers available quantitative and qualitative evidence in evaluating potential impairment of its investments. If the cost of an investment exceeds its fair value, Acacia evaluates, among other factors, general market conditions and the duration and extent to which the fair value is less than cost. Acacia also considers specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of operations and a new cost basis in the investment is established.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zLoyDWm9Wmw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_z2TQncf3udej">Long-Term Restricted Cash </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash relates primarily to the proceeds received from the issuance of Series A Redeemable Convertible Preferred Stock which are held in an escrow account (refer to Note 6). The amounts are to be released to the Company upon, among other things, (i) the consummation of a suitable investment or acquisition by the Company or (ii) the conversion of Series A Redeemable Convertible Preferred Stock into common stock. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Refer to Note 11 for additional information related to the subsequent period acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zuh4nTi8mO3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zoKMVuQnHAik">Patents</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patents include the cost of patents or patent rights acquired from third-parties or obtained in connection with business combinations. Patent costs are amortized utilizing the straight-line method over their remaining economic useful lives. Refer to Note 5 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zruaHSR5TAmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86A_zpvZ1zkYyGje">Impairment of Long-lived Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia reviews long-lived assets and intangible assets for potential impairment annually (quarterly for patents) and when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss is recorded in an amount equal to the excess of the asset’s carrying value over its fair value. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. In the event that management decides to no longer allocate resources to a patent portfolio, an impairment loss equal to the remaining carrying value of the asset is recorded. Refer to Note 5 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is generally estimated using the “Income Approach,” focusing on the estimated future net income-producing capability of the patent portfolios over their estimated remaining economic useful life. Estimates of future after-tax cash flows are converted to present value through “discounting,” including an estimated rate of return that accounts for both the time value of money and investment risk factors. Estimated cash inflows are typically based on estimates of reasonable royalty rates for the applicable technology, applied to estimated market data. Estimated cash outflows are based on existing contractual obligations, such as contingent legal fee and inventor royalty obligations, applied to estimated license fee revenues, in addition to other estimates of out-of-pocket expenses associated with a specific patent portfolio’s licensing and enforcement program. The analysis also contemplates consideration of current information about the patent portfolio including, status and stage of litigation, periodic results of the litigation process, strength of the patent portfolio, technology coverage and other pertinent information that could impact future net cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84C_ecustom--SeriesAandBWarrantsPolicyTextBlock_zuTOJOxjyock" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86C_zVQjbnwmj3A4">Series A and B Warrants</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the Series A and B Warrants are estimated using a Black-Scholes option-pricing model. Refer to Notes 6 and 7 for additional information related to the Series A and B Warrants and their fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84F_eus-gaap--DerivativesEmbeddedDerivatives_zRArdVHPPach" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zIbQuddiHXx5">Embedded derivatives</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Embedded derivatives that are required to be bifurcated from their host contract are valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019. Refer to Notes 6 and 7 for additional information related to the embedded derivatives and their fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_843_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zAgIWGu5eFW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zIEBNkgpHQm3">Fair Value Measurements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. Refer to Note 7 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_842_eus-gaap--StockholdersEquityPolicyTextBlock_zLIMZCIP7dyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_z8pF6IErMmu4">Treasury Stock</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Repurchases of the Company’s outstanding common stock are accounted for using the cost method. The applicable par value is deducted from the appropriate capital stock account on the formal or constructive retirement of treasury stock. Any excess of the cost of treasury stock over its par value is charged to additional paid-in capital and reflected as treasury stock in the consolidated balance sheets. Refer to Note 9 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvPvcmTx8j3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zIGubIqJW9Il">Stock-Based Compensation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which is generally one to three years. The fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) are determined by the product of the number of shares or units granted and the grant date market price of the underlying common stock. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing model. Forfeitures are accounted for as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RSUs granted in September 2019 with market-based vesting conditions vest based upon the Company achieving specified stock price targets over a three-year period. The effect of a market condition is reflected in the estimate of the grant-date fair value of the options utilizing a Monte Carlo valuation technique. Compensation cost is recognized with a market-based vesting condition provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Assumptions utilized in connection with the Monte Carlo valuation technique, that resulted in a fair value of $1.42 per unit, included: estimated risk-free interest rate of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember" title="Assumptions used for derivatives">1.38 percent</span>; term of <span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z0Hir3knAOO2" title="Assumptions used for derivatives">3.00 years</span>; expected volatility of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember" title="Assumptions used for derivatives">38 percent</span>; and expected dividend yield of <span id="xdx_903_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember" title="Assumptions used for derivatives">0 percent</span>. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. During the nine months ended September 30, 2021, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfsoNSr2NIc5" title="Option Forfeited">450,000</span> RSUs were forfeited, leaving <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn3p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkA1kLOVQEc" title="Option Forfeited">450,000</span> units with market-based vesting conditions outstanding and unvested at period end.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended September 30, 2021, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--RSAsMember_zJ99UTGtC3i7" title="Weighted Average Grant">324,401</span> RSAs at a weighted average grant-date fair value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--RSAsMember_zXdwiRqa7Bg2" title="Weighted average grant-date fair value">5.56 </span>per share, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3I4cREBWCte">473,000</span> RSUs at a weighted average grant-date fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdsbs1hsoSqb" title="Weighted average grant-date fair value">5.86</span> per unit and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsMember_zEBfRxUcHaa6">393,750</span> non-qualified stock options at a grant-date fair value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsMember_zogY04uAPWJa">1.79</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation is reported in the consolidated statements of operations in general and administrative expenses. Total stock-based compensation for the three and nine months ended September 30, 2021 was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn3p0_c20210701__20210930_zmrcwGz6Jdza" title="Stock-based compensation">300,000</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20210101__20210930_pn3p0" title="Stock-based compensation">1,279,000</span>, respectively. Total unrecognized stock-based compensation expense as of September 30, 2021 was $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20210930_pn3p0" title="Unrecognized stock-based compensation expense">5,952,000</span>, which will be amortized over a weighted average remaining vesting period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_zdmyqOeYYNDb" title="Weighted-average remaining vesting period">2.20</span> years. Total stock-based compensation for the three and nine months ended September 30, 2020 was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20200701__20200930_pn3p0" title="Stock-based compensation">488,000</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20200101__20200930_pn3p0" title="Stock-based compensation">1,243,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Profits Interest Units (“PIUs”) were accounted for in accordance with Accounting Standards Codification (“ASC”) 718-10, “Compensation - Stock Compensation.” The vesting conditions did not meet the definition of service, market or performance conditions, as defined in ASC 718. As such, the PIUs were classified as liability awards. Compensation expense was adjusted for changes in fair value prorated for the portion of the requisite service period rendered. Initially, compensation expense was recognized on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which was five years. Upon full vesting of the award, which occurred during the three months ended September 30, 2017, previously unrecognized compensation expense was immediately recognized in the period. The Company has a purchase option to purchase the vested PIUs that are not otherwise forfeited after termination of continuous service. The exercise price of the purchase option is the fair market value of the PIUs on the date of termination of continuous service. The individuals holding PIUs are no longer employed by the Company. Included in other long-term liabilities in the consolidated balance sheets as of September 30, 2021 and December 31, 2020, the PIUs totaled $591,000, which was their fair value as of December 31, 2018 after termination of service.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zhkUQWPPd5J3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86C_za3TxTxZzFm3">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in Acacia’s consolidated financial statements or consolidated income tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized, or if it is determined that there is uncertainty regarding future realization of such assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provision for income taxes for interim periods is determined using an estimate of Acacia’s annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, Acacia updates the estimate of the annual effective tax rate, and if the estimated tax rate changes, a cumulative adjustment is recorded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s effective tax rates were <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20210701__20210930_z11XD73sdRb4" title="Effective tax rate">0</span>% and (<span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20210101__20210930_zpSd4wOSJbW3" title="Effective tax rate">1</span>%) for the three and nine months ended September 30, 2021, respectively, and <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20200701__20200930_zgvk1NgPLcZh" title="Effective tax rate">0</span>% and (<span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20200101__20200930_z9kHwwZ0ewu9" title="Effective tax rate">4</span>%) for the three and nine months ended September 30, 2020, respectively. Tax expense/benefit for the periods presented primarily reflects the impact of state taxes and foreign tax withholding (or refund) incurred on revenue agreements executed with third-party licensees domiciled in foreign jurisdictions. The Company has recorded a full valuation allowance against our net deferred tax assets as of September 30, 2021 and December 31, 2020. These assets primarily consist of foreign tax credits, capital loss carryforwards and net operating loss carryforwards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZXOl0XkMU5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zviHK9QTSmF9">Recent Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Recently Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December of 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The update removed certain exceptions to the general principles in Topic 740 in U.S. GAAP. The Company adopted the update on January 1, 2021. The adoption of the update did not have a material effect on the Company’s financial position, results of operations or financial statement disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Not Yet Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” to replace the incurred loss methodology with an expected credit loss model that requires consideration of a broader range of information to estimate credit losses over the lifetime of the asset, including current conditions and reasonable and supportable forecasts in addition to historical loss information, to determine expected credit losses. Pooling of assets with similar risk characteristics and the use of a loss model are also required. Also, in April 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,” to clarify the inclusion of recoveries of trade receivables previously written off when estimating an allowance for credit losses. The amendments in these updates will currently be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in these updates may have on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” to simplify the accounting for convertible instruments by eliminating large sections of the existing guidance in this area. It also eliminates several triggers for derivative accounting, including a requirement to settle certain contracts by delivering registered shares. This update reduces the number of accounting models for convertible instruments, revises the derivatives scope exception, and provides targeted improvements for earnings per share. Upon adoption, companies have the option to apply a modified or full retrospective transition approach. The amendments in this update will currently be effective for the Company on January 1, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,” to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with “Revenue from Contracts with Customers (Topic 606).” At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and will be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z1ORXFzaCLxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zDJple5wwSO8">Accounting Principles</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. GAAP.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zZGNypmCv9a6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zfiRWS9j1Ysd">Principles of Consolidation</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying unaudited consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Noncontrolling interests in Acacia’s majority-owned and controlled operating subsidiaries (“noncontrolling interests”) are separately presented as a component of stockholders’ equity. Consolidated net income or (loss) is adjusted to include the net (income) or loss attributed to noncontrolling interests in the consolidated statements of operations. Refer to the accompanying Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders’ Equity for total noncontrolling interests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In 2020, in connection with the transaction with Link Fund Solutions Limited, which is more fully described in Note 3, the Company acquired equity securities of Malin J1 Limited (“MalinJ1”). MalinJ1 is included in the Company’s consolidated financial statements because the Company, through its interest in the equity securities of MalinJ1, has the ability to control the operations and activities of MalinJ1. Viamet HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of Acacia, is the majority shareholder of MalinJ1.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A wholly-owned subsidiary of Acacia is the general partner of the Acacia Intellectual Property Fund, L.P. (the “Acacia IP Fund”), which was formed in August 2010. The Acacia IP Fund has been included in the Company’s consolidated financial statements since 2010, as Acacia’s wholly-owned subsidiary, the general partner of Acacia IP Fund, has the ability to control the operations and activities of the Acacia IP Fund. The Acacia IP Fund was terminated as of December 31, 2017 and dissolved in 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_844_ecustom--SegmentReportingPolicyTextBlock_zADk5K4ldVx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zeJga3udMrb8">Segment Reporting</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia uses the management approach, which designates the internal organization that is used by management for making operating decisions and assessing performance as the basis of Acacia’s reportable segments. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84C_ecustom--EstimatesPolicytextBlock_z7iuQVnnEnC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_865_zSX0sSXVwUHk">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Acacia believes that, of the significant accounting policies described herein, the accounting policies associated with revenue recognition, the valuation of the equity instruments, the valuation of Series A redeemable convertible preferred stock (the “Series A Redeemable Convertible Preferred Stock”), embedded derivatives, Series A warrants (the “Series A Warrants”), Series B warrants (the “Series B Warrants”), stock-based compensation expense, impairment of patent-related intangible assets, the determination of the economic useful life of amortizable intangible assets, income taxes and valuation allowances against net deferred tax assets, require its most difficult, subjective or complex judgments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84E_eus-gaap--RevenueRecognitionPolicyTextBlock_zp4pqpx2Pche" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86F_z0axyN6kaGS5">Revenue Recognition</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue is recognized upon transfer of control (i.e., by the granting) of promised bundled IP Rights and other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive in exchange for those IP Rights. Revenue contracts that provide promises to grant the right to use IP Rights as they exist at the point in time at which the IP Rights are granted, are accounted for as performance obligations satisfied at a point in time and revenue is recognized at the point in time that the applicable performance obligations are satisfied and all other revenue recognition criteria have been met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technologies owned or controlled by Acacia. Revenues also included license fees from sales-based revenue contracts, the majority of which were originally executed in prior periods, which provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees (“Recurring Revenue Agreements”). Revenues may also include court ordered settlements or awards related to our patent portfolio or sales of our patent portfolio. IP Rights granted included the following, as applicable: (i) the grant of a non-exclusive, future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The IP Rights granted were generally perpetual in nature, extending until the legal expiration date of the related patents. The individual IP Rights are not accounted for as separate performance obligations, as (i) the nature of the promise, within the context of the contract, is to grant combined items to which the promised IP Rights are inputs and (ii) the Company's promise to grant each individual IP right described above to the customer is not separately identifiable from other promises to grant IP Rights in the contract.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since the promised IP Rights are not individually distinct, the Company combined each individual IP Right in the contract into a bundle of IP Rights that is distinct, and accounted for all of the IP Rights promised in the contract as a single performance obligation. The IP Rights granted were “functional IP rights” that have significant standalone functionality. Acacia’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. Acacia’s operating subsidiaries have no further obligation with respect to the grant of IP Rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the IP Rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 15-90 days of execution of the contract, or the end of the quarter in which the sale or usage occurs for Recurring Revenue Agreements. Contractual payments made by licensees are generally non-refundable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For sales-based royalties, the Company includes in the transaction price some or all of an amount of estimated variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Notwithstanding, revenue is recognized for a sales-based royalty promised in exchange for a license of IP Rights when the later of (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied. Estimates are generally based on historical levels of activity, if available.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenues from contracts with significant financing components (either explicit or implicit) are recognized at an amount that reflects the price that a licensee would have paid if the licensee had paid cash for the IP Rights when they are granted to the licensee. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money. As a practical expedient, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the entity grants promised IP Rights to a customer and when the customer pays for the IP Rights will be one year or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In general, the Company is required to make certain judgments and estimates in connection with the accounting for revenue contracts with customers. Such areas may include identifying performance obligations in the contract, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services, evaluating whether a license transfers to a customer at a point in time or over time, allocating the transaction price to separate performance obligations, determining whether contracts contain a significant financing component, and estimating revenues recognized at a point in time for sales-based royalties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Revenues were comprised of the following for the periods presented: </span></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zJ9sIY37LBn9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B7_zFDerkJoCRt2" style="font: 10pt Times New Roman, Times, Serif; display: none">Disaggregation of revenue</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Paid-up revenue agreements</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210701__20210930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_zxcmXZAq1LAd" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,100</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">19,385</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">23,110</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">24,477</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Recurring Revenue Agreements</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20210930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">482</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">81</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,675</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">922</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total revenue</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,582</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">19,466</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">24,785</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">25,399</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_z9c4bc72xOyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 9pt Sans-Serif; color: Red"><b/></span><span style="font: 10pt Times New Roman, Times, Serif">Refer to “<i>Inventor Royalties and Contingent Legal Expenses</i>” below for information on related direct costs of revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zJ9sIY37LBn9" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B7_zFDerkJoCRt2" style="font: 10pt Times New Roman, Times, Serif; display: none">Disaggregation of revenue</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Paid-up revenue agreements</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210701__20210930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_zxcmXZAq1LAd" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,100</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">19,385</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">23,110</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--PaidUpRevenueAgreementsMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">24,477</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Recurring Revenue Agreements</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20210930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">482</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">81</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,675</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--RecurringRevenueAgreementsMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">922</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total revenue</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210701__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">1,582</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">19,466</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">24,785</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Revenues"><span style="font: 10pt Times New Roman, Times, Serif">25,399</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 1100000 19385000 23110000 24477000 482000 81000 1675000 922000 1582000 19466000 24785000 25399000 <p id="xdx_847_ecustom--PatentPortfolioOperationsPolicyTextBlock_zt9WnCalrHff" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_869_zqjcrZxcdwW3">Patent Portfolio Operations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues include the costs and expenses incurred in connection with Acacia’s patent licensing and enforcement activities, including inventor royalties paid to original patent owners, patent maintenance and prosecution costs, contingent legal fees paid to external patent counsel, other patent-related legal expenses paid to external patent counsel, licensing and enforcement related research, consulting and other expenses paid to third-parties and the amortization of patent-related investment costs. These costs are included under the caption “Patent portfolio operations” in the consolidated statements of operations. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Inventor Royalties and Contingent Legal Expenses </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventor royalties are expensed in the consolidated statements of operations in the period that the related revenues are recognized. Patent costs, including any upfront advances paid to patent owners by Acacia’s operating subsidiaries, that are recoverable from future net revenues are amortized over the estimated economic useful life of the related patents, or as the prepaid royalties are earned by the inventor, as appropriate, and the related expense is included in amortization expense in the consolidated statements of operations. Any unamortized upfront advances recovered from net revenues are expensed in the period recovered and included in amortization expense in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. In instances where there are no recoveries from potential infringers, no contingent legal fees are paid; however, Acacia’s operating subsidiaries may be liable for certain out of pocket legal costs incurred pursuant to the underlying legal services agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventor royalty and contingent legal agreements generally provide for payment by the Company of contractual amounts 30 days subsequent to the fiscal quarter end during which related license fee payments are received from licensees by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p id="xdx_845_ecustom--ConcentrationsPolicyTextBlock_zdCisWyLDcGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_z629mh8x2Fg3">Concentrations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject Acacia to concentrations of credit risk are cash equivalents, equity securities and accounts receivable. Acacia places its cash equivalents and equity securities primarily in highly rated money market funds and investment grade marketable securities. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. Acacia has not experienced any significant losses on its deposits of cash and cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Four licensees individually accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_z08Z9l632Sma" title="Concentration risk percentage">32</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_z3sOv6LAIQUd" title="Concentration risk percentage">25</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeLicenseeMember_zxTh9mIiCwge" title="Concentration risk percentage">22</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicensee2Member_zLScaSSvNJK9" title="Concentration risk percentage">13</span>% of revenues recognized during the three months ended September 30, 2021, and one licensee accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_z30FpxRpeW0k" title="Concentration risk percentage">98</span>% of revenues recognized during the three months ended September 30, 2020. Three licensees individually accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_znyPUuufBOm3" title="Concentration risk percentage">50</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_zx39kZPTH5Yd" title="Concentration risk percentage">19</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeLicenseeMember_zENUWIIMvvqc" title="Concentration risk percentage">12</span>% of revenues recognized during the nine months ended September 30, 2021, and two licensees accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicensee3Member_z2vQAS6oMQnh" title="Concentration risk percentage">75</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_z7RGndZS4Sr1" title="Concentration risk percentage">9</span>% of revenues recognized during the nine months ended September 30, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company does not have any material foreign operations. Based on the jurisdiction of the entity obligated to satisfy payment obligations pursuant to the applicable revenue arrangement, for the three and nine months ended September 30, 2021, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_zXbwkFsoK2F8" title="Concentration risk percentage">8</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_z9U13b52KX1g" title="Concentration risk percentage">15</span>%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions. For the three and nine months ended September 30, 2020, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_zzAcapFYsMyg" title="Concentration risk percentage">0.1</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20200930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ForeignLicenseeMember_zdyx2eenqfSb" title="Concentration risk percentage">5</span>%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Two licensees represented <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_zlW1ntM3cEX8" title="Concentration risk percentage"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20210930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoLicenseeMember_zPMhqdsSsote">100</span></span>% of accounts receivable at September 30, 2021. Two licensees individually represented approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicenseeMember_zg6fPuOeDpqc" title="Concentration risk percentage">62</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneLicensee2Member_zVRo2X70XVZk" title="Concentration risk percentage">21</span>% of accounts receivable at December 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> 0.32 0.25 0.22 0.13 0.98 0.50 0.19 0.12 0.75 0.09 0.08 0.15 0.001 0.05 1 1 0.62 0.21 <p id="xdx_842_ecustom--RelatedPartyTransactionsPolicyTextBlock_zUtnhFN0ysLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zZ9svsDlVKPl">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2019, the Company purchased shares of common stock of Drive Shack, Inc. (“Drive Shack”) for an aggregate purchase price of $2.4 million. At the time, Drive Shack and Clifford Press, Chief Executive Officer and director of Acacia, were related parties as Mr. Press was a board member of Drive Shack until June 2021. The market value of the investment was $1.4 million as of December 31, 2020. During the nine months ended September 30, 2021, the Company sold its investment receiving proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromSaleOfLongtermInvestments_pn3n3_dm_c20210101__20210930_z8wZGQ7XLEvl" title="Proceeds from sale of investment">1.8 </span>million and recognized a loss of $<span id="xdx_909_eus-gaap--LossOnSaleOfInvestments_pn3p0_c20210101__20210930_zbEpXupgctJj" title="Loss on sale of investment">515,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">  </p> 1800000 515000 <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_znBggoYpGtE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_864_zApTIkBILrjc">Cash and Cash Equivalents</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia considers all highly liquid, equity securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Acacia’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily includes: domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Acacia’s cash equivalents are measured at fair value using observable inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p id="xdx_845_ecustom--EquitySecuritiesAtFairValuePolicyTextBlock_zKwKzjxaIxTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86A_zMr6TNNWWq8h">Equity Securities at Fair Value </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investments in equity securities are reported at fair value on a recurring basis, with related realized and unrealized gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or (expense). Dividend income is included in the consolidated statements of operations in other income or (expense). Refer to Note 7 for additional information related to fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equity securities at fair value for the periods presented were comprised of the following: </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--EquityMethodInvestmentsTextBlock_zmq1bnZ0ZgYa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B5_zKRfThUHtiU4" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Security Type</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Gross<br/> Unrealized<br/> Gain</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Gross<br/> Unrealized<br/> Loss</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2021:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - Life Sciences Portfolio (Note 3)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiCost_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">62,042</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">288,508</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zDnSvqc9dW89" style="width: 11%; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,812</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">348,738</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - other equity</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--EquitySecuritiesFvNiCost_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">35,178</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">3,289</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_zazoZSkOV5Gk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(85</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">38,382</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiCost_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">97,220</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">291,797</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930_znk7BHULQWn7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,897</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">387,120</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - Life Sciences Portfolio (Note 3)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiCost_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zMbxkYAtU5we" style="font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">32,765</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">72,689</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zMVeXtbV9Jy9" style="font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(583</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">104,871</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - other equity</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCost_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">4,086</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">1,410</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_z00aWUyRTGWh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,264</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">4,232</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNiCost_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">36,851</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">74,099</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231_zvWlukMVK3Q6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,847</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A6_zpdhH9K9HW7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--EquityMethodInvestmentsTextBlock_zmq1bnZ0ZgYa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B5_zKRfThUHtiU4" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Security Type</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Gross<br/> Unrealized<br/> Gain</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Gross<br/> Unrealized<br/> Loss</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fair Value</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2021:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - Life Sciences Portfolio (Note 3)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiCost_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">62,042</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">288,508</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zDnSvqc9dW89" style="width: 11%; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,812</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">348,738</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - other equity</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--EquitySecuritiesFvNiCost_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">35,178</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">3,289</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_zazoZSkOV5Gk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(85</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">38,382</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiCost_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">97,220</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">291,797</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20210101__20210930_znk7BHULQWn7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,897</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">387,120</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - Life Sciences Portfolio (Note 3)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiCost_iI_pn3n3_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zMbxkYAtU5we" style="font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">32,765</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">72,689</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_zMVeXtbV9Jy9" style="font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(583</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundPublicSecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">104,871</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities - other equity</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCost_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">4,086</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">1,410</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_z00aWUyRTGWh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,264</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesOtherEquityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">4,232</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNiCost_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities - cost"><span style="font: 10pt Times New Roman, Times, Serif">36,851</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Gain"><span style="font: 10pt Times New Roman, Times, Serif">74,099</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_iN_pn3n3_di_c20200101__20201231_zvWlukMVK3Q6" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Available-for-sale Securities, Gross Unrealized Loss"><span style="font: 10pt Times New Roman, Times, Serif">(1,847</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--EquityMethodInvestmentsFairValueDisclosure_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Equity securities at fair value"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 62042000 288508000 1812000 348738000 35178000 3289000 85000 38382000 97220000 291797000 1897000 387120000 32765000 72689000 583000 104871000 4086000 1410000 1264000 4232000 36851000 74099000 1847000 109103000 <p id="xdx_84E_eus-gaap--EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_zA5jIua165jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_ztj8KnAgfmB2">Equity Securities Without Readily Determinable Fair Value</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For equity securities that do not have readily determinable fair value, the Company elected to report them under the measurement alternative. They are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in any adjustments for illiquidity or preference of these securities. Changes in fair value are reported in the consolidated statements of operations in other income or (expense). Refer to Note 3 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_844_eus-gaap--EquityMethodInvestmentsPolicy_zEKMmci1k7Kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_862_zLpxVmZXnVai">Equity Method Investments </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Equity investments in common stock and in-substance common stock without readily determinable fair values in companies over which the Company has the ability to exercise significant influence, are accounted for using the equity method of accounting. Acacia includes its proportionate share of earnings and/or losses of its equity method investees in earnings on equity investment in joint venture in the consolidated statements of operations. Refer to Note 3 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_840_eus-gaap--InvestmentPolicyTextBlock_znHRNqpxtPPk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zSHlKiT5CP7b">Investment at Fair Value</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On an individual investment basis, Acacia may elect to account for investments in companies where the Company has the ability to exercise significant influence over operating and financial policies of the investee, at fair value. If the fair value method is applied to an investment that would otherwise be accounted for under the equity method of accounting, it is applied to all of the financial interests in the same entity that are eligible items (i.e., common stock and warrants). We elected the fair value method for our investment in Veritone, Inc. (“Veritone”) upon acquisition of the investment. Since March 2021, we have no more investment in Veritone stocks and warrants. Refer to Note 4 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_847_ecustom--ImpairmentOfInvestmentPolicyTextBlock_zRWgCZILRST4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86F_z8aUtYt7Lw5e">Impairment of Investments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia reviews its investments quarterly for indicators of other-than-temporary impairment. This determination requires significant judgment. In making this judgment, Acacia considers available quantitative and qualitative evidence in evaluating potential impairment of its investments. If the cost of an investment exceeds its fair value, Acacia evaluates, among other factors, general market conditions and the duration and extent to which the fair value is less than cost. Acacia also considers specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of operations and a new cost basis in the investment is established.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zLoyDWm9Wmw9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_z2TQncf3udej">Long-Term Restricted Cash </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted cash relates primarily to the proceeds received from the issuance of Series A Redeemable Convertible Preferred Stock which are held in an escrow account (refer to Note 6). The amounts are to be released to the Company upon, among other things, (i) the consummation of a suitable investment or acquisition by the Company or (ii) the conversion of Series A Redeemable Convertible Preferred Stock into common stock. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Refer to Note 11 for additional information related to the subsequent period acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_841_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zuh4nTi8mO3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zoKMVuQnHAik">Patents</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patents include the cost of patents or patent rights acquired from third-parties or obtained in connection with business combinations. Patent costs are amortized utilizing the straight-line method over their remaining economic useful lives. Refer to Note 5 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zruaHSR5TAmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86A_zpvZ1zkYyGje">Impairment of Long-lived Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia reviews long-lived assets and intangible assets for potential impairment annually (quarterly for patents) and when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss is recorded in an amount equal to the excess of the asset’s carrying value over its fair value. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. In the event that management decides to no longer allocate resources to a patent portfolio, an impairment loss equal to the remaining carrying value of the asset is recorded. Refer to Note 5 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fair value is generally estimated using the “Income Approach,” focusing on the estimated future net income-producing capability of the patent portfolios over their estimated remaining economic useful life. Estimates of future after-tax cash flows are converted to present value through “discounting,” including an estimated rate of return that accounts for both the time value of money and investment risk factors. Estimated cash inflows are typically based on estimates of reasonable royalty rates for the applicable technology, applied to estimated market data. Estimated cash outflows are based on existing contractual obligations, such as contingent legal fee and inventor royalty obligations, applied to estimated license fee revenues, in addition to other estimates of out-of-pocket expenses associated with a specific patent portfolio’s licensing and enforcement program. The analysis also contemplates consideration of current information about the patent portfolio including, status and stage of litigation, periodic results of the litigation process, strength of the patent portfolio, technology coverage and other pertinent information that could impact future net cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84C_ecustom--SeriesAandBWarrantsPolicyTextBlock_zuTOJOxjyock" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86C_zVQjbnwmj3A4">Series A and B Warrants</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the Series A and B Warrants are estimated using a Black-Scholes option-pricing model. Refer to Notes 6 and 7 for additional information related to the Series A and B Warrants and their fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_84F_eus-gaap--DerivativesEmbeddedDerivatives_zRArdVHPPach" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_zIbQuddiHXx5">Embedded derivatives</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Embedded derivatives that are required to be bifurcated from their host contract are valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019. Refer to Notes 6 and 7 for additional information related to the embedded derivatives and their fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_843_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zAgIWGu5eFW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_867_zIEBNkgpHQm3">Fair Value Measurements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. Refer to Note 7 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_842_eus-gaap--StockholdersEquityPolicyTextBlock_zLIMZCIP7dyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_866_z8pF6IErMmu4">Treasury Stock</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Repurchases of the Company’s outstanding common stock are accounted for using the cost method. The applicable par value is deducted from the appropriate capital stock account on the formal or constructive retirement of treasury stock. Any excess of the cost of treasury stock over its par value is charged to additional paid-in capital and reflected as treasury stock in the consolidated balance sheets. Refer to Note 9 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zvPvcmTx8j3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86D_zIGubIqJW9Il">Stock-Based Compensation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which is generally one to three years. The fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) are determined by the product of the number of shares or units granted and the grant date market price of the underlying common stock. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing model. Forfeitures are accounted for as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RSUs granted in September 2019 with market-based vesting conditions vest based upon the Company achieving specified stock price targets over a three-year period. The effect of a market condition is reflected in the estimate of the grant-date fair value of the options utilizing a Monte Carlo valuation technique. Compensation cost is recognized with a market-based vesting condition provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Assumptions utilized in connection with the Monte Carlo valuation technique, that resulted in a fair value of $1.42 per unit, included: estimated risk-free interest rate of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember" title="Assumptions used for derivatives">1.38 percent</span>; term of <span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember_z0Hir3knAOO2" title="Assumptions used for derivatives">3.00 years</span>; expected volatility of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember" title="Assumptions used for derivatives">38 percent</span>; and expected dividend yield of <span id="xdx_903_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20210101__20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ValuationTechniqueAxis__custom--BlackScholesMethodMember__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsMember" title="Assumptions used for derivatives">0 percent</span>. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. During the nine months ended September 30, 2021, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfsoNSr2NIc5" title="Option Forfeited">450,000</span> RSUs were forfeited, leaving <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_pn3p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkA1kLOVQEc" title="Option Forfeited">450,000</span> units with market-based vesting conditions outstanding and unvested at period end.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended September 30, 2021, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--RSAsMember_zJ99UTGtC3i7" title="Weighted Average Grant">324,401</span> RSAs at a weighted average grant-date fair value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--RSAsMember_zXdwiRqa7Bg2" title="Weighted average grant-date fair value">5.56 </span>per share, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3I4cREBWCte">473,000</span> RSUs at a weighted average grant-date fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdsbs1hsoSqb" title="Weighted average grant-date fair value">5.86</span> per unit and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsMember_zEBfRxUcHaa6">393,750</span> non-qualified stock options at a grant-date fair value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsMember_zogY04uAPWJa">1.79</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation is reported in the consolidated statements of operations in general and administrative expenses. Total stock-based compensation for the three and nine months ended September 30, 2021 was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn3p0_c20210701__20210930_zmrcwGz6Jdza" title="Stock-based compensation">300,000</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20210101__20210930_pn3p0" title="Stock-based compensation">1,279,000</span>, respectively. Total unrecognized stock-based compensation expense as of September 30, 2021 was $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20210930_pn3p0" title="Unrecognized stock-based compensation expense">5,952,000</span>, which will be amortized over a weighted average remaining vesting period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_zdmyqOeYYNDb" title="Weighted-average remaining vesting period">2.20</span> years. Total stock-based compensation for the three and nine months ended September 30, 2020 was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20200701__20200930_pn3p0" title="Stock-based compensation">488,000</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20200101__20200930_pn3p0" title="Stock-based compensation">1,243,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Profits Interest Units (“PIUs”) were accounted for in accordance with Accounting Standards Codification (“ASC”) 718-10, “Compensation - Stock Compensation.” The vesting conditions did not meet the definition of service, market or performance conditions, as defined in ASC 718. As such, the PIUs were classified as liability awards. Compensation expense was adjusted for changes in fair value prorated for the portion of the requisite service period rendered. Initially, compensation expense was recognized on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which was five years. Upon full vesting of the award, which occurred during the three months ended September 30, 2017, previously unrecognized compensation expense was immediately recognized in the period. The Company has a purchase option to purchase the vested PIUs that are not otherwise forfeited after termination of continuous service. The exercise price of the purchase option is the fair market value of the PIUs on the date of termination of continuous service. The individuals holding PIUs are no longer employed by the Company. Included in other long-term liabilities in the consolidated balance sheets as of September 30, 2021 and December 31, 2020, the PIUs totaled $591,000, which was their fair value as of December 31, 2018 after termination of service.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 1.38 percent 3.00 years 38 percent 0 percent 450000 450000 324401 5.56 473000 5.86 393750 1.79 300000 1279000 5952000 P2Y2M12D 488000 1243000 <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zhkUQWPPd5J3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_86C_za3TxTxZzFm3">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in Acacia’s consolidated financial statements or consolidated income tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized, or if it is determined that there is uncertainty regarding future realization of such assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provision for income taxes for interim periods is determined using an estimate of Acacia’s annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, Acacia updates the estimate of the annual effective tax rate, and if the estimated tax rate changes, a cumulative adjustment is recorded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s effective tax rates were <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20210701__20210930_z11XD73sdRb4" title="Effective tax rate">0</span>% and (<span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20210101__20210930_zpSd4wOSJbW3" title="Effective tax rate">1</span>%) for the three and nine months ended September 30, 2021, respectively, and <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20200701__20200930_zgvk1NgPLcZh" title="Effective tax rate">0</span>% and (<span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_c20200101__20200930_z9kHwwZ0ewu9" title="Effective tax rate">4</span>%) for the three and nine months ended September 30, 2020, respectively. Tax expense/benefit for the periods presented primarily reflects the impact of state taxes and foreign tax withholding (or refund) incurred on revenue agreements executed with third-party licensees domiciled in foreign jurisdictions. The Company has recorded a full valuation allowance against our net deferred tax assets as of September 30, 2021 and December 31, 2020. These assets primarily consist of foreign tax credits, capital loss carryforwards and net operating loss carryforwards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> 0 0.01 0 0.04 <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zZXOl0XkMU5j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_860_zviHK9QTSmF9">Recent Accounting Pronouncements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Recently Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December of 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The update removed certain exceptions to the general principles in Topic 740 in U.S. GAAP. The Company adopted the update on January 1, 2021. The adoption of the update did not have a material effect on the Company’s financial position, results of operations or financial statement disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Not Yet Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” to replace the incurred loss methodology with an expected credit loss model that requires consideration of a broader range of information to estimate credit losses over the lifetime of the asset, including current conditions and reasonable and supportable forecasts in addition to historical loss information, to determine expected credit losses. Pooling of assets with similar risk characteristics and the use of a loss model are also required. Also, in April 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,” to clarify the inclusion of recoveries of trade receivables previously written off when estimating an allowance for credit losses. The amendments in these updates will currently be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in these updates may have on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” to simplify the accounting for convertible instruments by eliminating large sections of the existing guidance in this area. It also eliminates several triggers for derivative accounting, including a requirement to settle certain contracts by delivering registered shares. This update reduces the number of accounting models for convertible instruments, revises the derivatives scope exception, and provides targeted improvements for earnings per share. Upon adoption, companies have the option to apply a modified or full retrospective transition approach. The amendments in this update will currently be effective for the Company on January 1, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,” to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with “Revenue from Contracts with Customers (Topic 606).” At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and will be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_800_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zsvFU5CLq6Uh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. <span id="xdx_823_zq6fDjbnU4I3">EQUITY SECURITIES PORTFOLIO INVESTMENT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 3, 2020, the Company entered into an Option Agreement with LF Equity Income Fund (“Seller”), which included general terms through which the Company was provided the option to purchase life sciences equity securities in a portfolio of public and private companies (“Life Sciences Portfolio”) for an aggregate purchase price of £223.9 million, approximately $<span id="xdx_90F_eus-gaap--PaymentsToAcquireInvestments_pn3n3_dm_c20200101__20200403__us-gaap--TransactionTypeAxis__custom--OptionAgreementMember__srt--CounterpartyNameAxis__custom--PortfolioCompaniesMember_zwMDlfL5mK6e" title="Payment to acquire equity securities">277.5</span> million at the exchange rate on April 3, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 4, 2020, the Company executed the Transaction Agreement between Link Fund Solutions Limited, Seller, and the Company. Pursuant to the Transaction Agreement, the Company agreed to purchase from Seller and Seller agreed to transfer to the Company the specified equity securities of all companies in the Life Sciences Portfolio at set prices at various future dates. The transfer dates would vary among the Life Sciences Portfolio companies as the Transaction Agreement gives the Company the exclusive right to determine when to call for transfer of each security, and because each Life Sciences Portfolio company (or its existing equity holders) may be required to approve the transfer due to rights of first refusals and other company-specific terms and conditions. Thus, the execution of the Transaction Agreement resulted in forward contracts for the Company to purchase equity securities in each public and private company at a specified price on a future date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with the Transaction Agreement, the Company transferred the total purchase price of £223.9 million into an escrow account. Upon the transfer of equity securities in the Life Sciences Portfolio to the Company, the associated funds were released from the escrow account to Seller based on the consideration amount assigned to the equity securities for such Life Sciences Portfolio company in the Transaction Agreement. As of December 31, 2020, all of the equity securities in the Life Sciences Portfolio were transferred to the Company pursuant to the Transaction Agreement. The Company has sold a portion of the equity securities of such Life Sciences Portfolio while retaining an interest in a number of operating businesses, including a controlling interest in one of the companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For accounting purposes, the total purchase price of the Life Sciences Portfolio was allocated to the individual equity securities based on their individual fair values as of April 3, 2020, in order to establish an appropriate cost basis for each of the acquired securities. The fair values of the public company securities were based on their quoted market price. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in a discount for the illiquidity of these securities. As of September 30, 2021 and December 31, 2020, the fair value of the Life Sciences Portfolio equity securities, excluding the equity method investment discussed below, was $354.6 million and $248.1 million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in the fair value of Acacia’s investment in the Life Sciences Portfolio are recorded as unrealized gains or losses in the consolidated statements of operations. In late September 2021, the Company sold one security which resulted in a gain of $18.6 million. The proceeds of that sale were settled and received in early October 2021, and therefore the Company recorded a $21.5 million other receivable as included in the consolidated balance sheet as of September 30, 2021. Accordingly, this trade date receivable from the sale of equity securities has been reflected as a noncash investing activity in the consolidated statement of cash flows for the nine months ended September 30, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the three and nine months ended September 30, 2021 and 2020, the consolidated statements of operations reflected the following from the Life Sciences Portfolio: </p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--UnrealizedGainLossOnInvestmentsTableTextBlock_pn3n3_zxL2We0nCSN5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zKXQW0rympAg" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of unrealized gains or losses</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of equity securities</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_zMEUkkqcH3d6" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">63,907</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">84,299</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">112,180</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">83,230</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of equity securities derivative</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_zuJEfw7epRQj" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">10,651</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_zdgMTswNPWpe" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">17,542</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of equity securities forward contract</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_zdxfROMNNJX2" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">(74,662</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_zw18vjWcmTk" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_ztucdF4aE139" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gain (loss) on sale of equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zNqcMfNxvUZ1" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">37,112</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--RealizedInvestmentGainsLosses_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">1,908</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_znTGs2UIlfOe" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">52,167</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zrfTas6FX2Qf" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">(4,202</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Gain on sale of prepaid investment and derivative</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivative_pn3n3_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zQb3u7swTyr6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivative"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivativey_pn3n3_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zmnv5aeeFWa6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivativey"><span style="font: 10pt Times New Roman, Times, Serif">2,845</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivative_pn3n3_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_z7nIFl2ff16c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivative"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivative_pn3n3_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zqCCa3FwKtGh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivative"><span style="font: 10pt Times New Roman, Times, Serif">2,845</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net realized and unrealized gain</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--GainLossOnInvestments_pn3n3_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_ztnyFAXHjkh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">101,019</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--GainLossOnInvestments_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">25,041</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--GainLossOnInvestments_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">164,347</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--GainLossOnInvestments_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">99,415</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">As part of the Company’s acquisition of equity securities in the Life Sciences Portfolio, the Company acquired a majority interest in the equity securities of MalinJ1 (63.9%), which were transferred to the Company on December 3, 2020. The acquisition of the MalinJ1 securities was accounted for as an asset acquisition as there was a change of control of MalinJ1 and substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset, an investment in Viamet Pharmaceuticals Holdings, LLC (“Viamet”). As such, the cost basis of the MalinJ1 securities was used to allocate to the Viamet investment, the single identifiable asset, and no goodwill was recognized. The Company through its consolidation of MalinJ1 accounts for the Viamet investment under the equity method as MalinJ1 owns 41.0% of outstanding shares of Viamet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 277500000 <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--UnrealizedGainLossOnInvestmentsTableTextBlock_pn3n3_zxL2We0nCSN5" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8BE_zKXQW0rympAg" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of unrealized gains or losses</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of equity securities</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_zMEUkkqcH3d6" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">63,907</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">84,299</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">112,180</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesLfFundSecuritiesMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">83,230</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of equity securities derivative</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_zuJEfw7epRQj" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">10,651</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_zdgMTswNPWpe" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesDerivativeMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">17,542</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of equity securities forward contract</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_zdxfROMNNJX2" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">(74,662</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_zw18vjWcmTk" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_d0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritesForwardContractMember_ztucdF4aE139" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gain (loss) on sale of equity securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zNqcMfNxvUZ1" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">37,112</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--RealizedInvestmentGainsLosses_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_pn3n3" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">1,908</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_znTGs2UIlfOe" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">52,167</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zrfTas6FX2Qf" style="font-size: 10pt; text-align: right" title="Loss on sale of trading security"><span style="font: 10pt Times New Roman, Times, Serif">(4,202</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Gain on sale of prepaid investment and derivative</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivative_pn3n3_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zQb3u7swTyr6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivative"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivativey_pn3n3_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zmnv5aeeFWa6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivativey"><span style="font: 10pt Times New Roman, Times, Serif">2,845</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivative_pn3n3_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_z7nIFl2ff16c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivative"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_ecustom--GainOnSaleOfPrepaidInvestmentAndDerivative_pn3n3_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EquitySecuritiesLFFundTradingSecurityMember_zqCCa3FwKtGh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Gain on sale of prepaid investment and derivative"><span style="font: 10pt Times New Roman, Times, Serif">2,845</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net realized and unrealized gain</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--GainLossOnInvestments_pn3n3_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_ztnyFAXHjkh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">101,019</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--GainLossOnInvestments_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">25,041</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--GainLossOnInvestments_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">164,347</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--GainLossOnInvestments_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--LFFundSecuritiesMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">99,415</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 63907000 84299000 112180000 83230000 0 10651000 0 17542000 0 -74662000 0 0 37112000 1908000 52167000 -4202000 0 2845000 0 2845000 101019000 25041000 164347000 99415000 <p id="xdx_80C_eus-gaap--InvestmentHoldingsTextBlock_zKzfd8qQ8iSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. <span id="xdx_827_z2hL1KiZKkxl">INVESTMENT AT FAIR VALUE</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2016 and 2017, Acacia made certain investments in Veritone. As a result of these transactions, Acacia received an aggregate total of 4,119,521 shares of Veritone common stock and warrants to purchase a total of 1,120,432 shares of Veritone common stock at an exercise price of $13.61 per share expiring between 2020 and 2027. During the nine months ended September 30, 2020, Acacia sold all remaining 298,450 shares Veritone common stock and recorded a realized loss of $3.3 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended September 30, 2020, Acacia exercised 154,312 warrants, and recognized a realized gain of $554,000 on the sale of common stock. During the nine months ended September 30, 2021, Acacia exercised all remaining 156,720 warrants, and recognized a realized gain of $3.6 million on the sale of common stock. The Company no longer has an investment in Veritone common stock and warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in the fair value of Acacia’s investment in Veritone are recorded as unrealized gains or losses in the consolidated statements of operations. For the three and nine months ended September 30, 2021 and 2020, the consolidated statements of operations reflected the following: </p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--GainLossOnInvestmentsTextBlock_pn3n3_zb8KfomJmqyl" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT AT FAIR VALUE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B4_zeRXAGEneIue" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of gain on investments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of investment, warrants</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20210701__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zHWFPxmYQpCk" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--UnrealizedGainLossOnInvestments_iN_pn3n3_di_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zBALI1iOvgBk" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">(3,081</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--UnrealizedGainLossOnInvestments_iN_pn3n3_di_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zyACk9VbfrKh" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">(2,752</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">225</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of investment, common stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20210701__20210930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_z2aYF2y3cM6c" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zfSP8TYgl9Xk" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zy9OuX3Ssi01" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">3,479</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gain on sale of investment, warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainOnSaleOfInvestments_pn3n3_d0_c20210701__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zw1VJthNG0oi" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainOnSaleOfInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zu11xIn4bKyc" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--GainOnSaleOfInvestments_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_pn3n3" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">3,591</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainOnSaleOfInvestments_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_pn3n3" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">554</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Loss on sale of investment, common stock</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--LossOnSaleOfInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zpanvTIk1fGf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--LossOnSaleOfInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_z2c64wloIrl1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--LossOnSaleOfInvestments_pn3n3_d0_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_z08tvJcl3vQ6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--LossOnSaleOfInvestments_iN_pn3n3_di_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zxbeb8UKZ8W3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">(3,316</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net realized and unrealized (loss) gain</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--GainLossOnInvestments_pn3n3_d0_c20210701__20210930_z7p5QeItbWLd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--GainLossOnInvestments_iN_pn3n3_di_c20200701__20200930_zwv5wA4AXM9f" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">(3,081</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--GainLossOnInvestments_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">839</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--GainLossOnInvestments_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">942</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--GainLossOnInvestmentsTextBlock_pn3n3_zb8KfomJmqyl" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT AT FAIR VALUE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B4_zeRXAGEneIue" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of gain on investments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of investment, warrants</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20210701__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zHWFPxmYQpCk" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--UnrealizedGainLossOnInvestments_iN_pn3n3_di_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zBALI1iOvgBk" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">(3,081</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--UnrealizedGainLossOnInvestments_iN_pn3n3_di_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zyACk9VbfrKh" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">(2,752</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_pn3n3" style="width: 11%; font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">225</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value of investment, common stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20210701__20210930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_z2aYF2y3cM6c" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zfSP8TYgl9Xk" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_d0_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zy9OuX3Ssi01" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_pn3n3" style="font-size: 10pt; text-align: right" title="Change in fair value of investment"><span style="font: 10pt Times New Roman, Times, Serif">3,479</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gain on sale of investment, warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainOnSaleOfInvestments_pn3n3_d0_c20210701__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zw1VJthNG0oi" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainOnSaleOfInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_zu11xIn4bKyc" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--GainOnSaleOfInvestments_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_pn3n3" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">3,591</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--GainOnSaleOfInvestments_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--WarrantInvestmentMember_pn3n3" style="font-size: 10pt; text-align: right" title="Gain on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">554</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Loss on sale of investment, common stock</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--LossOnSaleOfInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zpanvTIk1fGf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--LossOnSaleOfInvestments_pn3n3_d0_c20200701__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_z2c64wloIrl1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--LossOnSaleOfInvestments_pn3n3_d0_c20210101__20210930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_z08tvJcl3vQ6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--LossOnSaleOfInvestments_iN_pn3n3_di_c20200101__20200930__us-gaap--InvestmentTypeAxis__custom--CommonStockInvestmentMember_zxbeb8UKZ8W3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Loss on sale of investment"><span style="font: 10pt Times New Roman, Times, Serif">(3,316</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Net realized and unrealized (loss) gain</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--GainLossOnInvestments_pn3n3_d0_c20210701__20210930_z7p5QeItbWLd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--GainLossOnInvestments_iN_pn3n3_di_c20200701__20200930_zwv5wA4AXM9f" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">(3,081</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--GainLossOnInvestments_c20210101__20210930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">839</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--GainLossOnInvestments_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net realized and unrealized gain (loss) on investment"><span style="font: 10pt Times New Roman, Times, Serif">942</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 0 3081000 2752000 225000 0 0 0 3479000 0 0 3591000 554000 0 0 0 3316000 0 3081000 839000 942000 <p id="xdx_809_ecustom--PatentsNetOfAccumulatedAmortizationTextBlock_zTpxf0aZQPNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. <span id="xdx_826_zij6bxuAdYCi">PATENTS, NET OF ACCUMULATED AMORTIZATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia’s only identifiable intangible assets as of September 30, 2021 and December 31, 2020 are patents and patent rights. Patent-related accumulated amortization totaled $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_dm_c20210930_zWMfi9WnMjRl" title="Accumulated amortization">291.6</span> million and $<span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_dm_c20201231_zDLvRdd58j29" title="Accumulated amortization">319.9</span> million as of September 30, 2021 and December 31, 2020, respectively. Acacia’s patents have remaining estimated economic useful lives ranging from twenty-six to fifty-two months. The weighted average remaining estimated economic useful life of Acacia’s patents is approximately four years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the scheduled annual aggregate amortization expense as of September 30, 2021: </p> <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_pn3n3_zUT140DEdHl3" style="border-collapse: collapse; width: 40%" summary="xdx: Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B8_zuiqmEMygJp9" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of intangible assets</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_496_20210930_zz4FFSJwI0E1" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">For the years ending December 31,</span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="4" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzJix_ze9vNrN0UJf9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 27%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Remainder of 2021</span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,612</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzJix_zTiA3MPpqzjk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">10,448</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzJix_zFlxBGuOz923" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">10,381</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzJix_zEvY4MqUajF2" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">9,005</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzJix_z3cmojYdLkNi" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2025</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6,630</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzJix_zmEDNRUUDwe3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">750</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzJix_znHIRvRyAwCj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="color: rgb(238,238,238); font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Patents, net  </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">39,826</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the nine months ended September 30, 2021, Acacia accrued patent and patent rights acquisition costs totaling $<span id="xdx_90F_ecustom--AccruedPatentAcquisitionCosts_iI_pn3n3_dm_c20210930_zMIyiWiJNvVf" title="Accrued patent acquisition costs">13.0</span> million, of which $<span id="xdx_90C_eus-gaap--OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_iI_pn3n3_dm_c20210930_z11shg8Vq3Af" title="Accrued patent acquisition costs due within a year">8.0</span> million is due December 1, 2021 and $<span id="xdx_908_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_pn3n3_dm_c20210930_zJcRlYw3UMz7" title="Accrued patent acquisition costs due within 2 years">5.0</span> million is due February 18, 2023. Such amounts are included in accrued patent investment costs and other long-term liabilities in the consolidated balance sheet as of September 30, 2021, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 291600000 319900000 <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_pn3n3_zUT140DEdHl3" style="border-collapse: collapse; width: 40%" summary="xdx: Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B8_zuiqmEMygJp9" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of intangible assets</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_496_20210930_zz4FFSJwI0E1" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">For the years ending December 31,</span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="4" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzJix_ze9vNrN0UJf9" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 27%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Remainder of 2021</span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,612</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzJix_zTiA3MPpqzjk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">10,448</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzJix_zFlxBGuOz923" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">10,381</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzJix_zEvY4MqUajF2" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">9,005</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzJix_z3cmojYdLkNi" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2025</span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6,630</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzJix_zmEDNRUUDwe3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">750</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzJix_znHIRvRyAwCj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="color: rgb(238,238,238); font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Patents, net  </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">39,826</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 2612000 10448000 10381000 9005000 6630000 750000 39826000 13000000.0 8000000.0 5000000.0 <p id="xdx_803_ecustom--StarboardInvestmentTextBlock_zziu1Lyfzex3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. <span id="xdx_821_zMcYgilkxbti">STARBOARD INVESTMENT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series A Redeemable Convertible Preferred Stock </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 18, 2019, the Company entered into a Securities Purchase Agreement with Starboard Value LP (“Starboard”) and certain funds and accounts affiliated with, or managed by, Starboard (collectively, the “Buyers”) pursuant to which the Company issued (i) <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191101__20191118__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Stock issued">350,000</span> shares of Series A Redeemable Convertible Preferred Stock with a par value of $0.001 per share and a stated value of $100 per share, and (ii) Series A Warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20191118__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_pdd" title="Warrants issued, shares">5,000,000</span> shares of the Company’s common stock to the Buyers. The Securities Purchase Agreement also established the terms of certain senior secured notes and additional Series B Warrants which may be issued to Starboard in the future. On June 4, 2020, the Company entered into a Supplemental Agreement, as defined below under “Senior Secured Notes”, with certain contractual agreements affecting the Series A Redeemable Convertible Preferred Stock, reflected below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series A Redeemable Convertible Preferred Stock can be converted into a number of shares of common stock equal to (i) the stated value thereof plus accrued and unpaid dividends, divided by (ii) the conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20191118__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Conversion price">3.65</span> (subject to certain anti-dilution adjustments). Holders may elect to convert the Series A Redeemable Convertible Preferred Stock into common stock at any time. The Company may elect to convert the Series A Redeemable Convertible Preferred Stock into shares of Common Stock any time on or after November 15, 2025, provided that the closing price of the Company’s common stock equals or exceeds 190% of the conversion price for 30 consecutive trading days and assuming certain other conditions of the common stock have been met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock during the periods of May 15, 2021 through August 15, 2021 and May 15, 2022 through August 15, 2022, provided that there is not outstanding at least $50.0 million aggregate principal of senior secured notes to the Buyers pursuant to the Securities Purchase Agreement at the time of the redemption. Holders also have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock during the period of November 15, 2024 through February 15, 2025. Additionally, holders have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock upon the occurrence of (i) a change of control or (ii) various other triggering events, such as the suspension from trading or delisting of the Company’s common stock. If the Series A Redeemable Convertible Preferred Stock is redeemed at the option of the holders, the redemption price may include a make-whole amount or a stated premium, depending on the redemption scenario.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company may redeem all, and not less than all, of the Series A Redeemable Convertible Preferred Stock (i) upon a change of control or (ii) during the period of May 15, 2022 through August 15, 2022, provided that there is not outstanding at least $50.0 million aggregate principal of the senior secured notes at the time of the redemption, and assuming certain conditions of the common stock have been met. If the Series A Redeemable Convertible Preferred Stock is redeemed at the option of the Company, the redemption price would include a make-whole amount or a 15% premium depending on the circumstances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any Series A Redeemable Convertible Preferred Stock remains outstanding on November 15, 2027, the Company shall redeem such Series A Redeemable Convertible Preferred Stock in cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In all redemption scenarios, the redemption price for the Series A Redeemable Convertible Preferred Stock includes the stated value plus accrued and unpaid dividends. In addition, depending on the redemption scenario, the redemption price may also include a make-whole amount or stated premium as described above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When the Company issues Notes, the Holder may exchange the Series A Redeemable Convertible Preferred Stock for (i) Notes and (ii) Series B Warrants to purchase common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series A Redeemable Convertible Preferred Stock accrues cumulative dividends quarterly at annual rate of 3.0% on the stated value. Upon consummation of the approved investment in June 2020, the dividend rate increased to 8.0% on the stated value. Upon certain triggering events, the dividend rate will increase to 7.0% if the triggering event occurs before an approved investment or 10.0% on the stated value if the triggering event occurs after an approved investment. In connection with the approved investment in June 2020, the Company and the Buyers agreed that the dividend rate on the Series A Redeemable Convertible Preferred Stock would accrue at 3.0% so long as no triggering event occurs and the Company maintains $35.0 million in escrow. Series A Redeemable Convertible Preferred Stock also participates on an as-converted basis in any regular or special dividends paid to common stockholders. No accrued and unpaid dividends as of September 30, 2021. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Upon consummation of the approved acquisition in October 2021, the dividend rate increased to 8.0% on the stated value. Refer to Note 11 for additional information related to the subsequent period acquisition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders of the Series A Redeemable Convertible Preferred Stock have the right to vote with common stockholders on an as-converted basis on all matters. Holders of Series A Redeemable Convertible Preferred Stock will also be entitled to a separate class vote with respect to amendments to the Company’s organizational documents that generally have an adverse effect on the Series A Redeemable Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon liquidation of the Company, holders of Series A Redeemable Convertible Preferred Stock have a liquidation preference over holders of our common stock and will be entitled to receive, prior to any distribution to holders of our common stock, an amount equal to the greater of (i) the stated value plus accrued and unpaid dividends or (ii) the amount that would have been received if the Series A Redeemable Convertible Preferred Stock had been converted into common stock immediately prior to the liquidation event at the then effective conversion price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company determined that certain features of the Series A Redeemable Convertible Preferred Stock should be bifurcated and accounted for as a derivative. Each of these features are bundled together as a single, compound embedded derivative.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2019, total proceeds received and transaction costs incurred from the issuance of the Series A Redeemable Convertible Preferred Stock amounted to $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn3n3_dm_c20200519__20210930__us-gaap--SecuritiesFinancingTransactionAxis__custom--SeriesARedeemableConvertibleStockMember_zkNsLZ672zWc" title="Proceeds from issuance of preferred stock">35.0</span> million and $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_dm_c20200519__20210930__us-gaap--SecuritiesFinancingTransactionAxis__custom--SeriesARedeemableConvertibleStockMember_zs75OjSbOHoc" title="Payment of stock issuance costs">1.3</span> million, respectively. Proceeds received were allocated based on the fair value of the instrument without the Series A Warrants and of the Series A Warrants themselves at the time of issuance. The proceeds allocated to the Series A Redeemable Convertible Preferred Stock were then further allocated between the host preferred stock instrument and the embedded derivative, with the embedded derivative recorded at fair value and the Series A Redeemable Convertible Preferred Stock recorded at the residual amount. The portion of the proceeds allocated to the Series A Warrants, embedded derivative, and Series A Redeemable Convertible Preferred Stock was $4.8 million, $21.2 million, and $8.9 million, respectively. Transaction costs were also allocated between the Series A Redeemable Convertible Preferred Stock and the Series A Warrants on the same basis as the proceeds. The transaction costs allocated to the Series A Redeemable Convertible Preferred Stock were treated as a discount to the Series A Redeemable Convertible Preferred Stock. The transaction costs allocated to the Series A Warrants were expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company classifies the Series A Redeemable Convertible Preferred Stock as mezzanine equity as the instrument will become redeemable at the option of the holder in various scenarios or otherwise on November 15, 2027. As it is probable that the Series A Redeemable Convertible Preferred Stock will become redeemable, the Company accretes the instrument to its redemption value using the effective interest method and recognizes any changes against additional paid in capital in the absence of retained earnings. Accretion for the three and nine months ended September 30, 2021 was $<span id="xdx_908_eus-gaap--AccretionExpense_pn3p0_c20210701__20210930__us-gaap--SecuritiesFinancingTransactionAxis__custom--SeriesARedeemableConvertibleStockMember_zKHVd9iYmgRc" title="Accretion expense">991,000</span> and $<span id="xdx_90C_eus-gaap--AccretionExpense_pn3n3_dm_c20210101__20210930__us-gaap--SecuritiesFinancingTransactionAxis__custom--SeriesARedeemableConvertibleStockMember_zkyTiXbW3UI5" title="Accretion expense">2.8</span> million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the issuance of the Series A Redeemable Convertible Preferred Stock, the Company executed a Registration Rights Agreement with Starboard and the Buyers and a Governance Agreement with Starboard and certain affiliates of Starboard. Under the Registration Rights Agreement, the Company agreed to provide certain registration rights with respect to the Series A Redeemable Convertible Preferred Stock and shares of Common Stock issued upon conversion. In accordance with the Governance Agreement, the Company agreed to (i) increase the size of the Board of Directors from six to seven members, (ii) appoint Jonathan Sagal as a director of the Company, (iii) grant Starboard the right to recommend two additional directors for appointment to the board, (iv) form a Strategic Committee of the Board tasked with sourcing and performing due diligence on potential acquisition targets, (v) appoint certain directors to the Strategic Committee, and (vi) appoint a director to the Nominating and Corporate Governance Committee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following features of the Series A Redeemable Convertible Preferred Stock are required to be bifurcated from the host preferred stock and accounted for separately as an embedded derivative: (i) the right of the holders to redeem the shares (the “put option”), (ii) the right of the holders to receive common stock upon conversion of the shares (the “conversion option”), (iii) the right of the Company to redeem the shares (the “call option”), and (iv) the change in dividend rate upon consummation of an approved investment or a triggering event (the “contingent dividend rate feature”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These features are required to be accounted for separately from the Series A Redeemable Convertible Preferred Stock because the features were determined to be not clearly and closely related to the debt-like host and also did not meet any other scope exceptions for derivative accounting. Therefore, these features are bundled together and are accounted for as a single, compound embedded derivative liability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accordingly, we have recorded an embedded derivative liability representing the combined fair value of each of these features. The embedded derivative liability is adjusted to reflect fair value at each period end with changes in fair value recorded other income or (expense) in the “Change in fair value of the Series A and B warrants and embedded derivatives” financial statement line item of the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series A embedded derivative liabilities was $<span id="xdx_90C_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn3n3_dm_c20210930__us-gaap--SecuritiesFinancingTransactionAxis__custom--SeriesARedeemableConvertibleStockMember_zwK8Z9P5ipT5" title="Fair value of embedded derivative">41.4</span> million and $<span id="xdx_90A_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn3n3_dm_c20201231__us-gaap--SecuritiesFinancingTransactionAxis__custom--SeriesARedeemableConvertibleStockMember_zkMfyAsve7Ig" title="Fair value of embedded derivative">26.7</span> million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series A Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 18, 2019, in connection with the issuance of the Series A Redeemable Convertible Preferred Stock, the Company issued a detachable Series A Warrants to acquire up to purchase 5 million shares of common stock at a price of $3.65 per share (subject to certain anti-dilution adjustments) at any time during a period of eight years beginning on the instrument’s issuance date of the Series A Warrants. The fair value of the Series A Warrants was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_dm_c20191118__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zVduOVdhfJW3" title="Fair value of warrants">4.8</span> million upon issuance. The Series A Warrants will be recognized at fair value at each reporting period until exercised, with changes in fair value recognized in other income or (expense) in the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series A Warrants was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_dm_c20210930__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zmkROtM85Gnb" title="Fair value of warrants">18.5</span> million and $<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_dm_c20201231__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zDSBS5WvWmKa">6.6</span> million, respectively. As of September 30, 2021, the Series A Warrants have <span id="xdx_907_ecustom--WarrantsExercisedShares_do_c20210101__20210930__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAWarrantsMember_zFNzS50Vw9Uc" title="Warrants exercised">no</span>t been exercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series A Warrants are classified as a liability in accordance with ASC 480, “Distinguishing Liabilities from Equity”, as the agreement provides for net cash settlement upon a change in control, which is outside the control of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series B Warrants </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 25, 2020, pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, the Company issued Series B Warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_dm_c20200225__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zv5GbrN3S5a7" title="Warrants issued, shares">100</span> million shares of the Company’s common stock at an exercise price (subject to certain price-based anti-dilution adjustments) of either (i) $5.25 per share, if exercising by cash payment, within 30 months from the issuance date (i.e., August 25, 2022); or (ii) $3.65 per share, if exercising by cancellation of a portion of Notes. The Company issued the Series B Warrants for an aggregate purchase price of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn3n3_dm_c20200201__20200225__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zMyMexkZuAig" title="Proceeds from issuance of preferred stock">4.6</span> million. The Series B Warrants expire on November 15, 2027.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the issuance of the Notes on June 4, 2020, the terms of certain of the Series B Warrants were amended to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration date of November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms. As of September 30, 2021, the Series B Warrants have <span id="xdx_900_ecustom--WarrantsExercisedShares_do_c20210101__20210930__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zbleMgenLO05" title="Warrants exercised">no</span>t been exercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series B Warrants will be recognized at fair value at each reporting period until exercised, with changes in fair value recognized in other income or (expense) in the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series B Warrants was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_dm_c20210930__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zVvHHwpTRnP8" title="Fair value of warrants">229.6</span> million and $<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_dm_c20201231__srt--CounterpartyNameAxis__custom--StarboardValueMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zDr0DS4EoiC7" title="Fair value of warrants">52.3</span> million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series B Warrants are classified as a liability in accordance with ASC 480, “Distinguishing Liabilities from Equity”, as the agreement provides for net cash settlement upon a change in control, which is outside the control of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Senior Secured Notes</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Securities Purchase Agreement dated November 18, 2019 with Starboard and the Buyers, on June 4, 2020, the Company issued $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn3n3_dm_c20200101__20200604__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zri2UsNCqTqe" title="Proceeds from issuance of debt">115.0</span> million in Notes to the Buyers. Also on June 4, 2020, in connection with the issuance of the Notes, the Company entered into a Supplemental Agreement with Starboard (the “Supplemental Agreement”), pursuant to which the Company agreed to redeem $<span id="xdx_905_ecustom--RedemptionOfSecuredNotes_iI_pn3n3_dm_c20200930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__us-gaap--SecuritiesFinancingTransactionAxis__custom--SeptemberRedemptionMember_zLsTwy9lCgs" title="Repayment of debt">80.0</span> million aggregate principal amount of the Notes by September 30, 2020, and $<span id="xdx_903_ecustom--RedemptionOfSecuredNotes_iI_pn3n3_dm_c20201231__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__us-gaap--SecuritiesFinancingTransactionAxis__custom--DecemberRedemptionMember_zXgD1ONnFORb" title="Repayment of debt">35.0</span> million aggregate principal amount of the Notes by December 31, 2020, resulting in the total principal outstanding being paid by December 31, 2020. Per the Supplemental Agreement, interest is payable semiannually at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zei6ZnSUFmb6" title="Debt stated interest rate">6.00</span>% per annum, and in an event of default, the interest rate is increased to <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200604__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zYIcyIroiFtl" title="Debt stated interest rate">10.00</span>% per annum. The Notes include certain financial and non-financial covenants. Additionally, all or any portion of the principal amount outstanding under the Notes may, at the election of Starboard, be surrendered to the Company for cancellation in payment of the exercise price upon the exercise of Series B Warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 30, 2020, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with Merton Acquisition HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“Merton”) and Starboard, on behalf of itself and on behalf of certain funds and accounts under its management, including the holders of the Notes. Pursuant to the Exchange Agreement, the holders of the Notes exchanged the entire outstanding principal amount for new senior notes (the “New Notes”) issued by Merton having an aggregate outstanding original principal amount of $<span id="xdx_900_eus-gaap--IncreaseDecreaseInNotesPayableCurrent_pn3n3_dm_c20200101__20200630__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zkA8NOn0ZtN2" title="Notes exchanged">115.0</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The New Notes bear interest at a rate of 6.00% per annum and had a maturity date of December 31, 2020. The New Notes are fully guaranteed by the Company and are secured by an all-assets pledge of the Company and Merton and non-recourse equity pledges of each of the Company’s material subsidiaries. Pursuant to the Exchange Agreement, the New Notes (i) are deemed to be “Notes” for purposes of the Securities Purchase Agreement, (ii) are deemed to be “June 2020 Approved Investment Notes” for purposes of the Supplemental Agreement, and with the Company agreeing to redeem $80 million principal amount of the New Notes by September 30, 2020 and $35 million principal amount of the New Notes by December 31, 2020, and (iii) are deemed to be “Notes” for the purposes of the Series B Warrants, and therefore may be tendered pursuant to a Note Cancellation under the Series B Warrants on the terms set forth in the Series B Warrants and the New Notes. Delivery of notes in the form of the New Notes will also satisfy the delivery of Exchange Notes pursuant to Section 16(i) of the Certificate of Designations of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share. The New Notes will not be deemed to be “Notes” for the purposes of the Registration Rights Agreement, dated as of November 18, 2019, by and among the Company, Starboard and the Buyers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Because the New Notes are to be settled within twelve months pursuant to their terms, they are classified as current liabilities in the consolidated balance sheets. The Company capitalized $<span id="xdx_907_eus-gaap--DeferredFinanceCostsGross_iI_pn3n3_dm_c20200930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zwG59JrVgGCh" title="Capitalized lender fees">4.6</span> million in lender fees and $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pn3n3_dm_c20200930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zWS0zSted7" title="Unamortized discount">0.5</span> million in other issuance costs associated with the issuance of the Notes. The $4.6 million of lender fees are recognized as long-term deferred debt issuance costs and are included in other non-current assets in the consolidated balance sheets, and will be amortized to interest expense until November 15, 2027, the maturity date of Series A Redeemable Convertible Preferred Stock. The $0.5 million issuance costs are recognized as a discount on the Notes and will be amortized to interest expense over the contractual life of the Notes. There was $3.1 million and $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3p0_c20210930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zrmbQ1F2oYF7" title="Accrued interest">863,000</span> accrued and unpaid interest on the New Notes as of September 30, 2021 and December 31, 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 29, 2021, the Company redeemed $<span id="xdx_908_eus-gaap--RepaymentsOfSecuredDebt_pn3n3_dm_c20210101__20210129__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zUtTeJV7zK22" title="Repayment of debt">50.0</span> million of the New Notes and on March 31, 2021, the Company reissued $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_pn3n3_dm_c20210101__20210930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zqP8l3s0DDs3" title="Proceeds from issuance of debt">50.0</span> million of the New Notes. On June 30, 2021, the Company issued $30.0 million in additional New Notes (the “June 2021 Merton Notes”) and amended the maturity date of the New Notes to <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210129__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--CounterpartyNameAxis__custom--MertonMember_zy1M9PDT01d3" title="Debt maturity date">October 15, 2021</span>. On September 30, 2021, the Company issued $35.0 million in additional New Notes (the “September 2021 Merton Notes”) and amended the maturity date of the New Notes to December 1, 2021. The June and September 2021 Merton Notes cannot be used to exercise Series B Warrants issued to Starboard Value. The total principal amount outstanding of New Notes as of September 30, 2021 and December 31, 2020 was $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn3n3_dm_c20210930__us-gaap--LongtermDebtTypeAxis__custom--NewNotesMember_z5xPYi3ltAVg">180.0</span> million and $<span id="xdx_907_eus-gaap--LongTermDebt_iI_pn3n3_dm_c20201231__us-gaap--LongtermDebtTypeAxis__custom--NewNotesMember_zCmJBAeei48k">115.0</span> million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Modifications to Series A Redeemable Convertible Preferred Stock and Series B Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The June 4, 2020 Supplemental Agreement also provided for (i) a waiver of increased dividends under the original terms of the Series A Redeemable Convertible Preferred Stock that would have otherwise accrued due to the Company’s use of the $35.0 million proceeds received from Starboard and the Buyers upon the issuance of the Series A Redeemable Convertible Preferred Stock in November 2019, (ii) the replacement of original optional redemption rights for the Series A Redeemable Convertible Preferred Stock provided to both the Company and the holders that otherwise would have been nullified through the issuance of the Notes, and (iii) an amendment to the terms of the previously issued Series B Warrants to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration of the Series B Warrants on November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We analyzed the amendments to the terms of the Series A Redeemable Convertible Preferred Stock and determined that the amendments were not significant. Therefore, the amendments are accounted for as a modification on a prospective basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The incremental fair value of the Series B Warrants associated with the modification of their terms in connection with the issuance of the Notes was $<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_dm_c20210930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zEOtlWdTPO0c" title="Fair value of warrants">1.3</span> million and is recognized as a discount on the Notes and will be amortized to interest expense over the contractual life of the Notes. As of September 30, 2021, $<span id="xdx_90F_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_dm_c20210101__20210930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zEyeYmxPGXi2" title="Amortization of discount">1.2</span> million was amortized to interest expense and $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pn3p0_c20210930__us-gaap--TransactionTypeAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zAjLlS0B38dd" title="Unamortized discount">151,000</span> is remaining to be amortized until the maturity date of December 1, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 350000 5000000 3.65 35000000.0 1300000 991000 2800000 41400000 26700000 4800000 18500000 6600000 0 100000 4600000 0 229600000 52300000 115000000.0 80000000.0 35000000.0 0.0600 0.1000 115000000.0 4600000 500000 863000 50000000.0 50000000.0 2021-10-15 180000000.0 115000000.0 1300000 1200000 151000 <p id="xdx_80D_eus-gaap--FairValueDisclosuresTextBlock_zpKhLwp8QjW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. <span id="xdx_828_zCMtKAoIWlh7">FAIR VALUE MEASUREMENTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 96px"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td> <td><span style="font: 10pt Times New Roman, Times, Serif">Level 1 - <i>Observable Inputs</i>:  Quoted prices in active markets for identical investments;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 96px"><span style="font: 10pt Times New Roman, Times, Serif">(ii)</span></td> <td><span style="font: 10pt Times New Roman, Times, Serif">Level 2 - <i>Pricing Models with Significant Observable Inputs</i>:  Other significant observable inputs, including quoted prices for similar investments, interest rates, credit risk, etc.; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 96px"><span style="font: 10pt Times New Roman, Times, Serif">(iii)</span></td> <td><span style="font: 10pt Times New Roman, Times, Serif">Level 3 - <i>Unobservable Inputs</i>:  Unobservable inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entity’s own assumptions in determining the fair value of derivatives and certain investments.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whenever possible, the Company is required to use observable market inputs (Level 1 - quoted market prices) when measuring fair value. In such cases, the level at which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input requires judgment and considers factors specific to the asset or liability being measured. In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia holds the following types of financial instruments at September 30, 2021 and December 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Equity Securities at Fair Value. </i>Equity securities includes investments in public company common stock and are recorded at fair value based on the quoted market price of each share on the valuation date. The fair value of these securities are within Level 1 of the valuation hierarchy. Equity investments that do not have regular market pricing, but for which fair value can be determined based on other data values or market prices, are recorded at fair value within Level 2 of the valuation hierarchy. At September 30, 2021, our Level 2 equity securities include an investment measured with an applied pricing model that includes significant observable inputs to the public company common stock value. The fair value of the Level 2 equity securities investment as of September 30, 2021 was estimated based on a discount of 7.5 percent determined using the following significant inputs to the pricing model: expected term of restriction of 6 months and volatility of approximately 45 percent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Investments at Fair Value - Common Stock and Warrants. </i>Acacia’s equity investment in Veritone common stock was recorded at fair value based on the quoted market price of Veritone’s common stock on the applicable valuation date (Level 1). Warrants were recorded at fair value, as based on the Black-Scholes option-pricing model (Level 2). Refer to Note 4 for additional information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series A Warrants. </i>Series A Warrants are recorded at fair value, using Black-Scholes option-pricing model (Level 3). In the quarter ended March 31, 2021, there was a change in estimate with regard to the calculation of the volatility assumption used in the Black Scholes option-pricing model. As a result, the Series A Warrants are now measured as Level 3 as opposed to Level 2 as measured previously. The fair value of the Series A Warrants as of September 30, 2021 was estimated based on the following significant assumptions: volatility of 30 percent, risk-free rate of 1.16 percent, term of 6.04 years and a dividend yield of 0 percent.<b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series B Warrants. </i>Series B Warrants are recorded at fair value, using Black-Scholes option-pricing model (Level 3). In the quarter ended March 31, 2021, there was a change in methodology used to an acceptable Black-Scholes option-pricing model from a Monte Carlo valuation technique used to value the Series B Warrants as of December 31, 2020. The fair value of the Series B Warrants as of September 30, 2021 was estimated based on the following significant assumptions: (1) volatility of 30 percent, risk-free rate of 1.17 percent, term of 6.13 years and a dividend yield of 0 percent, and (2) volatility of 25 percent, risk-free rate of 0.08 percent, term of 0.90 years and a dividend yield of 0 percent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Embedded Derivative Liability. </i>Embedded derivatives that are required to be bifurcated from their host contract are evaluated and valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019 (Level 3). The binomial model utilizes the Tsiveriotis and Fernandes implementation in which a convertible instrument is split into two separate components within a single lattice framework: a cash-only component which is subject to the selected risk-adjusted discount rate and an equity component which is subject only to the risk-free rate. The model considers the (i) implied volatility of the value of our common stock, (ii) appropriate risk-free interest rate, (iii) credit spread, (iv) dividend yield, (v) dividend accrual (and a step-up in rates), and (vi) event probabilities of the various conversion and redemption scenarios.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The volatility of the Company’s common stock is estimated by analyzing the Company’s historical volatility, implied volatility of publicly traded stock options, and the Company’s current asset composition and financial leverage. The selected volatility, as described below, represents a haircut from the Company’s actual realized historical volatility. A volatility haircut is a concept used to describe a commonly observed occurrence in which the volatility implied by market prices involving options, warrants, and convertible debt is lower than historical actual realized volatility. The assumed base case term used in the valuation model is the period remaining until November 15, 2027, the Series A Redeemable Convertible Preferred Stock maturity date. The risk-free interest rate is based on the yield on the U.S. Treasury with a remaining term equal to the expected term of the conversion and early redemption options. The significant assumptions utilized in the Company’s valuation of the embedded derivative at September 30, 2021 are as follows: volatility of 30 percent, risk-free rate of 1.20 percent, term of 6.13 years, discount rate of 9.40 percent and a dividend yield of 0 percent. The fair value measurement of the embedded derivative is sensitive to these assumptions and changes in these assumptions could result in a materially different fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial assets and liabilities measured at fair value on a recurring basis were as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_pn3n3_z5kmnjed5E3k" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span id="xdx_8BC_zDbtPuaj44Q3" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of financial assets and liabilities at fair value</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Assets</span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2021:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities at fair value</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">119,280</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">267,840</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_zZVGoE48BD8" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">387,120</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">119,280</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">267,840</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFd2v3vOBIX9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">387,120</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities at fair value</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_z12hfjlqUkOg" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_zNn5o9jioYY8" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Investment at fair value - warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1363">–</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">2,752</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_zN4HkkyX1IZh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">2,752</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">2,752</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2Rk1i7V7BS7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">111,855</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2021:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z1XPiKQebxPi" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z0h2bMhasRM8" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">18,527</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">18,527</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A embedded derivative liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zGptlAREhr5b" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zbUAXEhdiYoe" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">41,411</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">41,411</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zszAV4gWLbAf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z3llNtszR3bb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">229,637</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">229,637</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRePaEdnRYff" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zulGZMy3unc2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">289,575</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">289,575</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zxBmcUIyZc3b" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z6jzNfrJFBzl" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A embedded derivative liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zFozVzESS9Mg" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_ztuwH6r7aNWe" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">26,728</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">26,728</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z1HETD3mtmD2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z3Hr5U8tBAhk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">52,341</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">52,341</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK9m32J7ly9a" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">79,069</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">85,709</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_zPROrwdnk37i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables set forth a summary of the changes in the estimated fair value of the Company’s Level 3 liabilities, which are measured at fair value on a recurring basis:<span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zJtwOdyWcwLg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B2_zIPeRQjNeech" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of changes in fair value Level 3 liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A <br/> Warrant <br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A<br/> Embedded<br/> Derivative<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series B<br/> Warrant<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at January 1, 2021</b></span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zSPzxpg6DGq4" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zujtjgtXKbQ1" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">26,728</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_znuUhmeXlKqa" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">52,341</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSR2lyFjgLFi" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">79,069</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Transfers to Level 3<br/></span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zlQZnye4JgA7" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zGrY5yXshLu2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1454">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zhyJh3RikVw3" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1455">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zHYe0aNOPkd7" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zXhrft1TTTZ" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,824</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zcWTPiOMsHl8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,463</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z0J95BCXdmh8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">178,198</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlebWdggdMs7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">204,485</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Balance at June 30, 2021</b></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zGFuWMIvIS17" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,464</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zwX7uhS4u3Fd" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,191</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z9mgILvYsVA6" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">230,539</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210701__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOxnHuGUb8xj" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">290,194</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zFbBIGc4Y8K4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zaWhKZtdHvw1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">220</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zYGjpF1DHtc6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(902</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zioDjYCWSYN8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(619</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at September 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_d0_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zGzvcijAnNYf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">18,527</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zk1RCguf9FSa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">41,411</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zPpqonDA4Ft2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">229,637</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210701__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zro8i4u4bx5c" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">289,575</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A <br/> Warrant <br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A<br/> Embedded<br/> Derivative<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series B<br/> Warrant<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at January 1, 2020</b></span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zp9cRBopGs62" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">3,568</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zDpoRIa5BQc3" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">17,974</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z84jGZDL2Lpa" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1479">–</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200101__20200630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zqmsElSo18Sc" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">21,542</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Transfers to Level 3<br/></span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_d0_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zzraf0BsSHQ" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z0hxfQQe1KUk" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1484">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zGFOHDDByka8" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,929</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20200101__20200630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2734OILGBl9" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">5,929</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zOu2doI0EZ87" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,384</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zzGpS86ipsdl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,539</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_ze9KisgH5gpg" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,361</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKhFU982rY3f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,284</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Balance at June 30, 2020</b></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zmbMqnh9IrR5" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,952</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zrg6VIxa6VV3" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,513</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z8qoSeDp3adl" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,290</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200701__20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGoptiET9TH" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,755</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zA2rM9qQmwK6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,348</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zXyzG31qtlfb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,831</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zhrd7tO3fLT3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(15,493</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlXHxnpiqD0c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(20,672</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at September 30, 2020</b></span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_d0_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zNOVurYjPAue" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,604</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zwGjuEo589wc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">25,682</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_ziAHBWp4jxia" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">42,797</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20200701__20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLHn752plRSa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">74,083</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"/> <p id="xdx_8A2_zZbK9lJySAu" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with U.S. GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of equity securities without readily determinable fair value, equity method investments and patents on a quarterly basis for indications of impairment, and other long-lived assets at least annually. When indications of potential impairment are identified, the Company may be required to determine the fair value of those assets and record an adjustment for the carrying amount in excess of the fair value determined. Any fair value determination would be based on valuation approaches, which are appropriate under the circumstances and utilize Level 2 and Level 3 measurements as required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_pn3n3_z5kmnjed5E3k" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span id="xdx_8BC_zDbtPuaj44Q3" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of financial assets and liabilities at fair value</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Level 1</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Level 2</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Level 3</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Assets</span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2021:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities at fair value</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">119,280</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">267,840</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_zZVGoE48BD8" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="border-bottom: Black 1pt solid; width: 11%; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">387,120</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">119,280</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">267,840</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zFd2v3vOBIX9" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">387,120</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Equity securities at fair value</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_z12hfjlqUkOg" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_zNn5o9jioYY8" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__us-gaap--EquitySecuritiesMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Investment at fair value - warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1363">–</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">2,752</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_zN4HkkyX1IZh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantInvestmentMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">2,752</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">109,103</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">2,752</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2Rk1i7V7BS7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--AssetsMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">111,855</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">September 30, 2021:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z1XPiKQebxPi" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z0h2bMhasRM8" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">18,527</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">18,527</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A embedded derivative liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zGptlAREhr5b" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zbUAXEhdiYoe" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">41,411</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">41,411</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zszAV4gWLbAf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z3llNtszR3bb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">229,637</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">229,637</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zRePaEdnRYff" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zulGZMy3unc2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">289,575</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_c20210930__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">289,575</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">December 31, 2020:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zxBmcUIyZc3b" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z6jzNfrJFBzl" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Series A embedded derivative liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zFozVzESS9Mg" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_ztuwH6r7aNWe" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">26,728</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_pn3n3" style="font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">26,728</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z1HETD3mtmD2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z3Hr5U8tBAhk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">52,341</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_pn3n3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">52,341</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_d0_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK9m32J7ly9a" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">79,069</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--BalanceSheetLocationAxis__us-gaap--LiabilityMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_pn3n3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Fair value of assets"><span style="font: 10pt Times New Roman, Times, Serif">85,709</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 119280000 267840000 0 387120000 119280000 267840000 0 387120000 109103000 0 0 109103000 2752000 0 2752000 109103000 2752000 0 111855000 0 0 18527000 18527000 0 0 41411000 41411000 0 0 229637000 229637000 0 0 289575000 289575000 0 6640000 0 6640000 0 0 26728000 26728000 0 0 52341000 52341000 0 6640000 79069000 85709000 <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zJtwOdyWcwLg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B2_zIPeRQjNeech" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of changes in fair value Level 3 liabilities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A <br/> Warrant <br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A<br/> Embedded<br/> Derivative<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series B<br/> Warrant<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at January 1, 2021</b></span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zSPzxpg6DGq4" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zujtjgtXKbQ1" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">26,728</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_znuUhmeXlKqa" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">52,341</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zSR2lyFjgLFi" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">79,069</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Transfers to Level 3<br/></span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zlQZnye4JgA7" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zGrY5yXshLu2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1454">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zhyJh3RikVw3" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1455">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zHYe0aNOPkd7" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">6,640</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zXhrft1TTTZ" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,824</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zcWTPiOMsHl8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,463</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z0J95BCXdmh8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">178,198</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210101__20210630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlebWdggdMs7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">204,485</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Balance at June 30, 2021</b></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zGFuWMIvIS17" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,464</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zwX7uhS4u3Fd" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,191</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z9mgILvYsVA6" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">230,539</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20210701__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOxnHuGUb8xj" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">290,194</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zFbBIGc4Y8K4" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zaWhKZtdHvw1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">220</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zYGjpF1DHtc6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(902</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20210701__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zioDjYCWSYN8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(619</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at September 30, 2021</b></span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_d0_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zGzvcijAnNYf" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">18,527</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zk1RCguf9FSa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">41,411</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210701__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zPpqonDA4Ft2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">229,637</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20210701__20210930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zro8i4u4bx5c" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">289,575</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A <br/> Warrant <br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series A<br/> Embedded<br/> Derivative<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Series B<br/> Warrant<br/> Liability</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at January 1, 2020</b></span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zp9cRBopGs62" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">3,568</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zDpoRIa5BQc3" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">17,974</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z84jGZDL2Lpa" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1479">–</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200101__20200630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zqmsElSo18Sc" style="width: 11%; font-size: 10pt; text-align: right" title="Derivative liability, beginning balance"><span style="font: 10pt Times New Roman, Times, Serif">21,542</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Transfers to Level 3<br/></span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_d0_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zzraf0BsSHQ" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_z0hxfQQe1KUk" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1484">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zGFOHDDByka8" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,929</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_pn3n3_c20200101__20200630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2734OILGBl9" style="font-size: 10pt; text-align: right" title="Transfers into Level 3"><span style="font: 10pt Times New Roman, Times, Serif">5,929</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zOu2doI0EZ87" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,384</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zzGpS86ipsdl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,539</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_ze9KisgH5gpg" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,361</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200101__20200630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zKhFU982rY3f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,284</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Balance at June 30, 2020</b></span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_d0_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zmbMqnh9IrR5" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,952</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zrg6VIxa6VV3" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,513</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_z8qoSeDp3adl" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58,290</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20200701__20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGoptiET9TH" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,755</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Remeasurement to fair value</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zA2rM9qQmwK6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,348</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zXyzG31qtlfb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,831</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_zhrd7tO3fLT3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(15,493</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20200701__20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zlXHxnpiqD0c" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(20,672</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<span style="font-size: 10pt"> </span></span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Balance at September 30, 2020</b></span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_d0_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsLiabilityMember_zNOVurYjPAue" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,604</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesAEmbeddedDerivativeLiabilityMember_zwGjuEo589wc" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">25,682</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20200701__20200930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsLiabilityMember_ziAHBWp4jxia" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">42,797</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20200701__20200930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zLHn752plRSa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">74,083</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"/> 0 26728000 52341000 79069000 6640000 6640000 11824000 14463000 178198000 204485000 18464000 41191000 230539000 290194000 63000 220000 -902000 -619000 18527000 41411000 229637000 289575000 3568000 17974000 21542000 0 5929000 5929000 3384000 11539000 52361000 67284000 6952000 29513000 58290000 94755000 -1348000 -3831000 -15493000 -20672000 5604000 25682000 42797000 74083000 <p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z0fkI4SvQ047" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. <span id="xdx_821_zefBAmB1niW6">COMMITMENTS AND CONTINGENCIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Facility Leases</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company primarily leases office facilities under operating lease arrangements that will end in various years through July 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 7, 2019, we entered into a building lease agreement (the “New Lease”) with Jamboree Center 4 LLC (the “Landlord”). Pursuant to the New Lease, we have leased approximately 8,293 square feet of office space in Irvine, California. The New Lease commenced on August 1, 2019. The term of the New Lease is 60 months from the commencement date, provides for annual rent increases, and does not provide us the right to early terminate or extend our lease terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 7, 2020, we entered into a building lease agreement (the “New York Office Lease”) with Sage Realty Corporation (the “New York Office Landlord”). Pursuant to the New York Office Lease, we have leased approximately 4,000 square feet of office space for our corporate headquarters in New York, New York. The New York Office Lease commenced on February 1, 2020. The term of the New York Office Lease is 24 months from the commencement date, provides for annual rent increases, and does not provide us the right to early terminate or extend our lease terms. During August 2021, we entered into a first amendment of the New York Office Lease, to commence for a period of three years upon landlords’ substantial completion of adequate substitution space, as defined. To date, the substitution space is not ready for use, accordingly the term extension has not begun.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating lease costs were $<span id="xdx_906_eus-gaap--OperatingLeaseCost_pn3p0_c20210701__20210930_zrjiEKtJyBD6" title="Operating lease costs, net of sublease income">155,000</span> and $<span id="xdx_903_eus-gaap--OperatingLeaseCost_pn3p0_c20200701__20200930_z51rOJ1fpYu6" title="Operating lease costs, net of sublease income">174,000</span> for the three months ended September 30, 2021 and 2020, respectively, and $<span id="xdx_905_eus-gaap--OperatingLeaseCost_pn3p0_c20210101__20210930_zmM3AphN5NRj" title="Operating lease costs, net of sublease income">457,000</span> and $<span id="xdx_90A_eus-gaap--OperatingLeaseCost_pn3p0_c20200101__20200930_zitkPtxlCxo9" title="Operating lease costs, net of sublease income">459,000</span> for the nine months ended September 30, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below presents aggregate future minimum payments due under the New Lease and the New York Office Lease discussed above, reconciled to long-term lease liabilities and short-term lease liabilities (included in accrued expenses and other current liabilities) included in the consolidated balance sheet as of September 30, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zYQioXzgu3R7" style="border-collapse: collapse; width: 40%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B9_z9otGpxq51zf" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of future minimum operating lease payments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_495_20210930_zPhAs40X9ILd" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Operating Leases</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maOLFMPzNL8_zxCD2Hqv0Pk3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 26%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Remainder of 2021</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">149</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maOLFMPzNL8_zCUrJidv2kK1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">370</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_pn3n3_maOLFMPzNL8_zY8NTYWvgYui" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">364</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_iI_pn3n3_maOLFMPzNL8_zET1tgSv8Ts2" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">218</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_iI_pn3n3_d0_maOLFMPzNL8_zoCNEil6fSRl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLFMPzNL8_zJT3wzL1sCs2" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total minimum payments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,101</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zW62Da70zQqh" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: short-term lease liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(430</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Long-term lease liabilities</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">671</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Inventor Royalties and Contingent Legal Expenses</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the investment in certain patents and patent rights, certain of Acacia’s operating subsidiaries executed related agreements which grant to the former owners of the respective patents or patent rights, the right to receive inventor royalties based on future net revenues (as defined in the respective agreements) generated as a result of licensing and otherwise enforcing the respective patents or patent portfolios.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia’s operating subsidiaries may retain the services of law firms that specialize in patent licensing and enforcement and patent law in connection with their licensing and enforcement activities. These law firms may be retained on a contingent fee basis whereby such law firms are paid on a scaled percentage of any negotiated fees, settlements or judgments awarded based on how and when the fees, settlements or judgments are obtained.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Patent Enforcement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain of Acacia’s operating subsidiaries are often required to engage in litigation to enforce their patents and patent rights. In connection with any of Acacia’s operating subsidiaries’ patent enforcement actions, it is possible that a defendant may request and/or a court may rule that an operating subsidiary has violated statutory authority, regulatory authority, federal rules, local court rules, or governing standards relating to the substantive or procedural aspects of such enforcement actions. In such event, a court may issue monetary sanctions against Acacia or its operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acacia is subject to claims, counterclaims and legal actions that arise in the ordinary course of business. Management believes that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on Acacia’s consolidated financial position, results of operations or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2017, the Federal Court of Canada allowed a counterclaim for invalidity of a patent asserted by Rapid Completions LLC and awarded costs payable by Rapid Completions LLC in amounts that are included in the 2021 and 2020 accrual balances discussed below. During the three months ended September 30, 2021, the Company made approximately $1.0 million in settlement payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 6, 2019, Slingshot Technologies, LLC, or Slingshot, filed a lawsuit in Delaware Chancery Court against the Company and Acacia Research Group, LLC, or collectively, the Acacia Entities, Monarch Networking Solutions LLC (“Monarch”), Acacia board member Katharine Wolanyk, and Transpacific IP Group, Ltd., or Transpacific. Slingshot alleges that the Acacia Entities and Monarch misappropriated its confidential and proprietary information, purportedly furnished to the Acacia Entities and Monarch by Ms. Wolanyk, in acquiring a patent portfolio from Transpacific after Slingshot’s exclusive option to purchase the same patent portfolio from Transpacific had already expired. Slingshot seeks monetary damages, as well as equitable and injunctive relief related to its alleged right to own the portfolio. On March 15, 2021, the court issued orders granting Monarch’s motion to dismiss for lack of personal jurisdiction and Ms. Wolanyk’s motion to dismiss for lack of subject matter jurisdiction. The remaining parties then commenced discovery, and have since served initial written requests and responses, and notices of the depositions of the parties’ corporate designees. The Acacia Entities maintain that Slingshot’s allegations are baseless, that the Acacia Entities neither had access to nor used Slingshot’s information in acquiring the portfolio, that the Acacia Entities acquired the portfolio as a result of the independent efforts of its IP licensing group, and that Slingshot suffered no damages given its exclusive option to purchase the portfolio had already ended and it has proven itself incapable of closing on the portfolio purchase.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2021 and 2020, there were no operating expenses related to settlement and contingency accruals. During the nine months ended September 30, 2021, we incurred $338,000 in operating expenses for settlement and contingency accruals. During the nine months ended September 30, 2020, operating expenses included a net income for settlement offset by contingency accruals totaling $<span id="xdx_908_ecustom--NetIncomeForSettlementOffsetByContingencyAccruals_pn3p0_c20200101__20200930_zhd1bgFna53j" title="Income from settlement">308,000</span>, net of prior accruals. At September 30, 2021 and December 31, 2020, our contingency accrual balance was $<span id="xdx_906_eus-gaap--LossContingencyAccrualAtCarryingValue_c20210930_pn3p0" title="Contingency accruals">587,000</span> and $<span id="xdx_90E_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn3n3_dm_c20201231_zy4230WGNSOa" title="Contingency accruals">1.3</span> million, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> 155000 174000 457000 459000 <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zYQioXzgu3R7" style="border-collapse: collapse; width: 40%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B9_z9otGpxq51zf" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of future minimum operating lease payments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_495_20210930_zPhAs40X9ILd" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">Operating Leases</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_pn3n3_maOLFMPzNL8_zxCD2Hqv0Pk3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 26%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Remainder of 2021</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">149</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_iI_pn3n3_maOLFMPzNL8_zCUrJidv2kK1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">370</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_pn3n3_maOLFMPzNL8_zY8NTYWvgYui" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">364</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_iI_pn3n3_maOLFMPzNL8_zET1tgSv8Ts2" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">218</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_iI_pn3n3_d0_maOLFMPzNL8_zoCNEil6fSRl" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtOLFMPzNL8_zJT3wzL1sCs2" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total minimum payments</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,101</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zW62Da70zQqh" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: short-term lease liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(430</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Long-term lease liabilities</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">671</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 149000 370000 364000 218000 0 1101000 430000 671000 308000 587000 1300000 <p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_znZoqUbX7sf4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. <span id="xdx_829_zJ9CaZ4j8l59">STOCKHOLDERS’ EQUITY</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Repurchases of Common Stock </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 5, 2019, Acacia’s Board of Directors approved a stock repurchase program, which authorized the purchase of up to $<span id="xdx_901_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn3n3_dm_c20190805__us-gaap--ShareRepurchaseProgramAxis__custom--StockRepurchaseProgramMember_zpuRECaiCtIa">10.0 </span>million of the Company’s common stock through open market purchases, through block trades, through 10b5-1 plans, or by means of private purchases, from time to time, through July 31, 2020. Stock repurchases for the periods presented, all of which were purchased as part of a publicly announced plan or program, were as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--AcceleratedShareRepurchasesTextBlock_zRhwhpin0KBh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B6_zqWEq4Bw0Jrj" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of repurchased shares</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total Number<br/> of Shares<br/> Purchased</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Average<br/> Price<br/> paid per<br/> Share</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Approximate<br/> Dollar<br/> Value of Shares<br/> that<br/> May Yet be<br/> Purchased<br/> under the<br/> Program</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Plan Expiration Date</span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">March 20, 2020 - March 31, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--TreasuryStockSharesAcquired_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="width: 11%; font-size: 10pt; text-align: right" title="Number of shares repurchased"><span style="font: 10pt Times New Roman, Times, Serif">576,898</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="width: 11%; font-size: 10pt; text-align: right" title="Average price paid per share"><span style="font: 10pt Times New Roman, Times, Serif">2.28</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ApproximateValueOfSharesThatMayYetBePurchased_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pn3p0" style="width: 11%; font-size: 10pt; text-align: right" title="Approximate value of shares that may yet be purchased"><span style="font: 10pt Times New Roman, Times, Serif">8,686,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 13%; font-size: 10pt; text-align: center"><span id="xdx_902_eus-gaap--StockRepurchaseProgramExpirationDate_dd_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z1jSPqRNZTKh" style="font: 10pt Times New Roman, Times, Serif">July 31, 2020</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">April 1, 2020 - April 23, 2020</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--TreasuryStockSharesAcquired_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of shares repurchased"><span style="font: 10pt Times New Roman, Times, Serif">1,107,639</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Average price paid per share"><span style="font: 10pt Times New Roman, Times, Serif">2.42</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--ApproximateValueOfSharesThatMayYetBePurchased_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pn3p0" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Approximate value of shares that may yet be purchased"><span style="font: 10pt Times New Roman, Times, Serif">6,001,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span id="xdx_901_eus-gaap--StockRepurchaseProgramExpirationDate_dd_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z2duEkvoJjWk" style="font: 10pt Times New Roman, Times, Serif">July 31, 2020</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total repurchases in 2020</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--TreasuryStockSharesAcquired_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of shares repurchased"><span style="font: 10pt Times New Roman, Times, Serif">1,684,537</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right" title="Average price paid per share"><span style="font: 10pt Times New Roman, Times, Serif">2.37</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In determining whether or not to repurchase any shares of Acacia’s common stock, Acacia’s Board of Directors consider such factors, among others, as the impact of the repurchase on Acacia’s cash position, as well as Acacia’s capital needs and whether there is a better alternative use of Acacia’s capital. Acacia has no obligation to repurchase any amount of its common stock under the Stock Repurchase Program. Repurchases to date were made in the open market in compliance with applicable SEC rules. The authorization to repurchase shares presented an opportunity to reduce the outstanding share count and enhance stockholder value. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Tax Benefits Preservation Plan</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 12, 2019, Acacia’s Board of Directors announced that it had unanimously approved the adoption of a Tax Benefits Preservation Plan (the “Plan”). Our stockholders ratified the adoption of the Plan in July 2019. The purpose of the Plan is to protect the Company’s ability to utilize potential tax assets, such as net operating loss carryforwards and tax credits to offset potential future taxable income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Plan is designed to reduce the likelihood that the Company will experience an ownership change by discouraging (i) any person or group from acquiring beneficial ownership of 4.9% or more of the Company’s outstanding common stock and (ii) any existing stockholders who, as of the time of the first public announcement of the adoption of the Plan, beneficially own more than 4.9% of the Company’s then-outstanding shares of the Company’s common stock from acquiring additional shares of the Company’s common stock (subject to certain exceptions). There is no guarantee, however, that the Plan will prevent the Company from experiencing an ownership change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the adoption of the Plan, Acacia’s Board of Directors authorized and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on March 16, 2019. On or after the distribution date, each right would initially entitle the holder to purchase one one-thousandth of a share of the Company’s Series B Junior Participating Preferred Stock, $0.001 par value for a purchase price of $12.00. On March 15, 2021 the rights expired pursuant to their terms.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has a provision in its Amended and Restated Certificate of Incorporation, as amended (the “Charter Provision”) which generally prohibits transfers of its common stock that could result in an ownership change. Like the Plan, the purpose of the Charter Provision is to protect the Company’s ability to utilize potential tax assets, such as net operating loss carryforwards and tax credits to offset potential future taxable income. The Charter Provision was approved by the Company’s stockholders on July 15, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b> </p> 10000000.0 <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--AcceleratedShareRepurchasesTextBlock_zRhwhpin0KBh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"><span id="xdx_8B6_zqWEq4Bw0Jrj" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule of repurchased shares</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total Number<br/> of Shares<br/> Purchased</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Average<br/> Price<br/> paid per<br/> Share</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Approximate<br/> Dollar<br/> Value of Shares<br/> that<br/> May Yet be<br/> Purchased<br/> under the<br/> Program</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Plan Expiration Date</span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">March 20, 2020 - March 31, 2020</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--TreasuryStockSharesAcquired_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="width: 11%; font-size: 10pt; text-align: right" title="Number of shares repurchased"><span style="font: 10pt Times New Roman, Times, Serif">576,898</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="width: 11%; font-size: 10pt; text-align: right" title="Average price paid per share"><span style="font: 10pt Times New Roman, Times, Serif">2.28</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_980_ecustom--ApproximateValueOfSharesThatMayYetBePurchased_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pn3p0" style="width: 11%; font-size: 10pt; text-align: right" title="Approximate value of shares that may yet be purchased"><span style="font: 10pt Times New Roman, Times, Serif">8,686,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 13%; font-size: 10pt; text-align: center"><span id="xdx_902_eus-gaap--StockRepurchaseProgramExpirationDate_dd_c20200920__20200930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z1jSPqRNZTKh" style="font: 10pt Times New Roman, Times, Serif">July 31, 2020</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">April 1, 2020 - April 23, 2020</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--TreasuryStockSharesAcquired_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Number of shares repurchased"><span style="font: 10pt Times New Roman, Times, Serif">1,107,639</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Average price paid per share"><span style="font: 10pt Times New Roman, Times, Serif">2.42</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_ecustom--ApproximateValueOfSharesThatMayYetBePurchased_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pn3p0" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Approximate value of shares that may yet be purchased"><span style="font: 10pt Times New Roman, Times, Serif">6,001,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: center; padding-bottom: 1pt"><span id="xdx_901_eus-gaap--StockRepurchaseProgramExpirationDate_dd_c20200401__20200423__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z2duEkvoJjWk" style="font: 10pt Times New Roman, Times, Serif">July 31, 2020</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total repurchases in 2020</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--TreasuryStockSharesAcquired_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Number of shares repurchased"><span style="font: 10pt Times New Roman, Times, Serif">1,684,537</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--TreasuryStockAcquiredAverageCostPerShare_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right" title="Average price paid per share"><span style="font: 10pt Times New Roman, Times, Serif">2.37</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 576898 2.28 8686000 2020-07-31 1107639 2.42 6001000 2020-07-31 1684537 2.37 <p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zkerc449FzF3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. <span id="xdx_824_zzJEAzxtxPYd">INCOME/LOSS PER SHARE</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the shares of common stock outstanding used in the calculation of basic and diluted net income (loss) per share: </p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zgbXg2sOefXg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME/LOSS PER SHARE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span id="xdx_8B9_zVrmlA3L6504" style="font: 10pt Times New Roman, Times, Serif; display: none">Calculation of basic and diluted net loss per share</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_499_20210701__20210930_zpblr4UDGed6" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_49E_20200701__20200930_z7qOwCUpQKp1" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_496_20210101__20210930_zFBF3yU6vn4f" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_497_20200101__20200930_z5QXqKuQujHd" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands, except share and per share information)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; font-weight: bold; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Numerator:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; width: 44%; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net income (loss) attributable to Acacia Research Corporation</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">89,604</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">38,348</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(55,507</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">33,205</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PreferredStockDividendsIncomeStatementImpact_i01N_pn3n3_di_zytxWlyW6E8c" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Dividend on Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(262</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(467</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(785</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,118</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_401_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_i01N_pn3n3_di_zykUE09mVaKh" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Accretion of Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(991</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(733</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(2,762</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(2,045</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40C_eus-gaap--UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_i01_pn3n3_d0_zuHjVJ4perMi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Undistributed earnings allocated to participating securities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(15,367</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(6,619</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(5,204</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net income (loss) attributable to common stockholders - Basic</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">72,984</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">30,529</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(59,054</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">24,838</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--DividendOnSeriesRedeemableConvertiblePreferredStock_d0_zvQN6GcEwcpj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Dividend on Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">467</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--AccretionOfSeriesRedeemableConvertiblePreferredStock_d0_z5ju7nq3fJL6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Accretion of Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">733</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStock_d0_zBu9eOfBc129" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,831</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--ChangeInFairValueOfSeriesWarrants_d0_zHLx0s1KWuw1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: Change in fair value of Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">63</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfDilutiveSeriesBWarrants_i_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: Change in fair value of dilutive Series B warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(902</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(5,557</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1633">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(5,557</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_ecustom--InterestExpenseAssociatedWithStarboardNotesNetOfTax_zOXosm3OcbC4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Interest expense associated with Starboard Notes, net of tax</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,536</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,889</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1638">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,889</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_d0_zz2ju8XPbY3j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Undistributed earnings allocated to participating securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">15,367</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6,619</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,204</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_d0_zIrNoG0YtTlk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Reallocation of undistributed earnings to participating securities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(8,877</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(296</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,645</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_ecustom--NetIncomeLossAvailableToCommonStockholderDiluted_zIr9KIFNSS4h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net income (loss) attributable to common stockholders - Diluted</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">80,171</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">29,205</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(59,054</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">21,381</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--EarningsPerShareBasicAndDilutedDeniminatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; font-weight: bold; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Denominator:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,949,504</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,467,885</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,759,873</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,949,706</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_iB_zEk8nkeJ0rCd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Potentially dilutive common shares:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series A Preferred Stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zKkMuV7VIDVa" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zETSzCWfjRT5" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">9,589,041</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zKirbQ2Yoor5" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zvKnaiHzRzR8" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Restricted stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zJF7f4mvOp0l" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">798,356</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zMkU0EdviRii" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">728,936</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zOJu5omQ8n8g" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zYRXlPFFIb9j" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">598,328</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Stock options</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zeaYyeQPthn" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">35,815</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zkUd73Hfl71h" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">21,624</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zPgEbZO4A6se" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zaVQrUnVwe71" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series A Warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zDzc4FbOzBkl" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">2,019,724</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z7WoPzAd95ti" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">310,367</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zZnhIcNFlxh6" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zUvgbSo8UNFj" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">103,456</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B Warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zW9XGGHHTqMk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">41,278,103</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zINAkGS70pp8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">31,506,849</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_ziIjUwWeiJv1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zPAZ0GYoyFfi" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">10,502,283</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_zzeKVIBoiv3g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">93,081,502</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">90,624,702</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,759,873</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">60,153,773</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_i01_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic net income (loss) per common share</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1.49</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.63</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1.21</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.51</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Diluted net income (loss) per common share</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.86</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1.21</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.36</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountAbstract_iB_zAA51t9fyYb9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity-based incentive awards</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zjonp0WplYTk" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">398,168</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zo9B1P8eBkx7" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">191,312</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zpCE74DNTtRh" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">2,230,624</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zUHZgQbwXMX1" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">310,083</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zAvEczJmdNx8" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zjhYgVn24X8j" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zSFBrX3kdS6e" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">5,000,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zhX75AYVh6T4" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_z2xXFsqBcTB" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_zLiFotOF4Xf5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,493,151</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_znuuZyWd7Af8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">100,000,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_zY6ZhpOBfTl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,493,151</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; padding-bottom: 2.5pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210701__20210930_zfPhf3MEWAYh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">398,168</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200701__20200930_zhxNnhzLXLXd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,684,463</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930_zpdjGBzpfpm3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">107,230,624</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200930_z70wa1rdKsb4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,803,234</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zgbXg2sOefXg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME/LOSS PER SHARE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span id="xdx_8B9_zVrmlA3L6504" style="font: 10pt Times New Roman, Times, Serif; display: none">Calculation of basic and diluted net loss per share</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_499_20210701__20210930_zpblr4UDGed6" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_49E_20200701__20200930_z7qOwCUpQKp1" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_496_20210101__20210930_zFBF3yU6vn4f" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_497_20200101__20200930_z5QXqKuQujHd" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Nine Months Ended</span></td><td style="font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands, except share and per share information)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom"> <td style="padding-left: 5pt; font-size: 10pt; font-weight: bold; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Numerator:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; width: 44%; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net income (loss) attributable to Acacia Research Corporation</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">89,604</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">38,348</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(55,507</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 11%; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">33,205</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PreferredStockDividendsIncomeStatementImpact_i01N_pn3n3_di_zytxWlyW6E8c" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Dividend on Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(262</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(467</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(785</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,118</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_401_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_i01N_pn3n3_di_zykUE09mVaKh" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Accretion of Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(991</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(733</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(2,762</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(2,045</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40C_eus-gaap--UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_i01_pn3n3_d0_zuHjVJ4perMi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Undistributed earnings allocated to participating securities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(15,367</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(6,619</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(5,204</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net income (loss) attributable to common stockholders - Basic</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">72,984</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">30,529</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(59,054</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">24,838</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--DividendOnSeriesRedeemableConvertiblePreferredStock_d0_zvQN6GcEwcpj" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Dividend on Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">467</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--AccretionOfSeriesRedeemableConvertiblePreferredStock_d0_z5ju7nq3fJL6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Accretion of Series A redeemable convertible preferred stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">733</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStock_d0_zBu9eOfBc129" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,831</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_ecustom--ChangeInFairValueOfSeriesWarrants_d0_zHLx0s1KWuw1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: Change in fair value of Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">63</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfDilutiveSeriesBWarrants_i_pn3n3" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: Change in fair value of dilutive Series B warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(902</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(5,557</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1633">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(5,557</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_ecustom--InterestExpenseAssociatedWithStarboardNotesNetOfTax_zOXosm3OcbC4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Interest expense associated with Starboard Notes, net of tax</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,536</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,889</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1638">–</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,889</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_d0_zz2ju8XPbY3j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Add: Undistributed earnings allocated to participating securities</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">15,367</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6,619</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,204</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_d0_zIrNoG0YtTlk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Reallocation of undistributed earnings to participating securities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(8,877</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(296</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(3,645</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_ecustom--NetIncomeLossAvailableToCommonStockholderDiluted_zIr9KIFNSS4h" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net income (loss) attributable to common stockholders - Diluted</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">80,171</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">29,205</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(59,054</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">21,381</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--EarningsPerShareBasicAndDilutedDeniminatorAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; font-weight: bold; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Denominator:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,949,504</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,467,885</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,759,873</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,949,706</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_iB_zEk8nkeJ0rCd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Potentially dilutive common shares:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series A Preferred Stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_d0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zKkMuV7VIDVa" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zETSzCWfjRT5" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">9,589,041</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zKirbQ2Yoor5" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__us-gaap--SeriesAPreferredStockMember_zvKnaiHzRzR8" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Restricted stock</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zJF7f4mvOp0l" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">798,356</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zMkU0EdviRii" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">728,936</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zOJu5omQ8n8g" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--RestrictedStockUnitsMember_zYRXlPFFIb9j" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">598,328</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Stock options</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zeaYyeQPthn" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">35,815</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zkUd73Hfl71h" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">21,624</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zPgEbZO4A6se" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--EmployeeStockOptionsMember_zaVQrUnVwe71" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series A Warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zDzc4FbOzBkl" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">2,019,724</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_z7WoPzAd95ti" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">310,367</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zZnhIcNFlxh6" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesAWarrantsMember_zUvgbSo8UNFj" style="font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">103,456</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B Warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20210701__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zW9XGGHHTqMk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">41,278,103</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200701__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zINAkGS70pp8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">31,506,849</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pn3d_d0_c20210101__20210930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_ziIjUwWeiJv1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pip0_c20200101__20200930__us-gaap--FinancialInstrumentAxis__custom--SeriesBWarrantsMember_zPAZ0GYoyFfi" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Potentially dilutive common shares"><span style="font: 10pt Times New Roman, Times, Serif">10,502,283</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_zzeKVIBoiv3g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">93,081,502</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">90,624,702</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48,759,873</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">60,153,773</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_i01_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic net income (loss) per common share</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1.49</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.63</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1.21</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.51</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Diluted net income (loss) per common share</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.86</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(1.21</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.36</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 5pt; font-size: 10pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountAbstract_iB_zAA51t9fyYb9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity-based incentive awards</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zjonp0WplYTk" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">398,168</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zo9B1P8eBkx7" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">191,312</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zpCE74DNTtRh" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">2,230,624</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EquityBasedIncentiveAwardsMember_zUHZgQbwXMX1" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">310,083</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series A warrants</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zAvEczJmdNx8" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zjhYgVn24X8j" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zSFBrX3kdS6e" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">5,000,000</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAWarrantsMember_zhX75AYVh6T4" style="font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Series B warrants</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_z2xXFsqBcTB" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">–</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_zLiFotOF4Xf5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,493,151</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_znuuZyWd7Af8" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">100,000,000</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBWarrantsMember_zY6ZhpOBfTl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,493,151</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5pt; font-size: 10pt; padding-bottom: 2.5pt; text-indent: -5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210701__20210930_zfPhf3MEWAYh" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">398,168</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200701__20200930_zhxNnhzLXLXd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,684,463</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20210101__20210930_zpdjGBzpfpm3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">107,230,624</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pip0_c20200101__20200930_z70wa1rdKsb4" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Antidilutive shares"><span style="font: 10pt Times New Roman, Times, Serif">68,803,234</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 89604000 38348000 -55507000 33205000 262000 467000 785000 1118000 991000 733000 2762000 2045000 -15367000 -6619000 0 -5204000 72984000 30529000 -59054000 24838000 0 467000 0 0 0 733000 0 0 0 -3831000 0 0 63000 -1348000 0 -1348000 -902000 -5557000 -5557000 1536000 1889000 1889000 15367000 6619000 0 5204000 -8877000 -296000 0 -3645000 80171000 29205000 -59054000 21381000 48949504 48467885 48759873 48949706 0 9589041 0 0 798356 728936 0 598328 35815 21624 0 0 2019724 310367 0 103456 41278103 31506849 0 10502283 93081502 90624702 48759873 60153773 1.49 0.63 -1.21 0.51 0.86 0.32 -1.21 0.36 398168 191312 2230624 310083 0 0 5000000 0 0 68493151 100000000 68493151 398168 68684463 107230624 68803234 <p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zQvSRAB0ruI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. <span id="xdx_82F_z4hFLwyCzOZ2">SUBSEQUENT EVENT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 8, 2021, the Company acquired all of the outstanding stock of a leading printing technology company, for a cash purchase price of $37.0 million, which includes an initial $33.0 million cash payment and a $4.0 million working capital adjustment. The business services a diverse group of customers that operate across healthcare, food and beverage, manufacturing and logistics, and other sectors. The acquisition triggered the release of $35.0 million held in escrow (refer to Note 2 “Long-Term Restricted Cash” for additional information).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> XML 14 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
 9 Months Ended
Sep. 30, 2021
Nov. 08, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 1-37721  
Entity Registrant Name Acacia Research Corporation  
Entity Central Index Key 0000934549  
Entity Tax Identification Number 95-4405754  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 767 THIRD AVENUE  
Entity Address, Address Line Two SUITE 602  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10017  
City Area Code (949)  
Local Phone Number 480-8300  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   49,591,852
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.21.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 217,957 $ 165,546
Restricted cash 761 0
Equity securities at fair value 387,120 109,103
Equity securities without readily determinable fair value 5,816 143,257
Investment securities - equity method investments 31,840 30,673
Investment at fair value 0 2,752
Accounts receivable 412 506
Other receivable (Note 3) 21,539 0
Prepaid expenses and other current assets 3,986 5,832
Total current assets 669,431 457,669
Long-term restricted cash 35,424 35,000
Patents, net of accumulated amortization 39,826 16,912
Leased right-of-use assets 671 951
Other non-current assets 4,482 4,988
Total assets 749,834 515,520
Current liabilities:    
Accounts payable 2,196 1,019
Accrued expenses and other current liabilities 5,586 3,707
Accrued compensation 4,019 2,265
Royalties and contingent legal fees payable 1,793 2,162
Accrued patent investment costs 8,000 0
Senior Secured Notes Payable 182,855 115,663
Total current liabilities 204,449 124,816
Series A warrant liabilities 18,527 6,640
Series A embedded derivative liabilities 41,411 26,728
Series B warrant liabilities 229,637 52,341
Long-term lease liabilities 671 951
Other long-term liabilities 5,591 591
Total liabilities 500,286 212,067
Commitments and contingencies
Series A redeemable convertible preferred stock, par value $0.001 per share; stated value $100 per share; 350,000 shares authorized, issued and outstanding as of September 30, 2021 and December 31, 2020; aggregate liquidation preference of $35,000 as of September 30, 2021 and December 31, 2020 13,686 10,924
Stockholders' equity:    
Common stock, par value $0.001 per share; 300,000,000 shares authorized; 49,591,852 and 49,279,453 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 50 49
Treasury stock, at cost, 4,604,365 shares as of September 30, 2021 and December 31, 2020 (43,270) (43,270)
Additional paid-in capital 649,349 651,416
Accumulated deficit (382,215) (326,708)
Total Acacia Research Corporation stockholders' equity 223,914 281,487
Noncontrolling interests 11,948 11,042
Total stockholders' equity 235,862 292,529
Total liabilities, redeemable convertible preferred stock, and stockholders' equity $ 749,834 $ 515,520
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.21.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 49,591,852 49,279,453
Common stock, shares outstanding 49,591,852 49,279,453
Treasury stock, shares 4,604,365 4,604,365
Redeemable Preferred Stock [Member]    
Series A redeemable convertible preferred stock, par value $ 0.001 $ 0.001
Series A redeemable convertible preferred stock, value per share $ 100 $ 100
Series A redeemable convertible preferred stock, shares authorized 350,000 350,000
Series A redeemable convertible preferred stock, liquidation preference $ 35,000 $ 35,000
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenues $ 1,582 $ 19,466 $ 24,785 $ 25,399
Patent portfolio operations:        
Inventor royalties 280 5,772 823 6,843
Contingent legal fees 285 6,609 5,735 6,855
Litigation and licensing expenses - patents 782 1,001 4,881 3,497
Amortization of patents 2,612 1,174 7,086 3,522
Other patent portfolio income 0 0 0 (308)
Patent portfolio expenses 3,959 14,556 18,525 20,409
Net patent portfolio (loss) income (2,377) 4,910 6,260 4,990
General and administrative expenses 10,345 7,692 23,014 18,089
Operating loss (12,722) (2,782) (16,754) (13,099)
Other income (expense):        
Change in fair value of investment, net 0 (3,081) (2,752) 3,704
Gain (loss) on sale of investment 0 0 3,591 (2,762)
Change in fair value of the Series A and B warrants and embedded derivatives 619 20,672 (203,866) (46,612)
Gain on sale of prepaid investment and derivative 0 2,845 0 2,845
Change in fair value of equity securities 66,502 20,488 115,509 99,449
Gain (loss) on sale of equity securities 37,688 2,737 53,124 (4,272)
Earnings on equity investment in joint venture 0 0 2,737 0
Loss on foreign currency exchange (17) (48) (193) (4,938)
Interest expense on Senior Secured Notes (2,531) (2,410) (5,601) (3,178)
Interest income and other 76 10 135 811
Total other income (expense) 102,337 41,213 (37,316) 45,047
Income (loss) before income taxes 89,615 38,431 (54,070) 31,948
Income tax (expense) benefit (11) (83) (531) 1,257
Net income (loss) including noncontrolling interests in subsidiaries 89,604 38,348 (54,601) 33,205
Net income attributable to noncontrolling interests in subsidiaries 0 0 (906) 0
Net income (loss) attributable to Acacia Research Corporation $ 89,604 $ 38,348 $ (55,507) $ 33,205
Net income (loss) attributable to common stockholders - Basic $ 72,984 $ 30,529 $ (59,054) $ 24,838
Basic net income (loss) per common share $ 1.49 $ 0.63 $ (1.21) $ 0.51
Weighted average number of shares outstanding - Basic 48,949,504 48,467,885 48,759,873 48,949,706
Net income (loss) attributable to common stockholders - Diluted $ 80,171 $ 29,204 $ (59,054) $ 21,380
Diluted net income (loss) per common share $ 0.86 $ 0.32 $ (1.21) $ 0.36
Weighted average number of shares outstanding - Diluted 93,081,502 90,624,702 48,759,873 60,153,773
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.21.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Series A Redeemable Convertible Preferred Stock [Member]
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 8,089 $ 50 $ (39,272) $ 652,003 $ (439,656) $ 1,833 $ 174,958
Balance at beginning, shares at Dec. 31, 2019 350,000 50,370,987          
Net income attributable to Acacia Research Corporation 33,205 33,205
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value 2,045 (2,045) (2,045)
Dividend on Series A Redeemable Convertible Preferred Stock (1,119) (1,119)
Stock options exercised 48 48
Stock options exercised, Shares   13,333          
Issuance of common stock for vesting of restricted stock units
Issuance of common stock for vesting of restricted stock units, shares   14,354          
Issuance of common stock for unvested restricted stock awards, net of forfeitures
Issuance of common stock for unvested restricted stock awards, net of forfeitures, shares   565,316          
Compensation expense for share-based awards 1,243 1,243
Repurchase of common stock $ (1) (3,998) (3,999)
Repurchase of common stock, Shares   (1,684,537)          
Ending balance, value at Sep. 30, 2020 $ 10,134 $ 49 (43,270) 650,130 (406,451) 1,833 202,291
Balance at ending, shares at Sep. 30, 2020 350,000 49,279,453          
Beginning balance, value at Jun. 30, 2020 $ 9,400 $ 49 (43,270) 650,843 (444,799) 1,833 164,656
Balance at beginning, shares at Jun. 30, 2020 350,000 49,306,137          
Net income attributable to Acacia Research Corporation 38,348 38,348
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value 734 (734) (734)
Dividend on Series A Redeemable Convertible Preferred Stock (467) (467)
Issuance of common stock for unvested restricted stock awards, net of forfeitures
Issuance of common stock for unvested restricted stock awards, net of forfeitures, shares   (26,684)          
Compensation expense for share-based awards 488 488
Ending balance, value at Sep. 30, 2020 $ 10,134 $ 49 (43,270) 650,130 (406,451) 1,833 202,291
Balance at ending, shares at Sep. 30, 2020 350,000 49,279,453          
Beginning balance, value at Dec. 31, 2020 $ 10,924 $ 49 (43,270) 651,416 (326,708) 11,042 292,529
Balance at beginning, shares at Dec. 31, 2020 350,000 49,279,453          
Net income attributable to Acacia Research Corporation             (54,601)
Net (loss) income including noncontrolling interests in subsidiaries (55,507) 906 (54,601)
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value 2,762 (2,762) (2,762)
Dividend on Series A Redeemable Convertible Preferred Stock (785) (785)
Stock options exercised $ 1 201 202
Stock options exercised, Shares   60,000          
Issuance of common stock for vesting of restricted stock units
Issuance of common stock for vesting of restricted stock units, shares   28,834          
Issuance of common stock for unvested restricted stock awards, net of forfeitures
Issuance of common stock for unvested restricted stock awards, net of forfeitures, shares   223,565          
Compensation expense for share-based awards 1,279 1,279
Ending balance, value at Sep. 30, 2021 $ 13,686 $ 50 (43,270) 649,349 (382,215) 11,948 235,862
Balance at ending, shares at Sep. 30, 2021 350,000 49,591,852          
Beginning balance, value at Jun. 30, 2021 $ 12,695 $ 50 (43,270) 650,194 (471,819) 11,948 147,103
Balance at beginning, shares at Jun. 30, 2021 350,000 49,616,602          
Net income attributable to Acacia Research Corporation             89,604
Net (loss) income including noncontrolling interests in subsidiaries 89,604 89,604
Accretion of Series A Redeemable Convertible Preferred Stock to redemption value 991 (991) (991)
Dividend on Series A Redeemable Convertible Preferred Stock (262) (262)
Stock options exercised 108 108
Stock options exercised, Shares   30,000          
Issuance of common stock for unvested restricted stock awards, net of forfeitures
Issuance of common stock for unvested restricted stock awards, net of forfeitures, shares   (54,750)          
Compensation expense for share-based awards 300 300
Ending balance, value at Sep. 30, 2021 $ 13,686 $ 50 $ (43,270) $ 649,349 $ (382,215) $ 11,948 $ 235,862
Balance at ending, shares at Sep. 30, 2021 350,000 49,591,852          
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.21.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net (loss) income including noncontrolling interests in subsidiaries $ (54,601) $ 33,205
Adjustments to reconcile net (loss) income including noncontrolling interests in subsidiaries to net cash (used in) provided by operating activities:    
Change in fair value of investment, net 2,752 (3,704)
(Gain) loss on sale of investment (3,591) 2,762
Depreciation and amortization 7,198 3,609
Amortization of debt discount and issuance costs 460 955
Change in fair value of Series A redeemable convertible preferred stock embedded derivative 14,683 7,708
Change in fair value of Series A warrants 11,887 2,036
Change in fair value of Series B warrants 177,296 36,867
Non-cash stock compensation 1,279 1,243
Loss on foreign currency exchange 193 4,938
Change in fair value of equity securities (115,509) (99,449)
(Gain) loss on sale of equity securities (53,124) 4,272
Gain on sale of prepaid investment and derivative 0 (2,845)
Earnings on equity investment in joint venture, net of distributions received (907) 0
Changes in assets and liabilities:    
Accounts receivable 94 248
Prepaid expenses and other assets (2,345) 1,038
Accounts payable and accrued expenses 7,002 614
Royalties and contingent legal fees payable (369) 12,052
Net cash (used in) provided by operating activities (7,602) 5,549
Cash flows from investing activities:    
Patent acquisition (13,000) (13,780)
Sale of investment at fair value 3,591 1,460
Purchases of equity securities (57,978) (33,800)
Maturities and sales of equity securities 64,235 316,746
Purchases of prepaid investment 0 (276,275)
Equity securities derivative and forward contract acquisition cost 0 (3,989)
Purchases of property and equipment (67) (177)
Net cash used in investing activities (3,219) (9,815)
Cash flows from financing activities:    
Repurchase of common stock 0 (3,998)
Issuance of Senior Secured Notes, net of lender fee 65,000 110,437
Senior Secured Notes issuance costs paid to other parties 0 (496)
Dividend on Series A Redeemable Convertible Preferred Stock (785) (1,120)
Issuance of Series B warrants 0 4,600
Proceeds from exercise of stock options 202 48
Paydown of Senior Secured Notes (50,000) 0
Reissuance of Senior Secured Notes 50,000 0
Net cash provided by financing activities 64,417 109,471
Increase in cash and cash equivalents and restricted cash 53,596 105,205
Cash and cash equivalents and restricted cash, beginning 200,546 92,359
Cash and cash equivalents and restricted cash, ending 254,142 197,564
Supplemental schedule of cash flow information:    
Interest paid 2,340 0
Income taxes paid 9 164
Noncash investing activities:    
Trade date receivable from sale of equity securities (Note 3) 21,539 0
Patent acquisition in exchange of notes receivable 4,000 0
Patent acquisition accrued liability - short-term 8,000 0
Patent acquisition accrued liability - long-term 5,000 0
Acquisition of prepaid investment securities $ 0 $ 231,480
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.2
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2021
Description Of Business And Basis Of Presentation  
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Description of Business

 

As used herein, “we,” “us,” “our,” “Acacia” and the “Company” refer to Acacia Research Corporation and/or its wholly and majority-owned and controlled operating subsidiaries, and/or where applicable, its management.

 

Acacia was incorporated on January 25, 1993 under the laws of the State of California. In December 1999, Acacia changed its state of incorporation from California to Delaware.

 

Acacia acquires businesses and operating assets that the Company believes to be undervalued and where the Company believes it can leverage its resources and skill sets to realize and unlock value. The Company intends to leverage its (i) access to flexible capital that can be deployed unconditionally, (ii) expertise in corporate governance and operational restructuring, (iii) willingness to invest in out of favor industries and businesses that suffer from a complexity discount and untangle complex, multi-factor situations, and (iv) expertise and relationships in certain sectors, to complete strategic acquisitions of businesses, divisions, and/or assets with a focus on mature technology, healthcare, industrial and certain financial segments. Acacia seeks to identify opportunities where the Company believes it is an advantaged buyer, where the Company can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to the Company’s unique capabilities, relationships, or expertise, or where Acacia believes the target would be worth more to the Company than to other buyers.

 

Acacia operates its business based on three key principles of People, Process and Performance and has built a management team with identified expertise in Research, Execution and Operation of the Company’s targeted acquisitions.

 

Acacia, through its operating subsidiaries, also currently engages in its legacy business of investing in, licensing and enforcing patented technologies. Acacia’s operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. In recent years, Acacia has also invested in technology companies. Acacia leverages its experience, expertise, data and relationships developed as a leader in the intellectual property (“IP”) industry to pursue these opportunities. In some cases, these opportunities will complement and/or supplement Acacia’s primary licensing and enforcement business.

 

Acacia’s operating subsidiaries generate revenues and related cash flows from the granting of IP rights (hereinafter, “IP Rights”) for the use of patented technologies that its operating subsidiaries control or own. Acacia’s operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation.

 

Acacia’s operating subsidiaries are principals in the licensing and enforcement effort, obtaining control of the rights in the patent portfolio, or control of the patent portfolio outright. Acacia’s operating subsidiaries own or control the rights to multiple patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.

 

Neither Acacia nor its operating subsidiaries invent new technologies or products; rather, Acacia depends upon the identification and investment in new patents, inventions and companies that own IP through its relationships with inventors, universities, research institutions, technology companies and others. If Acacia’s operating subsidiaries are unable to maintain those relationships and identify and grow new relationships, then they may not be able to identify new technology-based opportunities for sustainable revenue and/or revenue growth.

 

During the nine months ended September 30, 2021, Acacia obtained control of one new patent portfolio. During fiscal year 2020, Acacia obtained control of five new patent portfolios.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

  

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures required by U.S. GAAP in annual financial statements have been omitted or condensed in accordance with quarterly reporting requirements of the Securities and Exchange Commission (“SEC”). These interim unaudited condensed consolidated financial statements and notes hereto should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2020, as reported by Acacia in its Annual Report on Form 10-K filed with the SEC on March 29, 2021, as well as in our other public filings with the SEC. The condensed consolidated interim financial statements of Acacia include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of Acacia’s consolidated financial position as of September 30, 2021, and results of its operations and its cash flows for the interim periods presented. The consolidated results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the entire fiscal year.

 

Reclassifications

 

Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated results of operations or cash flows.

  

COVID-19 Pandemic

 

The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. While the Company does not expect the current situation to present direct risks to its business, and it has not had a material impact to date, the COVID-19 pandemic could adversely impact the Company’s operations, as well as the operations of its licensees and other business partners. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, results of operations and financial condition.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounting Principles

 

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. GAAP.

 

Principles of Consolidation

 

The accompanying unaudited consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

 

Noncontrolling interests in Acacia’s majority-owned and controlled operating subsidiaries (“noncontrolling interests”) are separately presented as a component of stockholders’ equity. Consolidated net income or (loss) is adjusted to include the net (income) or loss attributed to noncontrolling interests in the consolidated statements of operations. Refer to the accompanying Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders’ Equity for total noncontrolling interests.

 

In 2020, in connection with the transaction with Link Fund Solutions Limited, which is more fully described in Note 3, the Company acquired equity securities of Malin J1 Limited (“MalinJ1”). MalinJ1 is included in the Company’s consolidated financial statements because the Company, through its interest in the equity securities of MalinJ1, has the ability to control the operations and activities of MalinJ1. Viamet HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of Acacia, is the majority shareholder of MalinJ1.

 

A wholly-owned subsidiary of Acacia is the general partner of the Acacia Intellectual Property Fund, L.P. (the “Acacia IP Fund”), which was formed in August 2010. The Acacia IP Fund has been included in the Company’s consolidated financial statements since 2010, as Acacia’s wholly-owned subsidiary, the general partner of Acacia IP Fund, has the ability to control the operations and activities of the Acacia IP Fund. The Acacia IP Fund was terminated as of December 31, 2017 and dissolved in 2020.

 

Segment Reporting

 

Acacia uses the management approach, which designates the internal organization that is used by management for making operating decisions and assessing performance as the basis of Acacia’s reportable segments. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Acacia believes that, of the significant accounting policies described herein, the accounting policies associated with revenue recognition, the valuation of the equity instruments, the valuation of Series A redeemable convertible preferred stock (the “Series A Redeemable Convertible Preferred Stock”), embedded derivatives, Series A warrants (the “Series A Warrants”), Series B warrants (the “Series B Warrants”), stock-based compensation expense, impairment of patent-related intangible assets, the determination of the economic useful life of amortizable intangible assets, income taxes and valuation allowances against net deferred tax assets, require its most difficult, subjective or complex judgments.

 

Revenue Recognition

 

Revenue is recognized upon transfer of control (i.e., by the granting) of promised bundled IP Rights and other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive in exchange for those IP Rights. Revenue contracts that provide promises to grant the right to use IP Rights as they exist at the point in time at which the IP Rights are granted, are accounted for as performance obligations satisfied at a point in time and revenue is recognized at the point in time that the applicable performance obligations are satisfied and all other revenue recognition criteria have been met.

 

For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technologies owned or controlled by Acacia. Revenues also included license fees from sales-based revenue contracts, the majority of which were originally executed in prior periods, which provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees (“Recurring Revenue Agreements”). Revenues may also include court ordered settlements or awards related to our patent portfolio or sales of our patent portfolio. IP Rights granted included the following, as applicable: (i) the grant of a non-exclusive, future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The IP Rights granted were generally perpetual in nature, extending until the legal expiration date of the related patents. The individual IP Rights are not accounted for as separate performance obligations, as (i) the nature of the promise, within the context of the contract, is to grant combined items to which the promised IP Rights are inputs and (ii) the Company's promise to grant each individual IP right described above to the customer is not separately identifiable from other promises to grant IP Rights in the contract.

 

Since the promised IP Rights are not individually distinct, the Company combined each individual IP Right in the contract into a bundle of IP Rights that is distinct, and accounted for all of the IP Rights promised in the contract as a single performance obligation. The IP Rights granted were “functional IP rights” that have significant standalone functionality. Acacia’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. Acacia’s operating subsidiaries have no further obligation with respect to the grant of IP Rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the IP Rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 15-90 days of execution of the contract, or the end of the quarter in which the sale or usage occurs for Recurring Revenue Agreements. Contractual payments made by licensees are generally non-refundable.

 

For sales-based royalties, the Company includes in the transaction price some or all of an amount of estimated variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Notwithstanding, revenue is recognized for a sales-based royalty promised in exchange for a license of IP Rights when the later of (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied. Estimates are generally based on historical levels of activity, if available.

 

Revenues from contracts with significant financing components (either explicit or implicit) are recognized at an amount that reflects the price that a licensee would have paid if the licensee had paid cash for the IP Rights when they are granted to the licensee. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money. As a practical expedient, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the entity grants promised IP Rights to a customer and when the customer pays for the IP Rights will be one year or less.

 

In general, the Company is required to make certain judgments and estimates in connection with the accounting for revenue contracts with customers. Such areas may include identifying performance obligations in the contract, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services, evaluating whether a license transfers to a customer at a point in time or over time, allocating the transaction price to separate performance obligations, determining whether contracts contain a significant financing component, and estimating revenues recognized at a point in time for sales-based royalties.

 

Revenues were comprised of the following for the periods presented: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Paid-up revenue agreements  $1,100   $19,385   $23,110   $24,477 
Recurring Revenue Agreements   482    81    1,675    922 
Total revenue  $1,582   $19,466   $24,785   $25,399 

 

Refer to “Inventor Royalties and Contingent Legal Expenses” below for information on related direct costs of revenues.

  

Patent Portfolio Operations

 

Cost of revenues include the costs and expenses incurred in connection with Acacia’s patent licensing and enforcement activities, including inventor royalties paid to original patent owners, patent maintenance and prosecution costs, contingent legal fees paid to external patent counsel, other patent-related legal expenses paid to external patent counsel, licensing and enforcement related research, consulting and other expenses paid to third-parties and the amortization of patent-related investment costs. These costs are included under the caption “Patent portfolio operations” in the consolidated statements of operations. 

 

Inventor Royalties and Contingent Legal Expenses

 

Inventor royalties are expensed in the consolidated statements of operations in the period that the related revenues are recognized. Patent costs, including any upfront advances paid to patent owners by Acacia’s operating subsidiaries, that are recoverable from future net revenues are amortized over the estimated economic useful life of the related patents, or as the prepaid royalties are earned by the inventor, as appropriate, and the related expense is included in amortization expense in the consolidated statements of operations. Any unamortized upfront advances recovered from net revenues are expensed in the period recovered and included in amortization expense in the consolidated statements of operations.

 

Contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. In instances where there are no recoveries from potential infringers, no contingent legal fees are paid; however, Acacia’s operating subsidiaries may be liable for certain out of pocket legal costs incurred pursuant to the underlying legal services agreement.

 

Inventor royalty and contingent legal agreements generally provide for payment by the Company of contractual amounts 30 days subsequent to the fiscal quarter end during which related license fee payments are received from licensees by the Company.

 

Concentrations

 

Financial instruments that potentially subject Acacia to concentrations of credit risk are cash equivalents, equity securities and accounts receivable. Acacia places its cash equivalents and equity securities primarily in highly rated money market funds and investment grade marketable securities. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. Acacia has not experienced any significant losses on its deposits of cash and cash equivalents.

 

Four licensees individually accounted for 32%, 25%, 22% and 13% of revenues recognized during the three months ended September 30, 2021, and one licensee accounted for 98% of revenues recognized during the three months ended September 30, 2020. Three licensees individually accounted for 50%, 19% and 12% of revenues recognized during the nine months ended September 30, 2021, and two licensees accounted for 75% and 9% of revenues recognized during the nine months ended September 30, 2020.

 

The Company does not have any material foreign operations. Based on the jurisdiction of the entity obligated to satisfy payment obligations pursuant to the applicable revenue arrangement, for the three and nine months ended September 30, 2021, 8% and 15%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions. For the three and nine months ended September 30, 2020, 0.1% and 5%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions.

 

Two licensees represented 100% of accounts receivable at September 30, 2021. Two licensees individually represented approximately 62% and 21% of accounts receivable at December 31, 2020.

 

Related Party Transactions

 

During 2019, the Company purchased shares of common stock of Drive Shack, Inc. (“Drive Shack”) for an aggregate purchase price of $2.4 million. At the time, Drive Shack and Clifford Press, Chief Executive Officer and director of Acacia, were related parties as Mr. Press was a board member of Drive Shack until June 2021. The market value of the investment was $1.4 million as of December 31, 2020. During the nine months ended September 30, 2021, the Company sold its investment receiving proceeds of $1.8 million and recognized a loss of $515,000.

  

Cash and Cash Equivalents

 

Acacia considers all highly liquid, equity securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Acacia’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily includes: domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Acacia’s cash equivalents are measured at fair value using observable inputs.

 

Equity Securities at Fair Value

 

Investments in equity securities are reported at fair value on a recurring basis, with related realized and unrealized gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or (expense). Dividend income is included in the consolidated statements of operations in other income or (expense). Refer to Note 7 for additional information related to fair value measurements.

 

Equity securities at fair value for the periods presented were comprised of the following: 

                    
Security Type  Cost   Gross
Unrealized
Gain		   Gross
Unrealized
Loss		   Fair Value 
   (In thousands) 
September 30, 2021:                
Equity securities - Life Sciences Portfolio (Note 3)  $62,042   $288,508   $(1,812)  $348,738 
Equity securities - other equity   35,178    3,289    (85)   38,382 
Total  $97,220   $291,797   $(1,897)  $387,120 
                     
December 31, 2020:                    
Equity securities - Life Sciences Portfolio (Note 3)  $32,765   $72,689   $(583)  $104,871 
Equity securities - other equity   4,086    1,410    (1,264)   4,232 
Total  $36,851   $74,099   $(1,847)  $109,103 

 

Equity Securities Without Readily Determinable Fair Value

 

For equity securities that do not have readily determinable fair value, the Company elected to report them under the measurement alternative. They are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in any adjustments for illiquidity or preference of these securities. Changes in fair value are reported in the consolidated statements of operations in other income or (expense). Refer to Note 3 for additional information.

 

Equity Method Investments

 

Equity investments in common stock and in-substance common stock without readily determinable fair values in companies over which the Company has the ability to exercise significant influence, are accounted for using the equity method of accounting. Acacia includes its proportionate share of earnings and/or losses of its equity method investees in earnings on equity investment in joint venture in the consolidated statements of operations. Refer to Note 3 for additional information.

 

Investment at Fair Value

 

On an individual investment basis, Acacia may elect to account for investments in companies where the Company has the ability to exercise significant influence over operating and financial policies of the investee, at fair value. If the fair value method is applied to an investment that would otherwise be accounted for under the equity method of accounting, it is applied to all of the financial interests in the same entity that are eligible items (i.e., common stock and warrants). We elected the fair value method for our investment in Veritone, Inc. (“Veritone”) upon acquisition of the investment. Since March 2021, we have no more investment in Veritone stocks and warrants. Refer to Note 4 for additional information.

 

Impairment of Investments

 

Acacia reviews its investments quarterly for indicators of other-than-temporary impairment. This determination requires significant judgment. In making this judgment, Acacia considers available quantitative and qualitative evidence in evaluating potential impairment of its investments. If the cost of an investment exceeds its fair value, Acacia evaluates, among other factors, general market conditions and the duration and extent to which the fair value is less than cost. Acacia also considers specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of operations and a new cost basis in the investment is established.

 

Long-Term Restricted Cash

 

Restricted cash relates primarily to the proceeds received from the issuance of Series A Redeemable Convertible Preferred Stock which are held in an escrow account (refer to Note 6). The amounts are to be released to the Company upon, among other things, (i) the consummation of a suitable investment or acquisition by the Company or (ii) the conversion of Series A Redeemable Convertible Preferred Stock into common stock. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Refer to Note 11 for additional information related to the subsequent period acquisition.

 

Patents

 

Patents include the cost of patents or patent rights acquired from third-parties or obtained in connection with business combinations. Patent costs are amortized utilizing the straight-line method over their remaining economic useful lives. Refer to Note 5 for additional information.

 

Impairment of Long-lived Assets

 

Acacia reviews long-lived assets and intangible assets for potential impairment annually (quarterly for patents) and when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss is recorded in an amount equal to the excess of the asset’s carrying value over its fair value. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. In the event that management decides to no longer allocate resources to a patent portfolio, an impairment loss equal to the remaining carrying value of the asset is recorded. Refer to Note 5 for additional information.

 

Fair value is generally estimated using the “Income Approach,” focusing on the estimated future net income-producing capability of the patent portfolios over their estimated remaining economic useful life. Estimates of future after-tax cash flows are converted to present value through “discounting,” including an estimated rate of return that accounts for both the time value of money and investment risk factors. Estimated cash inflows are typically based on estimates of reasonable royalty rates for the applicable technology, applied to estimated market data. Estimated cash outflows are based on existing contractual obligations, such as contingent legal fee and inventor royalty obligations, applied to estimated license fee revenues, in addition to other estimates of out-of-pocket expenses associated with a specific patent portfolio’s licensing and enforcement program. The analysis also contemplates consideration of current information about the patent portfolio including, status and stage of litigation, periodic results of the litigation process, strength of the patent portfolio, technology coverage and other pertinent information that could impact future net cash flows.

 

Series A and B Warrants

 

The fair value of the Series A and B Warrants are estimated using a Black-Scholes option-pricing model. Refer to Notes 6 and 7 for additional information related to the Series A and B Warrants and their fair value measurements.

 

Embedded derivatives

 

Embedded derivatives that are required to be bifurcated from their host contract are valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019. Refer to Notes 6 and 7 for additional information related to the embedded derivatives and their fair value measurements.

 

Fair Value Measurements

 

U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. Refer to Note 7 for additional information.

 

Treasury Stock

 

Repurchases of the Company’s outstanding common stock are accounted for using the cost method. The applicable par value is deducted from the appropriate capital stock account on the formal or constructive retirement of treasury stock. Any excess of the cost of treasury stock over its par value is charged to additional paid-in capital and reflected as treasury stock in the consolidated balance sheets. Refer to Note 9 for additional information.

 

Stock-Based Compensation

 

The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which is generally one to three years. The fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) are determined by the product of the number of shares or units granted and the grant date market price of the underlying common stock. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing model. Forfeitures are accounted for as they occur.

 

RSUs granted in September 2019 with market-based vesting conditions vest based upon the Company achieving specified stock price targets over a three-year period. The effect of a market condition is reflected in the estimate of the grant-date fair value of the options utilizing a Monte Carlo valuation technique. Compensation cost is recognized with a market-based vesting condition provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Assumptions utilized in connection with the Monte Carlo valuation technique, that resulted in a fair value of $1.42 per unit, included: estimated risk-free interest rate of 1.38 percent; term of 3.00 years; expected volatility of 38 percent; and expected dividend yield of 0 percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. During the nine months ended September 30, 2021, 450,000 RSUs were forfeited, leaving 450,000 units with market-based vesting conditions outstanding and unvested at period end.

 

During the nine months ended September 30, 2021, the Company granted 324,401 RSAs at a weighted average grant-date fair value of $5.56 per share, 473,000 RSUs at a weighted average grant-date fair value of $5.86 per unit and 393,750 non-qualified stock options at a grant-date fair value of $1.79 per share.

 

Stock-based compensation is reported in the consolidated statements of operations in general and administrative expenses. Total stock-based compensation for the three and nine months ended September 30, 2021 was $300,000 and $1,279,000, respectively. Total unrecognized stock-based compensation expense as of September 30, 2021 was $5,952,000, which will be amortized over a weighted average remaining vesting period of 2.20 years. Total stock-based compensation for the three and nine months ended September 30, 2020 was $488,000 and $1,243,000, respectively.

 

Profits Interest Units (“PIUs”) were accounted for in accordance with Accounting Standards Codification (“ASC”) 718-10, “Compensation - Stock Compensation.” The vesting conditions did not meet the definition of service, market or performance conditions, as defined in ASC 718. As such, the PIUs were classified as liability awards. Compensation expense was adjusted for changes in fair value prorated for the portion of the requisite service period rendered. Initially, compensation expense was recognized on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which was five years. Upon full vesting of the award, which occurred during the three months ended September 30, 2017, previously unrecognized compensation expense was immediately recognized in the period. The Company has a purchase option to purchase the vested PIUs that are not otherwise forfeited after termination of continuous service. The exercise price of the purchase option is the fair market value of the PIUs on the date of termination of continuous service. The individuals holding PIUs are no longer employed by the Company. Included in other long-term liabilities in the consolidated balance sheets as of September 30, 2021 and December 31, 2020, the PIUs totaled $591,000, which was their fair value as of December 31, 2018 after termination of service.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in Acacia’s consolidated financial statements or consolidated income tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized, or if it is determined that there is uncertainty regarding future realization of such assets.

 

The provision for income taxes for interim periods is determined using an estimate of Acacia’s annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, Acacia updates the estimate of the annual effective tax rate, and if the estimated tax rate changes, a cumulative adjustment is recorded.

 

The Company’s effective tax rates were 0% and (1%) for the three and nine months ended September 30, 2021, respectively, and 0% and (4%) for the three and nine months ended September 30, 2020, respectively. Tax expense/benefit for the periods presented primarily reflects the impact of state taxes and foreign tax withholding (or refund) incurred on revenue agreements executed with third-party licensees domiciled in foreign jurisdictions. The Company has recorded a full valuation allowance against our net deferred tax assets as of September 30, 2021 and December 31, 2020. These assets primarily consist of foreign tax credits, capital loss carryforwards and net operating loss carryforwards.

  

Recent Accounting Pronouncements

 

Recently Adopted

 

In December of 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The update removed certain exceptions to the general principles in Topic 740 in U.S. GAAP. The Company adopted the update on January 1, 2021. The adoption of the update did not have a material effect on the Company’s financial position, results of operations or financial statement disclosures.

 

Not Yet Adopted

 

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” to replace the incurred loss methodology with an expected credit loss model that requires consideration of a broader range of information to estimate credit losses over the lifetime of the asset, including current conditions and reasonable and supportable forecasts in addition to historical loss information, to determine expected credit losses. Pooling of assets with similar risk characteristics and the use of a loss model are also required. Also, in April 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,” to clarify the inclusion of recoveries of trade receivables previously written off when estimating an allowance for credit losses. The amendments in these updates will currently be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in these updates may have on the Company’s consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” to simplify the accounting for convertible instruments by eliminating large sections of the existing guidance in this area. It also eliminates several triggers for derivative accounting, including a requirement to settle certain contracts by delivering registered shares. This update reduces the number of accounting models for convertible instruments, revises the derivatives scope exception, and provides targeted improvements for earnings per share. Upon adoption, companies have the option to apply a modified or full retrospective transition approach. The amendments in this update will currently be effective for the Company on January 1, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,” to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with “Revenue from Contracts with Customers (Topic 606).” At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and will be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.

 
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.21.2
EQUITY SECURITIES PORTFOLIO INVESTMENT
 9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
EQUITY SECURITIES PORTFOLIO INVESTMENT

3. EQUITY SECURITIES PORTFOLIO INVESTMENT

 

On April 3, 2020, the Company entered into an Option Agreement with LF Equity Income Fund (“Seller”), which included general terms through which the Company was provided the option to purchase life sciences equity securities in a portfolio of public and private companies (“Life Sciences Portfolio”) for an aggregate purchase price of £223.9 million, approximately $277.5 million at the exchange rate on April 3, 2020.

 

On June 4, 2020, the Company executed the Transaction Agreement between Link Fund Solutions Limited, Seller, and the Company. Pursuant to the Transaction Agreement, the Company agreed to purchase from Seller and Seller agreed to transfer to the Company the specified equity securities of all companies in the Life Sciences Portfolio at set prices at various future dates. The transfer dates would vary among the Life Sciences Portfolio companies as the Transaction Agreement gives the Company the exclusive right to determine when to call for transfer of each security, and because each Life Sciences Portfolio company (or its existing equity holders) may be required to approve the transfer due to rights of first refusals and other company-specific terms and conditions. Thus, the execution of the Transaction Agreement resulted in forward contracts for the Company to purchase equity securities in each public and private company at a specified price on a future date.

 

In accordance with the Transaction Agreement, the Company transferred the total purchase price of £223.9 million into an escrow account. Upon the transfer of equity securities in the Life Sciences Portfolio to the Company, the associated funds were released from the escrow account to Seller based on the consideration amount assigned to the equity securities for such Life Sciences Portfolio company in the Transaction Agreement. As of December 31, 2020, all of the equity securities in the Life Sciences Portfolio were transferred to the Company pursuant to the Transaction Agreement. The Company has sold a portion of the equity securities of such Life Sciences Portfolio while retaining an interest in a number of operating businesses, including a controlling interest in one of the companies.

 

For accounting purposes, the total purchase price of the Life Sciences Portfolio was allocated to the individual equity securities based on their individual fair values as of April 3, 2020, in order to establish an appropriate cost basis for each of the acquired securities. The fair values of the public company securities were based on their quoted market price. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in a discount for the illiquidity of these securities. As of September 30, 2021 and December 31, 2020, the fair value of the Life Sciences Portfolio equity securities, excluding the equity method investment discussed below, was $354.6 million and $248.1 million, respectively.

 

Changes in the fair value of Acacia’s investment in the Life Sciences Portfolio are recorded as unrealized gains or losses in the consolidated statements of operations. In late September 2021, the Company sold one security which resulted in a gain of $18.6 million. The proceeds of that sale were settled and received in early October 2021, and therefore the Company recorded a $21.5 million other receivable as included in the consolidated balance sheet as of September 30, 2021. Accordingly, this trade date receivable from the sale of equity securities has been reflected as a noncash investing activity in the consolidated statement of cash flows for the nine months ended September 30, 2021.

 

For the three and nine months ended September 30, 2021 and 2020, the consolidated statements of operations reflected the following from the Life Sciences Portfolio: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Change in fair value of equity securities  $63,907   $84,299   $112,180   $83,230 
Change in fair value of equity securities derivative   –    10,651    –    17,542 
Change in fair value of equity securities forward contract   –    (74,662)   –    – 
Gain (loss) on sale of equity securities   37,112    1,908    52,167    (4,202)
Gain on sale of prepaid investment and derivative   –    2,845    –    2,845 
Net realized and unrealized gain  $101,019   $25,041   $164,347   $99,415 

 

As part of the Company’s acquisition of equity securities in the Life Sciences Portfolio, the Company acquired a majority interest in the equity securities of MalinJ1 (63.9%), which were transferred to the Company on December 3, 2020. The acquisition of the MalinJ1 securities was accounted for as an asset acquisition as there was a change of control of MalinJ1 and substantially all of the fair value of the assets acquired was concentrated in a single identifiable asset, an investment in Viamet Pharmaceuticals Holdings, LLC (“Viamet”). As such, the cost basis of the MalinJ1 securities was used to allocate to the Viamet investment, the single identifiable asset, and no goodwill was recognized. The Company through its consolidation of MalinJ1 accounts for the Viamet investment under the equity method as MalinJ1 owns 41.0% of outstanding shares of Viamet.

 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENT AT FAIR VALUE
 9 Months Ended
Sep. 30, 2021
Schedule of Investments [Abstract]  
INVESTMENT AT FAIR VALUE

4. INVESTMENT AT FAIR VALUE

 

During 2016 and 2017, Acacia made certain investments in Veritone. As a result of these transactions, Acacia received an aggregate total of 4,119,521 shares of Veritone common stock and warrants to purchase a total of 1,120,432 shares of Veritone common stock at an exercise price of $13.61 per share expiring between 2020 and 2027. During the nine months ended September 30, 2020, Acacia sold all remaining 298,450 shares Veritone common stock and recorded a realized loss of $3.3 million.

 

During the nine months ended September 30, 2020, Acacia exercised 154,312 warrants, and recognized a realized gain of $554,000 on the sale of common stock. During the nine months ended September 30, 2021, Acacia exercised all remaining 156,720 warrants, and recognized a realized gain of $3.6 million on the sale of common stock. The Company no longer has an investment in Veritone common stock and warrants.

 

Changes in the fair value of Acacia’s investment in Veritone are recorded as unrealized gains or losses in the consolidated statements of operations. For the three and nine months ended September 30, 2021 and 2020, the consolidated statements of operations reflected the following: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Change in fair value of investment, warrants  $–   $(3,081)  $(2,752)  $225 
Change in fair value of investment, common stock   –    –    –    3,479 
Gain on sale of investment, warrants   –    –    3,591    554 
Loss on sale of investment, common stock   –    –    –    (3,316)
Net realized and unrealized (loss) gain  $–   $(3,081)  $839   $942 

 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.21.2
PATENTS, NET OF ACCUMULATED AMORTIZATION
 9 Months Ended
Sep. 30, 2021
Patents Net Of Accumulated Amortization  
PATENTS, NET OF ACCUMULATED AMORTIZATION

5. PATENTS, NET OF ACCUMULATED AMORTIZATION

 

Acacia’s only identifiable intangible assets as of September 30, 2021 and December 31, 2020 are patents and patent rights. Patent-related accumulated amortization totaled $291.6 million and $319.9 million as of September 30, 2021 and December 31, 2020, respectively. Acacia’s patents have remaining estimated economic useful lives ranging from twenty-six to fifty-two months. The weighted average remaining estimated economic useful life of Acacia’s patents is approximately four years.

 

The following table presents the scheduled annual aggregate amortization expense as of September 30, 2021: 

   
For the years ending December 31,   
(In thousands)
Remainder of 2021 $2,612 
2022  10,448 
2023  10,381 
2024  9,005 
2025  6,630 
Thereafter  750 
Patents, net   $39,826 

 

For the nine months ended September 30, 2021, Acacia accrued patent and patent rights acquisition costs totaling $13.0 million, of which $8.0 million is due December 1, 2021 and $5.0 million is due February 18, 2023. Such amounts are included in accrued patent investment costs and other long-term liabilities in the consolidated balance sheet as of September 30, 2021, respectively.

 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.21.2
STARBOARD INVESTMENT
 9 Months Ended
Sep. 30, 2021
Starboard Investment  
STARBOARD INVESTMENT

6. STARBOARD INVESTMENT

 

Series A Redeemable Convertible Preferred Stock 

 

On November 18, 2019, the Company entered into a Securities Purchase Agreement with Starboard Value LP (“Starboard”) and certain funds and accounts affiliated with, or managed by, Starboard (collectively, the “Buyers”) pursuant to which the Company issued (i) 350,000 shares of Series A Redeemable Convertible Preferred Stock with a par value of $0.001 per share and a stated value of $100 per share, and (ii) Series A Warrants to purchase up to 5,000,000 shares of the Company’s common stock to the Buyers. The Securities Purchase Agreement also established the terms of certain senior secured notes and additional Series B Warrants which may be issued to Starboard in the future. On June 4, 2020, the Company entered into a Supplemental Agreement, as defined below under “Senior Secured Notes”, with certain contractual agreements affecting the Series A Redeemable Convertible Preferred Stock, reflected below.

 

The Series A Redeemable Convertible Preferred Stock can be converted into a number of shares of common stock equal to (i) the stated value thereof plus accrued and unpaid dividends, divided by (ii) the conversion price of $3.65 (subject to certain anti-dilution adjustments). Holders may elect to convert the Series A Redeemable Convertible Preferred Stock into common stock at any time. The Company may elect to convert the Series A Redeemable Convertible Preferred Stock into shares of Common Stock any time on or after November 15, 2025, provided that the closing price of the Company’s common stock equals or exceeds 190% of the conversion price for 30 consecutive trading days and assuming certain other conditions of the common stock have been met.

 

Holders have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock during the periods of May 15, 2021 through August 15, 2021 and May 15, 2022 through August 15, 2022, provided that there is not outstanding at least $50.0 million aggregate principal of senior secured notes to the Buyers pursuant to the Securities Purchase Agreement at the time of the redemption. Holders also have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock during the period of November 15, 2024 through February 15, 2025. Additionally, holders have the option to redeem all or a portion of the Series A Redeemable Convertible Preferred Stock upon the occurrence of (i) a change of control or (ii) various other triggering events, such as the suspension from trading or delisting of the Company’s common stock. If the Series A Redeemable Convertible Preferred Stock is redeemed at the option of the holders, the redemption price may include a make-whole amount or a stated premium, depending on the redemption scenario.

 

The Company may redeem all, and not less than all, of the Series A Redeemable Convertible Preferred Stock (i) upon a change of control or (ii) during the period of May 15, 2022 through August 15, 2022, provided that there is not outstanding at least $50.0 million aggregate principal of the senior secured notes at the time of the redemption, and assuming certain conditions of the common stock have been met. If the Series A Redeemable Convertible Preferred Stock is redeemed at the option of the Company, the redemption price would include a make-whole amount or a 15% premium depending on the circumstances.

 

If any Series A Redeemable Convertible Preferred Stock remains outstanding on November 15, 2027, the Company shall redeem such Series A Redeemable Convertible Preferred Stock in cash.

 

In all redemption scenarios, the redemption price for the Series A Redeemable Convertible Preferred Stock includes the stated value plus accrued and unpaid dividends. In addition, depending on the redemption scenario, the redemption price may also include a make-whole amount or stated premium as described above.

 

When the Company issues Notes, the Holder may exchange the Series A Redeemable Convertible Preferred Stock for (i) Notes and (ii) Series B Warrants to purchase common stock.

 

The Series A Redeemable Convertible Preferred Stock accrues cumulative dividends quarterly at annual rate of 3.0% on the stated value. Upon consummation of the approved investment in June 2020, the dividend rate increased to 8.0% on the stated value. Upon certain triggering events, the dividend rate will increase to 7.0% if the triggering event occurs before an approved investment or 10.0% on the stated value if the triggering event occurs after an approved investment. In connection with the approved investment in June 2020, the Company and the Buyers agreed that the dividend rate on the Series A Redeemable Convertible Preferred Stock would accrue at 3.0% so long as no triggering event occurs and the Company maintains $35.0 million in escrow. Series A Redeemable Convertible Preferred Stock also participates on an as-converted basis in any regular or special dividends paid to common stockholders. No accrued and unpaid dividends as of September 30, 2021. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Upon consummation of the approved acquisition in October 2021, the dividend rate increased to 8.0% on the stated value. Refer to Note 11 for additional information related to the subsequent period acquisition.

 

Holders of the Series A Redeemable Convertible Preferred Stock have the right to vote with common stockholders on an as-converted basis on all matters. Holders of Series A Redeemable Convertible Preferred Stock will also be entitled to a separate class vote with respect to amendments to the Company’s organizational documents that generally have an adverse effect on the Series A Redeemable Convertible Preferred Stock.

 

Upon liquidation of the Company, holders of Series A Redeemable Convertible Preferred Stock have a liquidation preference over holders of our common stock and will be entitled to receive, prior to any distribution to holders of our common stock, an amount equal to the greater of (i) the stated value plus accrued and unpaid dividends or (ii) the amount that would have been received if the Series A Redeemable Convertible Preferred Stock had been converted into common stock immediately prior to the liquidation event at the then effective conversion price.

 

The Company determined that certain features of the Series A Redeemable Convertible Preferred Stock should be bifurcated and accounted for as a derivative. Each of these features are bundled together as a single, compound embedded derivative.

 

During 2019, total proceeds received and transaction costs incurred from the issuance of the Series A Redeemable Convertible Preferred Stock amounted to $35.0 million and $1.3 million, respectively. Proceeds received were allocated based on the fair value of the instrument without the Series A Warrants and of the Series A Warrants themselves at the time of issuance. The proceeds allocated to the Series A Redeemable Convertible Preferred Stock were then further allocated between the host preferred stock instrument and the embedded derivative, with the embedded derivative recorded at fair value and the Series A Redeemable Convertible Preferred Stock recorded at the residual amount. The portion of the proceeds allocated to the Series A Warrants, embedded derivative, and Series A Redeemable Convertible Preferred Stock was $4.8 million, $21.2 million, and $8.9 million, respectively. Transaction costs were also allocated between the Series A Redeemable Convertible Preferred Stock and the Series A Warrants on the same basis as the proceeds. The transaction costs allocated to the Series A Redeemable Convertible Preferred Stock were treated as a discount to the Series A Redeemable Convertible Preferred Stock. The transaction costs allocated to the Series A Warrants were expensed as incurred.

 

The Company classifies the Series A Redeemable Convertible Preferred Stock as mezzanine equity as the instrument will become redeemable at the option of the holder in various scenarios or otherwise on November 15, 2027. As it is probable that the Series A Redeemable Convertible Preferred Stock will become redeemable, the Company accretes the instrument to its redemption value using the effective interest method and recognizes any changes against additional paid in capital in the absence of retained earnings. Accretion for the three and nine months ended September 30, 2021 was $991,000 and $2.8 million, respectively.

 

In connection with the issuance of the Series A Redeemable Convertible Preferred Stock, the Company executed a Registration Rights Agreement with Starboard and the Buyers and a Governance Agreement with Starboard and certain affiliates of Starboard. Under the Registration Rights Agreement, the Company agreed to provide certain registration rights with respect to the Series A Redeemable Convertible Preferred Stock and shares of Common Stock issued upon conversion. In accordance with the Governance Agreement, the Company agreed to (i) increase the size of the Board of Directors from six to seven members, (ii) appoint Jonathan Sagal as a director of the Company, (iii) grant Starboard the right to recommend two additional directors for appointment to the board, (iv) form a Strategic Committee of the Board tasked with sourcing and performing due diligence on potential acquisition targets, (v) appoint certain directors to the Strategic Committee, and (vi) appoint a director to the Nominating and Corporate Governance Committee.

 

The following features of the Series A Redeemable Convertible Preferred Stock are required to be bifurcated from the host preferred stock and accounted for separately as an embedded derivative: (i) the right of the holders to redeem the shares (the “put option”), (ii) the right of the holders to receive common stock upon conversion of the shares (the “conversion option”), (iii) the right of the Company to redeem the shares (the “call option”), and (iv) the change in dividend rate upon consummation of an approved investment or a triggering event (the “contingent dividend rate feature”).

 

These features are required to be accounted for separately from the Series A Redeemable Convertible Preferred Stock because the features were determined to be not clearly and closely related to the debt-like host and also did not meet any other scope exceptions for derivative accounting. Therefore, these features are bundled together and are accounted for as a single, compound embedded derivative liability.

 

Accordingly, we have recorded an embedded derivative liability representing the combined fair value of each of these features. The embedded derivative liability is adjusted to reflect fair value at each period end with changes in fair value recorded other income or (expense) in the “Change in fair value of the Series A and B warrants and embedded derivatives” financial statement line item of the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series A embedded derivative liabilities was $41.4 million and $26.7 million, respectively.

 

Series A Warrants

 

On November 18, 2019, in connection with the issuance of the Series A Redeemable Convertible Preferred Stock, the Company issued a detachable Series A Warrants to acquire up to purchase 5 million shares of common stock at a price of $3.65 per share (subject to certain anti-dilution adjustments) at any time during a period of eight years beginning on the instrument’s issuance date of the Series A Warrants. The fair value of the Series A Warrants was $4.8 million upon issuance. The Series A Warrants will be recognized at fair value at each reporting period until exercised, with changes in fair value recognized in other income or (expense) in the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series A Warrants was $18.5 million and $6.6 million, respectively. As of September 30, 2021, the Series A Warrants have not been exercised.

 

The Series A Warrants are classified as a liability in accordance with ASC 480, “Distinguishing Liabilities from Equity”, as the agreement provides for net cash settlement upon a change in control, which is outside the control of the Company.

 

Series B Warrants

 

On February 25, 2020, pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, the Company issued Series B Warrants to purchase up to 100 million shares of the Company’s common stock at an exercise price (subject to certain price-based anti-dilution adjustments) of either (i) $5.25 per share, if exercising by cash payment, within 30 months from the issuance date (i.e., August 25, 2022); or (ii) $3.65 per share, if exercising by cancellation of a portion of Notes. The Company issued the Series B Warrants for an aggregate purchase price of $4.6 million. The Series B Warrants expire on November 15, 2027.

 

In connection with the issuance of the Notes on June 4, 2020, the terms of certain of the Series B Warrants were amended to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration date of November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms. As of September 30, 2021, the Series B Warrants have not been exercised.

 

The Series B Warrants will be recognized at fair value at each reporting period until exercised, with changes in fair value recognized in other income or (expense) in the consolidated statements of operations. As of September 30, 2021 and December 31, 2020, the fair value of the Series B Warrants was $229.6 million and $52.3 million, respectively.

 

The Series B Warrants are classified as a liability in accordance with ASC 480, “Distinguishing Liabilities from Equity”, as the agreement provides for net cash settlement upon a change in control, which is outside the control of the Company.

 

Senior Secured Notes

 

Pursuant to the Securities Purchase Agreement dated November 18, 2019 with Starboard and the Buyers, on June 4, 2020, the Company issued $115.0 million in Notes to the Buyers. Also on June 4, 2020, in connection with the issuance of the Notes, the Company entered into a Supplemental Agreement with Starboard (the “Supplemental Agreement”), pursuant to which the Company agreed to redeem $80.0 million aggregate principal amount of the Notes by September 30, 2020, and $35.0 million aggregate principal amount of the Notes by December 31, 2020, resulting in the total principal outstanding being paid by December 31, 2020. Per the Supplemental Agreement, interest is payable semiannually at a rate of 6.00% per annum, and in an event of default, the interest rate is increased to 10.00% per annum. The Notes include certain financial and non-financial covenants. Additionally, all or any portion of the principal amount outstanding under the Notes may, at the election of Starboard, be surrendered to the Company for cancellation in payment of the exercise price upon the exercise of Series B Warrants.

 

On June 30, 2020, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with Merton Acquisition HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (“Merton”) and Starboard, on behalf of itself and on behalf of certain funds and accounts under its management, including the holders of the Notes. Pursuant to the Exchange Agreement, the holders of the Notes exchanged the entire outstanding principal amount for new senior notes (the “New Notes”) issued by Merton having an aggregate outstanding original principal amount of $115.0 million.

 

The New Notes bear interest at a rate of 6.00% per annum and had a maturity date of December 31, 2020. The New Notes are fully guaranteed by the Company and are secured by an all-assets pledge of the Company and Merton and non-recourse equity pledges of each of the Company’s material subsidiaries. Pursuant to the Exchange Agreement, the New Notes (i) are deemed to be “Notes” for purposes of the Securities Purchase Agreement, (ii) are deemed to be “June 2020 Approved Investment Notes” for purposes of the Supplemental Agreement, and with the Company agreeing to redeem $80 million principal amount of the New Notes by September 30, 2020 and $35 million principal amount of the New Notes by December 31, 2020, and (iii) are deemed to be “Notes” for the purposes of the Series B Warrants, and therefore may be tendered pursuant to a Note Cancellation under the Series B Warrants on the terms set forth in the Series B Warrants and the New Notes. Delivery of notes in the form of the New Notes will also satisfy the delivery of Exchange Notes pursuant to Section 16(i) of the Certificate of Designations of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share. The New Notes will not be deemed to be “Notes” for the purposes of the Registration Rights Agreement, dated as of November 18, 2019, by and among the Company, Starboard and the Buyers.

 

Because the New Notes are to be settled within twelve months pursuant to their terms, they are classified as current liabilities in the consolidated balance sheets. The Company capitalized $4.6 million in lender fees and $0.5 million in other issuance costs associated with the issuance of the Notes. The $4.6 million of lender fees are recognized as long-term deferred debt issuance costs and are included in other non-current assets in the consolidated balance sheets, and will be amortized to interest expense until November 15, 2027, the maturity date of Series A Redeemable Convertible Preferred Stock. The $0.5 million issuance costs are recognized as a discount on the Notes and will be amortized to interest expense over the contractual life of the Notes. There was $3.1 million and $863,000 accrued and unpaid interest on the New Notes as of September 30, 2021 and December 31, 2020, respectively.

 

On January 29, 2021, the Company redeemed $50.0 million of the New Notes and on March 31, 2021, the Company reissued $50.0 million of the New Notes. On June 30, 2021, the Company issued $30.0 million in additional New Notes (the “June 2021 Merton Notes”) and amended the maturity date of the New Notes to October 15, 2021. On September 30, 2021, the Company issued $35.0 million in additional New Notes (the “September 2021 Merton Notes”) and amended the maturity date of the New Notes to December 1, 2021. The June and September 2021 Merton Notes cannot be used to exercise Series B Warrants issued to Starboard Value. The total principal amount outstanding of New Notes as of September 30, 2021 and December 31, 2020 was $180.0 million and $115.0 million, respectively.

 

Modifications to Series A Redeemable Convertible Preferred Stock and Series B Warrants

 

The June 4, 2020 Supplemental Agreement also provided for (i) a waiver of increased dividends under the original terms of the Series A Redeemable Convertible Preferred Stock that would have otherwise accrued due to the Company’s use of the $35.0 million proceeds received from Starboard and the Buyers upon the issuance of the Series A Redeemable Convertible Preferred Stock in November 2019, (ii) the replacement of original optional redemption rights for the Series A Redeemable Convertible Preferred Stock provided to both the Company and the holders that otherwise would have been nullified through the issuance of the Notes, and (iii) an amendment to the terms of the previously issued Series B Warrants to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration of the Series B Warrants on November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms.

 

We analyzed the amendments to the terms of the Series A Redeemable Convertible Preferred Stock and determined that the amendments were not significant. Therefore, the amendments are accounted for as a modification on a prospective basis.

 

The incremental fair value of the Series B Warrants associated with the modification of their terms in connection with the issuance of the Notes was $1.3 million and is recognized as a discount on the Notes and will be amortized to interest expense over the contractual life of the Notes. As of September 30, 2021, $1.2 million was amortized to interest expense and $151,000 is remaining to be amortized until the maturity date of December 1, 2021.

 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

7. FAIR VALUE MEASUREMENTS

 

U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The three-level hierarchy of valuation techniques established to measure fair value is defined as follows:

 

(i) Level 1 - Observable Inputs:  Quoted prices in active markets for identical investments;

 

(ii) Level 2 - Pricing Models with Significant Observable Inputs:  Other significant observable inputs, including quoted prices for similar investments, interest rates, credit risk, etc.; and

 

(iii) Level 3 - Unobservable Inputs:  Unobservable inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entity’s own assumptions in determining the fair value of derivatives and certain investments.

 

Whenever possible, the Company is required to use observable market inputs (Level 1 - quoted market prices) when measuring fair value. In such cases, the level at which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The assessment of the significance of a particular input requires judgment and considers factors specific to the asset or liability being measured. In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy.

 

Acacia holds the following types of financial instruments at September 30, 2021 and December 31, 2020:

 

Equity Securities at Fair Value. Equity securities includes investments in public company common stock and are recorded at fair value based on the quoted market price of each share on the valuation date. The fair value of these securities are within Level 1 of the valuation hierarchy. Equity investments that do not have regular market pricing, but for which fair value can be determined based on other data values or market prices, are recorded at fair value within Level 2 of the valuation hierarchy. At September 30, 2021, our Level 2 equity securities include an investment measured with an applied pricing model that includes significant observable inputs to the public company common stock value. The fair value of the Level 2 equity securities investment as of September 30, 2021 was estimated based on a discount of 7.5 percent determined using the following significant inputs to the pricing model: expected term of restriction of 6 months and volatility of approximately 45 percent.

 

Investments at Fair Value - Common Stock and Warrants. Acacia’s equity investment in Veritone common stock was recorded at fair value based on the quoted market price of Veritone’s common stock on the applicable valuation date (Level 1). Warrants were recorded at fair value, as based on the Black-Scholes option-pricing model (Level 2). Refer to Note 4 for additional information.

 

Series A Warrants. Series A Warrants are recorded at fair value, using Black-Scholes option-pricing model (Level 3). In the quarter ended March 31, 2021, there was a change in estimate with regard to the calculation of the volatility assumption used in the Black Scholes option-pricing model. As a result, the Series A Warrants are now measured as Level 3 as opposed to Level 2 as measured previously. The fair value of the Series A Warrants as of September 30, 2021 was estimated based on the following significant assumptions: volatility of 30 percent, risk-free rate of 1.16 percent, term of 6.04 years and a dividend yield of 0 percent. 

 

Series B Warrants. Series B Warrants are recorded at fair value, using Black-Scholes option-pricing model (Level 3). In the quarter ended March 31, 2021, there was a change in methodology used to an acceptable Black-Scholes option-pricing model from a Monte Carlo valuation technique used to value the Series B Warrants as of December 31, 2020. The fair value of the Series B Warrants as of September 30, 2021 was estimated based on the following significant assumptions: (1) volatility of 30 percent, risk-free rate of 1.17 percent, term of 6.13 years and a dividend yield of 0 percent, and (2) volatility of 25 percent, risk-free rate of 0.08 percent, term of 0.90 years and a dividend yield of 0 percent.

 

Embedded Derivative Liability. Embedded derivatives that are required to be bifurcated from their host contract are evaluated and valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019 (Level 3). The binomial model utilizes the Tsiveriotis and Fernandes implementation in which a convertible instrument is split into two separate components within a single lattice framework: a cash-only component which is subject to the selected risk-adjusted discount rate and an equity component which is subject only to the risk-free rate. The model considers the (i) implied volatility of the value of our common stock, (ii) appropriate risk-free interest rate, (iii) credit spread, (iv) dividend yield, (v) dividend accrual (and a step-up in rates), and (vi) event probabilities of the various conversion and redemption scenarios.

 

The volatility of the Company’s common stock is estimated by analyzing the Company’s historical volatility, implied volatility of publicly traded stock options, and the Company’s current asset composition and financial leverage. The selected volatility, as described below, represents a haircut from the Company’s actual realized historical volatility. A volatility haircut is a concept used to describe a commonly observed occurrence in which the volatility implied by market prices involving options, warrants, and convertible debt is lower than historical actual realized volatility. The assumed base case term used in the valuation model is the period remaining until November 15, 2027, the Series A Redeemable Convertible Preferred Stock maturity date. The risk-free interest rate is based on the yield on the U.S. Treasury with a remaining term equal to the expected term of the conversion and early redemption options. The significant assumptions utilized in the Company’s valuation of the embedded derivative at September 30, 2021 are as follows: volatility of 30 percent, risk-free rate of 1.20 percent, term of 6.13 years, discount rate of 9.40 percent and a dividend yield of 0 percent. The fair value measurement of the embedded derivative is sensitive to these assumptions and changes in these assumptions could result in a materially different fair value measurement.

 

Financial assets and liabilities measured at fair value on a recurring basis were as follows: 

                    
   Level 1   Level 2   Level 3   Total 
Assets  (In thousands) 
September 30, 2021:                
Equity securities at fair value  $119,280   $267,840   $–   $387,120 
Total  $119,280   $267,840   $–   $387,120 
                     
December 31, 2020:                    
Equity securities at fair value  $109,103   $–   $–   $109,103 
Investment at fair value - warrants   –    2,752    –    2,752 
Total  $109,103   $2,752   $–   $111,855 
                     
Liabilities                    
September 30, 2021:                    
Series A warrants  $–   $–   $18,527   $18,527 
Series A embedded derivative liabilities   –    –    41,411    41,411 
Series B warrants   –    –    229,637    229,637 
Total  $–   $–   $289,575   $289,575 
                     
December 31, 2020:                    
Series A warrants  $–   $6,640   $–   $6,640 
Series A embedded derivative liabilities   –    –    26,728    26,728 
Series B warrants   –    –    52,341    52,341 
Total  $–   $6,640   $79,069   $85,709 

 

The following tables set forth a summary of the changes in the estimated fair value of the Company’s Level 3 liabilities, which are measured at fair value on a recurring basis: 

                    
   Series A
Warrant
Liability		   Series A
Embedded
Derivative
Liability		   Series B
Warrant
Liability		   Total 
   (In thousands) 
                 
Balance at January 1, 2021  $–   $26,728   $52,341   $79,069 
Transfers to Level 3
   6,640    –    –    6,640 
Remeasurement to fair value   11,824    14,463    178,198    204,485 
Balance at June 30, 2021   18,464    41,191    230,539    290,194 
Remeasurement to fair value   63    220    (902)    (619) 
Balance at September 30, 2021  $18,527   $41,411   $229,637   $289,575 

 

   Series A
Warrant
Liability		   Series A
Embedded
Derivative
Liability		   Series B
Warrant
Liability		   Total 
   (In thousands) 
                 
Balance at January 1, 2020  $3,568   $17,974   $–   $21,542 
Transfers to Level 3
   –    –    5,929    5,929 
Remeasurement to fair value   3,384    11,539    52,361    67,284 
Balance at June 30, 2020   6,952    29,513    58,290    94,755 
Remeasurement to fair value   (1,348)   (3,831)   (15,493)    (20,672) 
Balance at September 30, 2020  $5,604   $25,682   $42,797   $74,083 

 

In accordance with U.S. GAAP, from time to time, the Company measures certain assets at fair value on a nonrecurring basis. The Company reviews the carrying value of equity securities without readily determinable fair value, equity method investments and patents on a quarterly basis for indications of impairment, and other long-lived assets at least annually. When indications of potential impairment are identified, the Company may be required to determine the fair value of those assets and record an adjustment for the carrying amount in excess of the fair value determined. Any fair value determination would be based on valuation approaches, which are appropriate under the circumstances and utilize Level 2 and Level 3 measurements as required.

 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

8. COMMITMENTS AND CONTINGENCIES

 

Facility Leases

 

The Company primarily leases office facilities under operating lease arrangements that will end in various years through July 2024.

 

On June 7, 2019, we entered into a building lease agreement (the “New Lease”) with Jamboree Center 4 LLC (the “Landlord”). Pursuant to the New Lease, we have leased approximately 8,293 square feet of office space in Irvine, California. The New Lease commenced on August 1, 2019. The term of the New Lease is 60 months from the commencement date, provides for annual rent increases, and does not provide us the right to early terminate or extend our lease terms.

  

On January 7, 2020, we entered into a building lease agreement (the “New York Office Lease”) with Sage Realty Corporation (the “New York Office Landlord”). Pursuant to the New York Office Lease, we have leased approximately 4,000 square feet of office space for our corporate headquarters in New York, New York. The New York Office Lease commenced on February 1, 2020. The term of the New York Office Lease is 24 months from the commencement date, provides for annual rent increases, and does not provide us the right to early terminate or extend our lease terms. During August 2021, we entered into a first amendment of the New York Office Lease, to commence for a period of three years upon landlords’ substantial completion of adequate substitution space, as defined. To date, the substitution space is not ready for use, accordingly the term extension has not begun.

 

Operating lease costs were $155,000 and $174,000 for the three months ended September 30, 2021 and 2020, respectively, and $457,000 and $459,000 for the nine months ended September 30, 2021 and 2020, respectively.

 

The table below presents aggregate future minimum payments due under the New Lease and the New York Office Lease discussed above, reconciled to long-term lease liabilities and short-term lease liabilities (included in accrued expenses and other current liabilities) included in the consolidated balance sheet as of September 30, 2021:

     
   Operating Leases 
   (In thousands) 
Remainder of 2021  $149 
2022   370 
2023   364 
2024   218 
Thereafter   – 
Total minimum payments   1,101 
Less: short-term lease liabilities   (430)
Long-term lease liabilities  $671 

 

Inventor Royalties and Contingent Legal Expenses

 

In connection with the investment in certain patents and patent rights, certain of Acacia’s operating subsidiaries executed related agreements which grant to the former owners of the respective patents or patent rights, the right to receive inventor royalties based on future net revenues (as defined in the respective agreements) generated as a result of licensing and otherwise enforcing the respective patents or patent portfolios.

 

Acacia’s operating subsidiaries may retain the services of law firms that specialize in patent licensing and enforcement and patent law in connection with their licensing and enforcement activities. These law firms may be retained on a contingent fee basis whereby such law firms are paid on a scaled percentage of any negotiated fees, settlements or judgments awarded based on how and when the fees, settlements or judgments are obtained.

 

Patent Enforcement

 

Certain of Acacia’s operating subsidiaries are often required to engage in litigation to enforce their patents and patent rights. In connection with any of Acacia’s operating subsidiaries’ patent enforcement actions, it is possible that a defendant may request and/or a court may rule that an operating subsidiary has violated statutory authority, regulatory authority, federal rules, local court rules, or governing standards relating to the substantive or procedural aspects of such enforcement actions. In such event, a court may issue monetary sanctions against Acacia or its operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material.

 

Acacia is subject to claims, counterclaims and legal actions that arise in the ordinary course of business. Management believes that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on Acacia’s consolidated financial position, results of operations or cash flows.

 

In December 2017, the Federal Court of Canada allowed a counterclaim for invalidity of a patent asserted by Rapid Completions LLC and awarded costs payable by Rapid Completions LLC in amounts that are included in the 2021 and 2020 accrual balances discussed below. During the three months ended September 30, 2021, the Company made approximately $1.0 million in settlement payments.

 

On September 6, 2019, Slingshot Technologies, LLC, or Slingshot, filed a lawsuit in Delaware Chancery Court against the Company and Acacia Research Group, LLC, or collectively, the Acacia Entities, Monarch Networking Solutions LLC (“Monarch”), Acacia board member Katharine Wolanyk, and Transpacific IP Group, Ltd., or Transpacific. Slingshot alleges that the Acacia Entities and Monarch misappropriated its confidential and proprietary information, purportedly furnished to the Acacia Entities and Monarch by Ms. Wolanyk, in acquiring a patent portfolio from Transpacific after Slingshot’s exclusive option to purchase the same patent portfolio from Transpacific had already expired. Slingshot seeks monetary damages, as well as equitable and injunctive relief related to its alleged right to own the portfolio. On March 15, 2021, the court issued orders granting Monarch’s motion to dismiss for lack of personal jurisdiction and Ms. Wolanyk’s motion to dismiss for lack of subject matter jurisdiction. The remaining parties then commenced discovery, and have since served initial written requests and responses, and notices of the depositions of the parties’ corporate designees. The Acacia Entities maintain that Slingshot’s allegations are baseless, that the Acacia Entities neither had access to nor used Slingshot’s information in acquiring the portfolio, that the Acacia Entities acquired the portfolio as a result of the independent efforts of its IP licensing group, and that Slingshot suffered no damages given its exclusive option to purchase the portfolio had already ended and it has proven itself incapable of closing on the portfolio purchase.

 

During the three months ended September 30, 2021 and 2020, there were no operating expenses related to settlement and contingency accruals. During the nine months ended September 30, 2021, we incurred $338,000 in operating expenses for settlement and contingency accruals. During the nine months ended September 30, 2020, operating expenses included a net income for settlement offset by contingency accruals totaling $308,000, net of prior accruals. At September 30, 2021 and December 31, 2020, our contingency accrual balance was $587,000 and $1.3 million, respectively.

 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ EQUITY
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

9. STOCKHOLDERS’ EQUITY

 

Repurchases of Common Stock

 

On August 5, 2019, Acacia’s Board of Directors approved a stock repurchase program, which authorized the purchase of up to $10.0 million of the Company’s common stock through open market purchases, through block trades, through 10b5-1 plans, or by means of private purchases, from time to time, through July 31, 2020. Stock repurchases for the periods presented, all of which were purchased as part of a publicly announced plan or program, were as follows: 

                  
   Total Number
of Shares
Purchased		   Average
Price
paid per
Share		   Approximate
Dollar
Value of Shares
that
May Yet be
Purchased
under the
Program		   Plan Expiration Date
                
March 20, 2020 - March 31, 2020   576,898   $2.28   $8,686,000   July 31, 2020
April 1, 2020 - April 23, 2020   1,107,639   $2.42   $6,001,000   July 31, 2020
Total repurchases in 2020   1,684,537   $2.37         

 

In determining whether or not to repurchase any shares of Acacia’s common stock, Acacia’s Board of Directors consider such factors, among others, as the impact of the repurchase on Acacia’s cash position, as well as Acacia’s capital needs and whether there is a better alternative use of Acacia’s capital. Acacia has no obligation to repurchase any amount of its common stock under the Stock Repurchase Program. Repurchases to date were made in the open market in compliance with applicable SEC rules. The authorization to repurchase shares presented an opportunity to reduce the outstanding share count and enhance stockholder value. 

 

Tax Benefits Preservation Plan

 

On March 12, 2019, Acacia’s Board of Directors announced that it had unanimously approved the adoption of a Tax Benefits Preservation Plan (the “Plan”). Our stockholders ratified the adoption of the Plan in July 2019. The purpose of the Plan is to protect the Company’s ability to utilize potential tax assets, such as net operating loss carryforwards and tax credits to offset potential future taxable income.

 

The Plan is designed to reduce the likelihood that the Company will experience an ownership change by discouraging (i) any person or group from acquiring beneficial ownership of 4.9% or more of the Company’s outstanding common stock and (ii) any existing stockholders who, as of the time of the first public announcement of the adoption of the Plan, beneficially own more than 4.9% of the Company’s then-outstanding shares of the Company’s common stock from acquiring additional shares of the Company’s common stock (subject to certain exceptions). There is no guarantee, however, that the Plan will prevent the Company from experiencing an ownership change.

 

In connection with the adoption of the Plan, Acacia’s Board of Directors authorized and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on March 16, 2019. On or after the distribution date, each right would initially entitle the holder to purchase one one-thousandth of a share of the Company’s Series B Junior Participating Preferred Stock, $0.001 par value for a purchase price of $12.00. On March 15, 2021 the rights expired pursuant to their terms.

 

The Company has a provision in its Amended and Restated Certificate of Incorporation, as amended (the “Charter Provision”) which generally prohibits transfers of its common stock that could result in an ownership change. Like the Plan, the purpose of the Charter Provision is to protect the Company’s ability to utilize potential tax assets, such as net operating loss carryforwards and tax credits to offset potential future taxable income. The Charter Provision was approved by the Company’s stockholders on July 15, 2019.

  
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME/LOSS PER SHARE
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
INCOME/LOSS PER SHARE

10. INCOME/LOSS PER SHARE

 

The following table presents the shares of common stock outstanding used in the calculation of basic and diluted net income (loss) per share: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands, except share and per share information) 
Numerator:                
Net income (loss) attributable to Acacia Research Corporation  $89,604   $38,348   $(55,507)  $33,205 
Dividend on Series A redeemable convertible preferred stock   (262)   (467)   (785)   (1,118)
Accretion of Series A redeemable convertible preferred stock   (991)   (733)   (2,762)   (2,045)
Undistributed earnings allocated to participating securities   (15,367)   (6,619)   –    (5,204)
Net income (loss) attributable to common stockholders - Basic   72,984    30,529    (59,054)   24,838 
                     
Add: Dividend on Series A redeemable convertible preferred stock   –    467    –    – 
Add: Accretion of Series A redeemable convertible preferred stock   –    733    –    – 
Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative   –    (3,831)   –    – 
Less: Change in fair value of Series A warrants   63    (1,348)   –    (1,348)
Less: Change in fair value of dilutive Series B warrants   (902)   (5,557)   –    (5,557)
Add: Interest expense associated with Starboard Notes, net of tax   1,536    1,889    –    1,889 
Add: Undistributed earnings allocated to participating securities   15,367    6,619    –    5,204 
Reallocation of undistributed earnings to participating securities   (8,877)   (296)   –    (3,645)
Net income (loss) attributable to common stockholders - Diluted  $80,171   $29,205   $(59,054)  $21,381 
                     
Denominator:                    
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic   48,949,504    48,467,885    48,759,873    48,949,706 
Potentially dilutive common shares:                    
Series A Preferred Stock   –    9,589,041    –    – 
Restricted stock   798,356    728,936    –    598,328 
Stock options   35,815    21,624    –    – 
Series A Warrants   2,019,724    310,367    –    103,456 
Series B Warrants   41,278,103    31,506,849    –    10,502,283 
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted   93,081,502    90,624,702    48,759,873    60,153,773 
                     
Basic net income (loss) per common share  $1.49   $0.63   $(1.21)  $0.51 
Diluted net income (loss) per common share  $0.86   $0.32   $(1.21)  $0.36 
                     
Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:                    
Equity-based incentive awards   398,168    191,312    2,230,624    310,083 
Series A warrants   –    –    5,000,000    – 
Series B warrants   –    68,493,151    100,000,000    68,493,151 
Total   398,168    68,684,463    107,230,624    68,803,234 

 
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENT
 9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENT

11. SUBSEQUENT EVENT

 

On October 8, 2021, the Company acquired all of the outstanding stock of a leading printing technology company, for a cash purchase price of $37.0 million, which includes an initial $33.0 million cash payment and a $4.0 million working capital adjustment. The business services a diverse group of customers that operate across healthcare, food and beverage, manufacturing and logistics, and other sectors. The acquisition triggered the release of $35.0 million held in escrow (refer to Note 2 “Long-Term Restricted Cash” for additional information).

 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.21.2
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)
 9 Months Ended
Sep. 30, 2021
Description Of Business And Basis Of Presentation  
Description of Business

Description of Business

 

As used herein, “we,” “us,” “our,” “Acacia” and the “Company” refer to Acacia Research Corporation and/or its wholly and majority-owned and controlled operating subsidiaries, and/or where applicable, its management.

 

Acacia was incorporated on January 25, 1993 under the laws of the State of California. In December 1999, Acacia changed its state of incorporation from California to Delaware.

 

Acacia acquires businesses and operating assets that the Company believes to be undervalued and where the Company believes it can leverage its resources and skill sets to realize and unlock value. The Company intends to leverage its (i) access to flexible capital that can be deployed unconditionally, (ii) expertise in corporate governance and operational restructuring, (iii) willingness to invest in out of favor industries and businesses that suffer from a complexity discount and untangle complex, multi-factor situations, and (iv) expertise and relationships in certain sectors, to complete strategic acquisitions of businesses, divisions, and/or assets with a focus on mature technology, healthcare, industrial and certain financial segments. Acacia seeks to identify opportunities where the Company believes it is an advantaged buyer, where the Company can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to the Company’s unique capabilities, relationships, or expertise, or where Acacia believes the target would be worth more to the Company than to other buyers.

 

Acacia operates its business based on three key principles of People, Process and Performance and has built a management team with identified expertise in Research, Execution and Operation of the Company’s targeted acquisitions.

 

Acacia, through its operating subsidiaries, also currently engages in its legacy business of investing in, licensing and enforcing patented technologies. Acacia’s operating subsidiaries partner with inventors and patent owners, applying their legal and technology expertise to patent assets to unlock the financial value in their patented inventions. In recent years, Acacia has also invested in technology companies. Acacia leverages its experience, expertise, data and relationships developed as a leader in the intellectual property (“IP”) industry to pursue these opportunities. In some cases, these opportunities will complement and/or supplement Acacia’s primary licensing and enforcement business.

 

Acacia’s operating subsidiaries generate revenues and related cash flows from the granting of IP rights (hereinafter, “IP Rights”) for the use of patented technologies that its operating subsidiaries control or own. Acacia’s operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation.

 

Acacia’s operating subsidiaries are principals in the licensing and enforcement effort, obtaining control of the rights in the patent portfolio, or control of the patent portfolio outright. Acacia’s operating subsidiaries own or control the rights to multiple patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.

 

Neither Acacia nor its operating subsidiaries invent new technologies or products; rather, Acacia depends upon the identification and investment in new patents, inventions and companies that own IP through its relationships with inventors, universities, research institutions, technology companies and others. If Acacia’s operating subsidiaries are unable to maintain those relationships and identify and grow new relationships, then they may not be able to identify new technology-based opportunities for sustainable revenue and/or revenue growth.

 

During the nine months ended September 30, 2021, Acacia obtained control of one new patent portfolio. During fiscal year 2020, Acacia obtained control of five new patent portfolios.

 
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

  

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures required by U.S. GAAP in annual financial statements have been omitted or condensed in accordance with quarterly reporting requirements of the Securities and Exchange Commission (“SEC”). These interim unaudited condensed consolidated financial statements and notes hereto should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2020, as reported by Acacia in its Annual Report on Form 10-K filed with the SEC on March 29, 2021, as well as in our other public filings with the SEC. The condensed consolidated interim financial statements of Acacia include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of Acacia’s consolidated financial position as of September 30, 2021, and results of its operations and its cash flows for the interim periods presented. The consolidated results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the entire fiscal year.

 

Reclassifications

 

Certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated results of operations or cash flows.

  
COVID-19 Pandemic

COVID-19 Pandemic

 

The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. While the Company does not expect the current situation to present direct risks to its business, and it has not had a material impact to date, the COVID-19 pandemic could adversely impact the Company’s operations, as well as the operations of its licensees and other business partners. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, results of operations and financial condition.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Accounting Principles

Accounting Principles

 

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. GAAP.

 
Principles of Consolidation

Principles of Consolidation

 

The accompanying unaudited consolidated financial statements include the accounts of Acacia and its wholly and majority-owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

 

Noncontrolling interests in Acacia’s majority-owned and controlled operating subsidiaries (“noncontrolling interests”) are separately presented as a component of stockholders’ equity. Consolidated net income or (loss) is adjusted to include the net (income) or loss attributed to noncontrolling interests in the consolidated statements of operations. Refer to the accompanying Consolidated Statements of Series A Redeemable Convertible Preferred Stock and Stockholders’ Equity for total noncontrolling interests.

 

In 2020, in connection with the transaction with Link Fund Solutions Limited, which is more fully described in Note 3, the Company acquired equity securities of Malin J1 Limited (“MalinJ1”). MalinJ1 is included in the Company’s consolidated financial statements because the Company, through its interest in the equity securities of MalinJ1, has the ability to control the operations and activities of MalinJ1. Viamet HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of Acacia, is the majority shareholder of MalinJ1.

 

A wholly-owned subsidiary of Acacia is the general partner of the Acacia Intellectual Property Fund, L.P. (the “Acacia IP Fund”), which was formed in August 2010. The Acacia IP Fund has been included in the Company’s consolidated financial statements since 2010, as Acacia’s wholly-owned subsidiary, the general partner of Acacia IP Fund, has the ability to control the operations and activities of the Acacia IP Fund. The Acacia IP Fund was terminated as of December 31, 2017 and dissolved in 2020.

 
Segment Reporting

Segment Reporting

 

Acacia uses the management approach, which designates the internal organization that is used by management for making operating decisions and assessing performance as the basis of Acacia’s reportable segments. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Acacia believes that, of the significant accounting policies described herein, the accounting policies associated with revenue recognition, the valuation of the equity instruments, the valuation of Series A redeemable convertible preferred stock (the “Series A Redeemable Convertible Preferred Stock”), embedded derivatives, Series A warrants (the “Series A Warrants”), Series B warrants (the “Series B Warrants”), stock-based compensation expense, impairment of patent-related intangible assets, the determination of the economic useful life of amortizable intangible assets, income taxes and valuation allowances against net deferred tax assets, require its most difficult, subjective or complex judgments.

 
Revenue Recognition

Revenue Recognition

 

Revenue is recognized upon transfer of control (i.e., by the granting) of promised bundled IP Rights and other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive in exchange for those IP Rights. Revenue contracts that provide promises to grant the right to use IP Rights as they exist at the point in time at which the IP Rights are granted, are accounted for as performance obligations satisfied at a point in time and revenue is recognized at the point in time that the applicable performance obligations are satisfied and all other revenue recognition criteria have been met.

 

For the periods presented, revenue contracts executed by the Company primarily provided for the payment of contractually determined, one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technologies owned or controlled by Acacia. Revenues also included license fees from sales-based revenue contracts, the majority of which were originally executed in prior periods, which provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees (“Recurring Revenue Agreements”). Revenues may also include court ordered settlements or awards related to our patent portfolio or sales of our patent portfolio. IP Rights granted included the following, as applicable: (i) the grant of a non-exclusive, future license to manufacture and/or sell products covered by patented technologies, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. The IP Rights granted were generally perpetual in nature, extending until the legal expiration date of the related patents. The individual IP Rights are not accounted for as separate performance obligations, as (i) the nature of the promise, within the context of the contract, is to grant combined items to which the promised IP Rights are inputs and (ii) the Company's promise to grant each individual IP right described above to the customer is not separately identifiable from other promises to grant IP Rights in the contract.

 

Since the promised IP Rights are not individually distinct, the Company combined each individual IP Right in the contract into a bundle of IP Rights that is distinct, and accounted for all of the IP Rights promised in the contract as a single performance obligation. The IP Rights granted were “functional IP rights” that have significant standalone functionality. Acacia’s subsequent activities do not substantively change that functionality and do not significantly affect the utility of the IP to which the licensee has rights. Acacia’s operating subsidiaries have no further obligation with respect to the grant of IP Rights, including no express or implied obligation to maintain or upgrade the technology, or provide future support or services. The contracts provide for the grant of the licenses, covenants-not-to-sue, releases, and other significant deliverables upon execution of the contract. Licensees legally obtain control of the IP Rights upon execution of the contract. As such, the earnings process is complete and revenue is recognized upon the execution of the contract, when collectability is probable and all other revenue recognition criteria have been met. Revenue contracts generally provide for payment of contractual amounts within 15-90 days of execution of the contract, or the end of the quarter in which the sale or usage occurs for Recurring Revenue Agreements. Contractual payments made by licensees are generally non-refundable.

 

For sales-based royalties, the Company includes in the transaction price some or all of an amount of estimated variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Notwithstanding, revenue is recognized for a sales-based royalty promised in exchange for a license of IP Rights when the later of (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied. Estimates are generally based on historical levels of activity, if available.

 

Revenues from contracts with significant financing components (either explicit or implicit) are recognized at an amount that reflects the price that a licensee would have paid if the licensee had paid cash for the IP Rights when they are granted to the licensee. In determining the transaction price, the Company adjusts the promised amount of consideration for the effects of the time value of money. As a practical expedient, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the entity grants promised IP Rights to a customer and when the customer pays for the IP Rights will be one year or less.

 

In general, the Company is required to make certain judgments and estimates in connection with the accounting for revenue contracts with customers. Such areas may include identifying performance obligations in the contract, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services, evaluating whether a license transfers to a customer at a point in time or over time, allocating the transaction price to separate performance obligations, determining whether contracts contain a significant financing component, and estimating revenues recognized at a point in time for sales-based royalties.

 

Revenues were comprised of the following for the periods presented: 

                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Paid-up revenue agreements  $1,100   $19,385   $23,110   $24,477 
Recurring Revenue Agreements   482    81    1,675    922 
Total revenue  $1,582   $19,466   $24,785   $25,399 

 

Refer to “Inventor Royalties and Contingent Legal Expenses” below for information on related direct costs of revenues.

  
Patent Portfolio Operations

Patent Portfolio Operations

 

Cost of revenues include the costs and expenses incurred in connection with Acacia’s patent licensing and enforcement activities, including inventor royalties paid to original patent owners, patent maintenance and prosecution costs, contingent legal fees paid to external patent counsel, other patent-related legal expenses paid to external patent counsel, licensing and enforcement related research, consulting and other expenses paid to third-parties and the amortization of patent-related investment costs. These costs are included under the caption “Patent portfolio operations” in the consolidated statements of operations. 

 

Inventor Royalties and Contingent Legal Expenses

 

Inventor royalties are expensed in the consolidated statements of operations in the period that the related revenues are recognized. Patent costs, including any upfront advances paid to patent owners by Acacia’s operating subsidiaries, that are recoverable from future net revenues are amortized over the estimated economic useful life of the related patents, or as the prepaid royalties are earned by the inventor, as appropriate, and the related expense is included in amortization expense in the consolidated statements of operations. Any unamortized upfront advances recovered from net revenues are expensed in the period recovered and included in amortization expense in the consolidated statements of operations.

 

Contingent legal fees are expensed in the consolidated statements of operations in the period that the related revenues are recognized. In instances where there are no recoveries from potential infringers, no contingent legal fees are paid; however, Acacia’s operating subsidiaries may be liable for certain out of pocket legal costs incurred pursuant to the underlying legal services agreement.

 

Inventor royalty and contingent legal agreements generally provide for payment by the Company of contractual amounts 30 days subsequent to the fiscal quarter end during which related license fee payments are received from licensees by the Company.

 
Concentrations

Concentrations

 

Financial instruments that potentially subject Acacia to concentrations of credit risk are cash equivalents, equity securities and accounts receivable. Acacia places its cash equivalents and equity securities primarily in highly rated money market funds and investment grade marketable securities. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. Acacia has not experienced any significant losses on its deposits of cash and cash equivalents.

 

Four licensees individually accounted for 32%, 25%, 22% and 13% of revenues recognized during the three months ended September 30, 2021, and one licensee accounted for 98% of revenues recognized during the three months ended September 30, 2020. Three licensees individually accounted for 50%, 19% and 12% of revenues recognized during the nine months ended September 30, 2021, and two licensees accounted for 75% and 9% of revenues recognized during the nine months ended September 30, 2020.

 

The Company does not have any material foreign operations. Based on the jurisdiction of the entity obligated to satisfy payment obligations pursuant to the applicable revenue arrangement, for the three and nine months ended September 30, 2021, 8% and 15%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions. For the three and nine months ended September 30, 2020, 0.1% and 5%, respectively, of revenues were attributable to licensees domiciled in foreign jurisdictions.

 

Two licensees represented 100% of accounts receivable at September 30, 2021. Two licensees individually represented approximately 62% and 21% of accounts receivable at December 31, 2020.

 
Related Party Transactions

Related Party Transactions

 

During 2019, the Company purchased shares of common stock of Drive Shack, Inc. (“Drive Shack”) for an aggregate purchase price of $2.4 million. At the time, Drive Shack and Clifford Press, Chief Executive Officer and director of Acacia, were related parties as Mr. Press was a board member of Drive Shack until June 2021. The market value of the investment was $1.4 million as of December 31, 2020. During the nine months ended September 30, 2021, the Company sold its investment receiving proceeds of $1.8 million and recognized a loss of $515,000.

  
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Acacia considers all highly liquid, equity securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, Acacia’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily includes: domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Acacia’s cash equivalents are measured at fair value using observable inputs.

 
Equity Securities at Fair Value

Equity Securities at Fair Value

 

Investments in equity securities are reported at fair value on a recurring basis, with related realized and unrealized gains and losses in the value of such securities recorded in the consolidated statements of operations in other income or (expense). Dividend income is included in the consolidated statements of operations in other income or (expense). Refer to Note 7 for additional information related to fair value measurements.

 

Equity securities at fair value for the periods presented were comprised of the following: 

                    
Security Type  Cost   Gross
Unrealized
Gain		   Gross
Unrealized
Loss		   Fair Value 
   (In thousands) 
September 30, 2021:                
Equity securities - Life Sciences Portfolio (Note 3)  $62,042   $288,508   $(1,812)  $348,738 
Equity securities - other equity   35,178    3,289    (85)   38,382 
Total  $97,220   $291,797   $(1,897)  $387,120 
                     
December 31, 2020:                    
Equity securities - Life Sciences Portfolio (Note 3)  $32,765   $72,689   $(583)  $104,871 
Equity securities - other equity   4,086    1,410    (1,264)   4,232 
Total  $36,851   $74,099   $(1,847)  $109,103 

 
Equity Securities Without Readily Determinable Fair Value

Equity Securities Without Readily Determinable Fair Value

 

For equity securities that do not have readily determinable fair value, the Company elected to report them under the measurement alternative. They are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. The fair values of the private company securities were estimated based on recent financing transactions and secondary market transactions and factoring in any adjustments for illiquidity or preference of these securities. Changes in fair value are reported in the consolidated statements of operations in other income or (expense). Refer to Note 3 for additional information.

 
Equity Method Investments

Equity Method Investments

 

Equity investments in common stock and in-substance common stock without readily determinable fair values in companies over which the Company has the ability to exercise significant influence, are accounted for using the equity method of accounting. Acacia includes its proportionate share of earnings and/or losses of its equity method investees in earnings on equity investment in joint venture in the consolidated statements of operations. Refer to Note 3 for additional information.

 
Investment at Fair Value

Investment at Fair Value

 

On an individual investment basis, Acacia may elect to account for investments in companies where the Company has the ability to exercise significant influence over operating and financial policies of the investee, at fair value. If the fair value method is applied to an investment that would otherwise be accounted for under the equity method of accounting, it is applied to all of the financial interests in the same entity that are eligible items (i.e., common stock and warrants). We elected the fair value method for our investment in Veritone, Inc. (“Veritone”) upon acquisition of the investment. Since March 2021, we have no more investment in Veritone stocks and warrants. Refer to Note 4 for additional information.

 
Impairment of Investments

Impairment of Investments

 

Acacia reviews its investments quarterly for indicators of other-than-temporary impairment. This determination requires significant judgment. In making this judgment, Acacia considers available quantitative and qualitative evidence in evaluating potential impairment of its investments. If the cost of an investment exceeds its fair value, Acacia evaluates, among other factors, general market conditions and the duration and extent to which the fair value is less than cost. Acacia also considers specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of operations and a new cost basis in the investment is established.

 
Long-Term Restricted Cash

Long-Term Restricted Cash

 

Restricted cash relates primarily to the proceeds received from the issuance of Series A Redeemable Convertible Preferred Stock which are held in an escrow account (refer to Note 6). The amounts are to be released to the Company upon, among other things, (i) the consummation of a suitable investment or acquisition by the Company or (ii) the conversion of Series A Redeemable Convertible Preferred Stock into common stock. During October 2021, the Company consummated a suitable acquisition, accordingly $35.0 million was released to the Company. Refer to Note 11 for additional information related to the subsequent period acquisition.

 
Patents

Patents

 

Patents include the cost of patents or patent rights acquired from third-parties or obtained in connection with business combinations. Patent costs are amortized utilizing the straight-line method over their remaining economic useful lives. Refer to Note 5 for additional information.

 
Impairment of Long-lived Assets

Impairment of Long-lived Assets

 

Acacia reviews long-lived assets and intangible assets for potential impairment annually (quarterly for patents) and when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. In the event the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss is recorded in an amount equal to the excess of the asset’s carrying value over its fair value. If an asset is determined to be impaired, the loss is measured based on quoted market prices in active markets, if available. If quoted market prices are not available, the estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. In the event that management decides to no longer allocate resources to a patent portfolio, an impairment loss equal to the remaining carrying value of the asset is recorded. Refer to Note 5 for additional information.

 

Fair value is generally estimated using the “Income Approach,” focusing on the estimated future net income-producing capability of the patent portfolios over their estimated remaining economic useful life. Estimates of future after-tax cash flows are converted to present value through “discounting,” including an estimated rate of return that accounts for both the time value of money and investment risk factors. Estimated cash inflows are typically based on estimates of reasonable royalty rates for the applicable technology, applied to estimated market data. Estimated cash outflows are based on existing contractual obligations, such as contingent legal fee and inventor royalty obligations, applied to estimated license fee revenues, in addition to other estimates of out-of-pocket expenses associated with a specific patent portfolio’s licensing and enforcement program. The analysis also contemplates consideration of current information about the patent portfolio including, status and stage of litigation, periodic results of the litigation process, strength of the patent portfolio, technology coverage and other pertinent information that could impact future net cash flows.

 
Series A and B Warrants

Series A and B Warrants

 

The fair value of the Series A and B Warrants are estimated using a Black-Scholes option-pricing model. Refer to Notes 6 and 7 for additional information related to the Series A and B Warrants and their fair value measurements.

 
Embedded derivatives

Embedded derivatives

 

Embedded derivatives that are required to be bifurcated from their host contract are valued separately from the host instrument. A binomial lattice framework is used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock issued by the Company in 2019. Refer to Notes 6 and 7 for additional information related to the embedded derivatives and their fair value measurements.

 
Fair Value Measurements

Fair Value Measurements

 

U.S. GAAP defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date, and also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. Refer to Note 7 for additional information.

 
Treasury Stock

Treasury Stock

 

Repurchases of the Company’s outstanding common stock are accounted for using the cost method. The applicable par value is deducted from the appropriate capital stock account on the formal or constructive retirement of treasury stock. Any excess of the cost of treasury stock over its par value is charged to additional paid-in capital and reflected as treasury stock in the consolidated balance sheets. Refer to Note 9 for additional information.

 
Stock-Based Compensation

Stock-Based Compensation

 

The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which is generally one to three years. The fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) are determined by the product of the number of shares or units granted and the grant date market price of the underlying common stock. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing model. Forfeitures are accounted for as they occur.

 

RSUs granted in September 2019 with market-based vesting conditions vest based upon the Company achieving specified stock price targets over a three-year period. The effect of a market condition is reflected in the estimate of the grant-date fair value of the options utilizing a Monte Carlo valuation technique. Compensation cost is recognized with a market-based vesting condition provided that the requisite service is rendered, regardless of when, if ever, the market condition is satisfied. Assumptions utilized in connection with the Monte Carlo valuation technique, that resulted in a fair value of $1.42 per unit, included: estimated risk-free interest rate of 1.38 percent; term of 3.00 years; expected volatility of 38 percent; and expected dividend yield of 0 percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues. The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations regarding dividend payments. During the nine months ended September 30, 2021, 450,000 RSUs were forfeited, leaving 450,000 units with market-based vesting conditions outstanding and unvested at period end.

 

During the nine months ended September 30, 2021, the Company granted 324,401 RSAs at a weighted average grant-date fair value of $5.56 per share, 473,000 RSUs at a weighted average grant-date fair value of $5.86 per unit and 393,750 non-qualified stock options at a grant-date fair value of $1.79 per share.

 

Stock-based compensation is reported in the consolidated statements of operations in general and administrative expenses. Total stock-based compensation for the three and nine months ended September 30, 2021 was $300,000 and $1,279,000, respectively. Total unrecognized stock-based compensation expense as of September 30, 2021 was $5,952,000, which will be amortized over a weighted average remaining vesting period of 2.20 years. Total stock-based compensation for the three and nine months ended September 30, 2020 was $488,000 and $1,243,000, respectively.

 

Profits Interest Units (“PIUs”) were accounted for in accordance with Accounting Standards Codification (“ASC”) 718-10, “Compensation - Stock Compensation.” The vesting conditions did not meet the definition of service, market or performance conditions, as defined in ASC 718. As such, the PIUs were classified as liability awards. Compensation expense was adjusted for changes in fair value prorated for the portion of the requisite service period rendered. Initially, compensation expense was recognized on a straight-line basis over the employee’s requisite service period (generally the vesting period of the equity award) which was five years. Upon full vesting of the award, which occurred during the three months ended September 30, 2017, previously unrecognized compensation expense was immediately recognized in the period. The Company has a purchase option to purchase the vested PIUs that are not otherwise forfeited after termination of continuous service. The exercise price of the purchase option is the fair market value of the PIUs on the date of termination of continuous service. The individuals holding PIUs are no longer employed by the Company. Included in other long-term liabilities in the consolidated balance sheets as of September 30, 2021 and December 31, 2020, the PIUs totaled $591,000, which was their fair value as of December 31, 2018 after termination of service.

 
Income Taxes

Income Taxes

 

Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in Acacia’s consolidated financial statements or consolidated income tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized, or if it is determined that there is uncertainty regarding future realization of such assets.

 

The provision for income taxes for interim periods is determined using an estimate of Acacia’s annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, Acacia updates the estimate of the annual effective tax rate, and if the estimated tax rate changes, a cumulative adjustment is recorded.

 

The Company’s effective tax rates were 0% and (1%) for the three and nine months ended September 30, 2021, respectively, and 0% and (4%) for the three and nine months ended September 30, 2020, respectively. Tax expense/benefit for the periods presented primarily reflects the impact of state taxes and foreign tax withholding (or refund) incurred on revenue agreements executed with third-party licensees domiciled in foreign jurisdictions. The Company has recorded a full valuation allowance against our net deferred tax assets as of September 30, 2021 and December 31, 2020. These assets primarily consist of foreign tax credits, capital loss carryforwards and net operating loss carryforwards.

  
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Recently Adopted

 

In December of 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” The update removed certain exceptions to the general principles in Topic 740 in U.S. GAAP. The Company adopted the update on January 1, 2021. The adoption of the update did not have a material effect on the Company’s financial position, results of operations or financial statement disclosures.

 

Not Yet Adopted

 

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” to replace the incurred loss methodology with an expected credit loss model that requires consideration of a broader range of information to estimate credit losses over the lifetime of the asset, including current conditions and reasonable and supportable forecasts in addition to historical loss information, to determine expected credit losses. Pooling of assets with similar risk characteristics and the use of a loss model are also required. Also, in April 2019, the FASB issued ASU No. 2019-04, “Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,” to clarify the inclusion of recoveries of trade receivables previously written off when estimating an allowance for credit losses. The amendments in these updates will currently be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in these updates may have on the Company’s consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” to simplify the accounting for convertible instruments by eliminating large sections of the existing guidance in this area. It also eliminates several triggers for derivative accounting, including a requirement to settle certain contracts by delivering registered shares. This update reduces the number of accounting models for convertible instruments, revises the derivatives scope exception, and provides targeted improvements for earnings per share. Upon adoption, companies have the option to apply a modified or full retrospective transition approach. The amendments in this update will currently be effective for the Company on January 1, 2024, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,” to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with “Revenue from Contracts with Customers (Topic 606).” At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and will be effective for the Company on January 1, 2023, with early adoption permitted. Management is currently evaluating the impact that the amendments in this update may have on the Company’s consolidated financial statements.

 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Disaggregation of revenue
                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Paid-up revenue agreements  $1,100   $19,385   $23,110   $24,477 
Recurring Revenue Agreements   482    81    1,675    922 
Total revenue  $1,582   $19,466   $24,785   $25,399 
Schedule of equity securities
                    
Security Type  Cost   Gross
Unrealized
Gain		   Gross
Unrealized
Loss		   Fair Value 
   (In thousands) 
September 30, 2021:                
Equity securities - Life Sciences Portfolio (Note 3)  $62,042   $288,508   $(1,812)  $348,738 
Equity securities - other equity   35,178    3,289    (85)   38,382 
Total  $97,220   $291,797   $(1,897)  $387,120 
                     
December 31, 2020:                    
Equity securities - Life Sciences Portfolio (Note 3)  $32,765   $72,689   $(583)  $104,871 
Equity securities - other equity   4,086    1,410    (1,264)   4,232 
Total  $36,851   $74,099   $(1,847)  $109,103 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.21.2
EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)
 9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Schedule of unrealized gains or losses
                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Change in fair value of equity securities  $63,907   $84,299   $112,180   $83,230 
Change in fair value of equity securities derivative   –    10,651    –    17,542 
Change in fair value of equity securities forward contract   –    (74,662)   –    – 
Gain (loss) on sale of equity securities   37,112    1,908    52,167    (4,202)
Gain on sale of prepaid investment and derivative   –    2,845    –    2,845 
Net realized and unrealized gain  $101,019   $25,041   $164,347   $99,415 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENT AT FAIR VALUE (Tables)
 9 Months Ended
Sep. 30, 2021
Schedule of Investments [Abstract]  
Schedule of gain on investments
                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands) 
Change in fair value of investment, warrants  $–   $(3,081)  $(2,752)  $225 
Change in fair value of investment, common stock   –    –    –    3,479 
Gain on sale of investment, warrants   –    –    3,591    554 
Loss on sale of investment, common stock   –    –    –    (3,316)
Net realized and unrealized (loss) gain  $–   $(3,081)  $839   $942 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.21.2
PATENTS, NET OF ACCUMULATED AMORTIZATION (Tables)
 9 Months Ended
Sep. 30, 2021
Patents Net Of Accumulated Amortization  
Schedule of intangible assets
   
For the years ending December 31,   
(In thousands)
Remainder of 2021 $2,612 
2022  10,448 
2023  10,381 
2024  9,005 
2025  6,630 
Thereafter  750 
Patents, net   $39,826 
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities at fair value
                    
   Level 1   Level 2   Level 3   Total 
Assets  (In thousands) 
September 30, 2021:                
Equity securities at fair value  $119,280   $267,840   $–   $387,120 
Total  $119,280   $267,840   $–   $387,120 
                     
December 31, 2020:                    
Equity securities at fair value  $109,103   $–   $–   $109,103 
Investment at fair value - warrants   –    2,752    –    2,752 
Total  $109,103   $2,752   $–   $111,855 
                     
Liabilities                    
September 30, 2021:                    
Series A warrants  $–   $–   $18,527   $18,527 
Series A embedded derivative liabilities   –    –    41,411    41,411 
Series B warrants   –    –    229,637    229,637 
Total  $–   $–   $289,575   $289,575 
                     
December 31, 2020:                    
Series A warrants  $–   $6,640   $–   $6,640 
Series A embedded derivative liabilities   –    –    26,728    26,728 
Series B warrants   –    –    52,341    52,341 
Total  $–   $6,640   $79,069   $85,709 
Schedule of changes in fair value Level 3 liabilities
                    
   Series A
Warrant
Liability		   Series A
Embedded
Derivative
Liability		   Series B
Warrant
Liability		   Total 
   (In thousands) 
                 
Balance at January 1, 2021  $–   $26,728   $52,341   $79,069 
Transfers to Level 3
   6,640    –    –    6,640 
Remeasurement to fair value   11,824    14,463    178,198    204,485 
Balance at June 30, 2021   18,464    41,191    230,539    290,194 
Remeasurement to fair value   63    220    (902)    (619) 
Balance at September 30, 2021  $18,527   $41,411   $229,637   $289,575 

 

   Series A
Warrant
Liability		   Series A
Embedded
Derivative
Liability		   Series B
Warrant
Liability		   Total 
   (In thousands) 
                 
Balance at January 1, 2020  $3,568   $17,974   $–   $21,542 
Transfers to Level 3
   –    –    5,929    5,929 
Remeasurement to fair value   3,384    11,539    52,361    67,284 
Balance at June 30, 2020   6,952    29,513    58,290    94,755 
Remeasurement to fair value   (1,348)   (3,831)   (15,493)    (20,672) 
Balance at September 30, 2020  $5,604   $25,682   $42,797   $74,083 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Tables)
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of future minimum operating lease payments
     
   Operating Leases 
   (In thousands) 
Remainder of 2021  $149 
2022   370 
2023   364 
2024   218 
Thereafter   – 
Total minimum payments   1,101 
Less: short-term lease liabilities   (430)
Long-term lease liabilities  $671 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ EQUITY (Tables)
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of repurchased shares
                  
   Total Number
of Shares
Purchased		   Average
Price
paid per
Share		   Approximate
Dollar
Value of Shares
that
May Yet be
Purchased
under the
Program		   Plan Expiration Date
                
March 20, 2020 - March 31, 2020   576,898   $2.28   $8,686,000   July 31, 2020
April 1, 2020 - April 23, 2020   1,107,639   $2.42   $6,001,000   July 31, 2020
Total repurchases in 2020   1,684,537   $2.37         
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME/LOSS PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Calculation of basic and diluted net loss per share
                    
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
   (In thousands, except share and per share information) 
Numerator:                
Net income (loss) attributable to Acacia Research Corporation  $89,604   $38,348   $(55,507)  $33,205 
Dividend on Series A redeemable convertible preferred stock   (262)   (467)   (785)   (1,118)
Accretion of Series A redeemable convertible preferred stock   (991)   (733)   (2,762)   (2,045)
Undistributed earnings allocated to participating securities   (15,367)   (6,619)   –    (5,204)
Net income (loss) attributable to common stockholders - Basic   72,984    30,529    (59,054)   24,838 
                     
Add: Dividend on Series A redeemable convertible preferred stock   –    467    –    – 
Add: Accretion of Series A redeemable convertible preferred stock   –    733    –    – 
Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative   –    (3,831)   –    – 
Less: Change in fair value of Series A warrants   63    (1,348)   –    (1,348)
Less: Change in fair value of dilutive Series B warrants   (902)   (5,557)   –    (5,557)
Add: Interest expense associated with Starboard Notes, net of tax   1,536    1,889    –    1,889 
Add: Undistributed earnings allocated to participating securities   15,367    6,619    –    5,204 
Reallocation of undistributed earnings to participating securities   (8,877)   (296)   –    (3,645)
Net income (loss) attributable to common stockholders - Diluted  $80,171   $29,205   $(59,054)  $21,381 
                     
Denominator:                    
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic   48,949,504    48,467,885    48,759,873    48,949,706 
Potentially dilutive common shares:                    
Series A Preferred Stock   –    9,589,041    –    – 
Restricted stock   798,356    728,936    –    598,328 
Stock options   35,815    21,624    –    – 
Series A Warrants   2,019,724    310,367    –    103,456 
Series B Warrants   41,278,103    31,506,849    –    10,502,283 
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted   93,081,502    90,624,702    48,759,873    60,153,773 
                     
Basic net income (loss) per common share  $1.49   $0.63   $(1.21)  $0.51 
Diluted net income (loss) per common share  $0.86   $0.32   $(1.21)  $0.36 
                     
Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:                    
Equity-based incentive awards   398,168    191,312    2,230,624    310,083 
Series A warrants   –    –    5,000,000    – 
Series B warrants   –    68,493,151    100,000,000    68,493,151 
Total   398,168    68,684,463    107,230,624    68,803,234 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.21.2
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - Integer
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Description Of Business And Basis Of Presentation    
Number of new patent portfolios acquired 1 5
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Product Information [Line Items]        
Revenues $ 1,582 $ 19,466 $ 24,785 $ 25,399
Paid Up Revenue Agreements [Member]        
Product Information [Line Items]        
Revenues 1,100 19,385 23,110 24,477
Recurring Revenue Agreements [Member]        
Product Information [Line Items]        
Revenues $ 482 $ 81 $ 1,675 $ 922
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Equity securities - cost $ 97,220 $ 36,851
Available-for-sale Securities, Gross Unrealized Gain 291,797 74,099
Available-for-sale Securities, Gross Unrealized Loss (1,897) (1,847)
Equity securities at fair value 387,120 109,103
Equity Securites Lf Fund Public Securities [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Equity securities - cost 62,042 32,765
Available-for-sale Securities, Gross Unrealized Gain 288,508 72,689
Available-for-sale Securities, Gross Unrealized Loss (1,812) (583)
Equity securities at fair value 348,738 104,871
Equity Securities Other Equity [Member]    
Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]    
Equity securities - cost 35,178 4,086
Available-for-sale Securities, Gross Unrealized Gain 3,289 1,410
Available-for-sale Securities, Gross Unrealized Loss (85) (1,264)
Equity securities at fair value $ 38,382 $ 4,232
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Product Information [Line Items]          
Proceeds from sale of investment     $ 1,800    
Loss on sale of investment     515    
Stock-based compensation $ 300 $ 488 1,279 $ 1,243  
Unrecognized stock-based compensation expense $ 5,952   $ 5,952    
Weighted-average remaining vesting period     2 years 2 months 12 days    
Effective tax rate 0.00% 0.00% 1.00% 4.00%  
Restricted Stock Units (RSUs) [Member]          
Product Information [Line Items]          
Option Forfeited     450    
Option Forfeited     $ 450    
Weighted Average Grant     $ 473,000    
Weighted average grant-date fair value     5.86    
R S As [Member]          
Product Information [Line Items]          
Weighted Average Grant     324,401    
Weighted average grant-date fair value     5.56    
Non Qualified Stock Options [Member]          
Product Information [Line Items]          
Weighted Average Grant     393,750    
Weighted average grant-date fair value     $ 1.79    
Measurement Input, Risk Free Interest Rate [Member] | Black Scholes Method [Member] | Restricted Stock Units [Member]          
Product Information [Line Items]          
Assumptions used for derivatives     1.38 percent    
Measurement Input, Expected Term [Member] | Black Scholes Method [Member] | Restricted Stock Units [Member]          
Product Information [Line Items]          
Assumptions used for derivatives     3.00 years    
Measurement Input, Price Volatility [Member] | Black Scholes Method [Member] | Restricted Stock Units [Member]          
Product Information [Line Items]          
Assumptions used for derivatives     38 percent    
Measurement Input, Expected Dividend Rate [Member] | Black Scholes Method [Member] | Restricted Stock Units [Member]          
Product Information [Line Items]          
Assumptions used for derivatives     0 percent    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Licensee [Member]          
Product Information [Line Items]          
Concentration risk percentage 32.00% 98.00% 50.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Licensee [Member]          
Product Information [Line Items]          
Concentration risk percentage 25.00%   19.00% 9.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Three Licensee [Member]          
Product Information [Line Items]          
Concentration risk percentage 22.00%   12.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Licensee 2 [Member]          
Product Information [Line Items]          
Concentration risk percentage 13.00%        
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Licensee 3 [Member]          
Product Information [Line Items]          
Concentration risk percentage       75.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Foreign Licensee [Member]          
Product Information [Line Items]          
Concentration risk percentage 8.00% 0.10% 15.00% 5.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Licensee [Member]          
Product Information [Line Items]          
Concentration risk percentage     100.00%   62.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Licensee [Member]          
Product Information [Line Items]          
Concentration risk percentage     100.00%    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Licensee 2 [Member]          
Product Information [Line Items]          
Concentration risk percentage         21.00%
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.21.2
EQUITY SECURITIES PORTFOLIO INVESTMENT (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Marketable Securities [Line Items]        
Gain on sale of prepaid investment and derivative     $ (0) $ 2,845
Net realized and unrealized gain (loss) on investment $ 0 $ 3,081 839 942
Equity Securites Lf Fund Securities [Member]        
Marketable Securities [Line Items]        
Change in fair value of investment 63,907 84,299 112,180 83,230
Equity Securites Derivative [Member]        
Marketable Securities [Line Items]        
Change in fair value of investment 0 10,651 0 17,542
Equity Securites Forward Contract [Member]        
Marketable Securities [Line Items]        
Change in fair value of investment 0 (74,662) 0 0
Equity Securities L F Fund Trading Security [Member]        
Marketable Securities [Line Items]        
Loss on sale of trading security 37,112 1,908 52,167 (4,202)
Gain on sale of prepaid investment and derivative 0   0 2,845
Gain on sale of prepaid investment and derivativey   2,845    
L F Fund Securities [Member]        
Marketable Securities [Line Items]        
Net realized and unrealized gain (loss) on investment $ 101,019 $ 25,041 $ 164,347 $ 99,415
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.21.2
EQUITY SECURITIES PORTFOLIO INVESTMENT (Details Narrative)
$ in Thousands
 3 Months Ended
Apr. 03, 2020
USD ($)
Option Agreement [Member] | Portfolio Companies [Member]  
Offsetting Assets [Line Items]  
Payment to acquire equity securities $ 277,500
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.21.2
INVESTMENT AT FAIR VALUE (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Investment Holdings [Line Items]        
Change in fair value of investment $ 0 $ (3,081) $ (2,752) $ 3,704
Change in fair value of investment 0 3,081 2,752 (3,704)
Loss on sale of investment     515  
Loss on sale of investment     (515)  
Net realized and unrealized gain (loss) on investment 0 3,081 839 942
Net realized and unrealized gain (loss) on investment 0 (3,081) (839) (942)
Warrant Investment [Member]        
Investment Holdings [Line Items]        
Change in fair value of investment 0 3,081 2,752 225
Change in fair value of investment 0 (3,081) (2,752) (225)
Gain on sale of investment 0 0 3,591 554
Common Stock Investment [Member]        
Investment Holdings [Line Items]        
Change in fair value of investment 0 0 0 3,479
Change in fair value of investment $ 0 0 0 (3,479)
Loss on sale of investment   0 0 3,316
Loss on sale of investment   $ 0 $ 0 $ (3,316)
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.21.2
PATENTS, NET OF ACCUMULATED AMORTIZATION (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Patents Net Of Accumulated Amortization    
Remainder of 2021 $ 2,612  
2022 10,448  
2023 10,381  
2024 9,005  
2025 6,630  
Thereafter 750  
Patents, net   $ 39,826 $ 16,912
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.21.2
PATENTS, NET OF ACCUMULATED AMORTIZATION (Details Narrative) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Patents Net Of Accumulated Amortization    
Accumulated amortization $ 291,600 $ 319,900
Accrued patent acquisition costs 13,000  
Accrued patent acquisition costs due within a year 8,000  
Accrued patent acquisition costs due within 2 years $ 5,000  
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.21.2
STARBOARD INVESTMENT (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 5 Months Ended 6 Months Ended 9 Months Ended 16 Months Ended
Jan. 29, 2021
Feb. 25, 2020
Nov. 18, 2019
Sep. 30, 2021
Jun. 04, 2020
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Fair value of embedded derivative       $ 41,411     $ 41,411   $ 41,411 $ 26,728
Proceeds from issuance of debt             50,000 $ 0    
Repayment of debt             50,000 (0)    
New Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Long-term Debt       180,000     180,000   180,000 115,000
Securities Purchase Agreement [Member] | Senior Secured Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Proceeds from issuance of debt         $ 115,000          
Debt stated interest rate         10.00%          
Series A Redeemable Convertible Stock [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Proceeds from issuance of preferred stock                 35,000  
Payment of stock issuance costs                 1,300  
Accretion expense       991     2,800      
Fair value of embedded derivative       41,400     41,400   41,400 26,700
September Redemption [Member] | Securities Purchase Agreement [Member] | Senior Secured Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Repayment of debt               $ 80,000    
December Redemption [Member] | Securities Purchase Agreement [Member] | Senior Secured Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Repayment of debt                   35,000
Series B Warrants [Member] | Securities Purchase Agreement [Member] | Senior Secured Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Fair value of warrants       1,300     1,300   1,300  
Unamortized discount       151     151   151  
Amortization of discount             1,200      
Starboard Value [Member] | Series A Preferred Stock [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock issued     350,000              
Conversion price     $ 3.65              
Starboard Value [Member] | Series A Warrants [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Warrants issued, shares     5,000,000              
Fair value of warrants     $ 4,800 18,500     $ 18,500   18,500 6,600
Warrants exercised             0      
Starboard Value [Member] | Series B Warrants [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Warrants issued, shares   100,000                
Proceeds from issuance of preferred stock   $ 4,600                
Fair value of warrants       229,600     $ 229,600   229,600 $ 52,300
Warrants exercised             0      
Merton [Member] | Securities Purchase Agreement [Member] | Senior Secured Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Proceeds from issuance of debt             $ 50,000      
Debt stated interest rate               6.00%    
Notes exchanged           $ 115,000        
Capitalized lender fees               $ 4,600    
Unamortized discount               $ 500    
Accrued interest       $ 863     $ 863   $ 863  
Repayment of debt $ 50,000                  
Debt maturity date Oct. 15, 2021                  
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Assets [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets $ 387,120 $ 111,855
Assets [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 387,120 109,103
Assets [Member] | Warrant Investment [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets   2,752
Assets [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 119,280 109,103
Assets [Member] | Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 119,280 109,103
Assets [Member] | Fair Value, Inputs, Level 1 [Member] | Warrant Investment [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets  
Assets [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 267,840 2,752
Assets [Member] | Fair Value, Inputs, Level 2 [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 267,840 0
Assets [Member] | Fair Value, Inputs, Level 2 [Member] | Warrant Investment [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets   2,752
Assets [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Assets [Member] | Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Assets [Member] | Fair Value, Inputs, Level 3 [Member] | Warrant Investment [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets   0
Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 289,575 85,709
Liability [Member] | Series A Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 18,527 6,640
Liability [Member] | Series B Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 41,411 26,728
Liability [Member] | Series A Embedded Derivative Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 229,637 52,341
Liability [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Liability [Member] | Fair Value, Inputs, Level 1 [Member] | Series A Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Liability [Member] | Fair Value, Inputs, Level 1 [Member] | Series B Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Liability [Member] | Fair Value, Inputs, Level 1 [Member] | Series A Embedded Derivative Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Liability [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 6,640
Liability [Member] | Fair Value, Inputs, Level 2 [Member] | Series A Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 6,640
Liability [Member] | Fair Value, Inputs, Level 2 [Member] | Series B Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Liability [Member] | Fair Value, Inputs, Level 2 [Member] | Series A Embedded Derivative Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 0 0
Liability [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 289,575 79,069
Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Series A Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 18,527 0
Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Series B Warrants [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets 41,411 26,728
Liability [Member] | Fair Value, Inputs, Level 3 [Member] | Series A Embedded Derivative Liability [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of assets $ 229,637 $ 52,341
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Derivative liability, beginning balance $ 290,194 $ 94,755 $ 79,069 $ 21,542
Transfers into Level 3     6,640 5,929
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) (619) (20,672) 204,485 67,284
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance 289,575 74,083 290,194 94,755
Fair Value, Inputs, Level 3 [Member] | Series A Warrants Liability [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Derivative liability, beginning balance 18,464 6,952 0 3,568
Transfers into Level 3     6,640 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) 63 (1,348) 11,824 3,384
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance 18,527 5,604 18,464 6,952
Fair Value, Inputs, Level 3 [Member] | Series A Embedded Derivative Liability [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Derivative liability, beginning balance 41,191 29,513 26,728 17,974
Transfers into Level 3    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) 220 (3,831) 14,463 11,539
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance 41,411 25,682 41,191 29,513
Fair Value, Inputs, Level 3 [Member] | Series B Warrants Liability [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Derivative liability, beginning balance 230,539 58,290 52,341
Transfers into Level 3     5,929
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease) (902) (15,493) 178,198 52,361
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance $ 229,637 $ 42,797 $ 230,539 $ 58,290
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]    
Remainder of 2021 $ 149  
2022 370  
2023 364  
2024 218  
Thereafter 0  
Total minimum payments 1,101  
Less: short-term lease liabilities (430)  
Long-term lease liabilities $ 671 $ 951
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]          
Operating lease costs, net of sublease income $ 155 $ 174 $ 457 $ 459  
Income from settlement       $ 308  
Contingency accruals $ 587   $ 587   $ 1,300
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY (Details) - Common Stock [Member] - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2020
Apr. 23, 2020
Dec. 31, 2020
Class of Stock [Line Items]      
Number of shares repurchased 576,898 1,107,639 1,684,537
Average price paid per share $ 2.28 $ 2.42 $ 2.37
Approximate value of shares that may yet be purchased $ 8,686 $ 6,001  
Stock Repurchase Program Expiration Date Jul. 31, 2020 Jul. 31, 2020  
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS’ EQUITY (Details Narrative)
$ in Thousands
Aug. 05, 2019
USD ($)
Stock Repurchase Program [Member]  
Equity, Class of Treasury Stock [Line Items]  
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 10,000
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME/LOSS PER SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Numerator:        
Net income (loss) attributable to Acacia Research Corporation $ 89,604 $ 38,348 $ (55,507) $ 33,205
Dividend on Series A redeemable convertible preferred stock (262) (467) (785) (1,118)
Accretion of Series A redeemable convertible preferred stock (991) (733) (2,762) (2,045)
Undistributed earnings allocated to participating securities (15,367) (6,619) 0 (5,204)
Net income (loss) attributable to common stockholders - Basic 72,984 30,529 (59,054) 24,838
Add: Dividend on Series A redeemable convertible preferred stock 0 467 0 0
Add: Accretion of Series A redeemable convertible preferred stock 0 733 0 0
Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative 0 (3,831) 0 0
Less: Change in fair value of Series A warrants 63 (1,348) 0 (1,348)
Less: Change in fair value of dilutive Series B warrants (902) (5,557) (5,557)
Add: Interest expense associated with Starboard Notes, net of tax 1,536 1,889 1,889
Add: Undistributed earnings allocated to participating securities 15,367 6,619 0 5,204
Reallocation of undistributed earnings to participating securities (8,877) (296) 0 (3,645)
Net income (loss) attributable to common stockholders - Diluted $ 80,171 $ 29,205 $ (59,054) $ 21,381
Denominator:        
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic 48,949,504 48,467,885 48,759,873 48,949,706
Potentially dilutive common shares:        
Potentially dilutive common shares 93,081,502 90,624,702 48,759,873 60,153,773
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted 93,081,502 90,624,702 48,759,873 60,153,773
Basic net income (loss) per common share $ 1.49 $ 0.63 $ (1.21) $ 0.51
Diluted net income (loss) per common share $ 0.86 $ 0.32 $ (1.21) $ 0.36
Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:        
Antidilutive shares 398,168 68,684,463 107,230,624 68,803,234
Equity Based Incentive Awards [Member]        
Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:        
Antidilutive shares 398,168 191,312 2,230,624 310,083
Series A Warrants [Member]        
Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:        
Antidilutive shares 0 0 5,000,000 0
Series B Warrants [Member]        
Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:        
Antidilutive shares 0 68,493,151 100,000,000 68,493,151
Series A Preferred Stock [Member]        
Potentially dilutive common shares:        
Potentially dilutive common shares 0 9,589,041 0 0
Restricted Stock Units [Member]        
Potentially dilutive common shares:        
Potentially dilutive common shares 798,356 728,936 0 598,328
Employee Stock Options [Member]        
Potentially dilutive common shares:        
Potentially dilutive common shares 35,815 21,624 0 0
Series A Warrants [Member]        
Potentially dilutive common shares:        
Potentially dilutive common shares 2,019,724 310,367 0 103,456
Series B Warrants [Member]        
Potentially dilutive common shares:        
Potentially dilutive common shares 41,278,103 31,506,849 0 10,502,283
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &B!;U,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !H@6]3%-^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2@,Q$(9?17+?G03-O@9A.2D=V^O=G8;A%] "&7S/SY MYAM(IX/0/N)S] $C64PWD^N')'18LR-1$ !)']&I5.?$D)M['YVB?(T'"$I_ MJ -"VS3WX)"44:1@!E9A(3+9&2UT1$4^GO%&+_CP&?L",QJP1X<#)> U!R;G MB>$T]1U< 3.,,+KT74"S$$OU3VSI #LGIV27U#B.];@JN;P#A[?MYJ6L6]DA MD1HTYE?)"CH%7+/+Y-?5P^/NB__H7\ E!+ P04 " !H@6]3F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &B!;U/+TM[2W 0 "P4 8 >&PO=V]R:W-H965T&UL ME9A=;^(X%(:O9WZ%Q=6N5)K$"05&%(E2NH-VAJ% 9]5=[86;&(B:Q(SM0/OO M]SB$A*)PPO:BY.N\>7PO/%LI2_YC%3UV+# M$[BS%#)F&D[ERE(;R5F0!<6116W[QHI9F#3ZO>S:5/9[(M51F/"I)"J-8R;? M[W@D=K<-IW&X, M7:VTN6/W>AJWXG.NGS53"F56H!&',$Q6*A$B^O&T,G"]# MUS8!V1,_0[Y31\?$-.5%B%=S,@YN&[8AXA'WM9%@\+/E0QY%1@DX?N6BC>*= M)O#X^*#^D#4>&O/"%!^*Z*\PT.O;1J=! KYD::1G8O>5YPUJ&3U?1"K[3W;[ M9SVO0?Q4:1'GP4 0A\G^E[WEB3@*H)TS 30/H"%N"'&Z/Q1;+DF3J#637/4L#9KFCN7G M\7?[>'HFODN^BT2O%1DE 0\^QEO 4@#1 ] =107G?'--7/N*4)LZ%3Q#/'PB MMM?$[E2%?\!QB_RXF9Z+YN>?P8O2$CZY?Q%)KY#T,DGOC.2]\%,8")HLWC>\ M*N-XN&,W'Q&*5D'10F4&@!!D& \16U5AX/%+%BF.<-P4'#>79>,Q95)S&;V3 M&=\(J:N0<"DM4XRH71"U+^P?R<"N,KPB5SZ(#X@-RB)-)&K]P M60F$BSA-M]W& C3CJ]!X+V1MPN+J+.%" Y_Y(?L\XPK2[:_)4$@8 MS,R,:PRTM','-^0<= @=*Z%3QU (W\B?_+T2%9>RX:_K>BVOBY&5%N_@'IV3 M+=@;&0> %RY#/VLWUL.X9+?5]#R[U6YY&&%I_@YNV3GA./'+3KDB0PZ" *9(ZNIP0+[!<^1'4DV&2[9OVF3Q M=3R[)X.?H\D3REG6" >W=I1SL1.5G#75XFF\&)$;FV* 9:%P<&\_!1R:,^CF MA=@EE7"XW 06"<^P2,!FG67!H+C'G[(5W^!4BFV8^)6]7*,Y><;0RJI!<9L_ M19L*I<%H_@XW9P=&C:)CVTX;8RO+!L4=/^O" 2P@SZ/@ K]UO>[O&$I9,"CN M\]]$-OM8BP2K8#4B7L=N=ES;QHC*RD OJPQYU=]/(L-DE7UY/NCF,N5 M^;K^ 5MYCGQAB75N<,%ZU8MM'1\>I'CS]<<8'^9%J,-8D@!Q6;3SDRJU,V6R/;?M>M]5U.BVHCMMC*NMH/\9T M2K9-I8AO9C/[K9GB:K$5-L@V@*SR\?T^VG=F^E21B"\AU+YNP^OE?FMJ?Z+% M)MO=>1%:BS@[7',6<&D>@/M+(?3AQ+R@V"#L_P=02P,$% @ :(%O4Q*; M'HGN!P Q2 !@ !X;"]W;W)K28LDBQ7AQ M]Z61Y.'H<#B<, MF &UQ7\S\5SUKI&9RH.4/\S-E_7Y)#"(1"Y2;5QP^/,D+D6>&T^ XV?K=')X MIQG8OW[U_I]Z\C"9!UZ)2YG_+UOK[?DDGJ"UV/!]KN_D\V?13B@T_E*95_6_ MZ+FU#28HW5=:%NU@0%!D9?.7_VH#T1N V<@ T@X@IPZ@[0!:3[1!5D_KBFM^ M<:;D,U+&&KR9BSHV]6B835::95QI!;]F,$Y??+]9?K_ZT6"*2$"P8_BE?_B52&$XKH<'Q\/G$(-#(,@A M$*3V1T?\7>Z5$J5&O*J$KCYX/-*#1UI[9&,>>;5%$!N4F@OQX8Q5 MXRJJ79FM]W1!\"()%V?SIWY,;#,O(CP )QM$[AQA0=*,#WN@?XGW.-.P0C4R%S?(7*#!:*-C&_"$7;\PDLB"& M,8X&\["-,*.DES9'\U@+9&XA?HFLH4"*BWL@:?'A5T)VYL)U\2 M#[>8PRJ,Z:YZ> )-;KHRAA=%A\'78L7(#I"-".Q;"?QK[* M\G%FJA:DPYLTT?HZ"FG("!N"=9D%P5@Z=#R&_41VR[4I1U-4@@"6&Q")Z;[8 MY]Q YH54.ON+&_7HA&[3%V0#L=+!-L-1@L?RH:,Z[.>ZKP+$Z!HI(SMG>-:#8] MB"QU5C[6D16/L"\V0GCS@]A\ @T)'6*WK0B.1HHAZ3B'^#GG-<"[NI[WE";, MHW+O9F)32MQGE!:O;36RC4E'.L1/.BM19E*AE5'*@-D(I0K=>B+K8)"8Q&$X MQ.JPPV$4C8ACTE$-\5/-L?1X:Z/9)$("QIB5Q8Z6BK!^QW*,MN,;XN>;E5 F MB9?HF2O%3P#LZ(GBD P[:8=9%+&Q9.A(A_A)YX!6% ]BO89\6,.3)VX.J]Y$ M;A,-PPP/:=UA1J(%&>%+TM$1\7=-+?1/)P?:T1B1)*)6I&V[D% V(D1(QW+$ MSW*=,,V-=GH3KDUEMF1R&(U*)MK1'3VEF\H[O'ZDU,5MR1"JRRH9@]I1&_53 M6U,;W@+H:(F"@%CTZ[ CF$!_/X*RXS;JY[9+6119<_1PS&[I&&*O/W-6_J': M\52<3W;0Y0CU)"87R'4H^2\X.IYS[S31SXF'R@(D(T11=^4P[R;;''NA=\#X(,-I!$E9;KL1',*E[HO9G' 3]'Z$5FP)U-K<0 MX+W>2I7])=93E%65X>5:KNTU>"G7$'<0V:;;6HF=-F5/'8YU:\,KD;9/V]/: MCX@_/BI0(=ILVI_[;%TKJ'8&L(C">'M'PQK%/_/M7'R;]#&-[&QUF 5)KW<] M7KA.'U#FE?DKLQQ;F0,15+^U9VC>\^6.R*F?R,TV@+B=L-XTJ)?4O:P?$4NF M4#NF0)-U5.&6+)(I"^FK\;^R[E-S@K 3]8>;_,6Y4K:("(<2SF'#1AH2VHD, MZA<9]PHH9*]>7F/)&Z4Y16P:!6Q*H_ 0MO\_'6WE,6.4+*R)OFEW/-E.HU"_ M1EFNUYG9<%#HS>'9+"M1RG<9%'XG7%MN1"RAE@!TV84@7T8$(.UT"?7KDF7O M$&RL[("[;V! M@<'[!41*-=_,FQLM=_5GYP>IM2SJRZW@ -L8P.\;"8UR>V.^9!_^Y\+%WU!+ M P04 " !H@6]3?0E]-"8# ";"@ & 'AL+W=O\[QVXIS^EK(G'@((]!)'"1\8H1#IE6ER/X08 M\P9-(9%W5I3%6,@I6YL\98 #+8HCT[&LMAECDAC#OKXV9\,^S41$$I@SQ+,X MQNSU&B*Z'1BV\7;A@:Q#H2Z8PWZ*U^"!>$SG3,[,,DM 8D@XH0EBL!H8(_MJ M;&N!COA)8,MWQDA965+ZI"8WP<"P%!%$X N5 LN?#8PABE0FR?%<)#7*FDJX M.W[+_EV;EV:6F,.81K]((,*!T350 "N<1>*!;G] 83D;I\/;H= MS<93Y/V83A<>.I]C!HD(01 ?1Q?H&WKT)NC\[ *=(9*@14@SCI. ]TTAZ50- MTR](KG,2YP,2#](&:EJ7R+$>J*,3J==F,[0:EB4];';QCT55*)LE9?,3 ME#R4F\,1SD1(&?D+01UMGM#=X6A:Q=\>\2F1%>I62=WZ/#7A/*LG;KWC:/7< MGMUUG3W@ND"GTVNYS7I>M^1U/\\KST0NY*-.DG4=M'LJ=%W@(>AV"=T^"+V0 MISK/V&L5NPZU_9Z@;;6:;7>/]'A49#HQ!@#P% MC7[?0;P$]N? ^]PMJW0/5O& $;EK(_GM*7 M6W/ '8^KVMKYJ-I?:RLBSQD)L.YL\IN0^+5;551N[S/O6SL6ECLS=SH'U;;= M8;8F"4<1K*3.:G3DVK"\$\HG@J:ZF5A2(5L3/0QE]PA,!&PO=V]R:W-H965T M&ULI5K;;MNX%OT5PIB'%AC'O.@:) $2RS,G0)L$<3I]&)P' MVJ9MGF\))*\N*6UN+FY2.GB15;?ZK40"GW?%&5] M.5@KM3T?C>KY6FQX?2:WHM2_+&6UX4J?5JM1O:T$7S2--L6(8AR--CPO!U<7 MS;6'ZNI"[E21E^*A0O5NL^'5CQM1R)?+ 1F\7GC,5VME+HRN+K9\):9"?=D^ M5/IL=(BRR#>BK'-9HDHL+P?7Y'S"8M.@0?R1BY?ZZ!@9*C,IOYF3V\7E )LG M$H68*Q."ZW_/8BR*PD32S_%7&W1PN*=I>'S\&OVWAKPF,^.U&,OB:[Y0Z\M! M,D +L>2[0CW*E_^(EE!HXLUE43=_T4N+Q0,TW]5*;MK&^@DV>;G_S[^W0APU MT''@!K1M0.T&04\#UC9@[[U#T#8(WGN'L&W04!_MN3?"95SQJXM*OJ#*H'4T M<]"HW[36>N6E292IJO2ON6ZGKK[<77_);I\F&1K?WV63N^G^:'K_Z3:[-I>G M3_K?Y\G=TQ3=_X;N'R:/UT^W&H"&Z,LT0Q]^^8A^07F)GM9R5_-R45^,E'XN M$WTT;Y_A9O\,M.<9&/HL2[6NT:1&H5>_!ZV;5FTK*[6412Z1+O(5-U6R M/O<(&!W"1UX!;TLMH)(5JN0/7J@ZF8.SE>Z_6HFI9'M6)O"F\X'2*G>>P!_/; MD.QMR 2 #!E.>@@?>0[B)>R4Q-?,!LD25_0T3&V^+HH$86C/ Q L":D]K $8 MQ0'NF0D([8A3+_$[[?R=?OY0R+K^Z.MNZO8"97%L2^#"@I0XO>ZB(AHY'0_% M2G$/_\Y*$.;E_[LH]=Q7-'6-+[2=S8V3,$L%?PHPH%ZQP"[K "R.4GL& U"4 M81+8"@#W3'#2EP*=WR%^PW._G_UU.3?=#K(-W.XF-*9V68-PU*GU&1@NBD.' M,(1CN,_^D,[_$+\!VI>W?7JC#VT_?_1Y']*9'^)W/^,UUZ; K#^6/*_0,R]V MPDP9N79%M3)V]5=4"@7*[-H4IXBZ$%/^[(D2@M$XI+; +HS%..B1MS-&Q.^, M?N>:?5M#]'Q9\\)2 "3O&A>'_)N0#("P,+4M H#2\D1]TV9GDXC?)_7UO4XW M-!65=L+HNJDT-^B%5Q77%J(Y%9N96.B%(EIHT'-3?>!QZ'J;B#CSC@NB.')L M,P ;4LP2>Z$R@8!Z.4/ZU.H\%?&;JB9-CO)C6XDMSQ='>=*(TVD"2N(:("=M M $N6V*4Z>SO0Y*U IRO[SFQ1O]GJRQKQURY7/U MYKLJ[UM&4=BG/_0KFS> MC!>0M.N0AL0VI1 H< 8"%"FUMQ7 4"GK68W0SI%1OR.[+96H=&^_6E CQ%24 MN:ST/ZV$GBGNI.H9!I 'T[EKJP#! L>;0[ PLA?F$PC&2-PG1&?4:/@^(5JO M9N8#:OAVYI'ZS>.35'HM(D%["E)V#1S! ME-DC= S@ D()LYE#[C)FQ+8$4+@0!SV;++0SCM1O'-N-W78"F DS^%]U4/Q[ M3\*[9BY)(V(OQ0 82P)[7&0 ;!@&.+:] !2.I$%?QG<6DOHMY.V!;=?S6HE2 M+'/0-E/ G1%GL .@Q.E\ .34C0F (C3LZ_G."U*_%S3;$/E)[^NS8K]9D"U[+IY,"!+1"PC98P=U9P83HY@'(( MA&,4]SA%UCE%YG>*1RIQI:I\ME-\IBV2DO]*)/;VYMW;D R #%-LEPYOH%-9 M.M?(_*[131Y;G>LYG^<7^E0NT!9 \"@K %@PU"; M:MM&0>$\6=.92?;V%I]?'OW;QMAM)>??UK+0*RZSHW_#ZWP.RD.=!XUIFCCR MN#"&0VJ_U0!@PS#%SFX0@*-!TF>VV-'+1+_3;&B:+1E+I*V>@U^%67/89;>A MD^-J>!;8*W( A<\BN_X"J"$YHW9M 8.%/VW&=ZI6VH"9\N)+#M<*!DD:I*$[?"!D$,6)_78L Y%QF":Q M[]&>'4987.P5^1'#3WO&DSF 2V],W *,IM?7, !@\ MD(!PA"5]9;@SK\QO7ENB/SN4(B"O[===8Q#%[+TM 4.)3!87Z)T+I;Y7>S_ M.Y1\">*ZS-1L][H;/! 21S2(;60&(/L&$_ N&9.0Q;']ZGQT]+G/1E2KYCNK M6O?YKE3[[SH.5P_?&PO=V]R:W-H965T&ULS5QK;Z-(%OTKR!II9Z1VAWJ H95$2L<\LMN=SL;I6:U6^X'8 ME02-#5[ 2<^_WP([QE"7(G1NHND/'6S?.G4I3A5U3A4M,1(NJT&IY1$W3/EI% M<3(Z/:Z^N\I.C]--L8P3<949^6:UBK(_/XME^G0R(J/G+Z[C^X>B_.+H]'@= MW8N9*+ZOKS+YZ6B/LHA7(LGC-#$R<7LL"QX>/Z/[U+O\5+XJ'DY$S,A;B+MHLB^OT*12[$ZH2G*?+O/K?>-K%FB-COLF+=+4K M+#-8Q*L LSL*6+L" M5KN&KG.P=P7L=@VLH\!D5V#2*D"Z"CB[ DYU=;>7H[J6TZB(3H^S],G(RFB) M5AY4A*A*RTL8)R5W9T4F?XUEN>+T^^79]^G%C3S#@SKKVIYWT]^_S%*\-_]ZYO+LKCJVO/]ZZO MJW+?SO]AG%WNCL)O7Z;>]>QOAO?/[QTDT> M)8O\^*B09U7F=C3?G<'G[1G0CC.8B2P6>9F26 C9L6^7PCA/DT>1%7%Y?"4[ M@\@RL3!F13K_P_C/5[&Z%=E_@9K.]36=IZN5[&Z],%,]S(T<8_)-]F<_D*<' M.ELLXG( B);&510OQK(=SZ-U7,C/&E!?#WHM"CGBR=;RHBR)D_M]G1/>UKA\ ZUP$(@:,)=R]F' M-5J=[5N=Z5M]V]9E(]\^7X /1OX025:\J.6W\-9!6LPRY;]6VZMAELDFINM, MX/SY/G^NS?]2SB5B2>E5>0I%%M]NBFJX*5+C;![-XTB.0;F(LOF#'(&R=9I% M9?>$3D1;3SE?^92OH[DX&'X7+W0C)I6B\I( MM85]M37(8NW)8FG)J+4#""?NR;G#$WG/$UG)D&C_&"Y$LC'):,8PB$!VT ME0T859!PID@XGJVV/2&D=[CX/5YO'19YOJCF=O,G-M_HHKU*[2S/C44[VRSFV_*V< M]V?QO)##U_;W31(7H-K3UC> MD@X4R0<#PG'1\()D'#"U^,TB$?,VKDPWY!Z MS[H#M %,M:MP9G&XJY #KX7\?,:;I,Q9)JGD&SU%V4(FG$CY(4O*X#L1%QLX M^<_Z' 9T("R@*1:0AP7D8P$%6$ A E"3E+430O16"#HIM3V+JM+3/=%UTV8":#YB>UPBW7XB*36 M_40O_+UD 9O/,['^:#"SM$"I"3+25JU9DS#>,GV ,.ZV^08H5,[HQ&P33HVS M+5FGV1Y#(#S3YE:+Z $0"'C00)1L%.J2CL:O)331:^@#&UI4U^'0@^Z_ *J8 M TUH((Z[=.)*^G2<0*W]B%[\Z58O_KY)>O)W%&:X7,U>C5+YHRI*F#]JG.2/ MH]Z#(#S.)Z[;Y@\@90'^ %$V/UP0:39_+7F)7O/V+6/T7P+WA112X[C+3)MT M#4"T%D]4+Y[PEC+T%0VX16(!3;& /"P@GZJ"DCFL;5L%6/6%O?4U65,+6*H7 ML.^QIK%+X3#WB7)[T^ZSD[6-5%V !A7UY-YERL+ZN5Y7(*QOZ MVH8,,DA 4RP@CZJ2>,SM29LX2-4%6$!A7]Y-XM1"GNJ%_+MX9/HZT%Q6Q:@NP@,*>M)LTJ;T)^E;>!'V9-P&$*=J2OM"; .) M;P+$@[P)(!#:'S?,FZ"U-T'?TIN@+_0F@#B]-T%K;X+^O#=QL+^O(W_5=2"F M2Q4"O<"0S0+-: MEF6V1%, Q+EFJV.'()B&(;4$9GH)_!YF"5-%&)W8K;'F7)_H$"I@B5X@[[&: MN(]57X %%/8FWB3+PQ%]DOTM0T91; $+A:0Q]1UX?'$:6\?QJHNP (* M^_)N$J>6IDPO30=L"-4C#2&%NIC=7LO&JLMCJAJF)FE?;:R5;"R@$$R[:Y2H M%3S3*_B?V/7)5(UH-R9SS51JE^PB'TQ-J_C@7D80'Y6$ !%E"( M -1D8"V5F5XJO]W^3Z;*8^HX78LBK-;&3*^-W\7;UN.T8<+UC\$IO6X\^Y(%,K$T, M6$ >!S:STTG[X2FLZ@(LH+ O[R91:M^&ZWV;%[G;!.0(46>]S'9:?L(Y$*8\ M^R-*"(3)7NITR5Q>>R*\Y[G[ ME]K;\!50Q3?H3 )QW+51A ?E<75ML7M-=1\12<+WU-3E4ZS.NUV?OX7]S5:FY+FGW9*PGF+& /"#M ML9*WCU5=@ 44]N7=9$JMB[E>%R.;W_K:A@PR6 H8"\CCP"HT599-L*H+L(#" MOKR;Q*FU*]=KUP'FMQYI""FP'BS' O*X*JI)>UN"CU5;@ 44]J3=?.E.;018 M>B/@)RQR"]@MWVV16[74M/X"CWOKJ9;CUIH][Z]&'=!JLY7$L(,\"WI'7UK8^5FT!%E#8 MDW:3)K598.G-@I\W^RQ@B1LP^X PQ:H!8D"K!H@#S3X(#S3[H', K!H@3&?V M60)Q,BV M[SK>?BC2=?7FW-NT*-)5=?@@HH7(R@#Y^UV:%L\?RI?Q[M\X??I_4$L#!!0 M ( &B!;U/VD^8 9 D HI 8 >&PO=V]R:W-H965T&ULK9I=;]NX$H;_"A'L10K4M412EE6D =(D/1N@38.X/7M-2W2LK2QZ)3D? M^^O/D%),11S*R>ZYB6UE2+W#CWEF*)T\J.I7O9:R(8^;HJP_':V;9OMQ.JW3 MM=R(^H/:RA+^LU+51C3PL[J;UMM*BLPTVA13&@2SZ4;DY='IB;EV4YV>J%U3 MY*6\J4B]VVQ$]?19%NKATU%X]'SA-K];-_K"]/1D*^[D0C8_MS<5_)KN>\GR MC2SK7)6DDJM/1V?AQ_,HT@V,Q7]S^5#WOA/MRE*I7_K'5?;I*-"*9"'31GGLNBT#V!CK^Z3H_V]]0-^]^?>_]BG =GEJ*6YZKX(\^:]:>C^1')Y$KL MBN96/?PN.X>,P%05M?E+'CK;X(BDN[I1FZXQ*-CD9?LI'KN!Z#6 ?O &M&M MAPVXIP'K&C#C:*O,N'4A&G%Z4JD'4FEKZ$U_,6-C6H,W>:FG<=%4\-\9:+"G1@L]?>=6;N MJL/"_>DDXK, 1O:^/ZBN&6,TB/96+WR*]CY%HV-WEOT)FP#B!DAM% 0.\"+- M"TG*_X.SND?=3ZHGZ'A7RPPLWI%MI>YS6(ED^?3FN9KM_9J-SM7Y6I1W6C-9 MB;PB]Z+82:)6<.%>MOZ^U]*PZ6@[CGKC3..(#B;#-9JP..#X9,1[T?&HZ./_ M"#T^>M0)A.!:% /-F-P841(EP\7C6M%X1G&Y\[W<^:C<"PED2W/1\J+,B-BH MJLG_-A1F*3.][3)H>"\TWE&6!(X3(9_-VK!TNO4(Z",&*R" MH7C7CM/8 ZC0 C4<)ZI6WM<,,7$K\JR'5!/]#T1$%Y[#P(^83.B<^V*_)6PX MCMA+4960')EQ[\:[)QU\^U-!]D7NX=>NDB:E,7S+ZZ;*ESN]?6N=U$EP+4-] M."RG41 M-J&LM]XZQ0@0 U\\HY9T=)QT^S'=BB>3=ICD+TVKG;1^H+)=>L5!,,RM$:M9 MZ$FMJ24<'2?W]0Z2[+)FPVC,&(50@U MFB>.48L\>KCT?&,5A3KA\FT2S]P)<,VBR,<1:C%(QVO-89W>1K+7UW[4$HN. M$^M&-":TIQ RZ]R7Q%"$32$+@F%PQ^WBN2<$4DLG.DZGA5/@$='T<@14M$L: MI-Q#K,)^N?)2L,41'(D'E9]F!UC\\ GV6*&CI=^ MWT33R3/[7B<";U#O%G0S3ID39ETS%LYB[BDIF(47&X?7B_%VUEUF9X8>4':J@-OQ6L.O[6]24WJA++L4 MLF3N"5G,DHZ-DVXP 3K.@G_:$[U^MMY)< DVF0V3*LP(:CZ/Y-YAZ(%*[AD5 M'2G0,(N*Q@A'PR'B,+-D'OK6CD4+)LYC%&!O'V-7SH90Y12AS5<$';"V8UVO5 MR'J?[Q>RA(VFB M\J[2P\488C+AB2\86_BQ \>=NVN.H6WOV=MX[>[O9G[TMO.L*(5X\ M'Z(%LPI#ZL$BLUADXUA\N;1><4#%7,8YXXX>D7JD<@M!?@""E4JES+JP(!]E ME>;MUFW/JM36E+GHDQ6D8G.R7<3(5]5Q2T)^H*H33YEZ*'T[%Q6+,$QOT^$P M(W:^,;:7X*RG7+X,P9*"Z783-. ^'@$;, MPB#A<>@1WWN..%[-795I)35^@,[&"5.1ZB\ZJX#4WSR.TQ?U8[4J3QO9_A]U M!BG6H"(8'APC9B$4IK[GA]S2E!\XW'R+ ^_)4M[EI3[30GUQ04J#(.*.,ZY= M FFY)]WC%KC\P%/#M_D",/ Y@CQ$C'C(G=B#,#>)HYGGM(-;YO)X-)M:[+;; M0NK\5!1$OYR2[=I:,WU.LV#QM6^I0/ H841&XX78N:9R\BR*CI0 MDSF'.SJ./C_[T:Z4)L,T3B\7BF_4.6=7SW"+$2]:^53WWO=99Q69SW9 M^/.@\1.AKOL9JJF3[9I0%G+GN'#:>ZML(ZL[\[)=3OLNUO[J_H6^,_,: MV^#ZY_#C>?M:GNVF?4OPFZB MC74AROH,O@0@[2J??&N_=&HK7EW;:F:1FW, MU[6$4%%I _C_2L%6ZG[H&^Q??SS]'U!+ P04 " !H@6]3,&=V MVAE:OB39-FWB&=MQ6^].$Z_5M/L*D9"$F@08 )2B_OK]S@% 4HJ=IC.[+XE( M >?RG?N17VVM>_!KI8+XV#;&OSY:A]!]=W+BJ[5JI9_93AE\L[2NE0&/;G7B M.Z=DS9?:YN3\]/0?)ZW4YNCB%;^[O;!\:;=2=$[YO6^EV5ZJQV]='9T?Y MQ;U>K0.].+EXU#H9J-2Z5<9K:X13R]='EV??73VG\WS@5ZVV M?O)9D"8+:Q_HX;9^?71* JE&58$H2/RW4=>J:8@0Q/B0:!X-+.GB]'.F_@/K M#ET6TJMKV_RFZ[!^??3MD:C54O9-N+?;GU32YP71JVSC^5^QC6=?G!Z)JO?! MMNDR)&BUB?_+CPF'R85OG[IPGBZ7#X5N->N'AS,[^^O[W[Y?;=6_'N!W'U?G[[]F8^%Y=OWXBKR_GMG-[> MW=_,;][^OW\"<0>9S[/, M5^>?)3A7W4P\.RW%^>GYV6?H/1LP>,;TGCV%@?*5TQU[R;NEN.H]#G@O+DTM MKJ37GM[>.>65"9).?8;G\X'G<^;Y_/^)^V=94#A_YSM9J==''0GO-NKH0IS- MQ%_F+:8(V2E"7O1>U6*MG-*F%'__V[?GYZ??;U7)G\Z^SV]Z?_C&]BZ_*M*K MRTI66N9S$NB'M-*IEZ*PTR&')5F&6!MM(+;:HD#?A GG]*TR/SB?,7I3A[^?*9 MZ!$1CK5LY-83M/1Y#B]3!1ZN9:.1=XV6,W%K8(5*M0MDFD1DY$PY+9]L),8+MC0)'Z=0@KZP^]!IN(A;)N/A(T(QX2+P#C["6@<5, M%A$+U6BU4;X V86*.FUDTR=L(V*/78#(HI)&-'APP(]5@ APC2IQ]P^Z:43D M:_$==/A#\3>]:6SU()C13/PRDB^T"("UZ@UH2CA/R6(@(KZ"%""]J!KQ&!BL;+@9J2I6,+L M2723M JNKT+O@"13 9DM=,.C21)I TP"D43Q)",NY8:\U]0H ^2$K/?$/"RQ M[Y<4"6QB. ,P(,7"3M3:5[8WH8AH!7@):1L/E*)%V=+'2U1%\/ Z]"QJ='3( MMYEJ2:\<'(9/K'7G66]\B:(/XQ )7(0*D3J@@,! 9*6KZ%>>$?3DTZ/\)43< M:#]PI?!*/K;580UMEA85D ('U;K2@X??;VPBOU$$&O\5XO=_!S6#'T!I(J_R=.J\D40M8;"5@I]A;] M3KGRD5OD3["BKD6V/TY["4-TSE8, ]NG@FN'>'449$<"=@B&-=J.QX$[P WX M5LR9O26PE &FX-8'+#5;*A=Q8O7<%H#K9*&8B1 M'[,3MV*<5,/:*24>U([T@[GA@ S$G;+X6!9W$6CVC#OEN(]-(2H +"CJ!DA- MN<@&DJ:,BO([9'V^%:C5K+:C3AQ,:#$0H2H1J-P44]-"1T" M*P- *GKJ@+$AR88H [H!HN2":E=#$TL/G9 BB-A.?)5ZH-N[U/Y\G5->3A&^Y^3AU7X>8YV];2FF M.7$\4!,\:_H!/ C* M1'K/S=*CGA^KZUX<%GLRIYZ14B!\^TLUA1MK%/F]H(BIA@2"Q?TTG21?84QC M0M&N2'?)A$O;:!O-2G=#&G7ST5&S,0PBA+V1?5BC#?Z#FASR5@8UFB&1&,V; MK)*N>A+9+HL#%GO@0?A<#HVB] M_*4<]I[XB5ZC5@.10)./ 0IPLBY@) MFN0-"1YMEM1K11Y4RU:LV!?;R:E<3Y :A"YP3]B M(4@>F@@=VI KZ<&-PS/4%C*50QV>F%G(NZ9D)U(@:7#_US6?LO%D.(U)"LHW M?:W$^]E\ED[Y_?X*E5ROJ -&>ZD*LT=0 YS9HTO#VA7W1J.-AVCU>!6PB&&NV6QZ HB>*0Z]'9\W#0 M=S9EW%3AJV%D3&6@C5[$Y)/VY32.XMR8FRW.%@0XLDWVRSC.3-OFV%/D\EC" MY]&7.3]T6FF&I7A 1YX:\L0!LR'9$U'EU M("GCD'MC>EC1@H.P..@'(0,#N0.]'2P6J-/++ 8*>S;:'7/S5NRWW$NN.9XD MXNLYZ:1RE!])CK">B3>]2UV$0+@IM)6\8U*T8Q)SU84X*N ,4"IJHS1 M9G'_3+Q(RQZ[O^SAV1)S8VSDB"=E*LR$BO<&T-#'3Q[14_.H/QD\:"#GT:/( MX102N=[$ACW/WZ;^2XN*/A$0[D/'+C[6(X8#BJ?3,V)^KU9]# HQ/_X/I6?2#LK0QB!GRPDG MKAX(%<5#>F-]3XL7IW@# TOMQ" ^@V4,M8./P2M&>&VK ^^9W,0^CT#]H4>> M5J[9%; 'XB\6>&8=2>8M%!H1%T.3Q+WY&!=---&TVO-2/H,]O[G.,+/?>#4@ M_>5.4TRTROAXWBP"?;_.0R3]\I"\]??>Q'YG,-J?NN.$-NX$ -.2W] M.+/EG4[:3&1&W:24YN00,PDE+PI&H5%BJB!20X8+&VU[#T"&B)N*5SQJ!TY[ M@WUGXOK=K[=OCL]>BCN81+4((K+GLJ-1X;W[1FB(&1=NNI)Z?*G/:Y MH%H,S$"9++P;^L^T.HR#A[?$H^'->*!Z6(^]94O%F/:>%:U=XQ#P:9,R_.K# M/]>4R$QX3@6R6-#RON-=:Z62OO2+-,^()!IFDHVF="#;.'?15EA7#[0"VJAH MXZV*%9W"M9&XYRRT(^_PTL/:%'R$Q&[OMX#LLI"]&&3BB60:M1OM8\"F9BNE MY<::U3%(MQD&$CI11 -6[=!IHEBQ^37T^LEN:?L5O0QW;5P>)B>C(2"Y=)%\ MF>2 7K7E>!@7EQ34FG9?@Q^3*<8[1"J%'[J3ZJ'9I=]HV(]9LS$&R.C1LVD4 M5S&=4"$=8NB)O$$XC@XX_-HS>^PWWI/)[^SH-U?\UP0^SK_Q)_?A[? '"Y?Q M=_KQ>/QK!W0 *S@R;+_$U=/9-R^.XG">'X+M^%?[A0W!MOQQS:M".H#OEQ:V M2@_$8/@SCHO_ E!+ P04 " !H@6]34&8$ML4H #-?0 & 'AL+W=O M@_%+OR54@S4,'Y1Q5LFQG ME;)C561G:^O5^P "0Q(Q"'!Q2&9^_>MK+A"4[.SNA\0BB9GIZ>GINQL_/%3U MYV:C=1M]V19E\^.S3=ON7KYXT:0;O4V:<;73)?RRJNIMTL+'>OVBV=4ZR6C0 MMG@QFTS.7VR3O'SVTP_TW6W]TP]5UQ9YJ6_KJ.FVVZ3>O])%]?#CL^DS\\5O M^7K3XA55&M5[]^.QJ^O+5*3Y/#_R> MZX?&^SO"G2RKZC-^N,E^?#9!@'2ATQ9G2."?>WVMBP(G C#^*7,^LTOB0/]O M,_M;VCOL99DT^KHJ_IYG[>;'9XMG4:9725>TOU4/?].RGS.<+ZV*AOX?/?"S MI_-G4=HU;;65P0#!-B_YW^2+X,$;L)@<&3"3 3."FQ[3^_=7O_TC^O VNKOY^=>;MS?75[]^ MC*ZNKS]\^O7CS:\_1[IS/V*YYX=F?LR>E^5[::) MWI29SL+Q+P!."^S, /MJ]NB$=WHWCN:3.)I-9M-'YIO;S<]IOOF1^:[2M.K* M-B_7T6U5Y&FNF^A_KY9-6P.Q_-\C"YS:!4YI@=/_"'8?G1MOZ\MFEZ3ZQV=P M'1M=W^MG/T6SDB)H6 MOH [V3914F9PI])JNTO*/JSL8#=-DW;RD3W4&*V@@_G83?1K?C:.?KZYNQSY4,.S: H47^B//[ #HRJ3+<@3X M:>AAVJ++M!+P$!I:XBI-X%':7 [?/&RJHMC3QVWR1U7G[7Y4/90P*WX%R[0U M/ ?FV[9Y%F>U$!#X^BJ*&"%5M<"7004538),2+&W#(I<,--M$GNM5IJ74:Z MR.&"$\B E-3?ZSCZM2K-:HPUF%PWM!&!^;__:S&;7GS?/ ZH G9>)X1Y'^3H M!(?/)M^71]:AGZ??/Z?S;?!X 5# #)%>B3 GL+$(]UN5\ 7B$IA7^AD0F.FZ M$>@B_<\.0!NK:_^$2A ^<"#55D=5'9T45=,\CX!2DNP/X(#P0%N9 R-ZPN=/ M>,!S'($#HJ1MZWS9R>/']H'X:GOTK3RZ + %0_# ./I-KW2-\[5]8@LV%QL?O==WF^/=MC;/6- XP1"=T=X@K]89P%8'D!0A:H-]C MFQI'-R7R1.",3#FER#RZ3@BZ1W_\Y;N\_!R][7#EJNAHM^H=T!_L)@:JS],- M'L"V@M->=7@%,MVD@%\FSE_AJD?SF*:^%A)/4@ 7-\5'#$22=D"&.5_=]PF M'/TRC6012W#TPR]30U]C)5_@\G+FF3DT6*;6WK G+HAN0? +RJ:?.17W1JN/Q#V=#(F;A\.IM,@SFGH M1/UE.FERE#ZX4HR,K,=1CR J/H(<%<+YKY%->[#O05P@YH"2C0!)<*QZK5.] M70),\RGJ3-,+FC_+&\#&/>,8N0:H#'J-> "&M:MJ$@XR/=P=0TXEZ.CT4++; MU562;LRA 6?(U[@L/TDWJDP*!99"4N9_LK!N-TF+Y 03@O#;^_,A?]LFGW%5 M)YPRG>:-0TD#<#3X/3Q E@@>EV#5:A6]4ZMI,\A]5$1C0:+!=9"$0D5)U9J8;^/C%:@, &69I<25';;'>^4#B59K>#NTNX88T@^ M6U2(S"9%V3,<*9>9@(Y2D+Q=31M"@H:MPL+JV!A>!&^A(>ROTS('0*,#J/6] M+CN!1G\!.Q5/)@/B'0:JVY PGD5=P)G@MG$Z[,\:$%9IJ U(F+V.K1_2?!)Q5 ML [ND(Y6]@;_IA6L@>?%@^^3HK.$XDFLO 2SI2.D#3S(*HFZ@OFL2I)Z*LG. MJB2DM 4L^QO5& M'?AJ8"!M:82V>T;"%.B$$2,T$ZL<&$)>;T5OW<$QE.VH!I',RGB;E&O:*E,V MXS?3AM_ZAP%(K;9YBGP.]":@_Q41.U M8.M/PMW ?*S+JC;Y(M3L#B\IBNJ! M385DG> ID_J;&9S#&#N-< %B:-L*GD3*SE,@]1C%UA^:7""H,2,:"OTE^J/+ M#&?\32CN-T=Q]KN\,83X)RS9[9"AHT:Y8F7 "+.3?*S',;)W$HQX#$#DSU&% M I&QS8GW@[1"@PD$%WF >+\5#*AYGH2OJ,]3JV61KX4[ U>#*X/'IHDG)J7A M5L3-@!91%6DL>\DS8>SJ0=.!I\0983L:<9$C%:0;.! M3![8NP/.H<7 )EP3 M]G,/4YM]$5RT8>96.!B_ZOS)1&#ME?Z2P^$(/]Q50!"D?N9@_\"7+%7Q)V]D M+?A$]1P_" ]!M@E0P\3'\(6DWJQRY)RP9+@:J93UX!D/ D<[)PZVV\$A$#4? M6Y?L1+LH;A*8)J5P,[KW.R5^G<,B?1D[VY]Q[YD<'#]QM7 I-VA!B(X?$\&W4[ M0X/12L@P(#4[.5,$3@W,$BZO*CS"CP4NLTTU9%=6:E#Y2,ZO:=R_ ?E@0 M68($#!=-Y4RD " 294U2Z$;8W@&J8A48"0"B:. :Q3G0+S VQ(+%*.P1L(A M\T$8[<]W-+K]:U9LW!&I0.8=MD'R -Q7\-D-9P;BCY=-L6/%CAG0(QD^&= M8"D EQF>EB.+4*]8@>RN\)PL]$,/C+U;+#?8'1HB#)X"#@^;(,O#(> EL-/G M*J"B!#T (^!71=< \XK!-&\[LAD9O:3QE=T*:;@F5?0%@@?6F<$FJCSWM%M MZ"#YQ;!L_IQ<.8 V6'A45NVHK49-!X(2?H,?62$K=-)83D'N4%DF^ MA2GQ^I_D]SP2]$9@F8 TVA+HX2"$,SQ$U!/7XN_Z&+ _@SBB3C&X@&R %'>: MI 6L!8(8-@U:QY=6YD,=BRVL0J_A(>#^N5Q07PDU)\SH$!LAARF KG'ND L# M-D+F"^JN=8@=XX9TM">".0;4K"X")":USSFG6MB&IR73I67;WL@9$.%+Y$X@ M[?6V4?"]$QQ6VH:PY^6N$X%[8LY16.3_-&:06T$GZ 4*$,&"S?F"DB50B?&/ M<;A"UPK 1#1Y;D+@$' 8JYQN-I$(2X)#\>D@]I"!NP# MG(5!;>"I4A9S QNDV?I+H\I6P95@W06/Q:UK#%NWE'&,>^*Y*,Q9VH'*[J&_ MF&]_#M/3H]=#>..J*\G=YYV;X8D,,\E9SX!!+VB9)07(NL@-1F=MW[!&#PAH MFN0+<+Z*K.)#AQ];5/SN\=Q%LZ(%@TG9@I0A#@BXU)X]VK7L+W&X"ZC<\AST MK]2BK_5@/>+NILV7%=#L4)(JX>'T/^Q7VY%2> MOORUH'H8 F@--V]\=FZ8N'!HOI*^39N!U0OB F]M0VJ_8GW LWC<]7QGY3.Q M6SC]:LE20,R#_A5@0^*1&:^0UM#11*954I> ;=HQX*%!+L-F3,M>EV%%EHT5 M'']L'=1D-$))3DSCH\MIH24QK+^NO1Y:#U9Z!2GJ(N]YMT!K$@\S8X>_:1!;<"":!N6.M -Y-;+^VV M74&.CCZ5_$F.G:(@AD>89JHC-E>*OH1LL><'8D_.(.RYSXF!<0(#(KU46& MI9UC^KVC-B3K96!BO ]K[3*?K4(VY.N%LV6 JZH0;_N 1&WO&FK40.UK]H4.J,2DLQJE/.+PH8RUW^Y0F R<-K*JI4;' M1[0'R4M1=A"Z=,!R57J,NC'NQ\Q&'HP9:+V,[*DW]TX="59[_G&$[-#-0T^: M+0!,=Z D(%DF;.,;\UZ,CGT_1..[J?)2A;J 0&>)%W,RUI3-0)Q#Z!@]FL=, M/9_^ >&D,R2'UI5CI9[UH YMHRQ:5^CX\G1 @%(+)^T(ZJ?*.PX9[>JRPMZ75,<7" M\6A%AA*N5!."A8M83XQS9O6=CB_5ZQS$%RA#O%WEPE#JXP94).6GO$6_@ID9 M?*/NX'I33%9A'EOP26%6&P5D(_N7.KE! JU 9I99\US=LOM1F3N16+4L^BZ: MQM/)!/^]C.>+,_AC-H^G4_QF=AJ?7EPHJ]:I0[4N.EW,HL44)CF_.(LN9S/U M$7-.[$HX_1D\0M.?GI_SK!>\SED\O[QTR3)B@@*O@+$MZI/F#.A,KVVH,'I' MCIDW)G9WR\ZS6^M=^^#"LM<8T/"C?GY&4%HU;2\."#]W%"$)N(PBWM$S$L5G MQ_<'SY\FPEAK*B%O:^;Z=E]NMF=)C"4HN@K%@VJF1I\N:CORD:Q!M,=2]L'# M56^,,D];B;UXJGBOR'=JYD>%M?;F1X;9:&#)PCK"")9U?S%FCDRB["3'$6%F MQ/N0U&B:H6#LBM8\S.L?+ 7F2YV-,$7"1(^)T4M4S++4 &R%^&W:+>^O$<]< M8P^;'%KB2 6S0O.531.2GX8&;P_\M9:BC#=D("/,BT"K7D;8,$U'QVGZYI!* M$'1!4?;$\F%"FDEP$97 J@CN6$QL(- 8Q^9B"6TY$D;)W>U Z""19_<<9S2' M%M"N"T&8:W,DE5 T%P.!N ]8+1:W!@8P U"%$) 5W\LY.M/M6$S5V[@2WRV9 M$XG1)35MI(?VI"Y=?,C<8.-ZKRN0"#!5[.4=,&;EN/I9:0$%RS/J6TX4U%0\ M@M)AX. X!(MHL"$.#Y#7IR0F#N6&43+K$T!_$QF.?7+WN-.WT;7RY@@[OM[H@4[\C_ML9F_S?H-=>?K"@2-*^8ZH,(!ZS"\U%V^49^4+S*N\0:/+ MN)W0$R6).6S*6]'D(H/6EZ3DE#% +T3OO$HA8$2)\%-K".FM32+R$F(D9&_. M'K8LV1 FNX<3\KQYR.2#LP!+'%3$ST0(:!A3M@WHWLQL#C-=/=]_(UM@]X L MM"N25#+.^M.QK#U(/W6AZQP]$NL-_%43ZLC,!4JKD9#0L=;(3;=2D]W,_ 01 MHIL7$(?K$Y$< (+WA^.D.!7=997I7=7DUO@2:EX%Z,[;SJ4QPA4@VQ:5I,J X&=#51P#9WCGORU* YCGP$KA(<2D92RH]48+XW1EQ+0J2%#,_L MV*;0X=C50>J(%R<*PS7S&6BTT6P63>?1Y2(ZFX#*&TUG$>K%00*A]1V06X53 M"LD-7. \&B .F.8K<2R15%03.VJM;ZD./)F9/T.M Z8,<-LMP9$QO4FURM0\DAKAR<_8**5>%FR M'&X^LF(O*YLL3A=I%CVXB=[78YZ2,GB3:%DEL,B63\#L6>#@>/8O7:GI7$@= M5G+_K?/+J#7" G#6[Z9NFYP9'/4R@S$'^+7-F_Q*JO!#JB#B,\FGMTLS^R/G M"T9L=$8K@_TXACLU/8LG0#"6"=$?;SPF).S ^-T:# ;XK_$G(SQ M!;AIO1($HGJS+?%GL4?,$1]( M! V(B-W633N"#0%ME(6_.X\0%1TY> IO:HC:=(AA;71.[WB4[H58/>WG3 M=)QZM :YC1Y>IRI3KO$:E:F2^5!-YYV &I'F^C#P.BA5MCHAIJ\P')SDM9!M M1[9FM42]1E(D,5%A'$D%S)TG8-OH+0[\G0;>A*@UGSH<+(IW 6E4/"*4 M11Z;Z*]1.Y."W4PEFICV(^5A]VBA1 MKY_#?47QI5FUQU\'ZF6^2IE_?!EEG3I4\W/!;#7+%9 MSEQBAV\.CR@XE:.>MRCTV:F^S^ZENDLW.NL*C3\=ZE%"0WOU<;_3[$SZN<:Z M,?X_$I4BHNJ[W$*/';*^EU*9I;Q=C*)W:);>I:2R-)X+ZX2+I9X#YSN?Q9-3 M=*'-%HOX;+* OTZF\0)4"_QU?KJ(+^:+P+>+X0EQU,=7D1@UC$A2ZG\<7EA2P$?]!"BXMX.IO8\A!EA(#9F(^WK]K8 M?!9?G*,G\&(6GP-0L-S98DZ+32>G\>)B^O2N3N/)XCR:QJ?3"0([.S^%\:?Q M;.ZV-3^/%V=37 8>OKR479U>R$*7\70R'^ 9?\_Q.+&Z)(.+((8<* M!0GW_0'_0DL1R\"[)G(YZQR*Q,JV7=&1:*,G%,=M&ZEV(+\V11<E/5INK8QAZ9*>(N44=" MU8*T\%JJ(G29&LVJZ9E0#G$>"PO.[%O*39]@^"$GGC_"B2V;?:^!\K- 3+XQ MY2*!Y Q4;;8B1Y+)E>KPUP>^3>J):V"FA?,E_0O]>B[SQ%R/@C#(O9%841&)"6\'M*.'+)UP/WU\V5"<5XUNK;6R6#+I4!1 M1)T#1\0RF6_UL*Q;CY@-41M ML:01^6NYI!7?:]*K2R?N*7X ZT?78/)3O1"E^IHRF_Z=5:8N"GC%W[63/(-X MP)V@0R2DSM]!ZVK!"NF9U^9K:UM34AT5?#>Y[\!PLXT59^N^QRB1&(P/VN9= M4F'Y\-J\(6;I9D=]VC]]G/:#:BZ?^0EEU_H>N[OT#-;&*U@@80!W)$U 8/!% M1(H8P9&4(S@$8!H@:+RZ,11U&, YO0/,]+9O;TTJD=;P=K #CY'F:3L& M6%D/+%',AT-SCB09BUQ@*J9,6F0SBNK"U[)\>EQ9S"-%[$/(93X+/V%_;LE?!6;L#00S_"BEMUH'RAY-ZN+:KJ ML[51'/?Q8\(9:!3UWF@D+5?,F$R)6'G*EI_[2[%3P^O1P^[X'B9%H#&] D/' MX',,?!R+C;&R&!O#]%00CQ*M4V.(@.&L2I\H +AZ;=,$O\YB/2A?CTK]P#3$ ME=DR@W_;&]3P@)[S9H-1G'= +Z./ "Y<3GR+/$+>9\(!'UGCN3GD\*R+ M*8P;8'HFZJ*)Z'#?VIJ#B0]Y\$87F=0;8O4#'(41B2=UP)O.GW.*MHF1X."V M4DM;,F,)S@A)Y*9QY-\:S/9=4RG.&T2-2!ZQ%7B%/ ZX,G]$ XG M6IIT)[P-07'PUR.%JB%\Z6.=AQ^ .-%)>. @=#M .\9"KSQX8^D#A(4/^^B[ M^=EX8IV6Z,4\@KV^:)A.O])%$6:G*@D]>@"9J'EC_^UGG+B2T&* MZ8>"A*C"! @4OI0;WT]/8?^3Y3A\#K$W!0$\U9 M\49P^07:25ERT.8D%-=R$,]=HB.&0/AD/*:;YG7:;4W(6&2\'"EH&Q1E]=H? ME P/*<-EU?(UMED-),-)%;S74OK+:9VTKRS9O-\^,*4L2YB>JY40&4T[8M MHH9$#T.%SG*7+?.WS?]S.N;E1H<:*OUS*-Q MD%A"C38"D6GAP(3[JFN\*GP2U3EPBC![)O*.F*910='!P:D?T$O2^AT[L$U( MQL5PH"/C3=&U2!L@ MTZ47.'PX0UT,BQOVW\M(\*S+BNV/%CLDYJ^LUHR%Y .E!VG57L#D$N+VB8 MR0%0H'E;J)2]IM1&@7.&76I*D(I,<9BD&-7!C$Z'>S_IS6,Y E4N@X+$CQBI+R1*]YD/WR)%I3,9 Q_Y5^'-- M9.5SY M^Z#;PJU^D#^FK<]%?.9L%6&# 9CZ6J%=%DGX>W:6; MBIH%4)+J""45_KRM,EWTN&T3G=/,7QMR>Q0D-K%!8A\/S TTZQG^TDOO=/4> M(.67^0K$$W-I46E@P0WJR:ZVN1;FE/G5X58#HH==XA8VJ0/]%Q@REF E;8O1 MBA70M\96O[:=F'<]^WX"DU@C^U!N'\8L_6;CAV/D/>.*.JE-+[_R"-4C1SC4 M-,F=W_' JN?B?>_]X'J$8% >^+5A=.#=-8&_%XK[39O\%,L[^PT.@4^;8L^>6_B18 G'$LDX%'GA M-5]) E<2M@[QKK6?*HU:5]Y2TS9:4)PB"U)DU>@1J3R_'@CLQ^ MQ9EP1=5QODEBC.WP26>,!."R$XM][@[#U+@'[3\!%R6GE$V2*=J?>\CO)4U[ M(VJW?6 F7SYZJ'26(TX!O/:;D'WY=)1QK?=.(\:<4594SI M5CT:9H4T"=^'7L?+TV=@3><]>!U@W%T #Q2,SBPII$:840;K&V#D,E!,E(LRV# M[JZ\7L;4-Q][QJW( -.H2#92=B9WCS,9%<6,'T\)95TF'3^>42:H8/NTCJHAKR+(Q#MD!<(+BA2NR#QW'G.IQY511R,4WA M ,];4MLK; ZP!HHIA-VBYXP\+%SN0-*TAQ[LO.'5T5]Y'45YO\->39SJ"1Q( M[1!;"N*RZF$7DUEG>)(*+Y7QQNCLI6_/@X$[6B&?L.V=C0$]'<\7.)J22>;C MR8192>1].[%_G9Y-*$O5_/NOI,B:&Z'F6(PYF49GX[/SZ/1B3C.?C1?GT?QR M'E]@MOGXXE+DQ4#3RMQTMGTR.!.6KN'#)@A'VE"&-;H-53S=# MZP=)Y-%7))%S72LE(L-'QN0TGEU<\L[CR[,9_34;SP#5BX5YX)11 M-^8H/P4,^O;&8]"4/!0RI^#] J;ZT]:7WU'/(Q00UV"C8H26]F@FO[J[MG-? M3!=>]^ N_A5&:;QLG)-:YH;]-3J&TY7B)12SZAR,*V^7:.4/GB420N48ES'8NC($==AQ7CPE>F%S&Z M%>_10UWL*2W98N,HQO+M5F\T'97=@<>T/E",;R4*)?U\'@$N1:B)LGT\O2<'IT ?IW/-"7GV/ !*R2\9F[Q2%OG#U MH"WVTX:&U&P<"AARNAV4+"JG<2;X#<+WMJV\$A5 K&]F&ZXE,:P]T/OXH-FX[=!B MPG'B\B.'/:":HKXI6]02)W1=\:AY4'A-^M4-3S8N%Y/7/I1;U(@3'TLFAOH\ M][(C%&4.@X&A!_>-H;"BH+IGZHXD##>V50CR'#5TH:PK"B86^6=-3;E:]O5P M80--DZ\D=\T/XP%JD"?6!)W?KXJ51PIC,H)Y+D^1*1/*V0GD2S",OM38.XZ2ZEP.M65C M;?*9WBWA93_*7<54!/18*<,XWZ#])>%HFQ'5[;+$O!2A;SP\!F1IFS,YC=;\ M;.1N3'U=3+,QY?*8P_"=Q] M?@[7%,4 E"[X[Q2;O^%$P;NAJK+"4V?2Y@> M?*XR8,,:\XL=VX -NNH^5XT[J'.]HF(WHVR]O;I[9;0M)6[6P6&?"+&>DO;) M*FF_5F-:?C2=Q;T@(W.HDX_5+D^CB]/)\Y?1';78X@9!".Y5V'B(!RH:&&AS M?+(8-JS00VJ*8=%G9=ZL('TCS;M!W&NLX#D+ G[P7G;EB]]$4-O:Y3#Z]DL" M9%/O(^;T4W';92(,C=^ H3/Z)=>FNLI48_@.ORK%S[4U>3E>X,9K10$(&F!\ MWELA&FI$%_T#.+U'*%*^.#T7"H%#-SYU.$AS@.>CZ=P>H*.B&U?331#/OK^F M(FWUCA.TY73GLW,X7<\-CJ#SD]$[6SL\.*T-Q'+!!I9K$YRV.)_"ZNPUY3 4 M6^6EE31*ZL;Y0?2?1*%$.XB])=$2)!]F%5.M+M<(>N$K+[SAS:T]'1?#U-S/ MR4\(42Z8;,)[O;1++X!+\3MN-VIZ%N@TD6>^.BU]>HF((4O8&LJ"LI> MP=4KF".I1^CMO*:7I#/')L N%X$C6<]J(H9Z9^ M^("WS:44$PRJ8N]8W Y)"R"&(W[O\F;0Z6_7\1*?"3,<\76O+C@.L<(D+V*7 M1YCCDUH?Y??8UU8957R8YF:3T>360=GY@;$<5\1N%BWHMJE-_58[FW[TRDWBB4N]QH*0DS]KI) M$EEW.;]CDHX])_LD@0-K)2YHWKZ(9N ]2>VVSM?8((;511N%;M"SWIK$RM[5; X3\!@(*&$@I@54R4/=O>J$%#T/$ QO50U04 MO \(+[QYDY) [D1ASIFK(F' _$A5PO9FP8C5"STT.9BQI[ M54%THYQ3G.)RNQW>:H2=/5&H3*"_!!3RNJ+6VZ2@8M27!8^Q#H?9CD,7,AWU M=4PG.F ZI_]>IJ..,AT'[[^'Y1SF71_A.=/19&%YSBN39GSMI1DKT:$6D[/! M:\]Y'%?.ZK;?O?/-;XP4.T; W,PT[ QU+'YE$5M=I*GX9O\ M [LUN#"4+N&5U!FKTF]VY3&,'"Y6#U*[-KIMV&3'#K[2^L)8#G:*IZZ-@+34 M-N=MY^ZAO "7KM:W7:C_E!17_]$+-?3BYQ?>*[;A]-?T(G%Z@5S9\MNV[;>1 M>5?Y%;^BVSW.+SI_#VP5^T<4>@5#)^.+LV=<,V ^@.BE%W8OJQ9(C?[<:+0/ M\ 'X?555K?F "]@WN/_T_U!+ P04 " !H@6]38:-(7Z,) "4&0 & M 'AL+W=O@-)DIIXHKB;KX MDMBNV>-?KF7@N,FZZJA YWDR5SKC%K9[U3*$%3YQ0 MEO8&_?YA+^,R[YR?NF?W^OQ4E3:5N;C7S)19QO7+!Y&JQ5DGZM0/OLC9W-*# MWOEIP6?B0=BOQ;W&7:_1DLA,Y$:JG&DQ/>M<1.\^C&B]6_!-BH5I73/R9*+4 M=[JY25E:K^HQ1^B\F=,^F*5&O>7+?S:,7:,2V-55@GC/I.Y_\^? MJSBT!([[.P0&E<# V>TW=-(R3.27EP6J\E9"S MYU=__WKS^$_V<'7Y]GC\=/7Y\;1GL1=) M].)*[P>O=[!#[PG[I'([-^PJ3T2R*M^#C8VA@]K0#X.]"A]$T67#?L@&_4&T M1]^P<7SH] UWZ+O)GX2Q@)MB8JP& M>/Z]9]-1L^G(;3KZOT=[KUZJW'>FX+$XZZ TC=!/HG,^[++7[:PR MP:Y+Q//@MU^.!X/^^P>4G=#N)GK_-F2+N8SGT!BG)>#!9B(7FJ<,&V4&FVM5 MSN;5HK8I"VY8H=63)"%ZH;PM,*PH=3Q'>0:IG IF8BGR&.D3WB:S3*@$%;!" M:3M5J51,32$Z267L\H\H/'$K6.PVI.6U![>D]J%6>U_+URXQ\",%A\\0EAE4 M!+5!I#,6M,]OOT2'P_>#P;![@E).(9V'C!=PZ%F"7T3ZPMZPP=%1=TP9^;/, M!1MM3<@SO+%5!!XUSPV/UU(R$78A1![]-ECU#1 MF.2>H:.4:4++X6"F\MG>;9;V<+,G-3-T(1.L^RN>40H&KYBF/D(A2025 RH= MA2 8%&M&!\5S[S#G0PE:[$K)2T#MGOTO25&ICJ7.7AJ?&6:8@H>NM M_U8E.?9U[T 2JSR1#J>4D-*$570(\11'J-T=6E ?FK&C*@K3@FNGT-&W\8%K MA[V%U0V0!5#APK>3'%X(5[P%U*K.B5Y:P.J"#S%[Q$HG'!EP9/G:HJI#BZ@[ MP%AE09*O(I:&K86)J4F1!65NN^QKH?+5O!&&MK'D'JP'JQ7KK>;&J%ARBO\4 MC(/J0=M 3E(!8Q-/!RZ9*Q91&BIFF+AUE7G(FP'-:^Z'M\RMQ19REE?L,1?! MIMV49%/^'/:U@UNST&47#L ?12RR"2P;1C4/4P56&-R*F7T$X>+1RNDZ[Q6O MH5W/4[4(<, ,"K5J:;Y"@JW6D=E[(X-VFU*^+$9YX@'N0 2;4<2N:>:E"P;T MX$Q B<&B"4@K%\8(5*IOYT[4EYT"%/-9T-:BJXI7*"QQ6S+LWQ66[O7*VMZ*A& M<W%!AH!\J7*HX'MJK5 MZHS@M&^I8.*-I?M;@=0JB@V@A+Y5.YBWZBP3=JZH\=2G"N=):2A2$SKZA@Z3 M;X;C4?>P)FG7\=X,1L?=:#D0HE(*X%%6, M$;)"+DUW',3E0(HYSZ;D$P)+Z$04G3[!-:;K.T --@7>IFKLQ7RBM%@AXF5H MD)T(XWC=5/WXXA6CS*GG+0\QVR(UX:GK^OX#"U^%:E!#%2!V P(PE;IF"I) MH21^@FCOUS11Y_+6SDTM88+9GP8O^O;A,PSV5GG,S;Q"B6-I0AFD@[TYIEV< MX!0H7DY1.0VFF3_C"SKC;RE!3^R.P^=H7R[BKY%S"Y?5^BKLM=QUA8+>HQ;D M91.R'27^#@4R%TF9B@ *=U="\$@^!.W/&NPSG%EY$JPF=^7.P!+W=*R&JE;Z;Y#3LC0,!\-^ MI0XI#WZF#NV+Z)\.((Y/HO'XVAY>Q2.1X._H')] F\T'1R-PL/# 7O; M/*G^![]3T1]0O-\&*+?=(!\>A7"618C ,1O#Z\,C=H P]*'5:6F+%UH47*Z0 M,P%LB\N#\'@T7KT+/J-K-9@@N36(4-S[4=B/* .#<=@?1?3HP7?-A\ E^ MY7]&[. 01XE?F^\T/QM<8?.RT?H^ZYEZS2N2J;=HCQ?$3W[ZHW."T@$]R&G: M)])LZ? ':QCC1%CLL4@$Y<=-NJPW<.-'.0%?8*C$+/C2GMTW!P"WF5F&#CL0 M\=" HWG3E0Q1--"?X#%.?54/@&3HQ^5V _XF.:8"=C_G.N.QP/DUIF/P'VA_ MT()!XO;VLOF\Y!?77Y/<5$/#>DV S>RX/XJEJ<[GU>A;)ZHR96F?Q\M>;T#5 MBLV42A9H?BX&ULK59-;^,V$+WS5PS4H-@ @JT/ M.[:SC@$GFVT#;((@R::'H@=:&DM")%(EZ3C;7]\A9+E#EOWLR\ M$6>ZENI%YX@&WJI2Z LO-Z8^[_=UDF/%=4_6*.B?I505-[1565_7"GGJC*JR M'P7!6;_BA?!F4_?N7LVFZ+4O'HHL-_9%?S:M M>8:/:+[6]XIV_0XE+2H4NI "%"XOO'EX?CFPY]V!YP+7>F<--I*%E"]V M>($EA"4FQB)P>KSB%9:E!2(:OV\POP4RX)KO)+E+T5J\@MO M[$&*2[XJS8-<_XR;>(86+Y&E=K^P;L[&0P^2E3:RVA@3@ZH0S9._;?*P8S . M#AA$&X/(\6X<.9:?N.&SJ9)K4/8TH=F%"]59$[E"V*(\&D7_%F1G9C=WS]>/ M3[?7=T\P?X+/\YL'>)Y_^7H][1M"MV?ZR0;ILD&*#B!-X%8*DVNX%BFF^_9] M8M51BUIJE]%1P$>L>Q '/D1!%![!B[M08X<7'\(C0:>K$D$NX4:\HC8D+J/A MU_E"&T7R^.V(DT'G9."<#/Z'?!Y%LMUXKFN>X(5'[:91O:(W&_3@D ?XM%*% MR"A;X1EPD=K%R(=YPI."DV12A 25H3Z%8B=ZVCZC*HP4V&-S#9Q:39.D;99, M3GZ!0)>)8IS+BAH]+PTEH._#"<^,,H!)US K3O6C>0 MR*JBAB1M)R^.Z9HK\D%DC(1ZI9*J M2%R]3\*X=Q9"C:J!H"-UX=*U0+-&%%9DP29MT:C7)I,RP 05!JI&VVBU#:1, M@]6"P#;R#+J\:%E23LJ2$F0_B:X@D[$_& 8M]\-IH)Q*9?%M>GE9_$'+4FH7 M[DG.7ERGEN OWQAW$4CC[J ^C, MJG.K! TKL1<>J4$Y56R])-28LBQ2ZL"46-&C:6UR29>WXJYS>T"WF#MN!^I#VL_O&U/T/9?^[*WM;UVZ8C+@BSI[J=:GK/V&\SH?%.LO:\1>[+YMW.2:GJY6[$/-X*97*XTA:)/65,C1L[WR[/EX6^_2"?@ZA5^ MI-6'V _&(9S:9>2/AI%;1M%P TD([##DGFI:T+\^8W\PFK"?-IFQDF6'F/W= M=#@)@5J4?2%UL(WY?V)!@<9TB9RR.S2L4Y\5PHX8/U@1GC95/)"E<3RAW\D@ M@N_=K/V=J:5"E;G93!/#E3#- -.][<:_>3/U;(\WL^,M5YEMC1*79!KT1C1M MJ68>:S9&UFX&6DA#$Y5;YC3"HK('Z/^EE*;=6 ?=4#S[$U!+ P04 " !H M@6]3WX["?DX# ?!P &0 'AL+W=OO&*A!T0*J==F.G=H&G&.Q 9H#L=,"?:.ED42L1'I):IWTUW=( MR:JWNPGZT@=),\.9;TZ.%@>I/ND*T5L8)PM=BS$C=HGO>/BKAP0,EY@T)S*4!AL?37\<7EV.H[A=\Y'O0) M#3:3G92?+'.;+_W(!H0U9L8B,/I\P2NL:PM$87SN,?W!I34\I8_H'USNE,N. M:;R2]1\\-]72G_F08\':VCS)PT?L\YE8O$S6VKWAT.F.R6/6:B.;WICXAHON MRU[Z.IP8S*(W#)+>('%Q=XYU]N;^^TF@/N;+3Q\@/75U?/=\V\DO8;UWQL[3^'\H\KO( M]LI>Z#W+<.G3G=2HOJ"_FHS@OWJDK%G&V8\_S)+X_%<-4M2OP'.J"R\XV]4( M7!@F2FY)IC52O1BI%4#=,-CL4'G'E@ 3.5QCYJ20QDX: 5,(^[[45J.C0=GK MHBE2Q_ZBL*L\.^D".^D"&&E83<(S2.;Q:$KX\]$T]H5V9.]2,\5S[*+)C&B4=, G$4C,63F>QI<'0I/EE:#JG2K61-0*TRWOP;IL/W7W=+[1[W[==PQ57*AH<:"3*/1 M^<3O8CPR1N[="MQ)0PO5D17]P5!9!3HOI#1'QCH8_HFKOP%02P,$% @ M:(%O4ZB8U /W$@ &UL MY5MM<]LVMO[.7X'Q=>\D,XHLR2]UVB0SMI/=[4Z39N)L^QDB(8D;BF )THKZ MZ^]S#@ 2I"A9]MW[Z?>&O_MKV6YO569WKP]F9[X+[ZDRU5%7YR]>U/(I;I7U;^*SR4^G354 MDG2M-%O2PO!O3_UO?'?<92Z-NM/9'VE2K=Z>7)^(1"UD MG55?].8?RMWGDNC%.C/\K]C89V?8,:Y-I==N,3ZOT]S^7WYW? @67$_V+)BY M!3,^M]V(3_E>5O+=FU)O1$E/@QK]P5?EU3A%6-Q/AF)V60V/4#OO+GF.=,[WT>ODN59$G<:ERJKE/[^#*U69:D2<5_I^)OX+1>?](-:SU4IIM?$T.GKD:A6 MM&I=R'PKP I%SZ=YI87$!G%=IA5M\KDNXQ54/KI9EM@+#T([JY5HN?F[S&HE M?OTL7OSW?UW/9I.?FY_X\_3GET+FB8AQ.C@(L:CSQ/ W,HYUG5?XL%BD62HK M'(!HCX0NH=\Y'$(BYMM1L-<+Z#H;\X/*MJ.(KN VO:VWJC3-CD5=FEKBL+C/ M9I7&J\YU4V-JT'Z1OA3GEY/19#(1E_0O__45#SZ5P[',Q5R)V#ZBDL@Q,J^9 MZ7HAS$I"KO17K-=K^"+#"]6?M9P6$ F)3.4I.&#(&$ :Q'!O,(BN M8M6M4;/(?3U@.*(U''LT42&B>6X2L]?,^G$C$YD9_6S!1$?K[(Y@B%#K)RS/ M+QJ>_TW-RQHQV_]R.18W29+2"7 B6.DJ4*GH62IU[,GK@LC2#C'87:KKY4UM#RJM19A"W9)!XD;@E#TJ0?HBK3Y5(Q"]0#I ,;,C7\A#36#FM3 M.-RQ*/4:CTM6(1!+5)::BC\L0K="SF?ZX\^F8^%C\0L_%#WUDE!?RS8R^2I4 M!;>KX_>HIT?"FOH:=@-=SNI$@2EK^4V]VF"%BN2:G*Z5@W,VB#CKM%[#B2C< MV5XS[Y,UL$*OP8AW4 MXT?55[LCT%JA8-JIJ3]AY5V^@Z2P:5383*-KW\P6O:KJ+%:1G7:^)XK Q?A+3K MJ1-/O*G/^!D.%H](ORNGR$7BY/'93JG$\XAG;'X8Z7R M78QF(#N8CMW>QD?>5'UW_N YK%NPYWAI23.'V(\X,K?B#UF6DG I(E?AHWC7 MIS\'(UJ1(#K4ZSJ3!&&C1B0",!"XLD_ZUR1 4PL0_WV$>\$&2*E-^0-M;A^9$_G MG@:":$C87F$#?]E0)^(_$O'4GK2E$#$%&],-G!K$A(OD@W>!!*>3/4?H8!.IQ07 MRF4W:'LD'R M(&/+?+;BEO%2=W93SPT25M(DA[2"([;YRS-1?9,WE%1%HST?-'L/F." W/H6#^"(@>!WNIHGD5#<@1_0NH%/V+S-*P+J>NZ[$):,F%F>X_C MI8H58B;E^@2MB;LPT 29&'!$S6@%WQV@/&+^64S2E%WHTO#.LK)5FL$JS*. MJDE%V'QYAXCE9WUT"]+='1(?HIYN(HDEU*H\%YHZ#$S7P/%438/:-+RBW4*) MV'C@,Q+"7E:C<+J@;&1A7C?C2Q1XA1S%![2FK@"J+ &"68\1QTXJ1 RFPHI$6+L3:5!30N"J1 M1+9PL%*,9:6K4CQ'[E:GK!V<"HXQT_%Y1RSLA=)%ZC*"ISHZ<&:M_OH+O@B M!M:15EM?"0$NJ,K:57[9+L$YY?(E)GR@/$&!R]==FE2([(6+,)O4,/[Q"5KD M$[2QN $?*\I,P?4Y[]+ IZ=R;_C4/<0&\U:595X4W!@,3RL39C[6)]3&UQQ: MNTFYB&XJRL57VFH'5$4OX> YT=BZ*@8A0H);51AWV:5P(EFD%<=A#H82(==I M#@XHV>Z4+"&G)4+;#1^;BU0NCZQ6P)JV#$.B7-N>C**>S $8HAR*EZ_GG+I M>S:^IMQP" _487[4:'7;OBNXMIBJB]J22[<>B7N!QJQM]70Q]7D'<3?*:3D M?+9]"Z.P =%T&VQT\\\@*.:DL$3_X*%ZBN.PO?8UZ&:?,B3"F,9$?8#P+&> MN[3=A#OK^GTAA_L:M8.6SHO;?)]1*G.)#L&Z-<2Y?;>CR-CF&6Y9 M.OCP/H7"5QJR8=]GTN^TUE"T@560ZB%#Y% )E*MA,-$_H?Q<)[R'363.O3LJ M.Z@$*[%T2=EYH!4=S$@&MR;8):J-#NTK:8]&8<1N[VRS);?'WQT#(W9*5;]TGC3++RQ[S39:$9 MQ0:ZT%"T@7^ALTQO:,41(?YPD"G) >/*I=6I;JQOHN4*4=1!1GJPA85=). ! M>,:1"AHT$,=_:A =*TC4+9T'K0G6:&M4+X*N8E%7+JSYSN*H17I6YX9(,CSH MHK*>3?J3#.P9P*^!K8?V]M;ZZ'5B[L!TB4:V /;@6H:VK,8J%R:7]5"VNK\X M(W=K#[TKD@K2U]T:E-,P?SA6P#ZJZVG07J7P^O3DV@6@@JR=EVMVWE!O(,2^ MO#EU"F(D^%RXHQB3:4-[]Q+G1,VK5UGZ346LVZS+E%0FJ>V6K>AB1H6U,F MUH6B&J="!KQ&YQL:<6;N0:>E@%I1,#>)[ZYH. M[P#P*)-_UZ;R">2"1@="\@"43-Y6,R*5.U?N81JE->W3S=VLE! -"5%2[J>^ M4Z]04804@9K?-<;4O5+'=Y)$;H'#7,T9'Z.!:_G)!K%(R4E3\. 5]44[A<%#& 79.CTN7IAZ_F^'"1N<"M-X!>!0V]$U MUF06XTO;(]C:3J)K?\J@^CV^%%?C*ZI&?QU\EF[?Y*Z)]42!">\"UYO[.W%Q#6UT M1O;>]N*!HU9TRU\#A>,(\(&366<^(Y_4RB93<+#=.MD8@C5979![H- M:*N,U( >17:P*+7]1H+^SO9L>[H3F\<#[25H>S-4,;OT1A9.+G%"AX@3(*XG M#&9ULZ5!?3_<\[(Z/D5B> $1'ID8VJZ:=KV1B]!W\%78,IR*=S4H. 5'6ZZ> MNMR*PJ[-_@NYM2C#K@4TA14AH03V-JIO8;[SWUM((AX1XN!!$,H^=(ZH'3X= MTYVRK,$Z[EIM8WG4L4(*QYFM!WPO4I?T>7/:Z3^/!9SJY>1J='WQ.MK+!#*- MP"]4JR:@M=)F+,A=;U+^NOST?3R^D 98N_:EI2^Z0W+2,-S)92 MKL2"VA\?1GL.S B@:^FA3%U1MRF)\%S+0#0&,J#Y(, "Y](L<[V,D:,]$J0= M=5*PQR+U<9$R.BI2BB,CY6W?4\YFKV%?ES-7TAO6A/\G3I+G9N[=W(PUNL\] MCWAXR,Z*<@=&1(\XQT&'U?.6IV(ZI=KK-4T!<17V:@SG2)WH"7ES)N!48W)H MP#87'_P 0WMP2I B)Z_=GYO)5K['1SA0G/@FJ!]0E^M.BU]_O8/\H).9W)#: M9"D<)S9NU24.FM0TJ)%M7^D-X6YJ[Z5)BG 4]1)+/]EKM^V,]38<91;.U4IF M"Q)K6B$16O CG>\/C %;5T3E5CO\R^6HR(Z6^&KKJMMC9 49[VC(+OM&>U:WG_ C$V]8Y31HOO6B@Z^T19A@ MC"SX')LFR+T PX_0@)Z>D/C#=IMF3-?*=FDHS6 ME$^16OA@M>/-QKUM2*L6-=1&+ %=P'5E+]:I&]HTLQF FV^%'05\!2>F(.$" M6>E2]>R?2Q&./W:0,']%_KSFCJ=M2MB%II<9[O15J65?UN<)SP7J?G;6IT%)V! M:.I&M-*7T=&28,"W(XU>7!WY*& K*#Q9-B>82HZ(YM4";9%V7N(N@(51@YT& M0K;+MBQZA\K3J<#U--_SO(]'#2_&Y,.10B,YP/FMCW&KN3K=\BZRO&MG%0R. M9Q9;5WIJB33:;A>$U[MWL'YZ10KOC8I2YT4:-Y[!I,M<=J91>W;7UMH.9MZ% M],CHE&+GM,V$^\Z&+T4ELODS!._#V"/M'(L8[)300/EA[MS96KL8U+0C]J&) ML;@-2HA=SVE/;Y&3M402ZD9E#TVSKO=2 5 D:Q%[INT %K0S\%6GUC($;WUV MP&^*F6Y7WW4=&3>?9^?77.?4'"-C*WB>KKT<"<5#.I?BIX1)K_\0-+ MS?L<4P9.-G1]U(E5+=8FUL G56DY5NR:$=TIQ'%[_*";3_/CWWXB5 *0D[60 MXK3C5.V<1VOPW53IN7W]_I!(VQ1WXR81-8_VC Z1?KE]NV-GNW,*C/'WME&; MURGV]7B/GTEN[:B<@>J<0<+GM$ MSRE[B/]XV2/JE3WV9KM#H_AA*63_RB-*(=%_LA0B^J60/VBF0F;;OUR:L#O9 M]Y@C.#C\1*K3'ZSJ;<,E,8J$%(39==*X\M=.^R=\GEBVV^6)UH'?Y4E)LA>> M1Z!R/0]0VLC _L_YS6-*&8A(.FY?XF1Q=#=;A-'LV*J^@P%<)Z&9I^EX!MVQ MXRI#;^^>!>]!KU6YY+>]2:'\QKY'W3YNWT;_*,LE#45G:H&E MD_&/ER?6-_D/E2[XK6IXF4JO^<^5DE B>@"_+S0.[S[0!LUK]N_^!U!+ P04 M " !H@6]3L;N32TL* "H&@ &0 'AL+W=OOP*B9CC-#RR)U][$](R=.FS/)J5:8R][:VLWYV9E) MUB+GIJ\VHL"7E=(YMWC5#V=FHP5/W:8\.XL'@\E9SF71N[IP<[?ZZD*5-I.% MN-7,E'G.]>Y:9.KQLA?UZHD[^;"V-'%V=;'A#^)>V,^;6XVWLX9**G-1&*D* MIL7JLK>(SJ]'M-XM^"+%H^F,&6FR5.H;O;Q/+WL#$DAD(K%$@>.Q%6]$EA$A MB/&]HMEK6-+&[KBF_L[I#EV6W(@W*OLJ4[N^[,UZ+!4K7F;V3CW^753ZC(E> MHC+C?MFC7SL<]5A2&JOR:C,DR&7AG_Q'98?.AMG@F0UQM2%VF:;5H$8#IZK;#>%D04ZYMQI?)?;9JW>+]W?LR^+#YQOV\69Q__GNYN/- M'Y_N+\XLB-.2LZ0B=.T)Q<\0FK./JK!KPVZ*5*3[^\\@5"-97$MV';](\%YL M^FPX"%D\B*,7Z T;38>.WO Y3;G4[ O/2L'>2I-DRI1:&/;/Q=)8C>#XUPL\ M1@V/D>,Q^M^M^2(A2L5SL^&)N.PAUXS06]&[FO;9,PS8Y_Y]G_UML;BEB 0M MPU:D[M:IRPVS:\$V6B8"(VZ1*666LJ5 6B4"69$RI'? D23& B4=AO$#VF/ M[MIPF3*K&.Q6F)70C+-,\J7,I-TQ6=3$;480U3GD4N./D0$&%9RJT(02ME M/#.*"6/Y,I/("P/A.K982Z&Y3M8[]KB6R1H&^%Y*B@.( 3JD !1#@LE<_A0! ML2F-8&K%U)+< *H"4F]*:T*0$!KFW7*9T7R??5J3J;00IYG8BJS##01( .Z@ MR(ID7IQ 0V$("I\+=;B&?5V+ @LT MVRAC)#Z$SC%O5 Y'(11,;5^GG#-D2\-[-O#&9">M,M]+9;&C]CP%H'E-QBXJ M^Y BK87ZD 9%!DGPTDU!VMQ%N M-R(=QI"<& "82]+8D"-1#ZS(ET('=5%PAG@+!*-9-HS<[.") @5 M*X7;WL(_Z;V%1QO*G#IUW9FZ@30I M2B DTW++J>E@'VH7^#C8J@SSSB65O:J,^>M?9G$T_[G\YJ1[:N)78A9V#!E@\\FV\RB?W[O#X9J0S!E/)X> M%:_4Y/3 QQB$1?Y+WV5A1^M""@H-Q/=J^UYL3X:0,"T5)M%R216K"MW6HYR* O%RA1MA MJU)0II:>9"U1%C/VA]KZ/(O&+L^F'F>;G+@3J< 6DOQ-1XM;--D"]DH#GU$( M8DK*G2O87E0MS;?3%8HF00K !%BK\9'DVD=DI M"^"$B2HX%#\V+O@"]ZE*.V]O4P>NX-2%0%B1.__4;JK"MP/VSKS^(RO)[C]; MNQ[&9VOGBJNH$ )UO4&(+L"Q%N"TZ!;]@^0=#LA9"?(D[!C1V0Y?HW[<^5YK M/>E'0[:#HHBX%&VP@G>#>LN\/VJV^%X*:[8H,QA6UE^Q9H6WRC-5]4!5UE&5 MZB:=ZMR+]XX178L&+A40\ \N9YXN@-^H$T6HX.SE>DB**W! 7=IU:M)SM?A= M U .P(S3M2Z3%,YUB22W=(A0F%#+# ! D%%N09='L>^DX!X'Y[3,1+!7S9[A MM,<@<#U0$/FN*XBKYY!]4A8(M_ D3MX7Z$O11(.6>1T\K8OG@:^ @=FK@!U% M7K$HFH?Q;(!1/)F&LQ&-7,1&OV$TG$W#*!X$CN\OKZY+<="4XDH0U@H2/!%D M, ^CP7"/8#NJO@9MQ3X@<-H@:+,K#J?C>/^M5:3AYE?M\8JB<#8>!Q]:]QPU M;@UY0-H-VW[&DZ,9$3:)^CJ)P%$75HR(37#]5O%$YGH>3X;1^ M-LH?$S*>S0@(-S,?Z]O/ FG\:QZ_(*^XS@)X/U"Z0I<#6+GF&1U**-U^YT5) M9HBJJK07/]Y7KVHGU%8./E5W R8 Q-<">4\<^L^'RYWH8#1MZBA$F1F/6#0* M1Y,ABZ:S,)HC0 9XGXUK4%:,LG$F\T&5'B1/.(Q9@?#^R8Y4JL["5\E[*LF$]L\^[^Y@0)Z&(XG9/MH&LZG MHWV_1.%X%!_WPI/\">?QW/^^:)1A.)R-R!=D1?+W)&(H!_%L])P+!O#M'# + M,XS1=XQG(8S/YB-@[_A%5B<1HFE&IA^&LV%$ _2=H_F01O$@G$SC_^ 0LL\X MG S(+#$&,P+[$5!_3NZ8CL+!;$@'8)XD2J=.>-=%-C=I877BD+GO4O#MFCS* N1VM:P!%'!91)ZER=P,\E=3R M5%<7!&$=- KKK;G >FI0.^=>-"(;H%=UG\89FF5MW36<[VL @MB0HM_U/1<$ MP<$&M'/74-)^!7DU#BC%PVGF;A%;"V0P#FIU@9!%3]9W-T6'Y#:*V+NC?D/8 MP2%UG!:MMD@/+,YW_M*RO5-J+FT.KQT<$"M3W8/XGA(^@*_IJH^G?Y;>$D[/ M/;OSG)IB@E3Q Z>V8W<:[541SI7%[M@GW_$W5Z;U229H3P-\L]&* \SW2H&; MQ7F16O*R2$4E'!U7N[#^CX1FMOD;9N'_?6B7^_]P/G+](.'<3*RP=="?CGLXF;C_1?R+ M51OW7\126:MR-UPCAH6F!?B^4HB)ZH48-'].7?T;4$L#!!0 ( &B!;U,W MTGY#)@P .,> 9 >&PO=V]R:W-H965TD M9#EQTA;8]B6Q+?)X/YZ[>XYZO3;VFULIY<5M653NS6#E??WRX,"E*U5*-S*U MJO D-[:4'E_M\L#55LF,-Y7%P70\?GY02ET-3E_S;U_LZ6O3^$)7ZHL5KBE+ M:3?O5&'6;P:30?O#I5ZN//UP6TJ815^9O! MV\G+=S-:SPO^KM7:]3X+LF1AS#?Z]1 MYJ [DC;V/[?2/[#ML&4AG9J;XG>=^=6;P$OS?K/*MIS1/)24SC^ M*]9A[=%T(-+&>5/&S="@U%7X+V^C'WH;3L8/;)C/6.QS$6KZ77IZ^MF8M M+*V&-/K IO)N**"BFX^GD$7F'G;V'+._P(7M-66H/5'DG9)6).=35U5)5J59.O-"PL3::V$^X)#_4IZX+(R56\D;%33)A*QK:V[A.*]@T,EP^N(05:615B4YU5.3MV[D8)%# MSNT-8CD4W$ M\[$H0_+EUI3T/&F%L;\RZ#E$I,V-SA!/'(\,J!I9H+CBL:Y2R[$?CK^Y4 G MVT"+?Z#.B\_!LWN"?H5F(BZ5+ #UN;&U(<#"F7?PLBOFIV! .Y+^P3^ Q&PX M'H\C),1>2% 0R%UIU!/2T%EI USC"#'MNN(7?1\4 O+3I\$I^_' MSWTAP-)T=A=+XA$L)?]'++UO+&$D9@9UA3Z6DHBE7%L\E= U8WT?LW=(&K36 MA;00J'+:9&$;U8]0P)H:7BTB5!QA97+\"GP&G0)(T; >8NI"$=P2[)690BAA M#R_1OF$<7\Q183<1ZQKPQHVI+9, 1O*&/)=&UGV M&U.FE>1=R4(MFPI)N%NYH:I#R5[#:^*)F!P=,58GQP&SLZ/C^/\%_V?@R$6A MQ()XG."VPSUTB31=DHUYXZEO(H*Z;$I1RTUH"EFC0N](=BL6 >-A#&;HQ(WC ME%J8&QAK56K0I O\@G 5IEK^B>T-QA1:+MI&18+=REC_P(+D*>!9-!E7'G*B M;?!1W8+GNKC=0#$D96,9S;V]ST1_;TB+RIE"4_@R\$.@@Y*;^;2D-BK 8+PJ M%Y#7TIB7R16X==84BD!RQV]W&FSGQZ2+7VAT,..\@DO17J&Q>Y9<*N+@Y&<( MI6,HK+,7"3Y.Q>'QF#X)1_;^"3WESP1SX\GXKRZ@61 ^=)L4*K;P'5\ MS ,(2ZARUL;EO")?5Y'-@-=\1_'"YU!LW#!IE\!+ M;U/0&QGSV/5<3RFH,PWV@H/5K4H;BJY5!4>YZTQ(GY5.5V)I>XV"!B4B2NN* M*G@L/$B76O$ TJJ6P/1=S79+(O"N:+EN_60[/RVXU< )$3J5HM* 90T%8%M7 M6HCV#M^J_DS R60OBB:V2%J%2884+I"&*"'P0Y<+:^VHQL*VE'[?;Y+8FH1F MYG.DA4'%_CDOEW(#D1P9+H(@M5"#'5C(=8*"7D:"2<>BUNI_,Z.*!^[J'#0- MK:H' 0ABD-R'D;:/22 K&;LC2AF",P0%C4CMA8J:AZA(.J %,;H^Q4L35)!L MBPVL!F*V H@:U%+'G2Z55.'@(BCCBVOCG*;FQ_B3E%\@%I3S ;7?D7@,M ,F#RE(2WS4=)NJ?5ILN$G?:,.% M)0&-0-LW^%DVJ.P6PQHUOF6#QW=^S14J/=$MG ]"Y,R^Z"#XT]098G.B1F# M3@1!R8 +%XH8Y[#9L@UB+S=,N\#0P!X;B$95H/SF#&3,[G$0QR \I"HUW#%> M.X?6#QJ)W(#R:%-A$XH0T .'A2C1J=H_%"0JDXQH(3U\4*E-%U6"<>OTKGLS M^^OB\]0]&\8:#;V*C%*5N+E%_6@+$P48)WZ%K4P$"ZE+N _KB5*&KXR^@OM1 MM#Q&U:(N)K%D,1T8^H-+7YKP$%[1,L3;B4M8ZXZN+0+4=3_7DE+;V!6X+ M]A(HZT-;B/Z5I$ 73M7QNS:JS*1(-DU0@2W"H$CT7(^G,C'NYA/FXSPZQ#E* MT878'C(8'-7>PY08&7:'R.3)9(3!'F&E(@>EMG6[XX8\86]%/V\O4ZX*J *Z MYL6U2E>5*H)\2L$TF-R36:N=1[5(HUN62^(EOM)H:Q3=^^ MWN2@F$Z7 *JTR+C?K&GJ[6&I*8K %XI-,#IN.$/Q\:S7A:EH)V9;3W>YY,%4.\'$>QMJ%G4X%#HN48?L.@R.V, MGX?JJ*MPPF"C344F'-.YH.#2@I3>L7U 3$/]RP M%3+]1H4,A=-A0P&>A9Z1Z?A.@F*W#5CG[<=EM=T*<*%@]24R084':!0D)6MI M&22>N-_VT.NDW+ MU,EIF6I;ATOB3U&+]L)D>]F5*:>7%?IXN)JZ"VVR(DX$R+G[H.30QGY$A8HH M+[@/CU([29IT(BNE>;9G&*90FRE#%:Y4LCUG]!)S-YUV('3OQ%Y^IH'R\H7L M-C/NS%QAE(7OJ$\0&\UQ;&BZ!&+4J>U\L@P5*UR@]!T#9*#+TUF5:5-'+)$: M%0OY80YOM=O)4NY^2K=X@61JLBI8(+OF MRSF)*-.550(#MX2Q8W^]U.^U21+0C63IIFWB;D>7BAK%#WOUF@D"W0MEXLGA MX0E=CA%3V*,+9>S_0 G\W7-8QUHDWP;@JRG5715,GN,;-8E]BL!I7A*2Q!.< MQ9:)HY-P#3@9'8I]K\$.>B\>2V67_'K5!5(7WD%VOW9O<-^&%Y?;Y>'U+^KO M$K0"O#;'UO'H^&@02G;[Q9N:7V,N# :!DC_27;FRM #/&PO=V]R:W-H965TC[C.TJV>.MS&ZR=JQ)4JE4 M'B 2%!&3 < +3M?OZ=!BJ+&LG.IS8--$@0:W0>G3S=UNC+VSN52>GHH"^W. M!KGWU;OQV"6Y+(4;F4IJO,F,+87'HUV.766E2,.BLAC'D\GAN!1*#\Y/P]B- M/3\UM2^4EC>67%V6PCY>R,*LS@;3P7K@5BUSSP/C\]-*+.5<^N^K&XNG<64"HS41?^UJR^ MEFT\!VPO,84+_VG5S(VQ8U([;\IV,9Y+I9NK>&AQZ"TXGCRS(&X7Q,'O9J/@ MY0?AQ?FI-2NR/!O6^":$&E;#.:7Y4.;>XJW".G\^_W1]^9^OK[_Y<'4[_^H? MQ_'TZ#U=???]QT\_G8X][/.L<=+:NFALQ<_8.J%OC?:YHRN=RG1[_1A^=<[% M:^,O:O/M?*/]/-LX;P%'WYYP>9^ M9W,_V-S_OP#XHBU.P'>N$HD\&R##G+3W%%$_ZW+A;0TNY<68D S=N-!(>TDW11"1U'QR#!_B4%P,IG0O^OB,5I/ MC&:5544T[>R$9XKWVH'I<#HY&A[NG01+^S$N;&6ZPU(3B.V=B-)K(X?'^\.# MO:-@!)>/&M+AI45&*[T$GA((6C*6M/$,70]UH1];J!C9[1.,DN; PU']D>-- M#/0TE2S+0"L3871( D:69-@)?G+A0%4)+GI>ST\]C[#AEVX(EU-EG.(#"@96 M$%J^?N%2(BH%E$A+F8)L.NUBYW_8$X.TD![8D"CP7PN6;:H;7NVV-FK'(W@' M ,DL"K5LN/(42H1:ZQ"5\HS'!C^J==HXTB;0)KGHIJ'^:"OA8#QE@J[8\U*D MD@\@3]EVGU"[G M6PX$9=">,U23J2IC?:U9UL+LM,8F' $*L// %_2*PDIXP7$SY%+GP9D0=6X* MCOI>%+6$$^*!+J26&8-STXA0XPQG(4M*DV?3^$](BM;8.@DR(7RD/.4B!=A" M*YR%*QXWHL.>B]1484<8$;_GT&M>P9O'D_<\$&ZG[]^,Z+JV_0 =L7IDZHM- MHI;=P1B.BC,Z!-:]S^!D.8 MK;T"\ST"$LY)CT0+2F_G,"/U6K4.R ?E J1;1%CE M)DA4:]JCR5S?9\JB7%8U!"3I>(L>M%/!/CDYTQG982\2L >Q-*X#2]T&LS,( M'M-O^Y%L9'[7]*TXM[&,1)H&[066?\+(:U M1I2AJLM:6 'AD4/*S4JB4 \W= D,"UR!/MTS8'T2!6<[$G&D.V@TXJJ(^J3; MACU(Y0[,J<'\&=V)>KJSZ4^8%:E,"B##G4VJ[E$$>0S\L&I1K\T;C4+'C3PA M]4@*I.>3\_DCR$8 =(MSH?5)#%QL 4N*5E<6M4,;B(PWG;8>#EL)N@[)(S+? MEJ4M=[GT#!L?&Y=7IBY2Y+WR#1%9%SS:+E[9JCP+UZ:*A[^W *EV"!!H!\5] M,<@Y'R'0AE!J!=]NA/4@?M4H%_0YDY8QGC<-R2OT?Y,I5<)&H< $6 7U.DJ5 MA+U>36/,'/4*S$'3]C>]!\?GF$&*C6.YJX4.M,5KA;C02K4E=,TY[@4$R_2] M"E^0H#8KYPS9G+:,N)4X6:ZDE^ ^:D/"C26<^0CIA.XW[6:0"M&NZI>;2^#$ M!W.SWF)=>]KV> E1L.$@X$2N%D&WD4$N:PGQI/\(V93P*:*+=/BN9*=W9LHW M4.Q>+OBGI>J)=W^I;D6_6[?H[ZQ;;1#1)HB5Z'VBH.[L"F,[\=J:/CU8)]6N MC[YQ[PNZE'89?B=P3&PO=V]R:W-H965TC,9C52VXFNFAF+# M*[Q9"KEF&H_R=J0VDK/<&JW+D>^Z\6C-BFIP>FSGKN7IL:AU653\6E)5K]=, M?I_Q4FQ/!MZ@F[@I;E?:3(Q.CS?LEL^Y_KRYEG@:]2AYL>:5*D1%)5^>#*;> M9!::]7;!GP7?JITQ-3M9"/'5/%SF)P/7!,1+GFF#P/!SQ\]X61H@A/&MQ1ST M+HWA[KA#_\/N'7M9,,7/1/FER/7J9) ,:,Z7K"[UC=B^X^U^(H.7B5+9_W3; MK W< 5#G/]^U'"*F/R^_BFODO L[Y9D@#UZ&^ZWLOX 7] M/@.+%SR#=\%D552WBEYS2>7X0Q$IRH M#\<&IYP[ID_CTTXK3I2BA+.R-:K8H.;5VE594XZ4R.U54+&DF MUFNH (3*OE*H4VE6Y; BM>(Y+2J[/&-E5I?,Z@4VH'N14:RC>5'6&NLJM(FB M A:G!Z50ZI!ND$_K94+.'JS)L];&ZL&(?%I)SLDN>>@5/?;2]#6$?$BNZC673 LY M(5=J.2UVT55UR MB9=M!0_\V ?601@;R(-Q$ID?S_&\A!Z2:99)WM7AU=!IZEG,(# _OC-N7/F. M&\(+^0S>J"89J WOA,5 PXR9,B,[&P;PK-@@'R"FXEDM"VVB./ B)VABCIW8 M2S'X[9?$][S?D2%D)82#GR=_E\PK4>9<*GI$9Y9P8]])D]#TCLA/ 9HZ;@14 MZH=.$B1DFN>3/O/T#9GOPC69[\;M;P/>)Y^^(?D=HDG^8_3W7"FH;,6J6\-< MNF2%I'>LK/E;/!D)Y49OR%YQQ\S'\:$4 7+E[=3FE2%LF93,]* X,*0T"MBI MKL ?4@=2TCH:AHO,\@.]'4X;+2',U/0_\XPBA(7RD!S1J* M;@N]HG/-Y$(PB98C-$>C,/T)GC6[IYX3!3'^)TG:P]NG!GM/ _25&F@ET/"_ M [?D)S>\A6BU6S_MYT6%)4XRM@+STW@W.8$36_V^55[G;1='=W,=;^QAX*>F MD=GNULD,DZAOXI%S7@D<6)I^^L6>CGA^Q,!''/9(^V'J/C[PN*GM3E[XPKRJ M#82)DX8I6FYHAA KBA>9X1BA)N.@6S!V8W*-\E>Z0.J_DYYV';@-=$(:%I(I MO>YU--]3+'RAZ[NA]X-H\(U W)GIEHWTQBF^"E&,5H480+.> V;>3X@%)F)C M6*!H$#F)%YFTQG[X W@?UY=.'>C3'O:%M8'G6J;U!'8#)XSBSF;V8!-ZCC]. M'"R $9(6.TFX0WST4M=W_"3X7PO9$2X-'#Y:\[C,#>QO>_0W*'26Q_ O\14A"3 M*9AUU+&*;#JJ[?/+G%'*VG3CI13KYBQF,]F?Q5X^@>V"3P6B&!IJ#3V"9%R?42R%4SP=?_,"FU?+%19%[3O4=]Q'KT*U]!024U>ZN0[UL_UE%A!>R9=7#+3%H@6\EBP[;9K:!N+410OT(QLGW<-B#S0YEKBA2(43,/+YYG!E/M\[?A!J1X%MC;)AE-5%[FN=!UMB(,'0M6K9LG&\$ M\=97>6@]"I6"&I.71?$R;X2VV7R:SB[\?.HZ,MKBA8?0-8WP]PLT;CO+1MG# MP:6N:HH'^7S:B@I72-?MA>==OD=1ND$;M+/@<3/+SD:GBTGT3PY?-6[#P1IB M)FOG;N+F@YIE122$!B5%!,$_=WB.QD0@IG&[P\SV5\; P_4#^KN4.^>R%@'/ MG?E+*ZIGV4D&"C>B,W3IMN]QE\]QQ)/.A/2%;>];OLY =H%"2@W 64B7=_46+Y5I"83[W;@H_>C!87*=44S>2TC8^R(L]6S7$T M7UTO5LL_KY>?KV#YE;_3G!@UVG*Y0UCT".4C"*_AD[-4!UA:A>KG^)S9["F5 M#Y06Y9. *VR',"X&4!;EZ F\\3[%<<(;/X;7K0/>=F@)EG?\#?#WV3J0YX+X MYPGXR1Y^DN G_T/!)Q%BWYV&5DB<9=Q8 ?T=9O/1: B_0L,7"U\DN35Z..GU M&0#5".>N:86]YQJ_[;1'!<(8<)MDXTX,)*S2M@(N)WESQ 8!ACLX'K5>6XH+ M0EE;9UQU#[*'&P W/;M*$6IH.R]K+O\8(#&"/QN_&A9PU@6VM9@[;2 M= H#",MK35H8=AS_<-RAB7ON;#IB7GS!L\F!/79QY"-%JXFCA?J7VR!Z#^&* M\UEW@?4+ :)03(6O L6=[9E;Y5W71FY]Y_ 92R (>(9Y0,>1-0I#M10> M8XI.)1IK9 R>0P-N+]MMN#HZ'WE$&ZNB VD9!FGK6%<>;#Q8G \]JZ1\T&G2 MD-=5A?$9HOZ>)U#4+2EV?)!HC4:Q1H!!QI)[SN,(_1$Y^.R8:@F__W92EL6; MC\Y6?URA;^ 2N6JU) 8^9Q&3??2F?R2ETMVLE[;]J.;=BR'\5X'G!^."-:K2 M4 S\ZIVE?G+L3_=S]ZP?-S_<^Z']2?A*V\#5M.'08OCJ. /?#\)^0ZY-PV?M MB!\D+5E]A3XZL)WEIX=-O&#_;S3_#E!+ P04 " !H@6]3 V7TADL- "R M(@ &0 'AL+W=OOP'AG M=MH96;ZD29LVR8QO;;T[3;Q6T^XK1$(2:A)@ %"*^NOW.P< 22FRZ\[L2R+2 MP+E^YRJ]V5CWX%=*!?&YJ8U_>[0*H?W^Y,27*]5(/[6M,OC+PKI&!CRZY8EO MG9(57VKJD_/3TUJMINWAZ='>47 M]WJY"O3BY-V;5B[53(6/[9W#TTE/I=*-,EY;(YQ:O#VZ./O^\A6=YP._:;7Q MH\^"-)E;^T /M]7;HU,22-6J#$1!XK^UNE)U380@QJ=$\ZAG21?'GS/U'UEW MZ#*77EW9^G==A=7;H^^.1*46LJO#O=W\K)(^+XE>:6O/_XI-//L*',O.!]ND MRWANM(G_R\_)#J,+WYT^@TJ-$'5I5O0SAM MR"FSX/!7C7OAW?7-[.K^]N[7VP_OQ87'V>W[F]E,7+R_%I<7L]L9O;V[ MOYG=O/_U@D]]=6=K76KEOWYS$B !T3DI$[?+R.W\$6ZOQ2_6A)47-Z92U>[] M$TC>BW^>Q;\\?Y+@3+53\>)T(LY/S\^>H/>B-\<+IO?B,7,H7SK=,F ^+,1E MYW' >W%A*G$IO?;T]LXIKTR0=.H)GM_T/+]AGM\\@Z<=>!ZR[I.$*'Z_]ZTL MU=NCED1T:W7T&'5QX47G5256RBEM)N*?__CN_/STAXV:\*>S'_*;SN^_L9W+ MKXKTZJ*4I9;YG(2UPDKE\U>V::79YK\B[)03P8IX2=Q#5.G*E;BRKK5.QF@U MU8EU0@VPW!K+3JQ* 8 M3C*M#:DJ9-L"OG)>JPE3;Z1!\D&:"=,LT$9ZH4V9I $?R/,O:3HD+7'^94;F2 M9@GZ)(>GFT1FX$QV6#C;C(B1V:X5.$JG>GEE^:G3<+B8)^?B(YEFL(?$._ ( M*QE8S.01,5>U5FOE"Y"=JZC36M9=LFVTV*$+$%F4TH@:#P[V8Q4@ J!1)N[^ M0=>UB'PM_@8=_E3\E\[4MGP0S&@J?AW(%]H$92J^L$/Y*_TUM"P)M_C3HE:? M-1P("5H=9!WU(G&@0Z7:VFX5<0$T*DU6E,#/!$1 17V&48+VH&M$[V*QM.!F MI"E9PHPDNDE:!=>5H7.P)%,!F0UTPZ-)$FD#FP0BB;I'3ES(-:'75,C@!$+6 M>^0>EMAW"XH$=C' !N08F$K*NU+VYE01&L%H(2TC0%LR,0J7)E;&V7<,0*6 BK$A">]":" MH3F:DV0+3'039DH M@F&%CN&P MX?;L!ON6S)G1$EC* %=PUP*6&M"L.D5T1U)23CW[]@=?@.FGCB-"SG7-EICL M.GXBP*P'!C]%I5,6Z:U$Y(-T2W2$&]O5%4456BNXM;%N7P!"LJ%W%B]=P=;L M?94R$%M^R$[<17%2#2NGE'A06](/[@8 V1!WRN+CI+B+AF9DW"G'+6@*40'# M@J*N8:E1#@?.9!,QF."AP6HGZ'.YF8B;SZKLZ0]OE6KI2RW@YVX&%!B(4)4HU&X MJ!VFA Z!E8%!2GIJ86-#DO51!FY9LBS_(T+AL@L&:8B,5A _0SF!.42Z@HHM M90DJG5NZ#^MHQ^+&J!V">V1J"H!X/U(<*X#Y)E(-BN39(E&OJ4) MH"1B6SC/]Q644,!&C8:B6FK&XO0AU4,RUY6(2197*X!J,HZ-"JWTEZFSJ'"W MAAD! ; %*4D]0)1<4.VJ:=CHH!-2!!';BJ]2#W1[E]J?KW/*RRG"=YP\O-K- M8ZRSMPW%-">. V<**D,IFW1(7&9(T,M'7(OT0&^;^^$H[D))3XVHG(1*!WW5A,\ M)OK>>!"4B72>FZ6#R(_5=2<.BQV94\](*1#8?JZF@+%&D=\)BIAJ2"!XW(_3 M2<(*VS0F%.V*=)=)H.>8ZS()6HU3+(ODO,']-CS M$"?+(F:".J$AF4>;!?5:D0?5LB4K]FP_.97K"5)##L_>),4^XM4"GP,*XIQ: M#R+7XR,6@H301&C?AUQ)]V[LGZ&VD*GLZ_#(S$+H&I,=28&DP?U?6W_)QI/C M-"8I*%]WE1(?I[-I.N5W^RM4Z6I \AIUJ3A[1'](J@!L,T.KP*W$ P5VBV/05$2Q3[7 MH[/GX:!K;!NB!0(\QHZB$$P(?L M1T2=5WN2LAUR;TP/2UI(D"WV^D'(P(;<@MX6'@O4Z646/84='VV/N7DK=EON M!=<<3Q+Q]9QT4CG*CR1'6$W%=>=2%R$0;@IM)>^$%.V$Q$RU(8[*>:W3 R & M*%65(=HL[I^)E^*)/ M$A9:#.IM7)D[?M1O+\LAE.:RIK;<%RN)466N@"K,$@U$30W9H *G\?^3V@,W MV!D9+&4I$'85CPEQ%(T&X39Y&#)BN61SE"4AKLKI_:-A07B1$ZW8(">6LN_D M.*?^=''1-W3%@D=]6$@W(TFUB2OSG)KZ"DHI@@9*MA\BC;;+XNST^#]\[+Y# M .'I](R8WZME%V-6S([_2]6#M(,RM-#(R7S$B8L;(EGQ#J&VOJ.]D%.\((*G MMJ(7GXUE#'6KA\PK!O/:1@=>@[F1?PZ8^E.',J)DL_'S3%2*ML'\^+3UC?K_*, M2]]I)+3^T9G8CO5.^TLXCBB'1#KWJC2RQ.Q6]'O %V>::(-<6E0;[LY M.J+4>_D=,C% 'S'JES@?F6#(.3DE26)=_='%FLPGN#=H>+%&DS!U9";NB+AW MF>1 M"V:L=C.#O/]A+N[OB]E$TNQD&@T>SD&,?JB^HCW6ANG>+(.NN)#I2<. M,QX=5YS'AY8F9S]Z-1YSDM.SH6B^M!5-7ISX5=6;=Y!HQ& @7F1*<4O"\'I& MM8P&LJ$WDD:20Z/&7=):]3UM8AD7OS3ZEFR;Q)-JOZ/6W)>('P+P%" L:YJ! M.:7%26;4CDII3@XQ MDU#RHF 4&B6F#"+UB[BPUK;S,$@?<6/QBH-^X+37^W?Z5*?QJN\T7CW9:5Q] M^.WV^OCLM;B#5U6CRT-=QM\DP:A:=%2LD])IBY4/MOD@57K-DSKLJM:VAOEE M'@MI]9% HG-BFHK?5[K>W8Y6%O<)9A$Z._[I5]*\X8A>0CUR=,YIG[:WHXW@ M) 42KW- M"#WT5J/0DCV&N$623=Y5"]*Y+*BMEP1Z-.M+U=Y(^_N9,B8=OH M3/$>)T92PGW63D\P3 =I%Q/#,WT!D087Z@_2 MTAM4BYX9*).'MWV3GO:K<3KSEGC4_/5!H*I<#0UX0RT!+8=+VDW'2>G+5JG_ M:HR_TYH@/\9O>OD[D3E]P]'R0KI425_ZQIT':1(-@]M:4U*231Q.:76NRP?: MDZU5]/%&Q;Z"DD:-'EDX"^T('5YZ>)M2 %EBN_.%288L9"]ZF7AL&^>.M?8Q M;:26+Q6'VIKE,4@WV0PD=**(-K#9,QD]#L"=+U+_K6$CTN"^)."_FW_ M@XR+^#N$X7C\-0?ZD"6 #-\O&PO=V]R:W-H965TO=5 M/SU4]==FI74;?5L79?/SBU7;;EZ_>M6D*[U.FG&UT27\LJSJ==+"Q_KN5;.I M=9+12^OBU6PR.7VU3O+RQ2\_T7?7]2\_5=NVR$M]74?-=KU.ZMT;750//[^8 MOC!?_)[?K5K\XM4O/VV2.WVCVR^;ZQH^O;*C9/E:ETU>E5&MES^_N)B^?C,[ MPQ?HB;_E^J'Q_HYP*[=5]14_7&4_OYC@BG2ATQ:'2."?>WVIBP)'@G7\4P9] M8>?$%_V_S>CO:?.PF=NDT9=5\?<\:U<_OUB\B#*]3+9%^WOU\%P(/I]NFK=;R,JQ@G9?\;_)- .&]L)@<>&$F+\QHW3P1K?)MTB:_ M_%17#U&-3\-H^ =ME=Z&Q>4EGLI-6\.O.;S7_G+SY>/'B]__$7UZ']U<_>6W MJ_=7EQ>_?8XN+B\_??GM\]5O?XFN/WVXNKQZ=Q,=75=%GN:Z>?G3JQ:FQ@%> MI3+-&YYF=F":\^AC5;:K)GI79CH+WW\%2[;KGIEUOYD-#GBC-^-H/HFCV60V M'1AO;N$PI_'F!\:[2--J6[9Y>1>9;4;_>W';M#7@S?\-3'!L)SBF"8Z?,$&= MEVF^*733!\C!89!(7S>;)-4_OP J;'1]KU_TCQU]7NDHK M!BK(FZA:TGLR;U[2ISJ#&33@<+N*OHQOQM%?+BZNQ]$ _$XL_$X&X>=M#&:^ MM/L"TNZ#XN!@_5 H/@YB&+;89EH)#!%D-,5%FL"C= (Y M?/.PJHIB1Q_7R1]5G;>[4?50PJCX%4S3UO ?&RVMTV>Y4D-2#J.+HH"9FAU M+:N+ &7+)B&FQ\=[FQ1X*DVT2NZUNM6ZC'21 S.A)Q]%O56EFXZ.% MP75#&Y$U__=_+6;3LQ^;X84JD!UU0NCA+SDZPM=GDQ_+ _/0S],?7Q(2-HB# ML%" #!U5B6M.8&,1[KGS^B%]XB6_@"U'2MG5^NY7'#^T# MX=5VB%!Y> '+%@C! ^/H=[W4-8[7=I$MV,!-,,"-)I!>P-N9!H%]6VA\_%[7 M;8Y_7]$:PB$/.P@A;P]]"FQM%5B4P76"]C3BGRE6@> ME^[A'W_Y(2^_1N^W.'-5;&FWZ@/@'^PF!JS/TQ4>P+J"TUYND00RW:0 7T;. MWX ?1?.8AKX4%$]26"YNBH\8D"3= AKF3+H?$UAR].LTDDDLPM$/OTX-?HV5 M?('3RYEGYM!D*HOICY/YK4Z3;:/]MW'5=;6]6Q&!&QB:*?86K\SB?YW&0*P- M8\)M7N!C@!AR(/2UPQQAX:#=A!#X=3J._I8G:T#@O\)A7U;1AP^7,1#.6UTD M#TA;A<"GR,TD@G0*AV1^))1M"7CG.%>,<,.U&"X0-2L8EC$K6,;%XX.9L>YT M"1LK(J#ZMN1A\&M^2%T!" O4Z% .7=<(!)@6<2N./HQ!TASAPW+<,O#5-3U@ M3MV@W / %[5:/O*+[1V0/R#V=#(F;A^^3*=!G-/@B7HVGC0YBDB<*49&UN&H M!P 5'P"."M?YKZ%-N[?O7E@@Y "3C0!)\%WU5J=Z?0MKFD]1*9N>T?A9W@ T M[AG&R#4&=8%3JPN<#NH"-_H.00D\;U/5*%_Z-(#!(?HU@+UQS M=?(59W5R,]-IWKC3:F =#7X/#Y!%AI@D!VZUL@Y"U;09% RJX?TU?*J&F?(: M&F)1/GJ@C,7)"A3"=W:-.-=F6V^JAI'FP*)(BSFTFT$L.+-8<#:(!5^ U\+\ M[YHV7R/8^Y!@<(1^).@.2[!B59C/$'X\H.8AI2$$D.Y"%5C5FB16XY\XD": M".2 G4H.>;O>\!D0NB3+)3 \@CN?)=+<&K5( WY1XPT;SV4D(+X4U)5M31M" M+@"' !.K0^_P),BZ##=XFOW0LS1"C5K?ZW(KJ]'?-F#,PX<,I!T@ [RD:DMH M@"-Y!>SF@ED[0 K,:N2FVP(WLD35:%E7:WRM\4 V-B1Z"RHM3,V+Y*[A(\9;(9,@-S>,<.(UR M6.VZ@B<1L_,44#U&6?^')A\5FAD(AD)_B_[89H9G#[#,A669BT&6^;L@[>\. M:?NXYN @_5RS9^3(?)M"$C2FQ;=B.QH/*$473%6"+%MD(4M$M;FQ! M8-8F+!WV8]:8";"6#(@>+%KYD M901_\MZL!9YH<.$'87#(TV'5,/ A>"$=-LL\:]BZ.=$WO= M;. 0B-0.S4N6OYL;Q6)1R#GW<%X%3!R('<0 NCA840>[9QR]-PH+B9?&N1!B M.XP[&OT-++&6%3-/M5>;&F1-G9,'@LXM!,5:E'"($8 M'L^ST79C<#!:"AH&J&8'9XS H8&3 V=1[D3Q$>:"R&%TNBJKHKHC-9X,AZKV M'4:P'Y:2%B$!PD53.:,W6!#)V28I=",\>0]4L0K,/EBBV%0:=0W 7^"Z" 4+ M4=@C0!$7S0=AE&9#"#WP_.<6C!Q=PRC!XGA% "7[NZ*E$A/W$*NNLBT0Z[9$ M7GN[\\C>> -^1[N;5!%#I1=WM6:UQKH(',#6R2X &NHF-:RTAG-#L:S;MN"7 M%=(4R, ,:8)%%! S/"U'%J'2LP3%HL)SLJOO>V#L4;%0L#LT!!@\!>('-D&V MI / :V"G+U6 10GZ=$; KXIM \PKCI;;=DM> 8OJ:/E=HDX7),&_PJ7!_:V M@2;J8_>T6P!H+_K%,&W^DIQS #:8>%16[:BM1LT6I#C\!C^RMECHI+%JICD< M1CU!]R@MDGP-0R+Y'^7W_"8HM< R 6BT)3!?0$/(\!!1B;T3#^;G@/T9P!%V MB@D-: .HN-$D+6 NT!)@TZ 2?6ME/%0 V68N]!T\!-P_%P+U-61SP@P.,:UR M& +P&L<.N3! (V2^H(M;%^R20XX6:V46 Q*23.G=C"]OP5'@B6O;6 M&#D#^L4M @6 M;,Z[E]P"EAB/)P>[=*U@F0@FS_$+' (.8YD391.*L"38%Y]NQ1XPI&'@YR%E]K ]Z@LY'HV2*-UIT9]L@*28-T%C\7-:_P!;BH3C_'$ MN=F^&)O&:2LYYUA7[M,DL*D'61 M>QG=[UU_!/JT0 TF%XKS/F45'SK\V*+B=X_G+IH531@,RN:MO.(6 43M&@QZS6O2USEH/!#!H\V4%:ZH)#QULC6W8H*:H!+,M![8PCX6) M<[P-60N\TJ T $.G0)7'&Y+X,MHD<-3PQ'8#XTEPPK+>78P_66G*C+W9;E"0 M*.+B]3WL5]B34WFZ\MU&0TKI+OA5I/ MC,B&Z,,."B"E/7Z0$.M=DG1D@+BQXE$5;+2 MP M-H58/;+&10* P66!F?/#KR *A ! MZH:U#O2!N?G2[7I;D!>FBR5_DM>I*(CA$:09ZXC-E:(O(5OL.*G8S=2[]MSG MQ, X@0&1HQ[#ORV^3 R=%,M^TB#1U',(N\B738%YG%A=,Q""=BNH2=5H[QME MQY,5?=A&3,_J(OW2SC']SE$;%.ZNWD1Z%#IV4H*E#?Y8DW3L^8<37ZMT]LD* M1#J80BF<= $ +"1C@B0>L.L<'X;*T,5H MO=,I^M@C/EB@+1O^!MU0 MY\A;@+VB^I^W5I# WQQ%#VWS(:\'DX7@K961#^2')?:$-BRNOB-#,_XA39J5 M,M)D_XAWOB_"T(\9A4++QG 6%W$03::U=2+!%+8W2Q>\X\TI9H<]AK4F)<&& MO,@[@0X]PLLU '5'TB.!$7'FE+5_G>4 [7#ZK-*LK?(ZGKV,Y+%#-A W$[,O M"D5OZRN:J=X83[3QP9#!#>C;/B!26UI#C1JP_8X=M3TJ,>FL1BF/." L[]IO M-RA,>DX;6=6M1L='M /)2WD3('3I@(54.HRZ,;[1S(9%C!EH7: <1C!TIPZD M'WC.>US9OIN'GC1;@#7=@)* :)FPC6_,>S$Z=MW(EN^FRDL5Z@*R.HN\F&5S M1_DIQ#D$C]&C>4BPV;_4T14B: 4RL\R:E^J: MW8_*T$1BU;+HAV@:3R<3_/<\GB].X(_9/)Y.\9O9<7Q\=J:L6J?VU;KH>#&+ M%E,8Y/3L)#J?S=1GS"*R,^'P)_ (#7]\>LJCGO$\)_'\_-RE/XD)"KP"WFU1 MGS1G0&=Z:>.8T0=RS+PS@<6! ,FY#9"<#V<9LO_MVCKH/MF >%^@9'"P UF& MAV< ;MBT0=S43T1+JZ;M1%+AYRW%F )6J(C!=2Q9<2PRD2.2TD 8K4XEG<': MXKYQFILSL'3 8A[]F>+F-4.CXQE5,OE()BL:C2D'"H ?-<;BH*W$7D1:7&SD MX#7CHU9=>^,C5V\TR WA;V$,T/KH&#('!E%VD,. ,"/BB24UVH\HO;=%:Q[F M^?>F ANKSD:8F6/B[R2-)*YH^7ZP;(7P;=HU[Z\1]V%C#YN\;N+M!=M',U]) M$Q+RAE"N]YS*%J.,RZ8G$=&+X:M.(F(_X46'">]J'TMPZ0*B[)'IPSQ(DUHO58]RQF !&H-:.HVN#)DWH7T'U8KL!R8A(GMUSI-8<6H"[+DYBR.9 !JNH M5V8%XN-@W5U\+Q@"#I8JB(#RXE[.T=F7AZ+2WL:5.)C)YDF,PJMI(QVP)W7I M@EB&@DU\H*Y ;,%0L9>YP9"5X^HF0P88+,^H[SE1T*7Q"$H'@;WC$"BB58DP MW ->%Y,8.91[C7*H'UGT=Z'AV$=WCSM]'UXK+Y_JN7A]55+J" /J =-4\#W$ M*/)9&]CEQGC<5(@G.3D8EBBND2NKLCK ;BG1'Y#HQVA5/:!K(GZB$Q1UY5M- M"40%ZTU&8:^VG*51I5^UF8O(4EF!M0'K?9MP#A0[,3(,Y5$;!KCRE9L];IGQO61CE/>0\FXO+S'-%R)J7>8.6H?&-H;M,4IO8WV!% MDPM?6H>7DE/&+ )!>N?Z"A M9HAYV4Z2\F#0$DY#4EU,ZA:GJ'KCD,D,:)(#&\B;KX2CZ%B@5"JP79@/[N=^ M>[&31J#+[A69:%,DJ20Z=H=C-6 O(=N%_G/TZ-RMX*^:3I7(X.B8; M84)6H+.;GI\@&G'C G?!^0E_]Q:"I,UQ9AR*V(S*]*9J1T2L479$L-F^ ML34+6[+T$$Q@Y&I$)#3P-)E\UJ2SM6UQM(BF M)]%D/(U.HL\/?OX22'];$8.VVRE ;CK(+;RJP.DCB6+,NZX3S*__[%44]7*. MP<$.)8P=FB%ZRUQT-@%;,6#1 /%T1<=(A0:,<]4:("A9D?#Y;0TL5=VLDO1K M#!(C'=M\#_HEHE]LA1%YI4%=$)MAN,F&'&90-"]W*5ZR6HR63WP).?,-E/G&E9#@P*A9E73D&.!9=0()9$ M$WVLQSPDI=XGT6V5P"1K1A2S9UD'IRW\NBTUH0\9%$K8E/5Q&L50.!6.^L/4 M;9-3^J-.2C\F[[^UN;M/1%X_<@Y*4B:%,'9JYM+D8\/ G,YHYA^BZ1A(?WH2 M3P"OAS!ZYC!Z-BS_#&^B/]XYWM2+T(-C'1"%AR8PO-4X@1N*0(@P*7)X,.L3 M9L3IC9$-)]AZ%4[$0@SPQ;G*[EE'(L"5;O?%YF!*7$?QZQ--*O![N8/DXL"+ MB\/2D<-C]$)$LJMNVA%L"#"X+/R=N]PP)WLYC/<:>/X:K:84E['6-:2F7I-6)F NICF>C\+H%=$KW5"$E1A M;D*2UT)<6_(I5+>(%)),C%DSPTJ<*U*>S@>16*KT;CR5IXW>X^Q_P]E[47EP MQ'Y4?F0:4L2]8^]1Q&J_(" $'(7I'IQ)5+52FS2)HPIE!3LGRW1[6$_4G8U M5RVP"B(FE65K&.[WEX&F49T]PU!C%X]7)BHFWTO@@*BW:#8W\=>>TL$G&9C# MTRCK#:7RQS,65%F62U).7G)#!NZ-8',,/3@+?DK0_=W^$06G[FI_$T[-%-(]GB_/H:'$";\\7\7PAOFX8ZOPL!D4#)SJ? MQF?G9S(1_$$3+<[BZ6QB*^64$:MF8S[.[.HXGB]-H&A]/)[C8V>DQO'\'$RQ6G@X?-SV=7Q MF4QT'D\G\T'^YGHD3(>;).PSGK_GB!-8DI=D* K>FJ(.Y*V/<+YG=%)X]@)( MK.XS0A)ZDJA&9DHMPV3^,(X0.;':!GDQ+,^4S=P4:6_M>8(](@>E@ES=J&B2 MTK?;X\+H@\$>(MLFCX0&7; 95B2+TN(_0<8:!F^KVO2ZL*D'S-IQEZ@[ MHS)'1F0M%5NZ3(W&W70\ YP'B,.SNQ[^@<\(K9">3(?D"?#JHIKUS$=[M"$< 8Y:8X!*4Z)#/DM5*\E+PYM:\[: )B_7B MN+0W3NV@(LL*:Y/9<*;D-I,0*7G^QJNSI)?"6<03Q3D7]L6J=*6-EHXQ7X," MZNBJW=;?ZW3_=Z&IJR2?#I>2.[QY@BK]C)+R0^-'GZCXS$L?]X H2K&<)CK: M21)00@:?-I4.[".X8**-$CP?"1F;G>N?.*!U-]JJ6-"HCB5@2,OVY7/J?[S_M M]&PA020>01OLTT7.9:%4-&$*%KN,19GR5V"[?]=.B/?" 7>"KM&0A/X&:G@+ M)G3'@V6^MNXK2D^F9BA-[KLRW6ACQ74/'S&4+3Z9!VTSV*GI2O_>\%U/%>-5Z!&TA\H.4U M0V">AG@[ L0I1X JP']!L_"*F%&WP;RMH$+9M@CP"=(DOU$<4!HJM/BN^2'N M<2^9O%)<(J(PYQ3C0<(7A7Q6F@S9E*M874:8%S\,(-/9OJ7M5))60AKF@ ,# MS5-OS6)E/MW$F/^,'A-275C' M9G&IV(,H:Z6>Z4-9PVVTHV)6?$M!*8<_+7 MH[6\80\9G@>MUTI*"K18R"DLVT#(8V0:/FM_8L_,#GG'2H/JO6(08(4RB&HJ MYMBV155]M::UXY%^>DT&*F2],RIHRQ62)C,N5IYV[==Z4!J*$9L8K'3<&9/@ MT%^U!/O41!_< +_,YT4(U;C^3L%Q:Q'/ P48]$ FDB)F!;?VP*,203EV4H7 MF53!8TT>P-"H%T=UP.=/7W+AD F*X\MMI6YM(:"0.%28 MA8?*%561=7,DV>%L>377=!HCQ,\DZ^1N44WAG\86P^Z@N(@1,56C?P*.(4+F MF'N.69#X]'Z"U[W>TZ9.GJM-S5P6R&PX"R14=HA'%<19+JA#2=^!#H_X%)UJ M;YJN9E6X![S61'MM6+C6S:@G?D^8I"PYE> H5,H$:5ZZ\@4,S#,6>:(US>MT MNS8Y5J+)"?J!YDMI25['I9+70X996;7,!FT:(&EJ9);<:VGHP<4:G,.9-]:( MX4Q!*ZWW?&V4&.6*Y'G20)?Q5^@5DMFGXRB4V-2\LB.O73&01NW0%;6EI,5X MHWD!,0&*1%[05#2*GG*6GP54GX+!J\*H(XYO%F:B:GZ;AXH"BJP(DL^1.[=P MJQS^ONG64UTM5>^+M@;?/!H'F9C4VRM0C.PZL(RNVC9>XQ]2R'+@M&&Z:>0= M,0VC@E+"O5/?PY>D]9N$8<^TC$ODRU%&MTVT=TSI]2 M=\)C=BRJ>Z@=I#,H\WU,ZWT 3)>/Y^#A/%MBY%ZQ^_+"M-<38U]9+N67?YXC[5?"N-L;G8=S''1@U-B$7ENH&/4I.F M6=-OQ@[RTJ0"D\9Y:-PA"/&"'9'L+0KL*[LJ91M5R))FRMJ2@6\8+ MRJ4Q3+O8:WER4-"@_((&((:[.EF+!@\DND,[RUB^:-VQ_1$6*5(],BC([!2T MRF9RB\&P/CIR:!J3R;?EL G\>4=HY_JSQ!)FANV8/G^VXX!YQM3IXUBPB#LV ML/OFC3TTXOXT.*$KU, 6L3F6A"E_'T0MW%T0^6/:^ES$9\Y#:I=+IYL-I]-9 M:P27Y3K@]:I;S\BE.S \';B?>L$ //1T$L3.F-SC/ MR OK&SOJ_=(K*G&EL* JW>9+D/$LZD0O!(BLT#!R;5]JX?"9WSC'JI'TL,O) MQH[,8/" 5,/J]*1M,9*[!":A\0X-VZ#6XW%=EYK)F95]*+/Q''U ".]36[= AV.'5F",%5>4D1F*YU(WCD_(J;1 M>K!8Y2 VZG2UL[4;XHM'C4NB0%B6_BU?YW_R30YBF>VE^L42?@NZ.SPUF6L8 MW5P>S6PXC^9S33#8,6GU8MDSDF/"4;%+MB2;6OG=;88.NH)I(]()DPU$N#E- MA9PIHK-X;?V2P&F-3>D\KNC7MZ'FG[?4JY@F%,>FX @!O) VB<@5R9I4H$KG M@CFX([-?<0A>4-\%WRPVSJGP26<0!\ME=SG'(-WA4TM(]$'(@U\>S'O&;D>A\:7;E;> M%W0BIFN:WU=8&C+Z/@:NP%/<4($YA;4C^L4=#<+\I-/PE#F%%!I2CFOH')3N M[+;T$Y3N:J>UUZ6=?;38I)TJWTRAX)$SFBG753=>O^Q.BVE:WDMWI89[%>.Y M) HAV_K^JESM&X:/J;[[:8K$<=C8!T 61>IT^OI@+5 M(#8'>;^"UP8A7*1248H]_VK[E[F;4T#44;V%F)3VZ$2B(X]J!5,31I@1]7 Q M'=H1@-RYAJ,VW1 M4X8P,%,H[#O8[.F-"*;[5%9)]WOG;$_H^C#815(759\+ M;ARR!>(" 84J,:2'8><:_'KUN4*8IB25QRVIZROVQKH#C"E$)J"+F5R17$A+ MVD@'/-AXSFLC=>%U^^?]]H?CR8192>1].[%_'9],J'K'_/NOE X9 MBE!S[$4RF48GXY/3Z/AL3B.?C!>GT?Q\'I]AL>#X[)P5E+Z&\KFY#^/16'78 M% $?-CD)I$UFV**FH8+5>UL1CDRULCI'W_Q!#6#TA!I ;NM"!5KPD2$YC6=G MY[SS^/QD1G_-QC, ]6)A'CAFT%S7U1*YYY4YRB\!@[Z^\A@T)<^&S"FXU -15P2VC?@:H)M+7&NG>22" M20HA"C"%F&LFC7+6#0O*#A^]1D)BSU5K^%3TE.JBGJ._34^@>)B0B44N^H,C">\#L M&*'RQ6^1N$0ESMTF$@55<3ILF"1\97H6H__]'D,YQ8Z*BRPT#D(L7Z]UEK-' MQ7L^:.@07JFSHC)-8QXI42[0]V_*2PV,L (6L)E)UQ;$$O;I>'T1D5U+%;ER*$>/LP94UCUM#4LNZ+V#(.[U7XNH1 M/-V#!^/]<'(^16;J7QRVYS/JK9B=+OJ/S8)JR/AR*\FZ36X MGI6V[,:,Y(-2\K^"(GTNV[5U-0SI-]NH>>CMQV)P\ ^E%O02!@.JT?[ M+H?I9+$I*ND!RT?W[AN#V45!K7ZH:ZE(@M@6.&*Z#$$AYL4U7$V^/AC,\Q/! :4$@9^^>+UHQ?EIC3V=*T7;% M39:_MLE7NL7/RZ47)H+)6.B*5(:COT/#4!)*;.;J=I,EYHZWKE4SM,C2-DUU MJK;YV2@$,?5;-$V E2LP"@/PGJ2Q\-F?4S06T ;AO^-!5N.2L6?#R=B_G-AK%0< ZN'2WKUW#76SCOX!8LE#%&F.,3T5#(%#-]$G M.$AS@*>CZ=P>H,.B*]?8B%8\^_&2.A6I#UQ ):<[GYW"Z7K!&%PZ/QE]L UT M>H>U>1]<]HD]BVB=MGD69?&P@YRCWNS;**U85-(\B1]$+U04BM^]4'\2W8*8 MQH(::EC#O1V\:+D7"/3&UIZE@%DQW!36SS]3+G?%9!-T2. G\<%KFS:9T"W>R]U4E -R :17,$=2 _AV/IH<>P:R9U!?K5&\ M"N>#[5D,B_L1*,!+P;98WEI,3V+UMA,!_:O.[O@*(?@@S\U.#HSNHR>8PS4P M+X.>>+$0XY/7E(["(]@)RS7D:CP;3#W4>=MJ?&LI*9JN:6_B:U!D.8?'2+P' M5I79(KB6ZFR-D";]2!"OH'9U3DX:7=)TI]GC;7-I2P%F:;%S+&Z#J 4KAB/^ MZ-+T,+YCY_&J:0@RG&#B[C\[O&*%.:7$+@\PQT=55$HGM+<9&X.F'^=FD]'D MU.+<6WW;"NK@G^SNN719]8@]L2NAR?34:S"0<%#F"7P4K; MRQGV_HY"JW9SGQY*4[QKAU: L2,2E1W1Z.<2>.AI6Y7:29*!>7QD;D04\QF% MDWE7<2J_M=TMEF;F;-MA[T(JB&FT%)8;KX?)2;O;YEDB%5=4Q(5=Q^' 6HE. MRTA8 H8.9,S2K/,[;.#(NJW+L? J')6?>RKLQUPORY>2N0NU+%AN=^9V%NZ- M?0D$:#P($0]L5 =047#C*1*\N479S\!H4A#H3F]A M'B1N^$;"$9J2M!P/Q(G0-HVY!RQXC"G;SW8YF..LATW'K_ M/2QGOTSF ,^9CB8+RW/>F J,2Z\"0XD.M9B<])(]9SQ=.!>!_>Z#[RO I #' M")B;F:[_H8[%E[*RB5B:@I+:^0JXHR+K\CJ/^4 M%%?_48+JL]9?D4/S;=(FO_P$IW^G+W51T!79)5C6F(MJO\4 +%9QO;Z8O7@% M;[K'?_EI YO]"&P5>VD5>@FO3L9G)R^XG,I\ -&+0V(*.: :_;G2:!_@ _#[ MLJI:\P$GP+1!6MXO_P]02P,$% @ :(%O4UHH?+:] P 20@ !D !X M;"]W;W)K&ULC59M;^(X$/Z>7V%%]Z&5LDWB)"2I M (G2ET7:4E3HGDZG^V#" -$F,6L[9?OO;^R$E*XH=U_(V)YYGGFSA_Z>BQ]R M"Z#(K[*HY,#>*K6[=EV9;:%D\HKOH,*3-1SRU9 M7MG#OMF;B6&?UZK(*Y@)(NNR9.+M!@J^']B^?=AXSC=;I3?<87_'-C '];*; M"5RY']HA*"!3 M&H'AYQ7&4!0:"-WXV6+:':4V/)8/Z/?%GOE+;@9W89 5K5A?J MF>^_0AN/<3#CA32_9-_H1M0F62T5+UMC]*#,J^;+?K5Y.#)(O$\,:&M C=\- MD?'REBDV[ N^)T)K(YH63*C&&IW+*UV4N1)XFJ.=&LY?'A]'SW^1IWLRGSQ, M)_>3\6BZ(*/Q^.EENIA,'\CLZ=MD/+F;DXL%6Q8@+_NN0F)M[F8MR4U#0C\A M2Y%D.DOP]6DHEL&O^.4,0=@2A(0@_(;C-)=ML!&R8Z46^QH9^ MA:J&4\D\"Z5OZ;7(5[-_PK7=\:[$5 -9Q_LD4$3_L6)A/!>42 MA*63^F%EZ13K/'NDDZR+266I+:\EJU;RTIJQ?/6EWEDM)V'H">#-59+\07S' M]SS]39T@B5"@@>/[>H>&3AC'UC-DM1"8>Y0:^]&[?9A0DO@(THLCDE)J+;AB M1<>DX2-4,?!AK]>@Q@U/Y 1I2LY4+^JJ%YVMWAR?PE5=@*X;_*QS]4:D=CI7 MV"BG*G@6[G0%#QS6*0XLD!'?K,7;#LB82T4>!)>R_;UGN;"^LP+K_5MI/E96 M5_#:NC/PUCL\^4*^Y6L@:S1QTOU*FF2>)$ M7H+2A>\D/B7Z- @3)PZ2D^!<;4$MB,(78V.DM[(=J'#@W>PPIZ3A+YF@:5T[2-*HQ; MHA3O27"R6]VCY[T$L3%#3!+S9#4O?;?;SU9LA^\C$)J\D*6"-IMY5 MC)TJFL'5+!3?F6&QY I'CQ&W..M!: 4\7W-,6[O0!-V_A^&_4$L#!!0 ( M &B!;U.J9B[#/@, (' 9 >&PO=V]R:W-H965T)*M.$/LH5\DDCH^)!_RJ-%.JJ\Z0S3PO65[^M5A@73E[)$ M05_64A7,D*HVOBX5LK1V*G(_"H*>7S NW,FHMCVJR4A6)N<"'Q7HJBB8^G&# MN=R-W= ]&)[X)C/6X$]&)=O@',US^:A(\UN4E![/N>AR.'07#"(=H[1'7>3: ZR_?,L,E(R1TH>YK0K%"76GM30G=P(,HB,(S>-V6@6Z-USV!-Q-;U(;FS&@/WN/2 !,I3+]5W/R .:XJQ0U' M#7]=+[51-$5_GPD:MT'C.FA\J@BZ7&F5(\@U5()N4\[_P10V=(LT2 6YU!KU M6VR?Q;57^$J7;(5CE^ZH1K5%MPWFG WF+#*%Z!QW"^X)_I7%(?8-%DM4CFW! M*\VQ#;%=":"5G,Y,.":3E292]85SFS&Q08<+6#.N8,ORJN8 &[KU"]V_0*_K M#8,^"8/8BX9#$L(P\L)!8$U=+^H&>SC@POD_N!05WS*[ >#7=X,H#'^#,/!Z M2?BB]KTDCGX"DC;BCJD45L2/G8L6J=./O5XO@HO6LG\['XERZ%B^+QQ:29KE M)["[?8^*A9 8&$!"5??ZT"$: D*M48[=J=,EXRGE?)CD>H3?*#GR!G'R6G/N MT3CM3%B__XR(Y3T(O2"T'8@2+XA#:^K%7C>VW1D.O3A,X*U+X1_MI0+5IMZ^ MF@BKA&E65&MM%_QUL]=>CC=_ASNF-G9<LLMI:&= M68L9_:10V0/T?2VE.2@V0/O;F_P+4$L#!!0 ( &B!;U, ^*,GU ( ' & M 9 >&PO=V]R:W-H965T5 FCRDC.N!FZJ]?K2\U2<0D[5F5@#QR]+(7.JT94K3ZTET,0FY\?)-7ZH^["5T_2,)8940 M6MTED57YB6HZ[$NQ)=)$(YHQ;*DV&\5EW&S*3$O\FF&>'DZF3]>S^=WU=$Y& M@>R1.\%UJL@U3R!YF^^A MO%ICN-,X#D\"SF!]1B*_14(_#$[@177-D<6+CN'AR4X*!D0LR81O0&D\95J1 M;Z.%TA+/R?<3).V:I&U)VO] LL++0? (9J]DA]IZ$M#$/BYQKTSW?4:E_TG,]59Q0M.W50V=^IG5Y M.IVV$P1)3_;,+ MG%ZRG&^EH\7:SI2%T#BAK)GB+P&D"<#O2R'TSC$$]4]F^!M02P,$% @ M:(%O4XVJ0 "; @ 1P4 !D !X;"]W;W)K&UL M?51-;^(P$+WG5XRB'EHI(B$!2BM "K35(BT?@G17VIM))L1J8F=MI[3[Z]=. M(,M*A0N9&<][;SQX9G3@XDUFB H^BIS)L9TI53ZZKHPS+(CL\!*9/DFY*(C2 MKMB[LA1(DAI4Y*[O>0.W()39DU$=6XO)B%]RB>BW70GMNRY+0 IFDG(' =&R'W<=IS^37"3\H'N29#>8F M.\[?C#-/QK9G"L(<8V48B/Z\XPSSW!#I,GX?.>U6T@#/[1/[2WUW?9<=D3CC M^4^:J&QL#VU(,"55KC;\\ V/]^D;OICGLOZ%0Y/;]VR(*ZEX<03K"@K*FB_Y M./;A##"\!/"/ +^NNQ&JJWPBBDQ&@A] F&S-9HSZJC5:%T>9^5.V2NA3JG%J ML@ZCYV6T=6#Y','J!<+9['7Q^EU'GR!U>6V-?NGFJ?^5<(MEAT(/ =\S^]>X0O: M'@0U7W"I!T0A4Q*6>@96*81Q7!55KH,)A 47BOXAY@5=4>JU2KU:J7>IY7.#.RC+$F,8UM/I$3QCG:K87VE8>FG#"I# M^$0B)"!+*-O#$\98[%! T'6LVSFS5,8K25@B[ZP-FM%.4!@^TW"X =\9='U+ M.SYT/:?7&QH[,'8P[!J[!P^.Y_6-V8>!,P@\*\I0+XU4:97[OF<=>^Y83#?] M!H('9^@/X*L6NV>/NT"QKT=80LPKIIIWWD;;+1$VP_$OO5DQ"R+VE$G(,=50 MKW/?MT$T8]LXBI?UJ.RXTH-7FYG>="A,@CY/.5=\YSJ'_E;(KVK%N4;?\ZQ0 WNE]?JFUU/)BN=,78LU M+^!F(63.-&SELJ?6DK-YQ91G/>HX02]G:6$/^]79@QSV1:FSM. /$JDRSYG\ M,>:9V YL8K<'C^ERI9V/K = XAG/-%& H-EPS_P+#." ,:W1J;=J32, M^W0K_5-E.]@R8XI_$-F?Z5RO!G9DHSE?L#+3CV+[F3?V5 3D:GJ%VWKMWYL MHZ146N0-,R#(TZ)>V??&#WL,D7."@38,M,)=*ZI0?F2:#?M2;)$TKT&:(2I3 M*VX EQ8F*%,MX38%/CW\-+I]1"^CN^<)NI^,IL^/D_O)'T]3=/G$9AE75_V> M!BWF;2]I)(YKB?2$Q!C=BT*O%)H4*

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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 301 362 1 false 70 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://acaciaresearch.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Sheet http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Sheet http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentation DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://acaciaresearch.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT Sheet http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestment EQUITY SECURITIES PORTFOLIO INVESTMENT Notes 9 false false R10.htm 00000010 - Disclosure - INVESTMENT AT FAIR VALUE Sheet http://acaciaresearch.com/role/InvestmentAtFairValue INVESTMENT AT FAIR VALUE Notes 10 false false R11.htm 00000011 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION Sheet http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortization PATENTS, NET OF ACCUMULATED AMORTIZATION Notes 11 false false R12.htm 00000012 - Disclosure - STARBOARD INVESTMENT Sheet http://acaciaresearch.com/role/StarboardInvestment STARBOARD INVESTMENT Notes 12 false false R13.htm 00000013 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://acaciaresearch.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://acaciaresearch.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://acaciaresearch.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - INCOME/LOSS PER SHARE Sheet http://acaciaresearch.com/role/IncomelossPerShare INCOME/LOSS PER SHARE Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENT Sheet http://acaciaresearch.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 17 false false R18.htm 00000018 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies) Sheet http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://acaciaresearch.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables) Sheet http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentTables EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables) Tables http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestment 21 false false R22.htm 00000022 - Disclosure - INVESTMENT AT FAIR VALUE (Tables) Sheet http://acaciaresearch.com/role/InvestmentAtFairValueTables INVESTMENT AT FAIR VALUE (Tables) Tables http://acaciaresearch.com/role/InvestmentAtFairValue 22 false false R23.htm 00000023 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Tables) Sheet http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationTables PATENTS, NET OF ACCUMULATED AMORTIZATION (Tables) Tables http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortization 23 false false R24.htm 00000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://acaciaresearch.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://acaciaresearch.com/role/FairValueMeasurements 24 false false R25.htm 00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://acaciaresearch.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://acaciaresearch.com/role/CommitmentsAndContingencies 25 false false R26.htm 00000026 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://acaciaresearch.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://acaciaresearch.com/role/StockholdersEquity 26 false false R27.htm 00000027 - Disclosure - INCOME/LOSS PER SHARE (Tables) Sheet http://acaciaresearch.com/role/IncomelossPerShareTables INCOME/LOSS PER SHARE (Tables) Tables http://acaciaresearch.com/role/IncomelossPerShare 27 false false R28.htm 00000028 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Details http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies 28 false false R29.htm 00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details) Sheet http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details) Details 29 false false R30.htm 00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details) Sheet http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details) Details 30 false false R31.htm 00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details) Sheet http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails EQUITY SECURITIES PORTFOLIO INVESTMENT (Details) Details http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentTables 32 false false R33.htm 00000033 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details Narrative) Sheet http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative EQUITY SECURITIES PORTFOLIO INVESTMENT (Details Narrative) Details http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentTables 33 false false R34.htm 00000034 - Disclosure - INVESTMENT AT FAIR VALUE (Details) Sheet http://acaciaresearch.com/role/InvestmentAtFairValueDetails INVESTMENT AT FAIR VALUE (Details) Details http://acaciaresearch.com/role/InvestmentAtFairValueTables 34 false false R35.htm 00000035 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details) Sheet http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails PATENTS, NET OF ACCUMULATED AMORTIZATION (Details) Details http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationTables 35 false false R36.htm 00000036 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details Narrative) Sheet http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetailsNarrative PATENTS, NET OF ACCUMULATED AMORTIZATION (Details Narrative) Details http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationTables 36 false false R37.htm 00000037 - Disclosure - STARBOARD INVESTMENT (Details Narrative) Sheet http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative STARBOARD INVESTMENT (Details Narrative) Details http://acaciaresearch.com/role/StarboardInvestment 37 false false R38.htm 00000038 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis) Sheet http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis) Details http://acaciaresearch.com/role/FairValueMeasurementsTables 38 false false R39.htm 00000039 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3) Sheet http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3 FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3) Details http://acaciaresearch.com/role/FairValueMeasurementsTables 39 false false R40.htm 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://acaciaresearch.com/role/CommitmentsAndContingenciesTables 40 false false R41.htm 00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://acaciaresearch.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://acaciaresearch.com/role/CommitmentsAndContingenciesTables 41 false false R42.htm 00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://acaciaresearch.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details 42 false false R43.htm 00000043 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://acaciaresearch.com/role/StockholdersEquityTables 43 false false R44.htm 00000044 - Disclosure - INCOME/LOSS PER SHARE (Details) Sheet http://acaciaresearch.com/role/IncomelossPerShareDetails INCOME/LOSS PER SHARE (Details) Details http://acaciaresearch.com/role/IncomelossPerShareTables 44 false false All Reports Book All Reports acacia_i10q-93021.htm acacia_ex1002.htm acacia_ex3101.htm acacia_ex3102.htm acacia_ex3201.htm acacia_ex3202.htm actg-20210930.xsd actg-20210930_cal.xml actg-20210930_def.xml actg-20210930_lab.xml actg-20210930_pre.xml http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acacia_i10q-93021.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 301, "dts": { "calculationLink": { "local": [ "actg-20210930_cal.xml" ] }, "definitionLink": { "local": [ "actg-20210930_def.xml" ] }, "inline": { "local": [ "acacia_i10q-93021.htm" ] }, "labelLink": { "local": [ "actg-20210930_lab.xml" ] }, "presentationLink": { "local": [ "actg-20210930_pre.xml" ] }, "schema": { "local": [ "actg-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 482, "entityCount": 1, "hidden": { "http://acaciaresearch.com/20210930": 69, "http://fasb.org/us-gaap/2021-01-31": 75, "http://xbrl.sec.gov/dei/2021": 5, "total": 149 }, "keyCustom": 57, "keyStandard": 305, "memberCustom": 40, "memberStandard": 22, "nsprefix": "ACTG", "nsuri": "http://acaciaresearch.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://acaciaresearch.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - INVESTMENT AT FAIR VALUE", "role": "http://acaciaresearch.com/role/InvestmentAtFairValue", "shortName": "INVESTMENT AT FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentHoldingsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION", "role": "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortization", "shortName": "PATENTS, NET OF ACCUMULATED AMORTIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:StarboardInvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - STARBOARD INVESTMENT", "role": "http://acaciaresearch.com/role/StarboardInvestment", "shortName": "STARBOARD INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:StarboardInvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://acaciaresearch.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://acaciaresearch.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://acaciaresearch.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - INCOME/LOSS PER SHARE", "role": "http://acaciaresearch.com/role/IncomelossPerShare", "shortName": "INCOME/LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUBSEQUENT EVENT", "role": "http://acaciaresearch.com/role/SubsequentEvent", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ACTG:BusinessDescriptionTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:DescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)", "role": "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies", "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ACTG:BusinessDescriptionTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:DescriptionOfBusinessPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)", "role": "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentTables", "shortName": "EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - INVESTMENT AT FAIR VALUE (Tables)", "role": "http://acaciaresearch.com/role/InvestmentAtFairValueTables", "shortName": "INVESTMENT AT FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Tables)", "role": "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationTables", "shortName": "PATENTS, NET OF ACCUMULATED AMORTIZATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://acaciaresearch.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://acaciaresearch.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcceleratedShareRepurchasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "role": "http://acaciaresearch.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcceleratedShareRepurchasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - INCOME/LOSS PER SHARE (Tables)", "role": "http://acaciaresearch.com/role/IncomelossPerShareTables", "shortName": "INCOME/LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "ACTG:DescriptionOfBusinessPolicyTextBlock", "ACTG:BusinessDescriptionTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "ACTG:NumberOfPatentPortfoliosAcquired", "reportCount": 1, "unique": true, "unitRef": "Integer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)", "role": "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative", "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ACTG:DescriptionOfBusinessPolicyTextBlock", "ACTG:BusinessDescriptionTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "ACTG:NumberOfPatentPortfoliosAcquired", "reportCount": 1, "unique": true, "unitRef": "Integer", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details)", "role": "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30_custom_PaidUpRevenueAgreementsMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "ACTG:EquitySecuritiesAtFairValuePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details)", "role": "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES : Trading Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "ACTG:EquitySecuritiesAtFairValuePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "ACTG:RelatedPartyTransactionsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfLongtermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ACTG:RelatedPartyTransactionsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfLongtermInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "ACTG:GainOnSaleOfPrepaidInvestmentAndDerivative", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details)", "role": "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails", "shortName": "EQUITY SECURITIES PORTFOLIO INVESTMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30_custom_EquitySecuritesLfFundSecuritiesMember", "decimals": "-3", "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2020-01-012020-04-03_custom_OptionAgreementMember_custom_PortfolioCompaniesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT (Details Narrative)", "role": "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative", "shortName": "EQUITY SECURITIES PORTFOLIO INVESTMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2020-01-012020-04-03_custom_OptionAgreementMember_custom_PortfolioCompaniesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - INVESTMENT AT FAIR VALUE (Details)", "role": "http://acaciaresearch.com/role/InvestmentAtFairValueDetails", "shortName": "INVESTMENT AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:GainLossOnInvestmentsTextBlock", "us-gaap:InvestmentHoldingsTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30_custom_WarrantInvestmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:GainOnSaleOfInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details)", "role": "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails", "shortName": "PATENTS, NET OF ACCUMULATED AMORTIZATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - PATENTS, NET OF ACCUMULATED AMORTIZATION (Details Narrative)", "role": "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetailsNarrative", "shortName": "PATENTS, NET OF ACCUMULATED AMORTIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ACTG:PatentsNetOfAccumulatedAmortizationTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - STARBOARD INVESTMENT (Details Narrative)", "role": "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative", "shortName": "STARBOARD INVESTMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ACTG:StarboardInvestmentTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2020-12-31_custom_NewNotesMember", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30_us-gaap_AssetsMember_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis)", "role": "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis", "shortName": "FAIR VALUE MEASUREMENTS (Details - Fair Value on a Recurring Basis)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30_us-gaap_AssetsMember_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-06-30_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3)", "role": "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "shortName": "FAIR VALUE MEASUREMENTS (Details - Changes to fair value measurement Level 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2020-12-31_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:AcceleratedShareRepurchasesTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2020-09-202020-09-30_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "role": "http://acaciaresearch.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS' EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:AcceleratedShareRepurchasesTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2020-09-202020-09-30_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2019-08-05_custom_StockRepurchaseProgramMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2019-08-05_custom_StockRepurchaseProgramMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - INCOME/LOSS PER SHARE (Details)", "role": "http://acaciaresearch.com/role/IncomelossPerShareDetails", "shortName": "INCOME/LOSS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:PreferredStockDividendsIncomeStatementImpact", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2019-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY", "role": "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "AsOf2019-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:BusinessDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "role": "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentation", "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ACTG:BusinessDescriptionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - EQUITY SECURITIES PORTFOLIO INVESTMENT", "role": "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestment", "shortName": "EQUITY SECURITIES PORTFOLIO INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "acacia_i10q-93021.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "ACTG_AccretionOfSeriesConvertiblePreferredStockToRedemptionValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accretion of Series A Convertible Preferred Stock to redemption value", "label": "AccretionOfSeriesConvertiblePreferredStockToRedemptionValue", "negatedLabel": "Accretion of Series A Redeemable Convertible Preferred Stock to redemption value" } } }, "localname": "AccretionOfSeriesConvertiblePreferredStockToRedemptionValue", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ACTG_AccretionOfSeriesRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Add: Accretion of Series A redeemable convertible preferred stock" } } }, "localname": "AccretionOfSeriesRedeemableConvertiblePreferredStock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_AccruedPatentAcquisitionCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued patent acquisition costs", "label": "Accrued patent acquisition costs" } } }, "localname": "AccruedPatentAcquisitionCosts", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ACTG_AccruedPatentInvestmentCostsCurrent": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued patent investment costs" } } }, "localname": "AccruedPatentInvestmentCostsCurrent", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ACTG_AcquisitionOfPrepaidInvestmentSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Acquisition of prepaid investment securities" } } }, "localname": "AcquisitionOfPrepaidInvestmentSecurities", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Anti-dilutive potential common shares excluded from the computation of diluted net income (loss) per common share:" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountAbstract", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "ACTG_ApproximateValueOfSharesThatMayYetBePurchased": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Approximate value of shares that may yet be purchased", "label": "Approximate value of shares that may yet be purchased" } } }, "localname": "ApproximateValueOfSharesThatMayYetBePurchased", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_BasisOfAccountingPoliesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPoliesPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_BlackScholesMethodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Black Scholes Method [Member]" } } }, "localname": "BlackScholesMethodMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_BusinessDescriptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "ACTG_ChangeInFairValueOfDilutiveSeriesBWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Less: Change in fair value of dilutive Series B warrants" } } }, "localname": "ChangeInFairValueOfDilutiveSeriesBWarrants", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_ChangeInFairValueOfEquitySecurities": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of equity securities", "negatedLabel": "Change in fair value of equity securities" } } }, "localname": "ChangeInFairValueOfEquitySecurities", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ACTG_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Less: Change in fair value of Series A redeemable convertible preferred stock embedded derivative" } } }, "localname": "ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockEmbeddedDerivative": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockEmbeddedDerivative", "negatedLabel": "Change in fair value of Series A redeemable convertible preferred stock embedded derivative" } } }, "localname": "ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockEmbeddedDerivative", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_ChangeInFairValueOfSeriesWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Less: Change in fair value of Series A warrants" } } }, "localname": "ChangeInFairValueOfSeriesWarrants", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_CommonStockInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Investment [Member]" } } }, "localname": "CommonStockInvestmentMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "domainItemType" }, "ACTG_ConcentrationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations" } } }, "localname": "ConcentrationsPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_ContingentLegalFees": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Contingent legal fees" } } }, "localname": "ContingentLegalFees", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ACTG_Covid19PandemicAndCaresActPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COVID-19 Pandemic" } } }, "localname": "Covid19PandemicAndCaresActPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_DecemberRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December Redemption [Member]" } } }, "localname": "DecemberRedemptionMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_DerivativeLiabilitiesNoncurrent1": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series B warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent1", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ACTG_DescriptionOfBusinessPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Business" } } }, "localname": "DescriptionOfBusinessPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_DisclosureDescriptionOfBusinessAndBasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description Of Business And Basis Of Presentation" } } }, "localname": "DisclosureDescriptionOfBusinessAndBasisOfPresentationAbstract", "nsuri": "http://acaciaresearch.com/20210930", "xbrltype": "stringItemType" }, "ACTG_DisclosurePatentsNetOfAccumulatedAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patents Net Of Accumulated Amortization" } } }, "localname": "DisclosurePatentsNetOfAccumulatedAmortizationAbstract", "nsuri": "http://acaciaresearch.com/20210930", "xbrltype": "stringItemType" }, "ACTG_DisclosureStarboardInvestmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Starboard Investment" } } }, "localname": "DisclosureStarboardInvestmentAbstract", "nsuri": "http://acaciaresearch.com/20210930", "xbrltype": "stringItemType" }, "ACTG_DividendOnSeriesRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Add: Dividend on Series A redeemable convertible preferred stock" } } }, "localname": "DividendOnSeriesRedeemableConvertiblePreferredStock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_EarningsOnEquityInvestmentInJointVenture": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Earnings on equity investment in joint venture" } } }, "localname": "EarningsOnEquityInvestmentInJointVenture", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ACTG_EarningsPerShareBasicAndDilutedDeniminatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominator [Abstract]", "label": "Denominator:" } } }, "localname": "EarningsPerShareBasicAndDilutedDeniminatorAbstract", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "ACTG_EmployeeStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Options [Member]" } } }, "localname": "EmployeeStockOptionsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquityBasedIncentiveAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Based Incentive Awards [Member]" } } }, "localname": "EquityBasedIncentiveAwardsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquityMethodInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Investment securities - equity method investments" } } }, "localname": "EquityMethodInvestmentsCurrent", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ACTG_EquitySecuritesDerivativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securites Derivative [Member]" } } }, "localname": "EquitySecuritesDerivativeMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquitySecuritesForwardContractMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securites Forward Contract [Member]" } } }, "localname": "EquitySecuritesForwardContractMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquitySecuritesLfFundPublicSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securites Lf Fund Public Securities [Member]" } } }, "localname": "EquitySecuritesLfFundPublicSecuritiesMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquitySecuritesLfFundSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securites Lf Fund Securities [Member]" } } }, "localname": "EquitySecuritesLfFundSecuritiesMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquitySecuritiesAtFairValuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities at Fair Value" } } }, "localname": "EquitySecuritiesAtFairValuePolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_EquitySecuritiesDerivativeAndForwardContractAcquisitionCost": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Equity securities derivative and forward contract acquisition cost" } } }, "localname": "EquitySecuritiesDerivativeAndForwardContractAcquisitionCost", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_EquitySecuritiesLFFundTradingSecurityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities L F Fund Trading Security [Member]" } } }, "localname": "EquitySecuritiesLFFundTradingSecurityMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquitySecuritiesOtherEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities Other Equity [Member]" } } }, "localname": "EquitySecuritiesOtherEquityMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "domainItemType" }, "ACTG_EquitySecuritiesWithoutReadilyDeterminableFairValue": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValue", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ACTG_EstimatesPolicytextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Use of Estimates" } } }, "localname": "EstimatesPolicytextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_ForeignLicenseeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign Licensee [Member]" } } }, "localname": "ForeignLicenseeMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_GainOnSaleOfPrepaidInvestmentAndDerivative": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainOnSaleOfPrepaidInvestmentAndDerivative", "negatedLabel": "Gain on sale of prepaid investment and derivative", "verboseLabel": "Gain on sale of prepaid investment and derivative" } } }, "localname": "GainOnSaleOfPrepaidInvestmentAndDerivative", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_GainOnSaleOfPrepaidInvestmentAndDerivativey": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gain on sale of prepaid investment and derivativey" } } }, "localname": "GainOnSaleOfPrepaidInvestmentAndDerivativey", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_ImpairmentOfInvestmentPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment of Investments" } } }, "localname": "ImpairmentOfInvestmentPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_IncreaseDecreaseInRoyaltiesAndContingentLegalFeesPayable": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInRoyaltiesAndContingentLegalFeesPayable", "verboseLabel": "Royalties and contingent legal fees payable" } } }, "localname": "IncreaseDecreaseInRoyaltiesAndContingentLegalFeesPayable", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_InterestExpenseAssociatedWithStarboardNotesNetOfTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Add: Interest expense associated with Starboard Notes, net of tax" } } }, "localname": "InterestExpenseAssociatedWithStarboardNotesNetOfTax", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_InterestIncomeExpenseAndOther": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Interest income and other" } } }, "localname": "InterestIncomeExpenseAndOther", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ACTG_IssuanceOfCommonStockForUnvestedRestrictedStockAwardsNetOfForfeitures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for unvested restricted stock awards, net of forfeitures" } } }, "localname": "IssuanceOfCommonStockForUnvestedRestrictedStockAwardsNetOfForfeitures", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ACTG_IssuanceOfCommonStockForUnvestedRestrictedStockAwardsNetOfForfeituresShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for unvested restricted stock awards, net of forfeitures, shares" } } }, "localname": "IssuanceOfCommonStockForUnvestedRestrictedStockAwardsNetOfForfeituresShares", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ACTG_IssuanceOfCommonStockForVestingOfRestrictedStockUnits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for vesting of restricted stock units" } } }, "localname": "IssuanceOfCommonStockForVestingOfRestrictedStockUnits", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ACTG_IssuanceOfCommonStockForVestingOfRestrictedStockUnitsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for vesting of restricted stock units, shares" } } }, "localname": "IssuanceOfCommonStockForVestingOfRestrictedStockUnitsShares", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ACTG_LFFundSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "L F Fund Securities [Member]" } } }, "localname": "LFFundSecuritiesMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "domainItemType" }, "ACTG_LitigationAndLicensingExpensesPatents": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Litigation and licensing expenses - patents" } } }, "localname": "LitigationAndLicensingExpensesPatents", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ACTG_MertonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Merton [Member]" } } }, "localname": "MertonMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_NetIncomeForSettlementOffsetByContingencyAccruals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Income from settlement" } } }, "localname": "NetIncomeForSettlementOffsetByContingencyAccruals", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ACTG_NetIncomeIncludingNoncontrollingInterestsInSubsidiaries": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net (loss) income including noncontrolling interests in subsidiaries" } } }, "localname": "NetIncomeIncludingNoncontrollingInterestsInSubsidiaries", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ACTG_NetIncomeLossAvailableToCommonStockholderDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetIncomeLossAvailableToCommonStockholderDiluted", "verboseLabel": "Net income (loss) attributable to common stockholders - Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholderDiluted", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ACTG_NetPortfolioIncomeLoss": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetPortfolioIncomeLoss", "totalLabel": "Net patent portfolio (loss) income" } } }, "localname": "NetPortfolioIncomeLoss", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ACTG_NewNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New Notes [Member]" } } }, "localname": "NewNotesMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_NonQualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Qualified Stock Options [Member]" } } }, "localname": "NonQualifiedStockOptionsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_NoncashInvestingActivitesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash investing activities:" } } }, "localname": "NoncashInvestingActivitesAbstract", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ACTG_NumberOfPatentPortfoliosAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of patent portfolios acquired", "label": "Number of new patent portfolios acquired" } } }, "localname": "NumberOfPatentPortfoliosAcquired", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "integerItemType" }, "ACTG_OneLicensee2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Licensee 2 [Member]" } } }, "localname": "OneLicensee2Member", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_OneLicensee3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Licensee 3 [Member]" } } }, "localname": "OneLicensee3Member", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_OneLicenseeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Licensee [Member]" } } }, "localname": "OneLicenseeMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_OptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option Agreement [Member]" } } }, "localname": "OptionAgreementMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_PaidUpRevenueAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paid Up Revenue Agreements [Member]" } } }, "localname": "PaidUpRevenueAgreementsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "ACTG_PatentAcquisitionAccruedLiabilityLongTerm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Patent acquisition accrued liability - long-term" } } }, "localname": "PatentAcquisitionAccruedLiabilityLongTerm", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_PatentAcquisitionAccruedLiabilityShortTerm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Patent acquisition accrued liability - short-term" } } }, "localname": "PatentAcquisitionAccruedLiabilityShortTerm", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_PatentAcquisitionInExchangeOfNotesReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Patent acquisition in exchange of notes receivable" } } }, "localname": "PatentAcquisitionInExchangeOfNotesReceivable", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_PatentPortfolioOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patent Portfolio Operations" } } }, "localname": "PatentPortfolioOperationsPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_PatentsNetOfAccumulatedAmortizationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PATENTS, NET OF ACCUMULATED AMORTIZATION" } } }, "localname": "PatentsNetOfAccumulatedAmortizationTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortization" ], "xbrltype": "textBlockItemType" }, "ACTG_PortfolioCompaniesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Portfolio Companies [Member]" } } }, "localname": "PortfolioCompaniesMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_PurchasesOfPrepaidInvestment": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchases of prepaid investment" } } }, "localname": "PurchasesOfPrepaidInvestment", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_RSAsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "R S As [Member]" } } }, "localname": "RSAsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_RecurringRevenueAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Recurring Revenue Agreements [Member]" } } }, "localname": "RecurringRevenueAgreementsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "ACTG_RedemptionOfSecuredNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Repayment of debt" } } }, "localname": "RedemptionOfSecuredNotes", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ACTG_RelatedPartyTransactionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_RoyaltiesAndContingentLegalFeesPayable": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Royalties and contingent legal fees payable" } } }, "localname": "RoyaltiesAndContingentLegalFeesPayable", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ACTG_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_SegmentReportingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_SeniorSecuredNotesIssuanceCostsPaidToOtherParties": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "SeniorSecuredNotesIssuanceCostsPaidToOtherParties", "negatedLabel": "Senior Secured Notes issuance costs paid to other parties" } } }, "localname": "SeniorSecuredNotesIssuanceCostsPaidToOtherParties", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_SeniorSecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Secured Notes [Member]" } } }, "localname": "SeniorSecuredNotesMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_SeptemberRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September Redemption [Member]" } } }, "localname": "SeptemberRedemptionMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_SeriesAEmbeddedDerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Embedded Derivative Liability [Member]" } } }, "localname": "SeriesAEmbeddedDerivativeLiabilityMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "ACTG_SeriesARedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Redeemable Convertible Preferred Stock [Member]" } } }, "localname": "SeriesARedeemableConvertiblePreferredStockMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "ACTG_SeriesARedeemableConvertibleStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Redeemable Convertible Stock [Member]" } } }, "localname": "SeriesARedeemableConvertibleStockMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_SeriesAWarrantsLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Warrants Liability [Member]" } } }, "localname": "SeriesAWarrantsLiabilityMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3" ], "xbrltype": "domainItemType" }, "ACTG_SeriesAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]" } } }, "localname": "SeriesAWarrantsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis", "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_SeriesAandBWarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A and B Warrants" } } }, "localname": "SeriesAandBWarrantsPolicyTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ACTG_SeriesBWarrantsLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Warrants Liability [Member]" } } }, "localname": "SeriesBWarrantsLiabilityMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3" ], "xbrltype": "domainItemType" }, "ACTG_SeriesBWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Warrants [Member]" } } }, "localname": "SeriesBWarrantsMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis", "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_StarboardInvestmentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STARBOARD INVESTMENT" } } }, "localname": "StarboardInvestmentTextBlock", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestment" ], "xbrltype": "textBlockItemType" }, "ACTG_StarboardValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Starboard Value [Member]" } } }, "localname": "StarboardValueMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_StockRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program [Member]" } } }, "localname": "StockRepurchaseProgramMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_ThreeLicenseeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Licensee [Member]" } } }, "localname": "ThreeLicenseeMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_TradeDateReceivableFromSaleOfEquitySecuritiesNote3": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Trade date receivable from sale of equity securities (Note 3)" } } }, "localname": "TradeDateReceivableFromSaleOfEquitySecuritiesNote3", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_TwoLicenseeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Licensee [Member]" } } }, "localname": "TwoLicenseeMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ACTG_UnrealizedGainLossOnDerivatives1": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "UnrealizedGainLossOnDerivatives1", "negatedLabel": "Change in fair value of Series B warrants" } } }, "localname": "UnrealizedGainLossOnDerivatives1", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ACTG_WarrantInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Investment [Member]" } } }, "localname": "WarrantInvestmentMember", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis", "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "domainItemType" }, "ACTG_WarrantsExercisedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants exercised", "label": "Warrants exercised" } } }, "localname": "WarrantsExercisedShares", "nsuri": "http://acaciaresearch.com/20210930", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r495", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://acaciaresearch.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r46", "r48", "r96", "r97", "r222", "r245" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative", "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r161", "r273", "r275", "r454" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r161", "r273", "r275", "r454" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r159", "r273", "r274", "r411", "r452", "r453" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r159", "r273", "r274", "r411", "r452", "r453" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r47", "r48", "r96", "r97", "r222", "r245" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative", "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AcceleratedShareRepurchasesTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accelerated share repurchase (ASR) programs. An ASR is a combination of transactions that permits an entity to purchase a targeted number of shares immediately with the final purchase price of those shares determined by an average market price over a fixed period of time. An accelerated share repurchase program is intended to combine the immediate share retirement benefits of a tender offer with the market impact and pricing benefits of a disciplined daily open market stock repurchase program. ASRs can be disclosed as part of stockholders' equity.", "label": "Schedule of repurchased shares" } } }, "localname": "AcceleratedShareRepurchasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r377" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r17", "r162", "r163" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r200", "r201", "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion expense" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r301", "r377" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r99", "r100", "r101", "r298", "r299", "r300", "r337" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net (loss) income including noncontrolling interests in subsidiaries to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r66", "r82", "r227", "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r82", "r227", "r234", "r235", "r368" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r82", "r190", "r195" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of patents" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r94", "r148", "r151", "r157", "r178", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r318", "r322", "r354", "r375", "r377", "r416", "r433" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r42", "r94", "r178", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r318", "r322", "r354", "r375", "r377" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Fair value of assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Member]" } } }, "localname": "AssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r286", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r328", "r331" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Accounting Principles" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r25", "r84" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r8", "r85" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r8", "r85", "r415" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Long-Term Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r78", "r84", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r78", "r359" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental schedule of cash flow information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r92", "r94", "r115", "r116", "r121", "r126", "r130", "r138", "r139", "r140", "r178", "r209", "r213", "r214", "r215", "r218", "r219", "r242", "r243", "r247", "r251", "r354", "r501" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative", "http://acaciaresearch.com/role/StockholdersEquityDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r267", "r268", "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants issued, shares" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r206", "r422", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r203", "r204", "r205", "r207", "r485" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r99", "r100", "r337" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16", "r377" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.001 per share; 300,000,000 shares authorized; 49,591,852 and 49,279,453 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r142", "r143", "r161", "r352", "r353", "r484" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r142", "r143", "r161", "r352", "r353", "r460", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r142", "r143", "r161", "r352", "r353", "r460", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r142", "r143", "r161", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r142", "r143", "r161", "r352", "r353", "r484" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r89", "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r61", "r411" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "ACTG_NetPortfolioIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "totalLabel": "Patent portfolio expenses" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patent portfolio operations:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r141", "r161" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r220", "r230" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r32", "r225", "r367" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt stated interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r33", "r221", "r345" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r366", "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Capitalized lender fees" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r82", "r198" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r329" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of the Series A and B warrants and embedded derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Series A warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Describes how an entity determines the fair values of its derivatives, including its valuation methodology and significant assumptions used.", "label": "Assumptions used for derivatives" } } }, "localname": "DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesEmbeddedDerivatives": { "auth_ref": [ "r326", "r327", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.", "label": "Embedded derivatives" } } }, "localname": "DerivativesEmbeddedDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r265", "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Dividends, Preferred Stock, Stock", "negatedLabel": "Dividend on Series A Redeemable Convertible Preferred Stock" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r58", "r104", "r105", "r106", "r107", "r108", "r112", "r115", "r126", "r129", "r130", "r134", "r135", "r338", "r339", "r427", "r445" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Basic net income (loss) per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic net income (loss) per common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r58", "r104", "r105", "r106", "r107", "r108", "r115", "r126", "r129", "r130", "r134", "r135", "r338", "r339", "r427", "r445" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted net income (loss) per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "INCOME/LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r330" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Series A embedded derivative liabilities", "verboseLabel": "Fair value of embedded derivative" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r52", "r53", "r54", "r99", "r100", "r101", "r103", "r109", "r111", "r137", "r180", "r258", "r265", "r298", "r299", "r300", "r310", "r311", "r337", "r360", "r361", "r362", "r363", "r364", "r365", "r455", "r456", "r457", "r513" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investments accounted under the equity method.", "label": "Equity Method Investments, Fair Value Disclosure", "verboseLabel": "Equity securities at fair value" } } }, "localname": "EquityMethodInvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r26", "r77", "r177", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Schedule of equity securities" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r351" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity securities at fair value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity securities - cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r174", "r448" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Gain (loss) on sale of equity securities", "negatedLabel": "(Gain) loss on sale of equity securities" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Available-for-sale Securities, Gross Unrealized Gain" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r174", "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Change in fair value of investment" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r174" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedLabel": "Available-for-sale Securities, Gross Unrealized Loss" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r9", "r11", "r169", "r432", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.", "label": "Equity Securities Without Readily Determinable Fair Value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r340", "r341", "r342", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r224", "r232", "r233", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r341", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r340", "r341", "r344", "r345", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r224", "r276", "r277", "r282", "r283", "r341", "r383" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r224", "r232", "r233", "r276", "r277", "r282", "r283", "r341", "r384" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r224", "r232", "r233", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r341", "r385" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Schedule of changes in fair value Level 3 liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Transfers into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance", "periodStartLabel": "Derivative liability, beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r224", "r232", "r233", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r167", "r168", "r170", "r171", "r172", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r228", "r256", "r336", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis", "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r196" ], "calculation": { "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Remainder of 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r196" ], "calculation": { "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r196" ], "calculation": { "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r196" ], "calculation": { "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r194", "r412" ], "calculation": { "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patents, net of accumulated amortization", "totalLabel": "Patents, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r355", "r356", "r357", "r358" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Loss on foreign currency exchange" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r64", "r82", "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Net realized and unrealized gain (loss) on investment", "negatedLabel": "Net realized and unrealized gain (loss) on investment" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails", "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.", "label": "Schedule of gain on investments" } } }, "localname": "GainLossOnInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r82", "r428" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain on sale of prepaid investment and derivative" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (loss) on sale of investment", "negatedLabel": "(Gain) loss on sale of investment" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOnSaleOfInvestments": { "auth_ref": [ "r59", "r60", "r82", "r424", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.", "label": "Gain on sale of investment" } } }, "localname": "GainOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Patents" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r197", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r148", "r150", "r153", "r156", "r158", "r413", "r425", "r429", "r449" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r94", "r102", "r148", "r150", "r153", "r156", "r158", "r178", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r317", "r339", "r354" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Net income attributable to Acacia Research Corporation", "totalLabel": "Net income (loss) including noncontrolling interests in subsidiaries", "verboseLabel": "Net (loss) income including noncontrolling interests in subsidiaries" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Net income (loss) attributable to common stockholders - Basic" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r56", "r82", "r146", "r176", "r423", "r443" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Earnings on equity investment in joint venture, net of distributions received" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r110", "r111", "r147", "r304", "r312", "r313", "r450" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r51", "r302", "r303", "r306", "r307", "r308", "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r79", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r81" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r81" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.", "label": "Notes exchanged" } } }, "localname": "IncreaseDecreaseInNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r81" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidInterest": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for interest that provides economic benefits in future periods.", "label": "Interest paid" } } }, "localname": "IncreaseDecreaseInPrepaidInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r66", "r226", "r231", "r234", "r235" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedLabel": "Interest expense on Senior Secured Notes" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r421", "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investment Holdings [Line Items]" } } }, "localname": "InvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentHoldingsTable": { "auth_ref": [ "r461", "r471", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.", "label": "Investment Holdings [Table]" } } }, "localname": "InvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentHoldingsTextBlock": { "auth_ref": [ "r461", "r471", "r472", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment holdings. This includes the long positions of investments for the entity. It contains investments in affiliated and unaffiliated issuers. The investments include securities and non securities (i.e. commodities and futures contracts).", "label": "INVESTMENT AT FAIR VALUE" } } }, "localname": "InvestmentHoldingsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r177", "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment at Fair Value" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r474", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r474", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r169", "r414", "r430", "r481", "r508" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "EQUITY SECURITIES PORTFOLIO INVESTMENT" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestment" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of future minimum operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r373" ], "calculation": { "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": { "auth_ref": [ "r373" ], "calculation": { "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "auth_ref": [ "r373" ], "calculation": { "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "auth_ref": [ "r373" ], "calculation": { "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [ "r373" ], "calculation": { "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r373" ], "calculation": { "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months", "verboseLabel": "Remainder of 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r94", "r152", "r178", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r319", "r322", "r323", "r354", "r375", "r376" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r94", "r178", "r354", "r377", "r420", "r439" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31", "r94", "r178", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r319", "r322", "r323", "r354", "r375", "r376", "r377" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liability [Member]" } } }, "localname": "LiabilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r12", "r223", "r229", "r232", "r233", "r418", "r435" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r34", "r208" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Contingency accruals" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossOnSaleOfInvestments": { "auth_ref": [ "r59", "r60", "r82", "r424", "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A loss would be recognized when the sale price of the investment is less than the carrying value of the investment. This element refers to the Loss included in earnings and not to the cash proceeds of the sale.", "label": "Loss on sale of investment", "negatedLabel": "Loss on sale of investment" } } }, "localname": "LossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails", "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r41", "r94", "r178", "r209", "r213", "r214", "r215", "r218", "r219", "r354", "r419", "r438" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r78" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r78", "r80", "r83" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r49", "r50", "r54", "r57", "r83", "r94", "r102", "r104", "r105", "r106", "r107", "r110", "r111", "r123", "r148", "r150", "r153", "r156", "r158", "r178", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r339", "r354", "r426", "r444" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss) attributable to Acacia Research Corporation", "totalLabel": "Net income (loss) attributable to Acacia Research Corporation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r49", "r50", "r54", "r110", "r111", "r321", "r325" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net income attributable to noncontrolling interests in subsidiaries" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r104", "r105", "r106", "r107", "r112", "r113", "r125", "r130", "r148", "r150", "r153", "r156", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Net income (loss) attributable to common stockholders - Basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r114", "r117", "r118", "r119", "r120", "r125", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net income (loss) attributable to common stockholders - Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r99", "r100", "r101", "r265", "r315" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r148", "r150", "r153", "r156", "r158" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r372", "r374" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease costs, net of sublease income" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: short-term lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r371" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/CommitmentsAndContingenciesDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r370" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Leased right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Accrued patent acquisition costs due within 2 years" } } }, "localname": "OtherCommitmentDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year.", "label": "Accrued patent acquisition costs due within a year" } } }, "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r26", "r441" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments classified as other.", "label": "Investment at fair value" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other patent portfolio income" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other receivable (Note 3)" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r74" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r74" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividend on Series A Redeemable Convertible Preferred Stock" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payment of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r70" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Patent acquisition" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payment to acquire equity securities" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r71" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchases of equity securities" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockAccretionOfRedemptionDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of accretion of the preferred stock redemption discount during the period.", "label": "Preferred Stock, Accretion of Redemption Discount", "negatedLabel": "Accretion of Series A redeemable convertible preferred stock" } } }, "localname": "PreferredStockAccretionOfRedemptionDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Dividend on Series A redeemable convertible preferred stock" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r37", "r241" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Series A redeemable convertible preferred stock, par value $0.001 per share; stated value $100 per share; 350,000 shares authorized, issued and outstanding as of September 30, 2021 and December 31, 2020; aggregate liquidation preference of $35,000 as of September 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r23", "r24" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r73" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Issuance of Senior Secured Notes, net of lender fee" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r73" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Reissuance of Senior Secured Notes", "verboseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r72" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Issuance of Series B warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r67", "r68", "r165" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Maturities and sales of equity securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfTradingSecuritiesHeldforinvestment": { "auth_ref": [], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturities, repayments and calls of securities classified as trading securities and held for investment purposes. Excludes proceeds from trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).", "label": "Sale of investment at fair value" } } }, "localname": "ProceedsFromSaleAndMaturityOfTradingSecuritiesHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfLongtermInvestments": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.", "label": "Proceeds from sale of investment" } } }, "localname": "ProceedsFromSaleOfLongtermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r72", "r297" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment.", "label": "Loss on sale of trading security" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemablePreferredStockMember": { "auth_ref": [ "r7", "r94", "r178", "r209", "r213", "r214", "r215", "r218", "r219", "r237", "r354" ], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series.", "label": "Redeemable Preferred Stock [Member]" } } }, "localname": "RedeemablePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r75" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedLabel": "Paydown of Senior Secured Notes", "verboseLabel": "Repayment of debt" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r87", "r415", "r436" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r8", "r84", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "periodEndLabel": "Cash and cash equivalents and restricted cash, ending" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndInvestmentsNoncurrent": { "auth_ref": [ "r482", "r483" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.", "label": "Long-term restricted cash" } } }, "localname": "RestrictedCashAndInvestmentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r265", "r301", "r377", "r437", "r458", "r459" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r99", "r100", "r101", "r103", "r109", "r111", "r180", "r298", "r299", "r300", "r310", "r311", "r337", "r455", "r457" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r144", "r145", "r149", "r154", "r155", "r159", "r160", "r161", "r272", "r273", "r411" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "ACTG_NetPortfolioIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r62" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostOfGoodsAndServicesSold", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Inventor royalties" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r142", "r161" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Calculation of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of financial assets and liabilities at fair value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r191", "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/PatentsNetOfAccumulatedAmortizationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Abstract]" } } }, "localname": "ScheduleOfInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r38", "r92", "r138", "r139", "r236", "r238", "r240", "r242", "r243", "r244", "r245", "r247", "r251", "r256", "r259", "r260", "r261", "r262", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r10", "r417", "r434" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Senior Secured Notes Payable" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuritiesFinancingTransactionAxis": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost.", "label": "Securities Financing Transaction [Axis]" } } }, "localname": "SecuritiesFinancingTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Measurement of financing transaction securities held." } } }, "localname": "SecuritiesFinancingTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r81" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Non-cash stock compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Option Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Weighted Average Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted average grant-date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r284", "r287" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r286", "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program." } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "verboseLabel": "Option Forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted-average remaining vesting period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at ending, shares", "periodStartLabel": "Balance at beginning, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r88", "r98" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r92", "r94", "r115", "r116", "r121", "r126", "r130", "r138", "r139", "r140", "r178", "r209", "r213", "r214", "r215", "r218", "r219", "r242", "r243", "r247", "r251", "r258", "r354", "r501" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative", "http://acaciaresearch.com/role/StockholdersEquityDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r40", "r52", "r53", "r54", "r99", "r100", "r101", "r103", "r109", "r111", "r137", "r180", "r258", "r265", "r298", "r299", "r300", "r310", "r311", "r337", "r360", "r361", "r362", "r363", "r364", "r365", "r455", "r456", "r457", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r99", "r100", "r101", "r137", "r411" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r258", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r258", "r265", "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock options exercised, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r15", "r16", "r265", "r285", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Compensation expense for share-based awards" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r40", "r258", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.", "label": "Stock Repurchase Program Expiration Date" } } }, "localname": "StockRepurchaseProgramExpirationDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r15", "r16", "r258", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Repurchase of common stock, Shares" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r15", "r16", "r258", "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r94", "r164", "r178", "r354", "r377" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Acacia Research Corporation stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r53", "r94", "r99", "r100", "r101", "r103", "r109", "r178", "r180", "r265", "r298", "r299", "r300", "r310", "r311", "r315", "r316", "r324", "r337", "r354", "r360", "r361", "r365", "r456", "r457", "r513" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r93", "r243", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r265", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Treasury Stock" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Series A redeemable convertible preferred stock, liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r7", "r237" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Series A redeemable convertible preferred stock, par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r7", "r237" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Series A redeemable convertible preferred stock, value per share" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Series A redeemable convertible preferred stock, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative", "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetailsNarrative", "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r167", "r168", "r170", "r171", "r172", "r228", "r256", "r336", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r501", "r502", "r503", "r504", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentDetails", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-ChangesToFairValueMeasurementLevel3", "http://acaciaresearch.com/role/FairValueMeasurementsDetails-FairValueOnRecurringBasis", "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesTradingSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Average price paid per share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r39", "r267" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfSeriesRedeemableConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r39", "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r16", "r258", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Number of shares repurchased" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r39", "r267", "r270" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 4,604,365 shares as of September 30, 2021 and December 31, 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic": { "auth_ref": [ "r124", "r127", "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) from continuing operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.", "label": "Undistributed earnings allocated to participating securities" } } }, "localname": "UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r124", "r127", "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Add: Undistributed earnings allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": { "auth_ref": [ "r122", "r124", "r127", "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Reallocation of undistributed earnings to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r82" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain (Loss) on Derivatives", "negatedLabel": "Change in fair value of Series A warrants" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": { "auth_ref": [ "r333" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.", "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax", "negatedLabel": "Loss on foreign currency exchange" } } }, "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Change in fair value of investment, net", "negatedLabel": "Change in fair value of investment, net", "negatedTerseLabel": "Change in fair value of investment", "verboseLabel": "Change in fair value of investment" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/InvestmentAtFairValueDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Schedule of unrealized gains or losses" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/EquitySecuritiesPortfolioInvestmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique." } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Fair value of warrants" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/StarboardInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted average number of shares outstanding - Diluted", "verboseLabel": "Potentially dilutive common shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails", "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Potentially dilutive common shares:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r114", "r130" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of shares outstanding - Basic" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r112", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted-average shares used in computing net income (loss) per share attributable to common stockholders - Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://acaciaresearch.com/role/IncomelossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=107671284&loc=SL5844817-113951" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515679&loc=d3e40733-113955" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123589689&loc=d3e48542-113965" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=56949186&loc=d3e50579-113967" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r481": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r486": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r487": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r488": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r489": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r490": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r491": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r492": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r493": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r494": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r495": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r496": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r497": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r498": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r499": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r500": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r501": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r502": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r503": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r504": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r505": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r506": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r507": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r508": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r509": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r510": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r511": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r512": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" } }, "version": "2.1" } ZIP 64 0001683168-21-005701-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-21-005701-xbrl.zip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�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end